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The following dissertation was written by the author.  
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contributions section of the manuscripts where the contribution of each co-author to this work 
is listed. 
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SUMMARY 
 
 Mitochondria are considered as the “powerhouses” of the cell. They provide the main 
source of cellular energy via the production of adenosine triphosphate (ATP) molecules that 
is accomplished through oxidative phosphorylation (OXPHOS) from nutritional sources. 
Mitochondria are highly dynamic organelles that continuously fuse and divide to mix and 
exchange their material, including proteins, DNA and metabolites, according to cellular 
energy requirements. The brain is especially dependent on ATP due to its high energy 
demand. Mitochondria produce the energy required for almost all cellular processes, from 
cell survival and death, to the regulation of intracellular calcium homeostasis, synaptic 
plasticity and neurotransmitter synthesis. Thus, impaired mitochondrial bioenergetics and 
dynamics lead inevitably to disease, ranging from subtle alterations in neuronal function to 
cell death and neurodegeneration. For instance, early stages of Alzheimer’s disease (AD) 
are associated with impaired mitochondrial bioenergetics and dynamics (fusion/fission) in the 
brain, which is paralleled by oxidative stress, particularly in mitochondria themselves, and 
ultimately lead to neuronal death.  
 In this context, the understanding of the intrinsic mechanisms regulating mitochondrial 
activity and dynamics is becoming of major importance, especially for the search of new 
drugs for the therapy and prevention of neurodegenerative diseases, such as AD. 
 
 The purpose of the joint-PhD thesis was therefore to deepen our understanding of the 
regulation of mitochondrial function, and to identify key factors (endogenous and / or 
exogenous) that are critical in the control of mitochondrial bioenergetics and dynamics. 
Hence, these factors could be used as tools to develop strategies against diseases involving 
mitochondrial dysfunction. To achieve this goal, the thesis was divided into two main parts. 
 1) Since a growing body of evidence suggests that neurosteroids have a strong 
neuroprotective potential, the first part is based on the hypothesis that neurosteroids may 
exert a determinant action against neurodegeneration by improving mitochondrial 
bioenergetics, (A) under “healthy” physiological conditions as well as (B) under pathological 
conditions (AD). 
 2) In the second part (C), we determined whether the biological clock, which 
coordinates a whole range of daily behaviors and physiological processes, is involved in the 
endogenous regulation of mitochondrial dynamics and bioenergetics. 
 
(A) In the first part of this thesis, the ability of different neurosteroids to regulate 
mitochondrial bioenergetics and redox homeostasis in neuronal cells was evaluated in vitro. 
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Neurosteroids constitute a category of steroids that are synthetized within the nervous 
system, independently of peripheral endocrine glands, and act on the nervous system in an 
auto/paracrine configuration. Neurosteroids are involved in a broad range of brain-specific 
functions and the gradual decline of neurosteroid levels with increasing age may be 
associated with the appearance of age-related neuronal dysfunction, cognitive impairments, 
and with neurodegenerative diseases, such as AD. Indeed, a growing body of evidence 
attests that neurosteroids possess strong neuroprotective properties. In particular, many 
studies are focused on estradiol which is also known to boost bioenergetic metabolism in 
cells. However, no studies sought to test the effects of other neurosteroids on mitochondrial 
bioenergetics and redox homeostasis in neuronal cells. 
 Therefore, to gain insights into the underlying mechanism of neuroprotective action of 
neurosteroids, we selected a panel of neurosteroids (progesterone, estradiol, estrone, 
testosterone, 3α-androstanediol, dehydroepiandrosterone (DHEA) and allopregnanolone) as 
potential candidates able to modulate mitochondrial function. Before characterizing the mode 
of action of neurosteroids on bioenergetics under pathological conditions, we first aimed to 
understand their effects per se using human SH-SY5Y neuroblastoma cells. We showed that 
most of the neurosteroids we tested were able to improve the bioenergetic metabolism in 
neuronal cells by increasing ATP levels, mitochondrial membrane potential and basal 
mitochondrial respiration. Each neurosteroid appeared to have a distinct bioenergetic profile, 
possibly because different receptors were involved in their effects on mitochondria. Indeed, 
neurosteroids seemed to act via their corresponding receptor since the effects on ATP levels 
were abolished in the presence of specific steroid receptor antagonists. In parallel to an 
increased mitochondrial respiration, we observed a rise in reactive oxygen species (ROS) 
levels after treatment with neurosteroids. In response to this slight enhancement of ROS 
which may result from the rise in oxygen consumption, antioxidant activity was up-regulated, 
suggesting that neurosteroids may directly or indirectly modulate redox homeostasis in 
neuronal cells.  
 Together, these first data indicated that neurosteroids were indeed able to boost 
mitochondrial function in a delicate balance. We can speculate that neurosteroids are acting, 
at least in part, via their corresponding receptors to regulate the expression of genes 
involved in glycolysis and oxidative phosphorylation, but also the content and activity of 
mitochondrial respiratory complexes. Further investigations are required to determine the 
underlying molecular mechanisms. 
 
(B) Based on these findings, we investigated in the next step whether neurosteroids were 
able to alleviate AD-related bioenergetic deficits. For that purpose, we treated different AD 
cell culture models with neurosteroids: i) human neuroblastoma cells (SH-SY5Y) 
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overexpressing the human amyloid precursor protein (APP) and amyloid-β peptide (Aβ); ii) 
human neuroblastoma cells stably transfected with the wild-type tau protein (wtTau) or; iii) 
the mutant tau protein (P301L) inducting abnormal tau hyperphosphorylation and; iv) their 
respective vector control cells. We first demonstrated that the presence of APP/Aβ and 
abnormally hyperphosphorylated tau protein differentially impacted mitochondrial respiration 
in cellular models of AD. In line with previous studies, both AD pathogenic features induced a 
decrease in ATP level. However, abnormal tau protein only impaired the maximal 
mitochondrial respiration and spare respiratory capacity, whereas the overexpression of 
APP/Aβ induced in addition a decrease in basal respiration, ATP turnover and glycolytic 
reserve. All the neurosteroids tested showed beneficial effects on ATP production and 
mitochondrial membrane potential in APP/Aβ overexpressing cells, while only progesterone 
and estradiol increased ATP levels in mutant tau cells. In addition, we showed that 
testosterone, that is also the main male steroid hormone, was more efficient to alleviate 
mitochondrial deficits induced by APP/Aβ, whereas neurosteroids belonging to the family of 
female steroid hormones, progesterone and estrogens, were more efficient with productivity 
rising bioenergetic outcomes in our cellular model of AD-related tauopathies. 
 Together, our findings lend further evidence to the neuroprotective effects of 
neurosteroids in AD pathology and indicate that these molecules represent promising tools 
able to increase mitochondrial bioenergetics via enhanced mitochondrial respiration, in 
healthy and pathological conditions, respectively. Our results provide a potential molecular 
basis for the beneficial and neuroprotective effects of neurosteroids, which may open new 
avenues for drug development with regard to targeting mitochondria in neurodegeneration.  
 
(C) The aim of the second part of this thesis was to investigate more closely how 
mitochondrial function is endogenously regulated within the cells. More specifically, we 
aimed to determine whether and how mitochondrial dynamics as well as bioenergetics were 
modulated by the biological clock in a circadian manner. The circadian clock is a hierarchical 
network of oscillators which coordinate a variety of daily behavioural and physiological 
processes to the optimal time of day, anticipating the periodical changes of the external 
environment for all living organisms. Since there are increasing evidences that metabolic 
homeostasis and the circadian clock are connected in numerous ways through reciprocal 
regulation, we asked whether mitochondrial bioenergetics and dynamics may exhibit 
circadian oscillations and whether mitochondria themselves may be able to influence the 
circadian clock. Using human primary fibroblasts as a peripheral clock model, we showed 
that the mitochondrial shape and OXPHOS metabolism are under the control of the clock 
and oscillate within a period length of about 24 hrs. More precisely, we found that ATP levels 
exhibit a circadian rhythmicity that is consistent with the rhythm of mitochondrial 
SUMMARY 
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fusion/fission activity we observed in vitro and in vivo in mouse brains. This rhythmicity 
appeared to be dependent of Drp1 activity, a protein involved in mitochondrial fission, since 
inhibiting or knocking down Drp1 abolished the ATP oscillation in vitro. In addition, the 
mitochondrial respiration pattern was in line with the observed mitochondrial network-
dependent ATP oscillations together with rhythmic oscillations of by-products of 
mitochondrial activity, ROS and NAD+ levels, both indicators of the redox environment. 
Furthermore, we also found that mitochondria may themselves influence the circadian clock 
through several retrograde signals, such as the activation of AMP-activated protein kinases 
(AMPK) which can regulate clock gene expression depending on the ratio AMP/ATP. 
 Thus, in this second part, we established a detailed molecular link between circadian 
control of mitochondrial dynamics and bioenergetics, suggesting a key role of the clock-
controlled mitochondrial network to anticipate energetic requirements of diverse cellular 
functions in response to environmental constraints. 
 
 Overall, the studies performed in the present thesis importantly helped to deepen our 
knowledge about the modulation of mitochondrial function in health and disease states. First, 
our work identifies neurosteroids as very promising molecules able to counteract the 
bioenergetic deficits in neurodegenerative diseases. Second, we show that mitochondrial 
dynamics and bioenergetics are controlled by the biological clock, and vice versa. Our 
findings could have multiple implications with regard to the regulation of metabolic 
homeostasis in health and disease states associated with mitochondrial impairments and / or 
circadian disruption. 
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A. Mitochondria  
 
 Mitochondria play a central role in eukaryotic cell survival and death because they are 
orchestrating both energy metabolism and apoptotic pathways. They are considered as the 
“powerhouses of cells”, providing the main source of cellular energy under the form of 
adenosine triphosphate (ATP) molecules that is accomplished through oxidative 
phosphorylation (OXPHOX) from nutritional sources. Thus, they contribute to plenty of 
cellular functions, including apoptosis, cell growth and differentiation, regulation of 
intracellular calcium homeostasis, alteration of the cellular reduction–oxidation (redox) state 
and synaptic plasticity. In this context, mitochondria are particularly important in the nervous 
system that has high energy demand and requires for about 20% of the body’s total basal 
oxygen consumption (1). As a result, mitochondrial dysfunctions have been associated with 
neurodegenerative diseases, such as Alzheimer’s disease (AD), that are characterized by a 
cerebral hypometabolism and an impaired homeostasis of the redox status (2). 
 
1. Mitochondrial structure and pivotal roles within cells 
 
 Today, it is widely accepted that mitochondria come from the endocytosis of an α-
proteobacteria by a precursor of eukaryotic cells and that this endosymbiosis provoked a 
move forward in the evolution by permitting the aerobic life (3). As a consequence of this 
endocytosis, mitochondria carry a residual genome (approximately 16 kilobase) coding for 13 
proteins essential for mitochondrial respiratory chain function (4). In addition, mitochondria 
comprise an inner and outer membrane, the intermembrane space and the matrix (Fig 1). 
The size, aspect and organization of mitochondrial membranes vary between species, 
tissues and physiological conditions and largely differ from the classical representation of 
mitochondrial ultrastructure. 
In humans, mitochondrial DNA (mtDNA) is transmitted in a non-Mendelian manner via the 
maternal oocyte (uniparental inheritance) whereas normally the paternal mitochondria are 
destroyed directly after fertilization. The replication and segregation of mtDNA are not 
coupled to cell cycle and the underlying mechanisms remain unclear (4). However, it appears 
that the quality control of mtDNA replication is not as efficient as nuclear DNA (nDNA), 
resulting in an increased risk of mtDNA mutations (5). Thus, to avoid the accumulation of 
such mutations, mitochondria are remarkably dynamic organelles that divide and fuse to 
ensure the mixing of mtDNA but also mitochondrial metabolites and proteins. 
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Fig. 1: Classical representation of mitochondrion ultrastructure (courtesy of M. Wanner Fabio). 
 
a) Mitochondria: versatile organelles 
 
 Since mitochondria are really small organelles (from 0.5 to 1.0 μm in diameter), the 
characterization and understanding of mitochondrial ultrastructure became possible only 
when techniques for electron and confocal microscopy were perfected (3). 
 Mitochondria possess a heterogeneous and complex morphology resulting from the 
continuous fusion and fission of mitochondrial membranes (6; 7). Thus, mitochondrial 
network is often compared to a syncytium that constantly cycle between a fused, 
intermediate and fragmented state (Fig 2). 
 
 
Fig.2: Different mitochondrial shapes (Adapted from (6)) 
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As mentioned above, mitochondrial dynamics allow the mixing and exchange of 
material between those organelles but also their redistribution within the cells. This 
phenomenon is of major importance, especially in neurons, that are long, excitable and, 
highly compartmentalized cells (4). The proper distribution of mitochondria is paramount to 
sustain the spatial and temporal demand of energy in neurons, that differs within the axons 
and synapses compared to dendrites and cell body. Thus, on one hand, mitochondrial fission 
enables the renewal, redistribution and proliferation of mitochondria into synapses, where 
they are important for calcium buffering and cycling of reserve pool of synaptic vesicles. On 
the other hand, mitochondrial fusion allows mitochondria to interact and communicate with 
each other, and facilitating mitochondrial movement and distribution across long distances 
and to the synapses (Fig.3) (5). 
 
 
Fig 3: Mitochondrial dynamics. (A) Mitochondria cyclically shift between elongated (tubular) and fragmented state. 
Following the fission event, the mitochondrion can either be transported, or enter in fusion again. Defective 
mitochondrion accumulates PINK1 kinase (PTEN-induced putative kinase 1), recruiting the E3 ubiquitin ligase 
parkin, which ubiquitylates mitochondrial proteins and triggers mitophagy (adapted from (8)). 
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 Besides, mitochondrial fusion/fission activity is also integrated with mitochondrial 
quality control pathways that detect and respond to cellular and mitochondrial dysfunction, 
which leads to mitophagy (Fig 3).  
 
(i) Mitochondrial fission 
 
 Mitochondrial division involves dynamin-related GTPases such as fission protein 1 
(FIS1) and dynamin-related protein 1 (DRP1), two proteins that are conserved through 
evolution (Fig. 4). The activity of DRP1 is highly regulated by post-translational modifications. 
The inactive form of DRP1 is dispersed in the cytosol and the activation by 
dephosphorylation is required to target mitochondrial membrane (9). FIS1 was proposed to 
be a DRP1 receptor located at the outer mitochondrial membrane but the exact mechanism 
remains unresolved (8). FIS1 fixes DRP1 that wraps around the mitochondrial surface, 
assembles on the outer membrane in multimeric ringlike structures to facilitate scission of the 
double membrane. This process requires the hydrolysis of GTP. Mutations in genes coding 
for DRP1 and FIS1 result in aberrant mitochondria morphology (hyperfused network), 
heterogeneous population of mitochondria with non-uniform mtDNA distribution, varied ability 
to produce ATP, increased capacity to generate reactive oxygen species and increased 
susceptibility of cells to undergo apoptosis (10). 
 
(ii) Mitochondrial fusion 
 
 Fusion events are a two step process and also require the action of two evolutionarily 
distinct dynamin-related GTPases (Fig. 4). The fusion of mitochondrial outer membranes is 
controlled by mitofusin 1 and 2 (MFN1/2), whereas optic atrophy 1 (OPA1) controls inner 
membrane fusion (9; 4). The mechanisms underlying fusion machinery is still poorly 
understood. However, mitochondrial fusion is essential to maintain a homogenous 
mitochondrial population and ensures inter-complementation of mtDNA (5). Mutations in 
MFN2 or OPA1 cause the autosomal dominant peripheral neuropathy, Charcot Marie-Tooth 
disease 2A, and autosomal dominant optic atrophy respectively, and result in an extensive 
fragmentation of the mitochondrial network (10). 
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Fig.4: Schematic mechanisms of mitochondrial fission and fusion. The localization, as well as some interactions 
and modifications of the principal proteins involved in the two processes are shown. Once dephosphorylated, 
DRP1 is recruited to the outer membrane by FIS1. The oligomerization of DRP1 is followed by constriction of the 
membrane and mitochondrial fission. The pro-fusion proteins (MFNs on the outer membrane and OPA1 on the 
inner membrane) oligomerize to induce fusion of the membranes (adapted from (9)). 
INTRODUCTION  Mitochondria 
15 
 
 
(iii) Mitophagy 
 
 Fusion/fission activity is also important for the removal of aged or damaged 
mitochondria through a specific form of autophagy, termed mitophagy (11). The exact 
mechanism underlying mitophagy, more specifically what triggers mitophagy, remains to be 
elucidated. In healthy conditions, mitochondria generate an electrochemical gradient, which 
powers the oxidative phosphorylation (OXPHOS) system (see section I.A.1.b.). It has been 
proposed that damages can lead to a loss of mitochondrial membrane potential. Uncoupled 
mitochondria accumulate the protein PTEN-induced putative kinase 1 (PINK1) at the surface 
of the mitochondrial outer membrane (11; 12) recruiting the E3 ubiquitin ligase parkin 
specifically to the damaged mitochondrion (Fig.3). Then, parkin ubiquitylates mitochondrial 
proteins leading to the formation of an autophagosomes and the digestion of the 
mitochondrion. This process mediates mitochondrial quality control. 
 
b) Orchestrating cellular energy production 
 
 ATP molecules are the universal fuel of living cells. These molecules are composed 
of an adenosine (nitrogen base), a ribose sugar, and three phosphate groups (Fig. 5). 
Breaking the bond between the second and third phosphates, which is a high-energy bond, 
will release the energy necessary for numberless cellular processes, including the synthesis 
of macromolecules (DNA, RNA, proteins…), transport of macromolecules (e. g. endocytosis 
and exocytosis), intra/extracellular cell signaling or locomotion (muscle contraction). In 
eukaryotic cells, ATP is mainly produced via two pathways: the glycolysis and the oxidative 
phosphorylation. 
 
 
 
Fig.5: A molecule of ATP (http://www.nature.com/scitable/topicpage/cell-energy-and-cell-functions-14024533). 
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(i) Cellular glycolysis
 
 Glycolysis is the first energy pathway which consists of converting molecules of 
glucose (coming from nutritional sources) into two molecules of pyruvates (Fig. 6). This 
requires a series of ten chemical reactions giving a net gain of two ATP molecules. Two 
NADH (nicotine adenine dinucleotide) molecules are also produced and serve as electron 
carriers for other biochemical reactions in the cell (13). Next, pyruvate enters in mitochondria 
and is converted into acetyl-CoA, a two-carbon energy carrier, that reaches the Krebs cycle, 
also known as the tricarboxylic acid cycle (TCA cycle), taking place within the mitochondrial 
matrix.  
 
Fig. 6: Cellular glycolysis. The glycolysis involves a series of enzymatic reactions (from 1 – 10) that consume two 
ATP molecules, produce 4 ATP molecules (net gain= 2 ATP) and two molecules of NADH. Molecules of pyruvate, 
end product of glycolysis, reach the Krebs cycle within mitochondria.  
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(i) Mitochondrial respiration  
 
 The enzymatic reaction involved in the Krebs cycle aims to convert: i) three NAD+ 
(nicotine adenine dinucleotide) into three reduced equivalent molecules (NADH); ii) one 
molecule of FAD+ (flavin adenine dinucleotide) into one equivalent of FADH2; iii) one 
molecule of GDP (guanosine diphosphate) into one molecule of GTP (guanosine 
triphosphate) (Fig. 7). The NADH and FADH2 generated by the Krebs cycle will be used by 
the oxidative phosphorylation (OXPHOS) pathway to generate ATP. 
 
 
 The second main pathway for the synthesis of ATP is the mitochondrial respiration, a 
process usually called oxidative phosphorylation (OXPHOS) (8; 3). Here, the electrons, 
carried by the electron donors NADH and FADH2, are used to generate a difference of 
potential across the inner mitochondrial membrane, by pumping protons from the matrix to 
the intermembrane space. The gradient of protons, which is generated during electron 
transfer, is ultimately used to power the synthesis of three additional ATP molecules for 
every electron that travels along the chain. 
 
  The transfer of electrons is carried out by four multisubunit protein complexes 
(encoded by mitochondrial or nuclear DNA) embedded in the inner mitochondrial membrane 
and known as the electron transport chain (ETC) (Fig. 7). First, NADH donates two electrons 
to the largest of the respiratory complexes, NADH dehydrogenase or complex I. These 
electrons are then passed to coenzyme Q (UQ), a lipid soluble redox carrier. The reaction is 
accompanied by the transfer of four protons from the matrix to the intermembrane space. In 
parallel, complex II, or succinate dehydrogenase that is also part of the Krebs cycle, 
catalyzes the reduction of FAD to FADH2, giving additional electrons into the quinone pool 
(UQ). Unlike complex I, no protons are pumped from the matrix by complex II that is also the 
only complex composed of proteins exclusively encoded by nuclear DNA. 
 Next, the reduced coenzyme Q freely diffuses through the inner membrane and gives 
its electrons to the complex III or ubiquinol cytochrome c oxidoreductase. The enzyme 
oxidizes coenzyme Q and transfers the liberated electrons to two molecules of another 
soluble redox protein, cytochrome c. The reaction is coupled by the translocation of four 
protons toward the intermembrane space. Finally, electrons are removed from cytochrome c 
and transferred to molecular oxygen (O2), producing two molecules of water. Again, four 
protons are pumped from the matrix into the intermembrane space. 
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Fig. 7: Bioenergetic of the electron transport chain and the Krebs cycle. Pyruvate is transferred within 
mitochondria and is converted into acetyl-coA that enters into the Krebs cycle. NADH, FADH2 and GTP molecules 
are generated in each cycle. NADH generated is shuttled to complex I and is converted to NAD+ driving 
OXPHOS. Transfer of electrons through the chain maintains the membrane potential via proton pumping into the 
intermembrane space. In this final step, ADP is phosphorylated to form ATP via complex V (ATP synthase).The 
number of subunits encoded either by nuclear or mitochondrial DNA (nDNA/mtDNA respectively) are indicated. 
UQ; coenzyme Q, Cyt c; cytochrome c. (adapted from (8) and (14)). 
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 The enzyme responsible for the OXPHOS final step is ATP synthase (Complex V), 
alternatively named F0F1 ATPase, which consists of two domains: F0, the transmembrane 
component acting as a proton channel that provides a proton flux back into the mitochondrial 
matrix; and F1, the catalytic component that uses the free energy produced during the 
generation of the oxidized forms of the electron carriers (NAD+ and Q) to drive ATP synthesis 
from ADP and inorganic phosphate (Pi). ATP synthase acts as a rotary molecular motor 
powered by the proton gradient and the mitochondrial membrane potential (MMP) generated 
by the ETC, with each turn of the rotor producing three molecules of ATP. Of note, MMP is 
estimated to be about 150–180 mV (negative in the matrix), and is a key parameter 
indicating the bioenergetic competence of mitochondria. The net gain of OXPHOS is about 
30-32 ATP molecules per molecule of glucose. 
 
(ii) Bioenergetic state and mitochondrial shape 
 
 Energy homeostasis requires a constant coordination between cellular energy 
demand (ATP consumption) and energy supply (ATP production). Thus, molecular sensors 
are available in cells, such as kinases and transcription factors, to regulate bioenergetic 
activity in answer to nutrient deprivation or to cellular stress (14). Notably, the alteration in 
the cellular AMP/ATP ratio activates the AMP-activated protein kinase (AMPK) which triggers 
an intracellular cascade of phosphorylation to activate glycolysis and OXPHOS (15). As 
mentioned in section I.A.1.a, mitochondria are dynamic organelles that cyclically shift 
between tubular and fragmented states. Increasing evidences suggest that alterations in 
energy production, notably in pathological conditions such as in AD (see section I.A.2), are 
paralleled by a disturbed mitochondrial dynamics (16-19). The causal relationship between 
both is not clear. For instance, studies showed that ATP levels and OXPHOS activity are 
affected by mitochondrial dynamics, with a decreased respiration and ATP production when 
mitochondria are in a fragmented state (20). On one hand, evidences suggested that 
mitochondrial dynamics can control energy metabolism, since a down regulation of OPA1 
and Mfn1 (involved in mitochondrial fusion) led to a decrease in OXPHOS and glucose 
utilization (20). On the other hand, studies showed that the collapse of MMP leads to 
fragmentation of the mitochondria and inhibits the fusion activity (21; 22). 
 Understanding the link between mitochondrial shape and function is a recent 
research field that aims to increase our knowledge about the underlying mechanism involved 
in the regulation of bioenergetics (see section II.C) and may offer opportunities to discover 
new drugs that target mitochondrial fusion or fission with a stimulatory effect on energy 
metabolism (14). 
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c) Mitochondrial: paradoxical organelles 
 
 As described above, mitochondria are the “powerhouses of cells”, providing energy 
via ATP generation. However, when mitochondria fulfill their physiological functions, they can 
also be compared to a double-edged sword that, on one hand, produces the energy 
necessary for cell survival, and on the other hand, induces the formation of reactive oxygen 
species (ROS) that can be harmful for cells when produced in excess with mitochondria as 
the first target of toxicity. 
 
(i) Mitochondria: source and target of reactive oxygen and nitrogen 
species 
 
 The production of ATP molecules by mitochondria requires about 85% of O2 used by 
cells. The fate of most electrons from NADH or FADH2 driven in the respiratory chain is the 
reduction of O2 into H2O by the mitochondrial complex IV. However, an inevitable by-product 
of ETC activity is the formation of superoxide anion radicals (O2˙
-), mostly by complexes I 
and III (Fig. 8). Indeed, a small portion of electrons (up to 2%), escaping from ETC, can react 
with O2 to form O2˙
- that can be converted into other ROS such as hydrogen peroxide (H2O2) 
and the highly reactive hydroxyl radical (OH˙) through enzymatic and non-enzymatic 
reactions (23-25). 
  The exact mechanisms underlying mitochondrial ROS production requires further 
clarification to identify the precise site of O2˙
- generation. Thus, O2˙
- production by the 
mitochondrial complex I is still discussed. It was suggested that O2˙
- was generated by 
reverse electron transfer in the absence of NAD+-linked substrates (in hypoxic conditions) 
(25; 26). The contribution of complex III in ROS-forming mechanisms is more understood 
and involves the autooxidation of ubisemiquinone anion radicals (UQ˙-). Indeed, UQ˙- can 
react with the O2 dissolved in the IMM, yielding to O2˙
- formation, especially when the MMP is 
high (25; 27; 26). Besides the ETC, ROS can be produced by the Krebs cycle enzyme α-
KGDH (α-ketoglutarate dehydrogenase) and by monoamine oxidases (MAO) located at the 
OMM (23). Nitric oxide (•NO) is another diffusible free radical that is synthesized by three 
main isoforms of the nitric oxide synthase (NOS) (Fig. 8). •NO can combine with O2˙
- to form 
reactive nitrogen species (RNS) peroxynitrite (OONO−) which can further react to yield 
hydroxyl radical •OH (25). 
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Fig.8: Pathways of reactive oxygen species (ROS) formation and detoxification. Superoxide anion radicals (O2˙
-) 
are generated by complexes I and III during electron transfer through ETC. O2˙
- can interact with •NO, produced 
by nitric oxide synthase (NOS), to generate peroxynitrite (ONOO-) or can also react to form •OH (hydroxyl 
radical). Detoxification involves the enzymatic activity of mitochondrial manganese superoxide dismutase (SOD) 
that converts O2˙
- to H2O2 (hydrogen peroxide) and may diffuse to the cytoplasmic compartment where glutathione 
peroxidase (GPX) and catalase convert H2O2 to H2O. Of note, •NO and its derivate (reactive nitrogen species or 
RNS) belong also to the group of ROS. eNOS/iNOS/nNOS; endothelial/inducible/neuronal nitric oxide synthase, 
GSH/GSSG; reduced/oxidized glutathione, GPX; glutathione peroxidase, GR; glutathione reductase. 
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 In physiological conditions, ROS can play a role of signaling molecules and are 
involved in processes such as immune response, inflammation, as well as synaptic plasticity, 
learning and memory (28-30). However, when produced in excess, those highly reactive 
species can induce an oxidative stress, damaging proteins and DNA, and inducing lipid 
peroxidation, with the corresponding mitochondrial structures as the first targets of toxicity. 
Especially, long polyunsaturated fatty acid chains of mitochondrial membranes are very 
susceptible to oxidation and may lead to the membrane depolarization and consecutively to 
mitochondrial impairments (31). ONOO− can induce nitration of proteins and impair their 
function (32), and •NO has been shown to inhibit the complex IV activity by competitive 
binding on its oxygen site (33). Furthermore, since mtDNA is localized close to ROS 
production sites, it is directly in contact with those harmful molecules and can exhibit 
oxidative damages. Taken together, oxidative stress, caused by ROS and RNS, can trigger 
cell death and has been implicated in the pathogenesis of many neurodegenerative 
diseases, such as AD. 
 
(ii) Antioxidant defenses: weapons against oxidative stress 
 
 Fortunately, cells are armed against oxidative stress and are endowed with robust 
antioxidant defenses to counteract excessive ROS production. First, O2˙
- can be detoxified by 
manganese superoxide dismutase (MnSOD) in the mitochondrial matrix or copper/zinc 
superoxide dismutase (Cu/Zn SOD) in the IMS and the cytosol, giving hydrogen peroxide 
(H2O2) (25). H2O2 is then detoxified to H2O by catalase or is supported by detoxification 
mechanisms involving glutathione (GSH) system (Fig.8). GSH constitute the most important 
redox buffer and mitochondrial antioxidant, due to its relatively high concentrations and 
inducible metabolism (25; 34). Glutathione peroxidase (GPX) degrades H2O2 and other ROS 
to water by converting GSH to its oxidized form GSSG. This latter is then reduced again to 
GSH by glutathione reductase (GR) using NADPH as a cofactor. The ratio GSH/GSSG is 
often used as a measure of cellular toxicity and regulates overall ROS levels to maintain 
physiological homeostasis (35).  
 However, it can happen that ROS production overwhelms endogenous antioxidant 
systems and can lead to harmful effects on cellular compounds. As mentioned above, 
oxidative stress can lead to a shutdown of energy production (36), possibly leading to a 
decrease of antioxidant defense (e.g. GSH). The enhancement of ROS triggers the “vicious 
cycle” of oxidative stress, mitochondrial dysfunction and apoptosis. Since neurons are post-
mitotic and excitable cells with high energy requirements, they are more sensitive to stress 
(37). Thus, this “vicious cycle” of oxidative stress has been implicated in many 
neurodegenerative diseases, notably AD but also in normal aging (38; 5; 39). However, the 
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exact cause and effect relationship between ROS production and detoxification remains 
unsolved and one can ask the question whether increased ROS production is a primary 
consequence of mitochondrial dysfunction or whether a primary defect in the ROS 
scavenging activity is responsible for an abnormal respiratory function. This ambiguous point 
is particularly challenging in many pathological cases involving mitochondrial dysfunction. 
 
(iii) Mitochondria and cell suicide 
 
 Another paradoxical aspect with regard to mitochondrial function is the role of this 
small organelle in both cell survival and cell death. Indeed, if the mitochondria are 
indispensable for cell survival by providing energy, they are also a starting point leading to 
cell suicide, a mechanism commonly known as apoptosis or programmed cell death. There 
are two main apoptotic pathways: i) the extrinsic pathway triggered by extracellular signals 
acting via plasma membrane receptor (e.g. death receptors, not described here); and ii) the 
intrinsic (or mitochondrial) pathway triggered by intracellular stimuli such as Ca2+ overload 
and over-generation of ROS (37). Mitochondria are central components of the apoptotic 
death machinery, integrating death signals through Bcl-2 family members and coordinating 
caspase activation through the release of cytochrome c (Cyt c). 
 Once the lethal signals are detected, mitochondrial permeability transition pores 
(mPTP) are opened and mitochondrial membranes become permeable (Fig. 9). This opening 
disrupts mitochondrial function and apoptotic signals are released from IMS into the cytosol, 
namely Cyt c and apoptosis-inducing factor (AIF) (40) that are regulated by pro- (bax, bak, 
bad, bim, bid) and anti-apoptotic proteins (bcl-2 and bcl-xl) of the Bcl-family (41). Here, Cyt c 
binds to Apaf-1 (apoptotic protease activating factor 1) which recruits procaspase 9 in the 
presence of deoxyadenosine triphosphate (dATP) to form the apoptosome. This results in 
the sequential activation of caspase 9 which in turn activates other caspases, such as 
caspase 3, that are in charge of the cell’s execution (42; 37).  
 In summary, mitochondria are paramount for proper cell function, especially in 
neurons that are postmitotic, excitable cells with high energy requirements. Thus, impaired 
mitochondrial function ineluctably leads to cell death and is involved in pathophysiological 
mechanisms of neurodegenerative diseases, including Alzheimer’s disease (AD). 
 
 
 
 
 
 
INTRODUCTION  Mitochondria 
24 
 
 
 
 
 
Fig.9: Simplified mitochondrial pathways of apoptosis. Apoptosis can result from the activation of two biochemical 
cascades, which are known as the extrinsic and the intrinsic (or mitochondrial, detailed here) pathways. The 
release of cytochrome c (Cyt c) from the intermembrane space (IMS) triggers the caspase cascade (see details in 
the text) yielding to the cell death by apoptosis. MMP; mitochondrial membrane potential, mPTP; mitochondrial 
permeability transition pore (adapted from (37)). 
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2. Mitochondrial dysfunction in Alzheimer’s disease 
 
 AD is an age-related neurodegenerative disorder that currently affects about 2% of 
the population in industrialized countries and accounts for more than 60% of all dementia 
cases (43). The disease is marked by a progressive physical and cognitive decline due to a 
reduced size of brain regions involved in learning and memory, such as temporal/frontal 
lobes and hippocampus, as the result of neuronal death and synaptic degenerations 
(Fig.10). In addition, positron emission tomography (Pet) studies performed in AD patients 
revealed a large hypometabolism and decrease of glucose uptake in the frontal cortex and 
temporal lobes, which correlates with the neuronal loss observed in these regions (44; 45). 
 
 
 
 
Fig. 10: AD results in shrinkage of brain regions involved in learning and memory. Positron emission tomography 
(Pet) images show glucose uptake (red and yellow=high levels of uptake) in a healthy person (top) and an AD 
patient (bottom). The AD patient exhibits a drop in energy metabolism in the frontal cortex and the temporal lobes 
(adapted from http://www.google.fr/images/Alzheimerdisease and (44)). 
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 This neuropathology will become increasingly burdensome and costly in the coming 
years as AD prevalence is expected to double within the next two decades (43). A post-
mortem examination is required to clearly diagnose AD with the detection of “plaques” 
(amyloid-β (Aβ) deposits) and “neurofibrillary tangles” (NFT, aggregated tau protein) in the 
brain parenchyma, especially in the entorhinal cortex, hippocampus, basal forebrain and 
amygdala, that are regions involved in learning and memory processes (44). 
 
a) Clinical symptoms and etiological factors 
 
 AD is a progressive neurodegenerative disease that usually begins in late life (onset ± 
65 years old) and is first marked by episodic memory deficits with preserved alertness and 
motor functions (46). Over time, progressive deterioration of other cognitive abilities appears, 
leading to profound impairments in language, abstraction and orientation. In addition, other 
neuropsychiatric symptoms can be detected such as mood disturbances, delusions and 
hallucinations, personality changes and behavior disorders (aggressiveness, depression, 
circadian disturbances) but may vary from one patient to another (46; 47). On average, death 
occurs a mere seven years following diagnosis, typically from medical complications 
(bronchitis or pneumonia) (43). Until now, there are no treatments to cure, prevent or slow 
the disease (47). 
 The complete etiological picture of AD remains unknown. However, the disease can 
be classified into two different forms: i) The sporadic AD (SAD) which represents the vast 
majority of AD case with an onset occurring at an age over 60 years; ii) The rare familial 
forms (FAD) which represent less than 1% of the total number of AD case and are 
characterized by an early disease onset at an age younger than 60 years (48; 49). Both 
forms of AD show the same clinical symptoms and neuropathology, as memory loss, amyloid 
deposits in the brain and neurofibrillary tangles. However, FAD is marked by a more rapid 
disease progression and can be transmitted to offspring in a Mendelian manner (50). 
  Genetic studies in FAD patients have identified autosomal dominant mutations in 
three different genes: the amyloid precursor protein (APP, more than 20 pathogenic 
mutations identified) and the presenilins 1 and 2 (PS1 and PS2, over 130 mutations 
identified) (51; 50). These genes are directly linked to the accumulation of Aβ deposits in the 
brain due to the increased production of Aβ peptide from its precursor protein APP (Fig. 
11A).  
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Fig.11: Mutations in APP and tau associated with FAD and frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) respectively. (A) Part of the APP amino-acid sequence where mutations associated 
with early-onset Alzheimer’s disease have been highlighted. Most mutations are clustered in the close vicinity of 
secretase-cleavage sites, thereby influencing APP processing, and are named after the nationality or location of 
the first family in which that specific mutation was demonstrated. (B) Mutations in the tau gene in frontotemporal 
dementia and parkinsonism linked to chromosome 17 (FTDP-17). Schematic diagram of the longest tau isoform 
(441 amino acids) with mutations in the coding region. Twenty missense mutations, two deletion mutations and 
three silent mutations are shown (adapted from (50) and (52)). 
 
 Surprisingly, no mutations in microtubules associated protein tau (MAPT), the protein 
responsible for NFT formation, has been so far detected in FAD. However, such mutations 
have been identified in familial frontotemporal dementia with Parkinsonism linked to 
chromosome 17 (FTDP-17) (52) (Fig. 11B) and lead to NFT formation. The identification of 
these genes enabled, among others, the generation of simple, double and even triple 
transgenic animal models bearing these mutations. Transgenic models have now become 
the most used tools to study AD pathogenic mechanism in vivo (51). 
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 Regarding SAD cases, no clear etiological factors have been established until now. 
The main risk factor remains age since the incidence rate for AD increases exponentially 
after 60 years, especially during the 7th and 8th decades of life (48). Epidemiological studies 
revealed that two thirds of AD patients are women and the sudden drop in estrogen levels 
after the menopause has been proposed to be one risk factor in AD (53; 54) (see section 
I.B.4). Susceptibility genes have also been identified, in particular gene coding for the E4 
isoform of apolipoprotein E (apoE4). Evidences showed that ApoE4 reduces Aβ clearance 
and increase Aβ aggregation, and individuals producing this isoform have an increased risk 
to develop AD (44; 48). Besides, the recent development of powerful and sophisticated 
genotyping approaches used in genome-wide association studies (GWAS) enabled to 
highlight others genes of “susceptibility” belonging to four main pathways: immune response, 
APP processing, lipid metabolism and endocytosis (reviewed in (48)). 
 Epidemiological findings include other risk factors such as behavioral (sedentary 
lifestyle), diets (high-calories, high-fat diets) and diverse environmental factors (low 
education level, history of head trauma). However, despite accumulating data, clear 
causative factors of AD have not been established. 
 
b) Histopathological hallmarks 
 
 The two key histopathological features of AD (amyloid deposits and neurofibrillary 
tangles) were already described in 1907 by Alois Alzheimer after post-mortem examination of 
the brain of a 51-year-old woman (Auguste D) who initially was diagnosed to suffer from a 
delusional disorder followed by a rapid loss of short term memory (55). Today, we know that 
those extracellular plaques are composed of the amyloid-beta (Aβ) peptide and the tangles 
(or intracellular neurofibrillary tangles, NFT) are formed by the aggregation of 
hyperphosphorylated tau, a microtubule-associated protein. These two histopathological 
hallmarks are frequently coupled with additional pathological changes including reactive 
microgliosis and, as mentioned above, neuronal loss and synaptic degeneration (47). 
 
(i) Neurofibrillary tangles and hyperphosphorylated tau 
 
 Tau belongs to the family of microtubule-associated proteins (MAP) that stabilizes 
microtubule function and assembly, and maintains appropriate functions of motor proteins 
within cells (56). Tau, which is expressed in most neurons, is mainly concentrated in axons 
and almost totally absent in dendrites (57). Since microtubules are important structures for 
axonal transport, cell polarity and shape, alterations in tau may seriously impair normal 
cellular physiology. AD and other tauopathies, like the FTDP-17, are similarly characterized 
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by an aberrant intracellular accumulation of tau within neurons, which results in tau 
hyperphosphorylation and its assembly into abnormal filaments (Fig.12) (52; 51).  
 
 
Fig.12: Hyperphosphorylated tau and neurofibrillary tangles (NFT). (A) Tau stabilizes microtubules that are 
essential for the trafficking of cellular cargo along the axons of neurons. (B) In AD, tau is abnormally 
hyperphosphorylated, which reduces its binding on microtubules and leads to tau sequestration into NFT. The 
loss of tau binding induces microtubules instability, reduces axonal transport and contributes to synaptic 
degeneration (adapted from (60)).  
 
 
 The causes of tau aggregation in AD are not fully understood and no tau mutation has 
been found in FAD. Since tau is a phosphoprotein containing 5 tyrosine residues and 80 
serine/threonine residues, it can be potentially phosphorylated by many kinases, including 
glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (cdk5), extracellular 
signal-regulated kinase 2 (ERK2), protein kinase A and C, calcium-calmodulin dependent 
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protein kinase II (CaMKII), and mitogen-associated protein affinity-regulating kinases 
(MARK) (58). Studies have shown that tau is three to four times more phosphorylated in AD 
brain than in normal brain, especially at the microtubules binding site (59; 58). This induces 
conformational changes which result in the detachment of tau from microtubules, causing 
them to depolymerize, as well as tau aggregation in NFT (Fig.12). This histopathological 
hallmark of AD generates problems with synaptic integration that inexorably leads to 
neurodegeneration (60; 61). 
 
(ii) Amyloidogenic pathway and Aβ deposits 
 
 Although the causative factors of AD remain unknown, the leading hypothesis is still 
that Aβ accumulation, a product of amyloid precursor protein (APP) processing, is an 
underlying pathological component of the disease. The discovery of mutations in genes that 
code for APP, PS1 or PS2 and responsible for FAD cases, have led Hardy and Higgins to 
propose the “Amyloid cascade hypothesis” in 1992 (62). This hypothesis posits that Aβ 
deposition is the causative agent of AD pathology and the direct results of this deposition are 
the formation of NFT, neuronal dysfunction and death, leading to dementia (62; 63). APP is a 
type 1 integral glycoprotein (110-130 kDa) that is ubiquitously expressed in human tissues 
(64; 65). The physiological functions of APP remain unclear but previous studies highlighted 
its role in cell adhesion, synaptic plasticity, regulation of neuronal survival and neuritis 
outgrowth (reviewed in (66)). APP is located at the plasma membrane (or the luminal side of 
the endoplasmic reticulum (ER) and Golgi apparatus) and contains a 40 or 42 amino acid 
sequence, respectively, called Aβ40 and Aβ42 (67). APP undergoes two proteolysis pathways 
by secretases: a non-amyloidogenic pathway and an amyloidogenic pathway (Fig. 13A). In 
the first one (non-amyloidogenic), APP is cleaved by the α-secretase, an enzyme that 
belongs to the ADAM family (a disintegrin and metalloproteinase family enzymes), which 
produces the α-APPs and the membrane-anchored C83 fragments (65). The latter is 
subsequently catalyzed by γ-secretase (for which presenilin 1 and 2 (PS1 and PS2) act as 
catalytic subunits) to form the nontoxic or neurotrophic products, the APP intracellular 
domain (AICD) and P3 fragment (Fig. 13A). 
 In the amyloidogenic pathway, APP is first cleaved by β-secretase (mostly β-site of 
APP cleaving enzyme or BACE) that cut APP at the N-terminus to form β-APPs and C99 
fragments. The latter is subsequently cleaved by γ-secretase producing Aβ and AICD. Of 
note, the released Aβ can vary in length, depending on the site of cleavage, of those Aβ42 
that is more hydrophobic and has a higher propensity to form fibril aggregates found in the 
brain of AD patients, whereas Aβ40 is more common but less fibrillogenic (Fig. 13B) (65; 50). 
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Fig. 13: APP processing and Aβ assembly stages. (A) APP is cleaved by α-, β- and γ-secretase to produce 
various APP products, including Aβ peptide (see details in the text). (B) Aβ peptide exists in multiple assembly 
states, including monomers, oligomers, protofibrils and fibrils which can accumulate in amyloid plaques in the 
brain of AD patients (adapted from (65)).  
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 Aβ is produced as a monomer and does not appear to be toxic under this form (65). 
Nevertheless, Aβ readily aggregates to form oligomers, protofibrils and fibrils, and the 
oligomeric species of Aβ have been found to be the earliest pathological and toxic form, 
inducing oxidative stress, disrupting Ca2+ homeostasis, impairing synaptic plasticity and 
leading to neuronal death (Fig.14) (65; 44). However, the “Amyloid cascade hypothesis” has 
more recently been challenged by the “Alzheimer mitochondrial cascade hypothesis”, which 
place mitochondria in the center of the pathophysiological events taking place in AD.  
 
 
 
 
Fig.14: Toxic effects of Aβ in neurons. Aβ peptide-induced oxidative stress leads to lipid peroxidation (at the 
plasma and mitochondrial membranes) and to oxidation of proteins including membrane transporters, receptors 
(GTP-binding proteins…) or ion channels (voltage-dependent chloride channel, N-methyl-D-aspartate receptor). 
Aβ can also alter calcium homeostasis and impair endoplasmic reticulum (ER) and mitochondrial functions, 
leading to an increased ROS production, decreased ATP production and, finally, cell death (adapted from (44)). 
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c) Mitochondria: a common target of Aβ and tau 
 
 There is increasing evidence supporting that mitochondrial dysfunction is a prominent 
and early event of AD, since energy deficiency is a fundamental characteristic of AD brains 
(68) as well as of peripheral cells derived from AD patients (69). Indeed, brain glucose 
hypometabolism has been observed in living AD patients even before the onset of clinical 
symptoms (70). This characteristic is also observed in AD mouse models in which 
mitochondrial dysfunctions can be detected before the appearance of Aβ deposits, NFT and 
cognitive impairments (reviewed in (71), see APPENDIX 1). In addition, a decreased activity 
of enzymes involved in glycolysis, Krebs cycle and ETC, such as α-ketoglutarate 
dehydrogenase(α-KGDH), pyruvate dehydrogenase (PDH), and cytochrome c oxidase (COX, 
complex IV) (72; 73; 69), have been reported in AD post-mortem brains as well as in 
platelets and fibroblasts coming from AD patients. In parallel, post-mortem tissues revealed 
an increased level of protein oxidation/nitration and lipid peroxidation in brain areas 
containing Aβ deposits and NFT (74). Taken together, these data support the hypothesis that 
mitochondrial dysfunction is a highly relevant event in AD and has been proposed as a 
possible link between Aβ and tau pathology. 
 
(i) Aβ toxicity and mitochondria 
 
 Aβ peptide has been shown to interact with mitochondria in numerous ways (Fig. 15) 
(67). Evidence demonstrated that APP harbors a mitochondrial targeting signal and, 
specifically in human AD brain, accumulates in the protein import channels of mitochondria 
and may interact with translocases of the outer and inner mitochondrial membranes (TOM 
and TIM respectively) (75). Additional findings using cellular models overexpressing APP 
showed the presence of this protein in mitochondria, which led to the hypothesis that Aβ 
peptide may be produced within this organelle and contribute to mitochondrial dysfunction 
(76; 77). In agreement, studies performed in AD patients and animal models of AD showed 
an accumulation of Aβ in mitochondria, a phenomenon occurring early in the disease 
development, well before the formation of plaques (78-80). Within mitochondria, Aβ may 
directly interact with proteins, such as cyclophilin D (Cyp D) which is involved in the 
mitochondrial permeability transition pore (mPTP) and potentiate free radical production, or 
can directly bind the Aβ-binding alcohol dehydrogenase (ABAD), a protein up-regulated in 
the brain of AD patients and involved in mitochondrial estradiol metabolism (see section 
I.B.4.b ).  
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 Metabolic effects of Aβ and its precursor APP in cellular models of AD are in 
agreement with observations made in postmortem brains of AD patients. Indeed, studies 
performed on mice, PC12 cells, or human SH-SY5Y neuroblastoma cells overexpressing 
APP indicated a decrease in ATP production, an impaired MMP, as well as a decrease in 
mitochondrial complex IV activity, paralleled by an increase in ROS levels (76; 81; 82; 19). 
Of note, in the presence of a γ-secretase inhibitor that prevent Aβ production, ATP and ROS 
levels were normalized, indicating that Aβ is directly involved in these mechanisms (76). In a 
recent study, quantitative iTRAQ proteomics was used to quantify the amount of protein 
deregulated after the treatment of native SH-SY5Y cells with Aβ42 (0.5 μM, 5 days). Data 
showed that 69 proteins were deregulated by Aβ42, and more than 25% of those proteins 
were involved in mitochondrial function and energy metabolism, again supporting the notion 
that mitochondrial dysfunction is a target of Aβ toxicity (83). This assumption was confirmed 
by in vivo data coming from studies performed on various transgenic mouse models. Indeed, 
mitochondrial dysfunction was detected early in the disease progression in simple transgenic 
mice bearing a mutation in APP or in double transgenic mice bearing mutations in APP and 
PS1 or APP and PS2. These mice presented a decrease in ATP level, decreased MMP, 
decrease complex IV activity, decreased mitochondrial respiration and increased oxidative 
stress in their brains (84-89). Of note, mitochondrial deficits were paralleled by soluble Aβ 
accumulation and were already detected before the presence of Aβ deposits and cognitive 
impairments (reviewed in (71)). 
 
 Finally, in addition to its metabolic impact, Aβ seems also to impair mitochondrial 
dynamics. For instance, in APP overexpressing cells, mitochondria appeared to be highly 
fragmented and abnormally distributed within cells compared to control cells (19). 
Quantification of proteins involved in fusion/fission activity revealed that DRP1 and OPA1 
were reduced, whereas FIS1 was significantly increased in APP cells (17-19). The disturbed 
fusion/fission activity observed in cells overexpressing APP leads mitochondria to a 
fragmented state that might, vice versa, have an effect on bioenergetic functions of these 
organelles. 
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Fig.15: Pathogenic convergence of Aβ and hyperphosphorylated tau on mitochondria. Aβ and tau are able to 
impair mitochondrial respiration by inhibiting the ETC (more precisely, complex IV and complex I respectively) 
inducing a decrease in oxygen consumption, ATP production and an increase in ROS level. This oxidative stress 
induced by ETC dysfunction can surpass cellular and mitochondrial scavenger (MnSOD, Cu/ ZnSOD) and 
impacts on MMP as well as mitochondrial DNA (mtDNA). Within mitochondria, Aβ can bind ABAD and CypD, 
leading to an enhanced ROS production and the opening of the mitochondrial permeability transition pore 
(mPTP). In parallel, Aβ can also be responsible of metabolic impairments, by inhibiting enzymes involved in 
glycolysis and the Krebs cycle, as well as the calcium-induced excitotoxicity in neurons. Finally, Aβ and tau can 
disturb mitochondrial fusion/fission activity, leading to abnormal mitochondrial network. CI complex I, CII complex 
II, CIII complex III, CIV complex IV, CV complex V, cyt c cytochrome c, Cu/Zn SOD copper/zinc superoxide 
dismutase, MnSOD manganese superoxide dismutase, ROS reactive oxygen species, mtDNA mitochondrial 
DNA, ΔΨ mitochondrial membrane potential, TOM/TIM translocases of the outer/inner mitochondrial membranes, 
ABAD Aβ-binding alcohol dehydrogenase, FIS, fission protein 1, CypD cyclophilin D (adapted from (67) and  
(90)). 
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(ii) Role of hyperphosphorylated tau in mitochondrial dysfunction 
 
 As mentioned above (section I.A.2.b), when tau is abnormally hyperphosphorylated, 
the binding of tau on microtubules is reduced which leads to microtubule dissociation and 
impairs the transport of distinct cargoes along the axons, including mitochondria. Indeed, 
animal studies using transgenic mice overexpressing mutant tau protein revealed an 
impaired anterograde mitochondrial transport, reducing the number of mitochondria at the 
synapse (reviewed in (59), see APPENDIX 2). In consequence, energy deprivation was 
observed at the synapse, which led to synaptic degeneration and neuronal death (91). 
Proteomic studies analyzing the brain proteins of mutant tau transgenic mice (P301L tau 
mice) showed a deregulation of metabolism-related proteins, mainly components of 
mitochondrial respiratory chain complexes (including complex V), antioxidant enzymes and 
synaptic proteins (92). Of note, a decrease in complex V levels was also observed in the 
brain of FTDP-17 patients (92). Moreover, functional analysis performed on P301L tau mice 
showed that these animals presented an age-related mitochondrial dysfunction with a 
decrease of complex I activity, a decrease in mitochondrial respiration and ATP levels, and 
an increase of ROS production (92; 89). More recently, studies using human-derived 
neuroblastoma cells (SH-SY5Y) overexpressing either the wild type tau (wtTau) or P301L 
mutant tau showed that mutant cells had a decrease in ATP levels and an increased 
vulnerability to oxidative stress (16). In addition, compared to wtTau cells, P301L-transfected 
cells displayed smaller mitochondria with globular cristae and extensive branching of cristae 
membranes, and an impaired mitochondrial motility together with a down-regulation of both 
mitochondrial fusion and fission (16). Morphological signs were consistent with reductions in 
ATP turnover in mutant cells. Little is known about the role of tau in the impairment of 
mitochondrial dynamics. However, further evidences coming from animal studies, showed 
that the overexpression of human tau induced mitochondrial elongation in both Drosophila 
and mouse neurons (93). In this study, the authors shed new lights on tau’s role in 
mitochondrial dynamics and hypothesized that disruption of mitochondrial dynamics could be 
a direct mechanism of tau toxicity in neurons in vivo. However, since AD is marked by both 
Aβ and tau pathologies, both molecules have to be taken into account to dissect the 
underlying mechanisms of mitochondria dysfunction. 
 
(iii) Pathogenic convergence of Aβ and tau on mitochondria 
 
 Recent evidences suggest that Aβ peptide and abnormally hyperphosphorylated tau 
protein may act synergistically to trigger mitochondrial dysfunction in AD (73; 94; 71). Firstly, 
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in vivo studies revealed that injection of Aβ42 fibrils in the brain of mutant tau transgenic mice 
(P301L mice) led to a 5-fold increase in NFT pathology (95). These results were confirmed 
by in vitro studies which showed that mitochondria coming from P301L mouse brains 
displayed an enhanced vulnerability in the presence of Aβ42 compared to wild-type control 
brains (84; 85). Indeed, isolated mitochondria from P301L mice showed a decreased MMP 
and an impaired OXPHOS activity in the presence of oligomeric or fibrillar Aβ. Of note, the 
oligomeric Aβ was more toxic than the fibrillar Aβ, suggesting that they both exert different 
degrees of toxicity.  
 Secondly, crossing APP mice with mutant tau mice enabled to understand more 
precisely AD-related neurodegenerative mechanisms mediated by Aβ and tau. Indeed, 
APPxTau double transgenic mice exhibited NFT pathology in spinal cord and pons already at 
3 months of age, compared to 6 months of age in simple tau transgenic mice (96; 97). Aβ 
plaques were also detected earlier (6 months of age compared to 12 months in APP 
transgenic mice), suggesting the existence of interplays between the two key proteins (86; 
97). Together, these findings indicated that Aβ pathology may triggers, or at least aggravates 
tau pathology. 
 Other studies investigated more precisely mitochondrial deficits in mouse models with 
deficiencies in both Aβ and tau proteins. In a triple transgenic mouse model of AD (tripleAD, 
APPxPS2xP301L), proteomic mass spectrometry analysis revealed that more than a third of 
dysfunctional proteins were mitochondrial proteins with major deficiencies found in subunits 
of complex I and IV of the ETC (89). The investigation of OXPHOS function revealed that 
deregulation of complex I activity was related to tau, whereas deregulation of complex IV 
activity was dependent of Aβ. Interestingly, a decrease in MMP was already detected at 8 
months of age in tripleAD mice compared to 12 months of age in theirs double transgenic 
littermates (APPxPS2). Moreover tripleAD mice exhibited stronger defects on OXPHOS, 
synthesis of ATP, and reactive oxygen species, emphasizing synergistic, age-associated 
effects of Aβ and tau upon mitochondria ((89) and see also APPENDIX 3). Of note, as in 
tripleAD mice, mitochondrial dysfunction preceded AD symptoms in another triple transgenic 
mouse model (3xTgAD), and impairments were further associated with higher ROS levels in 
aged transgenic mice (98). Together, these findings highlighted the key role of mitochondria 
in AD pathogenesis and consolidate the notion that a synergistic effect of tau and Aβ 
enhances the pathological mitochondria dysfunction at an early stage of AD. 
 
(iv) Alzheimer mitochondrial cascade hypothesis 
 
 Placing mitochondria in the center of the degenerative processes is the basis of the 
“Alzheimer mitochondrial cascade hypothesis”. This hypothesis was first stated in 2004 by 
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Swerdlow and colleagues (99), and postulated that mitochondrial function may affect APP 
expression and processing as well as Aβ accumulation which triggers the amyloid cascade. 
In fact, the amyloid cascade hypothesis has been postulated with regard to FAD cases with 
mutations in APP or PS1/PS2 genes that represent less than 1% of total AD patients and 
cannot explain the etiology of sporadic AD (SAD) cases. As mentioned in section I.A.2.a, 
aging is the first “risk factor” of SAD. The role of mitochondria in aging has been widely 
investigated for decades (100; 101; 36) and a growing body of evidence championed the 
idea that somatic mtDNA mutations, accumulating over a person’s lifespan, may influence 
aging and may cause neurodegeneration, such as in AD (reviewed in (102)). In this way, the 
Alzheimer mitochondrial cascade hypothesis maintains that the decline of mitochondrial 
function observed during aging, namely the decreased in energy production and the increase 
in ROS production and oxidative stress, eventually surpasses a threshold and triggers the 
amyloidogenic pathway leading to Aβ accumulation (Fig. 16).  
 Aβ can perturb mitochondrial function by influencing OXPHOS activity, impairing 
mitochondrial fusion/fission activity and disturbing calcium homeostasis. The improper 
mitochondrial function generates a decrease in MMP and ATP production - paralleled by an 
increase in ROS production which, again, influences APP processing - induces mtDNA 
mutation, augments tau hyperphosphorylation and NFT formation which in turn disturbs 
mitochondrial trafficking and function. Thus, several vicious cycles are triggered, each 
accelerating the other, which finally leads to synaptic dysfunction and neuronal death by 
apoptosis (Fig.16). 
 In this context, with regard to their critical roles in the early pathogenesis of AD, 
mitochondria represent attractive targets for treatment strategies. 
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Fig.16: A hypothetical sequence of the pathogenic steps of the Alzheimer mitochondrial cascade hypothesis. The 
main cytotoxic pathway of Aβ (red arrows) involves Aβ-induced mitochondrial function, increased ROS 
production, activation of neurofibrillary tangles (NFT) formation, synaptic failure, and neurodegeneration. Several 
other pathways feed this cascade via feeding back (dark red arrows) or forward (dashed arrows) revealing several 
vicious cycles within a larger vicious cycle. All of them, once set in motion, amplify their own processes, thus 
accelerating the development of AD. ROS reactive oxygen species, mtDNA mitochondrial DNA, MMP 
mitochondrial membrane potential, TOM translocases of the outer mitochondrial membranes, ABAD Aβ-binding 
alcohol dehydrogenase, CypD cyclophilin D, ETC electron transport chain (adapted from (67)). 
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(v) Mitochondria as therapeutic target in neurodegeneration 
 
 The role of mitochondrial dysfunction in neurodegeneration is not restricted to AD but 
is becoming increasingly apparent in a broad range of degenerative diseases, including 
Parkinson’s and Huntington’s disease and amyotrophic lateral sclerosis (103). Accordingly, 
many studies are focused on the search of drug candidates that preferentially target 
mitochondria and current pharmacological concepts aim to: increase mitochondrial 
respiration and ATP production, reduce mitochondrial ROS production, stabilize the mPTP, 
and induce mitochondrial biogenesis. For instance, a study using APP/Aβ overexpressing 
cells showed that a treatment with Ginkgo Biloba extract attenuated Aβ-induced 
mitochondrial dysfunction by decreasing Aβ secretion and ROS levels, improving 
mitochondrial respiration, as well as increasing ATP synthesis and mitochondrial biogenesis 
(82). 
 
 Since oxidative stress is a redundant mechanism in neurodegeneration, various 
antioxidants, including creatine, vitamin E and C, β-carotenes or co-enzyme Q, have been 
tested in vitro, in vivo and even in human with anecdotal but no generally recognized degree 
of success (104; 103; 105; 106). More recently, new mitochondria-targeted antioxidants and 
peptides that selectively block mitochondrial oxidative damage have been developed (107; 
108). These compounds use the MMP to accumulate within mitochondria, reducing side 
effects by avoiding non-specific interaction with other targets. One of these compounds, 
MitoQ, has been shown to decrease oxidative stress, Aβ accumulation, astrogliosis, synaptic 
loss, and apoptosis in the brain of 3xTgAD mice, which prevented cognitive decline (107).  
 
 Other studies aimed to increase energy metabolism by boosting mitochondria or 
inducing mitochondrial biogenesis. Notably, resveratrol and thiazolidinedione represents drug 
candidates that are able to induce mitochondrial biogenesis and it was recently proposed 
that AD patients might benefit thiazolidinedione mitochondrial effects (106).  
 
 Further investigations and larger clinical trials are needed to judge the therapeutic 
efficacy of these compounds. Here, we propose neurosteroids as new candidates to boost 
mitochondrial function in health and disease states (see sections II.A and B). 
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B. Neurosteroids 
 
1. Definition 
 
 The term “neurosteroid” appears for the first time in the 80s and defines those 
steroids that are synthesized de novo in the nervous system. They accumulate within the 
nervous system, independent from peripheral steroidogenic glands (109; 110). Indeed, in 
1981, the pioneering studies of Baulieu and coworkers have demonstrated the production of 
steroids within the brain itself (111). They showed that the level of some steroids, such as 
dehydroepiandrosterone (DHEA), was even four times higher in the anterior brain of rats 
than in plasma and nearly 18 times higher than in the posterior brain with regard to its 
sulfated form (DHEAS). Later on, a number of studies showed that other steroids were 
synthesized in the brain, and enzymatic activities of proteins involved in steroidogenesis 
were shown in neurons as well as in glial cells (112; 109; 113; 110; 114). Unlike steroidal 
sex hormones that are released in the blood and act at a distance from their glands of origin 
in an endocrine way, neurosteroids were identified to be synthesized within the nervous 
system and act on the nervous system in an auto/paracrine configuration. 
 The family of neurosteroids includes different categories of steroids: i) non-exclusive 
neurosteroids such as estradiol, testosterone, pregnenolone (PREG), progesterone (PROG) 
or dehydroepiandrosterone (DHEA) that are steroidal hormones synthesized in neurons, glial 
cells or per endocrine glands, ii) semi-exclusive neurosteroids such as allopregnanolone that 
is mainly synthesized in the nervous system but also produced in substantial amounts within 
endocrine glands; iii) exclusive neurosteroids such as epiallopregnanolone that are steroids 
only produced in nerve cells (115; 116). All neurosteroids derive from cholesterol and other 
blood borne steroidal precursors, and have closely related structures based on the classic 
cyclopentanophenanthrene 4-ring structure (Fig.17). The first step of steroidogenesis takes 
place within mitochondria. 
 
 
Fig. 17: Structure of pregnenolone, illustrating the 
cycloperhydropentano-phenanthrene structure common to all steroids. 
The carbon atoms are indicated by numbers, and the rings are 
designated by letters according to standard conventions. Substituents 
and hydrogens are labeled as α or β if they are positioned behind or in 
front of the plane of the page, respectively (adapted from (115)). 
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2. Neurosteroidogenesis 
 
 The transfer of cholesterol from the cytosol to the mitochondrial matrix constitutes the 
rate-limiting step of steroidogenesis. Cholesterol is essentially insoluble (critical micellar 
concentration, ~25–40 nM) (117) and its transfer requires the involvement of a multiprotein 
complex that is composed of protein located in the cytosol and at the outer and inner 
mitochondrial membrane (118). Once in the mitochondrial matrix, cholesterol is converted 
into pregnenolone that is further metabolized into subsequent neurosteroids either in 
mitochondria or in the endoplasmic reticulum (ER) major pathway. 
 
a) Cholesterol transfer to mitochondria 
 
 Intracellular cholesterol required for the subsequent steroid synthesis is known to 
come from three different sources (119): i) cholesterol is synthesized de novo in the 
endoplasmic reticulum (ER) from acetate. Then, it is trafficked to the Golgi apparatus where 
it can be targeted to the mitochondria by binding the protein acyl-CoA binding domain-
containing 3 (ACBD3). Passive diffusion from the ER to the mitochondria is also possible; ii) 
cholesterol comes from the plasma membrane, more specifically, in human, from plasma 
low-density lipoproteins (LDLs) derived from dietary cholesterol and is trafficked through the 
endosomal pathway (120); iii) Cholesterol can be mobilized from the lipid droplets where, 
irrespective of source, it can be esterified by acyl-coenzyme A (CoA): cholesterol 
acyltransferase (ACAT) and stored as cholesterol esters. 
 
 Once at the mitochondrial membrane, the regulation of the cholesterol flow into 
mitochondria is accomplished by a multiprotein complex, also called “transduceosome” 
(118). This multicomplex is composed of: ACBD3, the protein kinase A regulatory subunit I 
alpha (PKA-RIα), the steroidogenesis acute regulatory protein (STAR), the translocator 
protein (18 kDa, TSPO) and the voltage-dependent anion channel (VDAC) (Fig. 18). The 
main actor of this transduceosome is the translocator protein (TSPO), previously known as 
the peripheral-type benzodiazepine receptor (PBR), which is a ubiquitous mitochondrial 
protein enriched at the outer/inner mitochondrial membrane contact sites (121). Briefly, free 
cholesterol accumulates outside of mitochondria and binds to StAR protein, a hormone-
induced mitochondrial-targeted protein that initiates cholesterol transfer into mitochondria. 
Then, cholesterol is transported inside mitochondria by TSPO that forms a channel-like 
structure from its five transmembrane helices and is associated with VDAC and the adenine 
nucleotide transporter (ANT). TSPO is fundamental in neurosteroid production since the 
translocation of cholesterol from the outer membrane to the inner membrane of mitochondria 
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is the rate-limiting step of steroid synthesis (119). In fact, the ability of cholesterol to enter 
into mitochondria to be available to cytochrome P450 cholesterol side chain cleavage 
enzyme (P450scc), located in the inner side of the mitochondrial membrane and responsible 
for the conversion of cholesterol to pregnenolone (PREG), will determine the efficiency of 
steroidogenesis. Of note, a recent study showed that mitochondrial fusion was coupled with 
an increased steroidogenesis, suggesting that mitochondrial dynamics could play an 
essential role in steroid synthesis (122). 
 
 
 
Fig. 18: Transfer of cholesterol in mitochondria. Cholesterol, coming from different sources, accumulates outside 
of mitochondria and binds to the steroidogenic acute regulatory protein (StAR). Upon ligand activation, cholesterol 
is transported inside mitochondria by the transduceosome composed of translocator protein (TSPO), located in 
the outer mitochondrial membrane (OMM), voltage-dependent anion channel (VDAC), the protein acyl-CoA 
binding domain-containing 3 (ACBD3), protein kinase A regulatory subunit I alpha (PKA-RIa), StAR and the 
adenine nucleotide transporter (ANT). After transfer in the mitochondrial matrix, cholesterol is converted in 
pregnenolone by the cytochrome P450 side chain cleavage (P450scc) located in the inner mitochondrial 
membrane (IMM). LDLs; low density lipoproteins (adapted from (119)). 
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b) Enzymatic pathways of steroidogenesis 
 
 The enzymes involved in neurosteroidogenesis belong mainly to two families: i) 
cytochrome P450 enzymes and ii) hydroxysteroid dehydrogenase (reviewed in (123; 115)). 
The first family represents a group of oxidative enzymes containing about 500 amino acids 
and a single heme group, and can be found either in mitochondria (P450 type 1) or in the 
endoplasmic reticulum (P450 type 2). The name cytochrome P450 (pigment 450) comes 
from the fact that these enzymes absorb the light at 450 nm in their reduced states. The 
enzymes of the second family, the hydroxysteroid dehydrogenase (HSD), have molecular 
masses of about 35 to 45 kDa. They do not possess heme groups, and nicotinamide adenine 
dinucleotides (phosphates) (NADH/NAD+ or NADPH/NADP+) are the cofactors necessary to 
either reduce or oxidize a steroid by two electrons via a hydride transfer mechanism. Each 
enzyme of both families is able to catalyze several reactions involved in 
neurosteroidogenesis and can form different neurosteroids (Fig. 19).  
 
 Thus, once within the mitochondrial matrix, cholesterol is directly converted to PREG 
by P450scc. This process involves three distinct chemical reactions: the 22-hydroxylation of 
cholesterol, 20-hydroxylation of 22(R)-hydroxycholesterol, and oxidative scission of the C20–
22 bond of 20(R),22(R)-dihydroxycholesterol (the side-chain cleavage event) (115). These 
three reactions occur on a single active site that is in contact with the IMM and lead to the 
formation of PREG, the precursor of all steroids. After its synthesis within mitochondria, 
PREG can follow several pathways to form different neurosteroids (112) (Fig 19). 
 
 PREG can either be catalyzed by 3β-hydroxysteroid dehydrogenase (3β-HSD) to 
form progesterone (PROG) or by the cytochrome P450c17 enzyme (P450c17), also called 
17α- hydroxylase/17, 20-lyase, to form dehydroepiandrosterone (DHEA). P450c17 catalyzes 
the 17α-hydroxylation of PREG in a two step reaction giving, first, 17-hydroxyPREG (17OH-
PREG) and, then the final product, DHEA. Each step requires the molecules NADPH and O2. 
The same enzyme metabolizes PROG that is converted into androstenedione with the 17-
hydroxyPROG as an intermediate product of the reaction. The enzymes 3β-HSD is also 
involved in other reactions and uses NAD+ as cofactor to oxidize hydroxysteroids, such as 
17OH-PREG and DHEA, into their respective ketosteroids, 17OH-PROG and 
androstenedione. Then, androstenedione is either converted into testosterone by another 
hydroxysteroid dehydrogenase called 17β-HSD or in estrone by P450aro, also called 
aromatase. Of note, 17β-HSD possesses several isoforms, and one of them (17β-HSD- 10) 
is located in the mitochondrial matrix and is also known under the name of Aβ binding 
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alcohol dehydrogenase (ABAD). ABAD was recently linked to AD because of its ability to 
bind Aβ peptide, thus inducing mitochondrial dysfunction (124; 79) (see section I.B.4.b). 
17β-HSD and P450aro are involved in the synthesis of estradiol from estrone and 
testosterone respectively. At this level, the 5α-reductase enzyme (5α-R), a microsomal 
NADPH-dependent protein, intervenes to catalyze the transfer of two atoms of hydrogen 
from NADH to form the 5α-reduced metabolite of testosterone, dihydrotestosterone (DHT). 
Finally, the enzyme 3α-hydroxysteroid oxido-reductase (3α-HSOR), also called 3α-
hydroxysteroid dehydrogenase, catalyzed the reversible conversion of DHT in the 
neuroactive steroid 3α-androstanediol. The latter enzymes intervene also at another level, in 
the second main steroidogenic pathway that derives from PROG. In fact, PROG is 
successively metabolized by the 5α-R and the 3α-HSOR to form dihydroprogesterone (DHP) 
and 3α/5α-tetrahydroprogesterone (3α/5α-THP), also known under the name 
allopregnanolone, another neuroactive steroid. PREG and DHEA can also  be sulfated and 
de-sulfated by the hydroxysteroid sulfotransferase (HST) and sulfatase respectively, to form 
PREG sulfate and DHEA sulfate. 
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Fig.19: Schematic representation of main biochemical pathways for neurosteroids biosynthesis in the vertebrate 
brain (see details in the text). 17OH-PREG; 17-hydroxypregnenolone, 17OH-PROG; 17-hydroxyprogesterone, 
DHEA; dehydroepiandrosterone, DHP; dihydroprogesterone, ALLOPREG; allopregnenolone, DHT; 
dihydrotestosterone, P450scc; cytochrome P450 cholesterol side chain cleavage, P450c17;cytochrome P450c17, 
3β-HSD; 3β-hydroxysteroid dehydrogenase, 5α-R; 5α-reductase, Arom.; aromatase, 21-OHase; 21-hydroxylase, 
3α-HSOR; 3α-hydroxysteroid oxydoreductase,17β-HSD; 17β-hydroxysteroid dehydrogenase, HST; 
hydroxysteroid sulfotransferase, STS; steroid sulfatase. 
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 The expression and activity of enzymes involved in neurosteroid biosynthesis were 
demonstrated in different regions of the brain, and also in the peripheral nervous system (112; 109; 
113). Studies mainly performed in amphibian and bird models showed that the activity of those 
enzymes could be regulated by neurotransmitters and neuropeptides (Table 1), but little is known 
regarding the neuronal mechanisms regulating neurosteroid synthesis in the mammalian brain 
(reviewed in (112)). The fact that the ability to produce neurosteroids was conserved during 
vertebrate evolution suggests that this category of molecules plays an important role in living things. 
 
Table 1: Effects of neurotransmitters and neuropeptides on steroidogenic enzyme activity in the brain.  
 
P450scc 
3β-
HSD 
P450c17 
3α-
HSOR 
P4507α Aromatase HST 
GABA ↓ ↓ ↓ nd nd → nd 
Dopamine nd ↓ nd ↓ nd ↓ nd 
Glutamate nd nd nd nd nd ↓ nd 
Melatonin nd nd nd nd ↓ nd nd 
Endozepines ↑ ↑ ↑ nd nd nd nd 
Vasotocin/mesotocin nd ↑ ↑ nd nd nd nd 
Neuropeptide Y (NPY) nd nd nd nd nd nd ↓ 
↑; stimulatory, ↓; inhibitory, →; no effect, nd; not determined (adapted from (112)). 
 
 
3. Mechanism of action of neurosteroids and physiological roles 
 
 The lipophilic nature of neurosteroids allows them to act both via membrane receptor 
or to cross cellular membranes and to act through a conventional genomic pathway via 
nuclear receptors (Fig.20). The genomic action of steroids seems to be important during 
neonatal life where it has been shown that neurosteroids, as PROG or estradiol, are able to 
promote dendritic growth, spinogenesis, synaptogenesis and cell survival, particularly in the 
cerebellum (114). Among classical nuclear steroid receptor, we found estrogen receptors 
(ER), androgen receptors (AR) and progestin receptors (PR). The most studied steroid 
nuclear receptors are the estrogen receptors α and β (ERα/β) that are expressed in 
metabolic tissue such as adipose tissue, skeletal muscle, liver and pancreas, as well as in 
the central nervous system. Studies demonstrated that these receptors play a role in the 
regulation of glucose homeostasis and lipid metabolism (125) while other studies showed 
that they were also implicated in neuroprotection (see section I.B.5). More recently, the 
pregnane X receptor was identified as a new nuclear receptor activated by progesterone and 
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allopregnanolone, and its activation seemed to be involved in cholesterol homeostasis and 
neurosteroid synthesis (126-128). 
 
 
 
Fig. 20: Different potential mechanisms of action of neuroactive steroids, including hormonal steroids, in the 
nervous system. (A) Neuroactive steroids may bind to ion channels associated to neurotransmitter receptors (1), 
to putative steroid receptors in the plasma membrane (2), to classical nuclear steroid receptors associated with 
the plasma membrane (3) or to classical nuclear steroid receptors located in the cytoplasm (4). Intracellular 
signaling pathways activated by neuroactive steroids are depicted. The activation of classical nuclear receptors 
(4) results in their dimerization and binding to steroid responsive elements (SRE) in the promoters of specific 
genes and the consequent regulation of transcription (5). In addition, membrane and cytoplasmic signaling 
modulated by neuroactive steroids can also impact transcriptional activity (6) (adapted from (132)). (B) Schematic 
representation of structural domains of steroid nuclear receptors. AF1/2; activation function 1/2, DBD; DNA 
binding domain, LBD; ligand binding domain (adapted from (133)). 
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Neurosteroids can also act via membrane receptors as allosteric modulators of 
neurotransmitter receptors. They have been found to act as allosteric modulators of the 
GABAA/central-type benzodiazepine receptor complex, NMDA receptors, kainate receptors, 
AMPA receptors, sigma receptors and glycine receptors (129-131; 110). More precisely, 
DHEA and its sulfate ester DHEAS are known to be excitatory neurosteroids and can act as 
antagonists at GABAA receptors or as agonists at sigma receptors (115). Pregnenolone 
sulfate is also known as a negative regulator of GABAA, kainite, and AMPA receptors, and as 
positive regulator of NMDA receptors, thus acting as an excitatory neurosteroid (115; 110). In 
contrary, allopregnanolone is a positive GABAA-R allosteric modulator that strengthens the 
effects of GABA. Allopregnanolone acts on GABAA-R at nanomolar concentrations at sites 
distinct from those bound by GABA, benzodiazepines, and barbiturates, functioning as an 
allosteric modulator to open the channel and increase chloride flux (Fig 21).  
 Furthermore, it is known that neurosteroids modulate neurotransmitter binding sites or 
receptors including calcium channels and P2X receptors in the brain, spinal cord, as well as 
the dorsal root ganglia (DRG) (134). Of note, recent clinical and pharmaceutical studies 
showed that estrogens can interact with several neurotransmitter systems, as cholinergic and 
serotoninergic system, to influence cognitive performance in animals and humans (135). 
 Thus, neurosteroids seem to play an important role in the nervous system during 
development as well as in adult brain, by regulating gene transcription and different 
neurotransmitter systems. Their implication was already demonstrated in several 
pathologies, especially in AD. 
 
 
 
Fig. 21: Structure of the GABAA (A) and the NMDA (B) receptors. Both can be modulated by neurosteroids 
(adapted from (136)). 
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4. Neurosteroids, Aging and Alzheimer’s disease 
 
a) Age-related changes in brain neurosteroid levels 
 
 Because steroid hormones are lipophilic molecules, those that are synthesized by the 
peripheral steroidogenic glands can easily cross the blood-brain barrier and act on the 
nervous system in an endocrine way. The blood levels of these neuroactive steroids are 
known to decrease with age (137). In women, estrogen levels drop after the menopause, 
whereas men present a gradual reduction in testosterone over the life course eliminating 
approximately 2% of circulating testosterone every year (138; 53). Of note, the age-related 
decrease of steroid hormones has been presented as a risk factor to develop 
neurodegenerative diseases, including AD ((90), see APPENDIX 4). However, since 
neurosteroids are locally synthesized within the nervous system, steroid blood levels do not 
necessarily correspond to steroid brain concentrations (137). Thus, the age-related changes 
in neurosteroid levels are challenging to investigate in humans due to the presence of blood-
derived steroid hormones. 
 Studies performed in rats showed that the synthesis of PREG sulfate was decreased 
in the hippocampus of aged rats (2 years old) compared to young rats (3 months old) (139). 
The hippocampus is a brain region involved in learning and memory, and the decrease of 
PREG sulfate in this region correlated with cognitive impairments in old rats. Of note, these 
cognitive deficits were transiently reduced after intrahippocampal injection of PREG sulfate, 
suggesting that this neurosteroid plays a role in the maintenance of cognitive function during 
aging. More recently, Caruso and colleagues (2013) compared neurosteroid levels in the 
limbic region of young (7 months old) and old mice (24 months old) (140). They showed an 
alteration in neurosteroid levels with a general trend toward lower steroid levels in the brain 
of aged mice compared to young mice.  
 Together, these data indicate that neurosteroid levels decline gradually with 
advancing age which may induce a range of age-related neuronal dysfunction, cognitive 
impairments and neurodegeneration due to the loss of neurosteroid protective effects (see 
section I.B.5). 
 
b) Disturbed neurosteroidogenesis in Alzheimer’s disease  
 
 Studies performed in AD patients as well as in animals and cellular models of AD 
showed some alterations in the synthesis of neurosteroids that declined during brain aging 
paralleled by a loss of important nervous functions, such as memory (141; 140; 142). TSPO, 
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which regulates the first step of steroidogenesis, was over-expressed in post-mortem brains 
from AD patients, resulting in an increased level of PREG in the hippocampal region of those 
brains (119). Interestingly, the level of 22(R)-hydroxycholesterol, a steroid intermediate in the 
conversion of cholesterol to PREG, was found at lower levels in AD brain compared to 
control, which suggest that TSPO does not function normally in Alzheimer patients (141; 
121). Another study showed that DHEA was significantly elevated in AD brain and cerebro-
spinal fluid when compared to control subjects (141). Similar results were obtained in vitro in 
oligodendrocytes, where DHEA production was up-regulated under oxidative stress condition 
induced by treatment with Aβ peptide (143). In a study using 3xTg-AD mice, modified levels 
of specific neurosteroids, in particular in the levels of progesterone and testosterone 
metabolites, were measured in aged mice (24 months) compared to young (7 months), and 
were associated with age-related neuropathological changes in the brain, such as Aβ 
accumulation and gliosis (140). In accordance, several neurosteroids were quantified post-
mortem in various brain regions of aged AD patients and aged non-demented controls. 
Results showed a general trend towards lower steroid levels in AD patients compared to 
controls, associated with a negative correlation between neurosteroid levels and Aβ as well 
as hyperphosphorylated tau protein in some brain regions (137). Finally, several reports 
propose the role of allopregnanolone as a plasmatic biomarker for AD, since it was shown 
that the level of this neurosteroid is decreased by 25 % in the plasma of demented patients 
compared with control subjects (144; 142). 
 In accordance, recent findings corroborated that AD key proteins - Aβ and 
hyperphosphorylated tau - distinctly impacted neurosteroidogenesis in a cellular AD model 
(Fig. 22) ((145; 146) and see also APPENDIX 5).  
 Overexpression of wtTau protein induced an increase in the production of PROG, 3α- 
androstanediol and 17OH-PROG, in contrast to overexpression of the abnormally 
hyperphosphorylated tau bearing the P301L mutation which led to a decrease in the 
production of these neurosteroids. In parallel, a decrease of PROG and 17OH-PROG 
production was observed in APP overexpressing cells, whereas 3α-androstanediol and 
estradiol levels were increased. These results provided the first evidence that AD key 
proteins are able to modulate, directly or indirectly, the biological activity of the enzymatic 
machinery producing neurosteroids. Other in vitro experiments using native SH-SY5Y cells 
treated with aggregated Aβ42 fibrils for 24 h were in line with these findings (145). A treatment 
with “non-toxic” Aβ concentrations (within the nanomolar range, non-cell death inducing Aβ42 
concentrations) revealed an increase in estradiol production, whereas toxic Aβ 
concentrations (within the micromolar range, leading to cell death) showed the opposite 
effect (145). 
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Fig. 22: Disturbed neurosteroidogenesis in AD. PREG; pregnenolone, 17OH-PREG; 17-hydroxypregnenolone; 
PROG; progesterone, 17OH-PROG; 17-hydroxyprogesterone,  DHEA; dehydroepiandrosterone, DHP; 
dihydroprogesterone, ALLOPREG; allopregnanolone, DHT; dihydrotestosterone, Tau; abnormally 
hyperphosphorylated tau protein, Aβ; amyloid-β protein. 
 
 
 As mentioned in section I.A.2.c, recent reports indicate that Aβ may also interact 
directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding 
alcohol dehydrogenase) in executing its toxic effects (79). ABAD belongs to the family of 
17β-hydroxysteroid dehydrogenase and is able to metabolize estradiol within the 
mitochondrial compartment. ABAD is up-regulated in AD brain areas affected by Aβ 
pathology such as the cortex and hippocampus, as well as in AD transgenic mouse models 
(79; 147). Studies performed in double transgenic mice overexpressing mutant APP and 
ABAD showed that the binding of Aβ on ABAD exacerbates mitochondrial dysfunction 
induced by Aβ, namely a decrease of mitochondrial complex IV activity, diminution of O2 
consumption and increase of ROS (147). Furthermore, these mice presented an early onset 
of cognitive impairment and histopathological changes compared to APP mice, suggesting 
that Aβ-ABAD interaction is an important mechanism underlying Aβ toxicity. The inhibition of 
Aβ-ABAD interaction, using a decoy peptide, was able to restore mitochondrial deficits 
induced by Aβ in vivo and improve neuronal and cognitive function (147). 
 To gain insights into the pathological mechanisms of Aβ upon mitochondria, we 
investigated the role of a novel small ABAD-specific compound inhibitor (AG18051) on Aβ-
induced mitochondrial toxicity and estradiol metabolism in SH-SY5Y cells ((124), see 
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APPENDIX 6). We found that AG18051 partially blocked Aβ-ABAD interaction and prevented 
the Aβ-induced down-regulation of ABAD activity by normalizing estradiol levels. 
Furthermore, AG18051 was protective against Aβ and reduced Aβ-induced impairment of 
mitochondrial respiration, oxidative stress and cell death. Our results emphasized the 
inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for 
the prevention and treatment of AD, and suggest that the endogenous modulation of 
mitochondrial estradiol metabolism is important for mitochondrial activity (90). 
 Taken together, these data suggest that disturbances in neurosteroid metabolism 
may be an underlying mechanism in AD. Neurosteroids may act in a delicate balance on the 
brain and mitochondrial function, and offer interesting therapeutic opportunities because of 
their pleiotropic effects in the nervous system. 
 
5. Evidence of neuroprotective action of neurosteroids against Alzheimer’s 
disease 
 
 The exact mechanisms underlying neurosteroids action in the nervous system are still 
unclear. However, studies based on behavioral responses evoked in animals by steroid 
injections suggested neurosteroid involvement in various neurophysiological processes 
including the development of the nervous system, adaptive responses of neuronal and glial 
cells under pathological conditions, and neuronal plasticity.  
 For instance, in vitro studies demonstrated that nanomolar concentration of DHEA 
and DHEAS stimulated the outgrowth of axons and dendrites, respectively, in primary 
cultures of embryonic mouse neurons (148). In accordance, subcutaneous injection of DHEA 
enabled an increased neurogenesis in the dentate gyrus of rats (149). Progesterone and 
estradiol also appears to stimulate cerebellar development since they were shown to 
promote dendritic growth, spinogenesis and synaptogenesis in developing Purkinje cells 
(114). Indeed, those neurosteroids have the ability to bind to microtubule-associated protein 
2 (MAP2), known to promote tubulin polymerization or microtubule stability, in cultured 
neurons (112). Furthermore, in vivo studies showed that testosterone, estradiol and PROG 
are able to regulate the phosphorylation of tau protein, which is essential for its association 
with axonal microtubules and the regulation of axonal growth (132). In addition, progesterone 
is able to stimulate myelin synthesis in the peripheral nervous system by acting on neuronal 
gene expression via its classic nuclear receptor (150; 151). Other studies demonstrated that 
neurosteroids, such as pregnenolone sulfate, PROG or allopregnanolone enhances memory 
in rodents and exerts behavioral effects, probably via their non-genomic action (115). 
 Taken together, these findings suggest that neurosteroids may represent promising 
therapeutics for the treatment of neurodegenerative disorders by their ability to regulate brain 
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function, from the cellular level to the modulation of high cognitive functions. Indeed, a 
growing body of evidence highlighted the role of neurosteroids in neuroprotection. Studies 
showed that these molecules were protective against excitotoxicity, brain oedema, 
inflammatory processes and oxidative stress in a wide range of diseases including brain and 
spinal cord injury, stroke, Parkinson’s disease, epilepsy or AD (reviewed in (152)). The 
following evidences are focused on the neuroprotective effects of neurosteroids in AD. 
 
 The potential neuroprotective role of neurosteroids has been widely investigated, 
especially those of sex hormone-related neuroactive steroids (non-exclusive neurosteroids). 
Indeed, epidemiological studies showed that cognitive decline and the risk to develop 
neurodegenerative diseases, such as AD, could be associated with an age-related loss of 
estrogens (estrone (E1), estradiol (E2), and estriol (E3)), testosterone as well as 
progesterone in both, women and men (153; 53; 54). Studies demonstrated that estrogen 
depletion in postmenopausal women represents a significant risk factor for the development 
of AD and that a hormonal replacement therapy (HRT) might decrease this risk and even 
delay disease progression (154; 155). But, beneficial effects of HRT are still under debate 
since results from the “Woman's health initiative memory study” (WHIMS) showed negative 
effects of long-term HRT with, however, synthetic estradiol and medroxyprogesterone 
instead of using natural hormones, in older women (156; 157) (see APPENDIX 4). In 
contrast, animal studies showed that treatment with estradiol was able to protect the brain 
against excitotoxicity, Aβ peptide-induced toxicity, free radical generators and ischemia 
(158). Estrogens are able to enhance cerebral blood flow, to prevent atrophy of cholinergic 
neurons, and to modulate the effects of trophic factors in the brain (159). 
 Studies using animal models of AD have shown that a treatment with estradiol had an 
impact on APP processing, decreasing Aβ levels and its aggregation into plaques in mice 
expressing mutations in human APP (Swedish and Indiana mutation) compared to wild-type 
mice (160). The underlying mechanisms are still poorly understood but it has been proposed 
that estrogens are able to trigger the α-secretase pathway (non-amyloidogenic) via activation 
of extracellular-regulated kinase 1 and 2 (ERK 1 and 2) and through protein kinase C (PKC) 
signalling pathway (153). In accordance, in female AD triple transgenic mice (3xTgAD), the 
depletion of sex steroid hormones induced by ovariectomy, enhanced significantly Aβ 
accumulation and had a negative impact on cognitive performance (161-163). Those effects 
were prevented by a treatment with estradiol.  
 At the cellular level, estradiol can act as transcription factor by binding nuclear 
receptors, such as ER α and β. It has been shown that estradiol enhanced the expression of 
anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulated the expression of Bim, 
a pro-apoptotic factor, preventing the initialisation of the cell death program by mitochondria 
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(153; 164). Estradiol can also exert direct and indirect antioxidant effects by: i) up-regulating 
the expression of manganese superoxide dismutase (Mn-SOD) and gluthatione peroxidase 
(165); ii) increasing glutathione (GSH) levels and decreasing oxidative DNA damage in 
mitochondria, as observed in a study using ovariectomized female rats (166); iii) modulating 
the redox state of cells by acting on several signalling pathways, such as MAPK (mitogen-
activated protein kinase), G protein regulated signalling, NFκB, c-fos, CREB, 
phosphatidylinositol-3-kinase, PKC and Ca2+ influx (167; 164). On the basis of this complex 
mode of action, estradiol seem to be able to decrease oxidative stress markers, including 
lipid peroxidation, protein oxidation and DNA damage, but can also directly regulate 
mitochondrial function (reviewed in (90)) (Fig 23). 
 
Fig.23: Estradiol and mitochondrial dysfunction in AD. In AD, mitochondrial dysfunction was found to be a central 
pathological mechanism which occurs already in early stages of the disease (see details in section I.A.2). It has 
been shown that estradiol can increase glucose utilization by cells as well as ETC activity, stabilize the MMP and 
prevent ROS production and calcium-induced excitotoxicity. In the graph, E2 designates where estradiol 
potentially acts on the mitochondria to compensate Aβ-induced toxicity. ABAD Aβ-binding alcohol 
dehydrogenase, CI complex I, CII complex II, CIII complex III, CIV complex IV, CV complex V, cyt c cytochrome c, 
Cu/Zn SOD copper/zinc superoxide dismutase, MnSOD manganese superoxide dismutase, TCA tricyclic acid, E2 
estradiol, ROS reactive oxygen species, mtDNA mitochondrial DNA, ER estrogen receptor (adapted from (90)). 
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 Human and animal studies suggested that androgen deprivation represents a risk 
factor for AD pathogenesis in men (153; 168). Notably, in a triple transgenic mouse model of 
AD (3xTgAD), it has been shown that orchiectomized males presented an increased Aβ 
accumulation in the brain, coupled with impaired cognitive performances compared to sham 
operated mice (169). Treatment with androgens significantly attenuated the increase in AD 
pathology (168; 169). Testosterone appears to prevent tau hyperphosphorylation in a model 
of heat shock-induced phosphorylation through GSK signalling inhibition (170). Rosario and 
colleagues (168) demonstrated less abnormal tau accumulation in gonadectimized male 
3xTgAD mice treated with testosterone. Estradiol is aromatized from testosterone and other 
androgens, and this implies that testosterone may exert indirect effects on mitochondria, 
though some studies have shown that testosterone has anti-apoptotic effects mediated 
through the androgen receptor (137). Overk and colleagues (171) examined basal levels of 
serum and brain testosterone in male 3xTgAD mice and found that testosterone levels rise 
with disease progression. This increase in testosterone in aged male 3xTgAD mice was 
correlated with reduced Aβ plaque pathology. This suggests that testosterone may have 
some neuroprotective benefits against the AD disease course, but that testosterone 
administration is associated more with lesser Aβ protein burden rather than a reduction in 
abnormal tau protein. In fact, testosterone alters processing of amyloid precursor protein and 
enhances expression of neprilysin, an enzyme responsible for Aβ degradation (172). 
 The effects of PROG in AD mice have also been investigated. For instance, PROG 
was able to improve the cognitive performance and reduced tau hyperphosphorylation in 
mice bearing a double mutation in APPswxPS1 compared to wild-type mice (162). Those 
mice were characterized by decreased hippocampally-mediated cognitive performances and 
presented decreased levels of allopregnanolone in the hippocampus, suggesting that a part 
of the deficit in hippocampal function may be due to reduced capacity to form 
allopregnanolone in the hippocampus. Interestingly, recent studies demonstrated a protective 
role of allopregnanolone in AD triple transgenic mice (3xTgAD), showing reduced Aβ 
generation in hippocampus, cortex and amygdala, increased proliferation of neuronal 
progenitor cells and reversed neurogenic and cognitive deficits compared to non-transgenic 
littermates (173; 174). 
 Together, these data suggest that neurosteroids represent interesting tools for the 
therapy and prevention of neurodegenerative diseases, especially AD. With regard to AD-
related mitochondrial dysfunction, extensive studies only focused on beneficial effects of 
estradiol, while the effects of other neurosteroids on mitochondria have not been investigated 
up to now (see section II.A and II.B). 
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C. Circadian rhythms 
 
1. Concept of circadian rhythm 
 
 Circadian rhythms are believed to be an evolutionary adaptation to daily 
environmental cycles that are synchronized by the 24 hours patterns of light and temperature 
produced by the earth’s rotation around its axis (175). They coordinate our physiology at a 
fundamental level and govern a wide variety of physiological and metabolic functions in most 
organisms, from cyanobacteria and fungi to insects and mammals (176). Circadian 
oscillations (from the Latin “circa diem” = about a day) occur with a period length of about 24 
hours and play a key role in the adaptation of living organisms to the environmental changes, 
such as light/dark cycles which are associated with food availability. These oscillations are 
defined by their period length (τ), amplitude (A) and phase (ϕ) (Fig. 24A). 
 
 
Fig. 24: (A) Parameters of a hypothetical rhythm. Given a variation of an element “X” in units of time “t”, several 
parameters of a rhythm can be measured, such as amplitude (A, in blue, defined as the maximum absolute value 
of a periodically varying quantity), period length (τ, in green, the time spent between two peaks) and phase (ϕ, in 
red, that represents the position of a peak in function of time). (B) Examples of circadian rhythms in human. 
Melatonin (left) is secreted during the night (gray shading) with a peak in anti-phase with the body temperature 
(middle). Cortisol secretion (right) starts during the night, with a peak at the beginning of the light phase (adapted 
from (177)). 
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 A biological rhythm (or oscillation) must meet three general criteria to be called 
“circadian”. First, the rhythm has to be innate, endogenous, with a free-running period length 
of about 24 hours, and self-sustained in constant condition (e.g. in constant darkness). This 
criterion is important to distinguish circadian oscillations from daily oscillations that are 
responses to external and environmental cues. A rhythm is considered as endogenous only if 
it persists in constant conditions. Second, the rhythm has to be entrainable (synchronized) by 
external stimuli, also called “Zeitgebers” (time giver), such as light/dark cycles or 
feeding/fasting cycles. Finally, temperature compensation is the third criterion that defines 
circadian rhythms, meaning that the period length of these rhythms are unaffected by 
temperature changes within physiological permissible limits (176). 
 Overall, this allows the organism to coordinate a variety of daily behavioral and 
physiological processes to the optimal time of day by anticipating the periodic changes of the 
external environment. The most obvious circadian rhythm observed in humans (and other 
animals) is the sleep-wake cycle. During the light phase (or circadian day), catabolic 
processes are predominant to facilitate engagement with the external world. In contrast, the 
dark phase (or circadian night) promotes anabolic functions of growth, repair and 
consolidation (177). For example, body temperature drops during the night and melatonin is 
secreted, facilitating sleep during which growth hormones are released (Fig. 24B). Cortisol 
levels increase during the night, with a peak at the beginning of the activity period, preparing 
the body for physical and mental demands of awakening. 
 Molecular mechanisms underlying circadian rhythms have been unraveled during the 
last decade and involve interconnected feedback loops of gene transcription and translation 
(178).  
 
2. Clock genes and circadian machinery 
 
 The maintenance of a rhythm with a period length of about 24 hours is made possible 
by self-sustained transcriptional-translational feedback loops. In these loops, it is possible to 
distinguish positive and negative components. The first loop begins with the 
heterodimerization of transactivating (positive) components CLOCK and BMAL1 (Fig. 25), 
two transcription factors that reach the nucleus and initiate the transcription of clock-
controlled genes (CCG) containing E-box (5′-CACGTG-3′) or E′-box (5′-CACGTT-3′) cis-
regulatory elements (178). Notably, the CLOCK/BMAL1 heterodimer triggers the 
transcription/translation of the clock genes Period (isoforms Per1-3) and Cryptochrome 
(isoforms Cry1 and 2) that constitute negative (transinhibiting) components of the molecular 
feedback loop (179) (Fig. 25). In the cytoplasm, PER and CRY proteins dimerize and are 
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translocated into the nucleus where they repress transcription of their own genes by directly 
inhibiting CLOCK/BMAL1 (178). Degradation of the negative limb proteins PER and CRY is 
required to terminate the repression phase and restart a new cycle of transcription.  
 Additional components contribute to the robustness of this molecular clockwork 
circuitry. For instance, REV-ERBα (reverse orientation c-erb α) and ROR (orphan nuclear-
receptor genes) interconnect the circadian transcription of the positive and negative “limbs” 
of the molecular clock. REV-ERBα transcription is activated by CLOCK/BMAL1 complex 
through the binding to E-box sequences present in its promoter, resulting in its circadian 
accumulation. REV-ERBα protein leads to periodic repression of Bmal1 transcription. This 
repression leads to a rhythmic expression of Bmal1 in antiphase with Rev-Erbα expression 
(180). Posttranslational mechanisms such as protein phosphorylation also play important 
roles in generating oscillations of approximately 24 hours. For example, casein kinase 1ε 
(CK1ε) phosphorylates PER, CRY, and BMAL1 proteins (178). Hypophosphorylated PER 
proteins have a higher metabolic stability than their hyperphosphorylated counterparts and 
this may lead to an increased accumulation of PER proteins. 
 
 
 
Fig. 25: Schematic representation of the molecular circadian clock machinery. The system consists of two 
feedback loops: CLOCK/BMAL1 heterodimer forms the positive component in this loop, while the PER/CRY 
complex acts as the negative component. Details are described in the text. CCG; clock controlled genes, P; 
phosphate (adapted from (178)). 
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 Mutations in clock genes are accompanied by a spectrum of behavioral abnormalities, 
including mania, hyperactivity or increased alcohol consumption, and disturb neurochemical 
systems, such as dopaminergic and glutamatergic neurotransmission (176). Identification of 
clock genes enabled the development of transgenic models that help to understand in more 
details the underlying mechanisms of the molecular clock machinery and its impact on 
behavioral outputs (reviewed in (181)). 
 In mammals, the circadian molecular clock is virtually present in all cells of the body 
(179). To synchronize all these clocks, the circadian timekeeping system possesses a 
complex hierarchical architecture, with a central pacemaker in the brain and subsidiary 
clocks in the rest of the body.  
 
3. Organization of the circadian clock 
 
 One of the main properties of the circadian system is its ability to synchronize the 
individual circadian clock at all levels. Thus, clocks contained in peripheral tissues (peripheral 
clocks) are kept in a stable phase-relationship to maintain a coherent function of the entire 
organism. In turn, these individual oscillators can send back information to the master clock 
present in the brain’s suprachiasmatic nuclei (SCN) that adapts organism’s physiology in 
response to environmental parameters. 
 
a) Master clock 
 
 The SCN of the anterior hypothalamus is the site of the master circadian clock in the 
mammalian brain (182). Indeed, lesion experiments in the brain of rodents enabled the 
identification of this structure located above the optic chiasma. SCN-lesioned animals were 
arrhythmic in entrained condition and presented a disruption of locomotor activity and a loss 
of rhythmicity in corticosterone secretion (183; 184). Circadian locomotor activity was 
restored in SCN-lesioned animal by transplantation of fetal SCN tissue into the third ventricle 
(185). A determinant demonstration of the clock function of the SCN was made possible 
using the Tau (τ) mutant hamster (182). The Tau mutation shortens circadian period length 
from 24 hours in the wild type to 20 hours in homozygote mutant animals. This shortened 
period length results from a missense mutation within the substrate recognition site of the 
enzyme CK1ε (see section I.C.2) (186). Again, transplantation studies revealed that SCN 
grafts from wild-type animals restores the circadian period length of Tau mutant hamsters 
suggesting that circadian parameters are determined by the genotype of the donor, not the 
host (182). In addition, in vitro studies revealed that electrical activity of SCN neurons follows 
a circadian pattern. This rhythmic firing is maintained even after three weeks in culture (187). 
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This property is the direct consequence of the tight coupling between SCN neurons via 
conventional synapses (likely GABAergic), electrical synapses (i.e. gap junctions) and 
neuropeptidergic coupling (e.g. vasoactive intestinal peptide (VIP)) to avoid the damping of 
the oscillations (176). 
 
 
 
 
Fig. 26: Subdivision of the circadian system: input to the clock, clock mechanism, and clock output. This division 
can be made at the cellular level as well as at the systemic level. SCN suprachiasmatic nuclei, CNS central 
nervous system (adapted from (179)). 
 
 
 The role of SCN in the regulation of circadian system has been investigated for many 
years (reviewed in (188) and (189)). The key function of this structure is to serve as relay 
between external environment and the body by: i) perceiving environmental inputs; ii) 
integrating time-related information; iii) transmitting adjusted timing information to other 
tissues and organs that subsequently send feedback information to the SCN (Fig. 26). 
 For example, when light is detected by the retina, signals are transmitted to the SCN 
(=input from the external environment) (Fig.27). There, signals are integrated to adjust the 
information about the time of the day (light onset: dawn or light offset: dusk). The SCN can 
send various output signals (hormones, metabolites, neuronal signals…) through which the 
generated rhythms are manifested via control of various metabolic, physiological, and 
behavioral processes. 
 Thus, SCN is on the top of the hierarchical organization of the circadian system and 
serve as a central conductor orchestrating the peripheral clocks. 
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b) Peripheral clocks 
 
 When the molecular components of the circadian clock were identified, it has been 
shown that clock genes are also expressed rhythmically outside the SCN and even outside 
the brain in many peripheral tissues (190). The mRNA expression of main clock genes, such 
as Bmal1, Reverbα or Per1-3, has been found in cells coming from different peripheral 
systems (heart, lung, liver, stomach, spleen, kidney…) (182). Of note, in the peripheral 
tissues, mRNA peaks of clock genes occurred approximately 4 hours after those in the SCN 
(191; 180; 192; 193). In addition, genome-wide transcriptome profiling studies showed that 
gene expression exhibit robust circadian oscillation in the above mentioned organs, 
suggesting that many cellular functions are under the control of the circadian clock (reviewed 
in (182) and (190)). For instance, depending on the tissue, it has been shown that between 
2% and 10% of all analyzed genes were rhythmically expressed, especially in the liver which 
contains about 1000 circadian transcripts (194). Many of these genes encode key enzymes 
involved in metabolic pathways including food processing, carbohydrate and lipid 
metabolism, cholesterol utilization and xenobiotic detoxification (190). Indeed, it makes 
sense that the production or sequestration of chemically incompatible processes may be 
potentially harmful if they take place during the same time window. For instance, if glycogen 
synthase and phosphatase were expressed at the same time, it would be incompatible with 
the conversion of glucose in glycogen, and vice versa (182). Similarly, xenobiotic 
detoxification starts slightly before feeding time, anticipating the absorption of toxins present 
in food (e.g. plant alkaloids, coumarin…) (190). Daily feeding-fasting cycles represent the 
main synchronizer (Zeitgeber) of the peripheral organs, including the liver, kidney, pancreas 
and heart muscle (Fig. 27).  
 This observation led Schiebler and colleagues (190) to propose a new hypothesis 
postulating that the most important roles of peripheral clock can be summarized in three 
points: i) the anticipation of metabolic pathways to optimize food processing; ii) the limitation 
of metabolic processes with adverse side effects to time periods when they are needed; iii) 
the sequestration of chemically incompatible reactions to different time windows. Even if 
peripheral clocks are self-sustained, autonomous oscillators, a functional SCN is required to 
maintain phase coherence between them (Fig. 27). The properties of peripheral clocks are 
similar to the master clock, which make them preferential models to understand in more 
details the circadian machinery and the implications in health and disease.  
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Fig. 27: Schematic organization of the circadian system. Circadian clocks are found in all cells of various organs. 
The master clock is located in the SCN (red clock) and synchronizes the other central clocks that are located in 
different part of the brain (cortex, thalamus…) to regulate metabolic integration and motor coordination. The main 
synchronizers are the light (yellow), food intake (green) and locomotor activity (red). SCN and other organs 
communicate via hormonal signaling (melatonin, ghrelin, leptin, insulin/glucagon, adrenaline…), metabolic 
signaling (carbohydrate, fatty acids, amino acids) or neuronal connections (adapted from (179)). 
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c) Studying circadian systems using peripheral cells 
 
 Circadian systems can be studied from cellular level and up to systemic and 
behavioral levels. In human, several protocols were developed to reveal the endogenous 
circadian component of rhythms (195). In these protocols one or more circadian markers are 
usually measured, namely melatonin (in blood or saliva), cortisol (in plasma) or core body 
temperature (see also Fig. 24B). The main issues in human is that environmental 
components can influence these markers such as light, temperature, body position, food 
intake, and many other factors. These environmental components can easily be controlled in 
animal studies. Since rodents voluntary use a running wheel in their home cage, locomotor 
activity served as a particularly reliable and convenient measure of the output of their 
circadian system (196). A panel of protocols is available to study circadian parameters in 
rodents. Usually, animals are placed in constant conditions (e.g. constant darkness: dark-
dark (DD)) with the subjective time-of-day referred to as the circadian time (CT), in contrast 
to entrainable conditions (e.g. light-dark cycle (LD): 12 hours light – 12 hours dark) where the 
time of the day is given by the zeitgeber time (ZT). Besides, the identification of the 
molecular clock machinery allowed a move forward in the understanding of the circadian 
system and promoted the development of transgenic models that are widely used in the 
circadian research fields (197; 181; 198-200).  
 
 In 1998, Balsalobre and colleagues demonstrated that immortalized rat fibroblasts in 
culture possess robust autonomous and self-sustained circadian rhythm (201). Since then, 
the identification of the molecular clock machinery in isolated human fibroblasts has been 
widely demonstrated. The cultivation and genetic manipulation of fibroblasts are easy to 
perform and these are some of the main reasons why fibroblasts are a valuable model of 
peripheral oscillator (202; 203). Indeed, protocols have been developed to measure clock 
function in skin cells using lentivirally-delivered circadian luciferase reporter vectors (Fig. 28). 
For example, fibroblast period length can be measured via cyclical expression of the 
circadian reporter Bmal1: luciferase (202-204).  
 
 As mentioned in section I.C.3.a, SCN neurons are tightly coupled one with another, 
which results in a robust circadian rhythmicity even in vitro. In contrast, rhythmic patterns of 
peripheral cells, including fibroblast, have the tendency to damp after several cycles due to 
phase desynchronization of individually oscillating cells (205; 204). Thus, fibroblasts need to 
be resynchronized after few days in culture to be able to continue to detect a circadian 
rhythmicity. Two classical methods used to synchronize peripheral oscillators are: (i) serum 
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shock, that consists in the incubation of the cells in a high percentage horse serum medium 
for 1-2 hours (201); (ii) activation of the glucocorticoid receptor by the use of dexamethasone 
(an analog of glucocorticoids) (206; 207). 
 More recently, a study performed on human primary fibroblasts cultivated from skin 
biopsies showed that the period length of human circadian behavior could be approximated 
by measurement of the circadian period length in fibroblasts (203). These data indicated for 
the first time that it may be possible to study circadian parameters of an individual using 
those of its fibroblasts and may enable to unravel relationships between circadian clock 
defects and associated diseases, using peripheral cells. 
 
 
 
 
Fig. 28: Protocol to study the circadian rhythms of human skin fibroblasts. A punch skin biopsy is harvested (1) 
and cultivated under sterile conditions. Fibroblasts that grow around the biopsy are isolated, amplified and 
infected with a circadian reporter (2) coding for firefly luciferase under a clock gene promoter, i.e. Bmal1. The 
infected cells are selected and then, after synchronization of circadian rhythms, the light emitted by the cells is 
measured in the Lumicycle (Actimetrics) (3). 
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4. Clock control of cellular metabolism and vice versa 
 
 Circadian clock may represent an evolutionary advantage, by enhancing metabolic 
efficiency through temporal separation of anabolic and catabolic reactions (Fig. 29). 
Understanding the relationship between metabolic system and the molecular clock 
represents an emerging field of research with the aim to increase our knowledge about 
metabolic impairments linked to circadian disruption, such as sleep disorders, 
cardiometabolic diseases or type 2 diabetes (208). 
 
Fig.29: Rhythmicity of metabolic processes according to time of day. The clock coordinates appropriate 
metabolic responses with the light/dark cycle and enhances energetic efficiency through temporal separation 
of anabolic and catabolic reactions in peripheral tissues. Circadian misalignment, which occurs during sleep 
disruption, shift work, and dietary alterations, disrupts the integration of circadian and metabolic systems, 
leading to adverse metabolic health effects (adapted from (209)) 
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 Recent studies have highlighted the role of some molecules coming from metabolic 
activity in the regulation of the circadian clock (210-212). One potential candidate is NAD+ 
that is, among others, involved in cellular redox reactions. Indeed, in vivo studies showed 
that the expression of the key rate-limiting enzyme in the NAD+ salvage pathway, the 
NAMPT (nicotinamide phosphoribosyltransferase), is directly regulated by CLOCK/BMAL1 
(Fig.30) (213). Other findings revealed that NAD+ display circadian oscillations in peripheral 
tissues (e.g. in the liver or in adipocytes), even when the mice are kept in DD conditions 
(constant darkness) (214). NAD+ is also a co-factor for several enzymes, including members 
of the sirtuin family. It was recently shown that the circadian clock modulates the activity of 
SIRT1 (sirtuin 1), a NAD+-dependent protein deacetylase involved in the deacetylation of 
histones and several transcription factors (215). SIRT1 (and other sirtuins) has emerged as a 
key metabolic sensor that regulates gluconeogenesis, lipid metabolism, insulin sensitivity and 
other metabolic processes (reviewed in (216)). The circadian oscillation of NAD+ levels 
appears to regulate SIRT1 activity, which then coordinates the daily pattern of metabolic 
processes mentioned above (215). In turn, SIRT1 modulates the circadian clock via a 
negative feedback loop by interacting with CLOCK, BMAL1 and PER2 (Fig.30) (217; 211). 
 In addition, the cellular redox state, translated by the ratios NAD+/NADH and 
NADP+/NADPH, seems to affect the circadian system. McKnight and colleagues (218) were 
the firsts to show that high levels of NAD+ and NADP+ (oxidized state) decrease the binding 
of CLOCK/BMAL1 to DNA, whereas the reduced forms (NADH and NADPH) increase this 
binding. Interestingly, more recent studies showed a 24 hours redox cycle in red blood cells 
that are cells devoid of nuclei, suggesting that the cellular redox state is self-sustained even 
in the absence of the transcriptional control of circadian gene expression (219; 220). 
 Finally, another measure of cellular metabolic state is the ratio AMP/ATP (ATP 
consuming pathways/ATP generating pathways). A major sensor of this ratio is the enzyme 
AMPK (adenosine monophosphate-dependent protein kinase) which is activated by 
phosphorylation when the ratio AMP/ATP increases. Studies showed that AMPK can directly 
modulate the circadian clock by phosphorylating CRY1 and PER2 (221; 222). This led to the 
degradation of both clock components and consequently affected the negative limb of the 
molecular circadian machinery. 
 Together, these data underpin the emerging relationship between the molecular clock 
and metabolic system. Of note, even if mitochondria play a central role in both metabolism 
and redox homeostasis, its implication in the regulation of the circadian system (and vice 
versa) is only hypothetical (223) and no clear link has been established until now (see 
section II.C). 
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Fig. 30: Cross talk between the core clock mechanism and metabolic pathways. The core clock can directly or 
indirectly synchronize diverse metabolic processes. The clock receives reciprocal input from nutrient signaling 
pathways (including SIRT1 and AMPK), which function as rheostats to coordinate metabolic processes with daily 
cycles of sleep/wakefulness and fasting/feeding. NAMPT; nicotinamide phosphoribosyltransferase, SIRT1; sirtuin 
1, AMPK; adenosine monophosphate-dependent protein kinase (adapted from (211)). 
 
 
REFERENCES 
69 
 
D. References 
 
(1) Shulman R.G., Rothman D.L., Behar K.L. et al. (2004) Energetic basis of brain activity: implications for 
neuroimaging. Trends in neurosciences 27:489-495 
(2) Yin F., Boveris A., Cadenas E. (2014) Mitochondrial energy metabolism and redox signaling in brain aging and 
neurodegeneration. Antioxid Redox Signal 20:353-371 
(3) Scheffler I.E. (2008) Mitochondria. 2nd edn. Wiley-Liss, Hoboken, N.J. 
(4) Friedman J.R., Nunnari J. (2014) Mitochondrial form and function. Nature 505:335-343 
(5) Chan D.C. (2006) Mitochondria: dynamic organelles in disease, aging, and development. Cell 125:1241-1252 
(6) Benard G., Rossignol R. (2008) Ultrastructure of the mitochondrion and its bearing on function and 
bioenergetics. Antioxid Redox Signal 10:1313-1342 
(7) Westermann B. (2010) Mitochondrial fusion and fission in cell life and death. Nature reviews Molecular cell 
biology 11:872-884 
(8) Osellame L.D., Blacker T.S., Duchen M.R. (2012) Cellular and molecular mechanisms of mitochondrial 
function. Best practice & research Clinical endocrinology & metabolism 26:711-723 
(9) Campello S., Scorrano L. (2010) Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep 
11:678-684 
(10) Knott A.B., Perkins G., Schwarzenbacher R. et al. (2008) Mitochondrial fragmentation in neurodegeneration. 
Nat Rev Neurosci 9:505-518 
(11) Twig G., Elorza A., Molina A.J. et al. (2008) Fission and selective fusion govern mitochondrial segregation 
and elimination by autophagy. The EMBO journal 27:433-446 
(12) Youle R.J., Narendra D.P. (2011) Mechanisms of mitophagy. Nature reviews Molecular cell biology 12:9-14 
(13) Alberts B. (2008) Molecular biology of the cell. 5th edn. Garland Science, New York 
(14) Lu B. (2011) Mitochondrial dynamics and neurodegeneration. Springer, New York 
(15) Hardie D.G. (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature 
reviews Molecular cell biology 8:774-785 
(16) Schulz K.L., Eckert A., Rhein V. et al. (2012) A new link to mitochondrial impairment in tauopathies. Mol 
Neurobiol 46:205-216 
(17) Wang X., Su B., Fujioka H. et al. (2008) Dynamin-like protein 1 reduction underlies mitochondrial morphology 
and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. The American 
journal of pathology 173:470-482 
(18) Wang X., Su B., Lee H.G. et al. (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's 
disease. J Neurosci 29:9090-9103 
(19) Wang X., Su B., Siedlak S.L. et al. (2008) Amyloid-beta overproduction causes abnormal mitochondrial 
dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 
105:19318-19323 
(20) Picard M., Shirihai O.S., Gentil B.J. et al. (2013) Mitochondrial morphology transitions and functions: 
implications for retrograde signaling? American journal of physiology Regulatory, integrative and 
comparative physiology 304:R393-406 
(21) Ishihara N., Jofuku A., Eura Y. et al. (2003) Regulation of mitochondrial morphology by membrane potential, 
and DRP1-dependent division and FZO1-dependent fusion reaction in mammalian cells. Biochemical 
and biophysical research communications 301:891-898 
(22) Legros F., Lombes A., Frachon P. et al. (2002) Mitochondrial fusion in human cells is efficient, requires the 
inner membrane potential, and is mediated by mitofusins. Mol Biol Cell 13:4343-4354 
(23) Adam-Vizi V., Chinopoulos C. (2006) Bioenergetics and the formation of mitochondrial reactive oxygen 
species. Trends in pharmacological sciences 27:639-645 
(24) Balaban R.S., Nemoto S., Finkel T. (2005) Mitochondria, oxidants, and aging. Cell 120:483-495 
(25) Jezek P., Hlavata L. (2005) Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and 
organism. The international journal of biochemistry & cell biology 37:2478-2503 
(26) Turrens J.F. (2003) Mitochondrial formation of reactive oxygen species. The Journal of physiology 552:335-
344 
(27) Korshunov S.S., Skulachev V.P., Starkov A.A. (1997) High protonic potential actuates a mechanism of 
production of reactive oxygen species in mitochondria. FEBS Lett 416:15-18 
(28) Giorgio M., Trinei M., Migliaccio E. et al. (2007) Hydrogen peroxide: a metabolic by-product or a common 
mediator of ageing signals? Nature reviews Molecular cell biology 8:722-728 
(29) Kishida K.T., Klann E. (2007) Sources and targets of reactive oxygen species in synaptic plasticity and 
memory. Antioxid Redox Signal 9:233-244 
(30) Veal E.A., Day A.M., Morgan B.A. (2007) Hydrogen peroxide sensing and signaling. Molecular cell 26:1-14 
REFERENCES 
70 
 
(31) Harper M.E., Bevilacqua L., Hagopian K. et al. (2004) Ageing, oxidative stress, and mitochondrial uncoupling. 
Acta physiologica Scandinavica 182:321-331 
(32) Goldstein S., Merenyi G. (2008) The chemistry of peroxynitrite: implications for biological activity. Methods in 
enzymology 436:49-61 
(33) Brown G.C., Borutaite V. (2002) Nitric oxide inhibition of mitochondrial respiration and its role in cell death. 
Free Radic Biol Med 33:1440-1450 
(34) Sies H. (1997) Oxidative stress: oxidants and antioxidants. Experimental physiology 82:291-295 
(35) Tsuru R., Hojo Y., Gama M. et al. (2006) Redox imbalance in patients with coronary artery disease showing 
progression of atherosclerotic lesions. Journal of cardiology 48:183-191 
(36) Wallace D.C. (2001) A mitochondrial paradigm for degenerative diseases and ageing. Novartis Foundation 
symposium 235:247-263; discussion 263-246 
(37) Galluzzi L., Blomgren K., Kroemer G. (2009) Mitochondrial membrane permeabilization in neuronal injury. 
Nat Rev Neurosci 10:481-494 
(38) Beal M.F. (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58:495-505 
(39) Trifunovic A. (2006) Mitochondrial DNA and ageing. Biochim Biophys Acta 1757:611-617 
(40) Kroemer G., Galluzzi L., Brenner C. (2007) Mitochondrial membrane permeabilization in cell death. 
Physiological reviews 87:99-163 
(41) Reed J.C., Jurgensmeier J.M., Matsuyama S. (1998) Bcl-2 family proteins and mitochondria. Biochim 
Biophys Acta 1366:127-137 
(42) Desagher S., Martinou J.C. (2000) Mitochondria as the central control point of apoptosis. Trends in cell 
biology 10:369-377 
(43) Prince M., Bryce R., Albanese E. et al. (2013) The global prevalence of dementia: a systematic review and 
metaanalysis. Alzheimer's & dementia : the journal of the Alzheimer's Association 9:63-75 e62 
(44) Mattson M.P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639 
(45) Sultzer D.L., Mahler M.E., Mandelkern M.A. et al. (1995) The relationship between psychiatric symptoms and 
regional cortical metabolism in Alzheimer's disease. The Journal of neuropsychiatry and clinical 
neurosciences 7:476-484 
(46) Karantzoulis S., Galvin J.E. (2011) Distinguishing Alzheimer's disease from other major forms of dementia. 
Expert review of neurotherapeutics 11:1579-1591 
(47) Perrin R.J., Fagan A.M., Holtzman D.M. (2009) Multimodal techniques for diagnosis and prognosis of 
Alzheimer's disease. Nature 461:916-922 
(48) Reitz C., Mayeux R. (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. 
Biochemical pharmacology 88:640-651 
(49) Brookmeyer R., Johnson E., Ziegler-Graham K. et al. (2007) Forecasting the global burden of Alzheimer's 
disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 3:186-191 
(50) Van Dam D., De Deyn P.P. (2006) Drug discovery in dementia: the role of rodent models. Nature reviews 
Drug discovery 5:956-970 
(51) Gotz J., Ittner L.M. (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev 
Neurosci 9:532-544 
(52) Goedert M., Jakes R. (2005) Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 
1739:240-250 
(53) Vest R.S., Pike C.J. (2013) Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav 63:301-
307 
(54) Vina J., Borras C. (2010) Women live longer than men: understanding molecular mechanisms offers 
opportunities to intervene by using estrogenic compounds. Antioxid Redox Signal 13:269-278 
(55) Hippius H., Neundorfer G. (2003) The discovery of Alzheimer's disease. Dialogues in clinical neuroscience 
5:101-108 
(56) Trinczek B., Biernat J., Baumann K. et al. (1995) Domains of tau protein, differential phosphorylation, and 
dynamic instability of microtubules. Mol Biol Cell 6:1887-1902 
(57) Matus A. (1990) Microtubule-associated proteins and the determination of neuronal form. Journal de 
physiologie 84:134-137 
(58) Wang J.Z., Xia Y.Y., Grundke-Iqbal I. et al. (2013) Abnormal hyperphosphorylation of tau: sites, regulation, 
and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 33 Suppl 1:S123-139 
(59) Eckert A., Nisbet R., Grimm A. et al. (2014) March separate, strike together--role of phosphorylated TAU in 
mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842:1258-1266 
(60) Brunden K.R., Trojanowski J.Q., Lee V.M. (2009) Advances in tau-focused drug discovery for Alzheimer's 
disease and related tauopathies. Nature reviews Drug discovery 8:783-793 
REFERENCES 
71 
 
(61) Perez P.D., Hall G., Kimura T. et al. (2013) In vivo functional brain mapping in a conditional mouse model of 
human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures. Mol 
Neurodegener 8:9 
(62) Hardy J.A., Higgins G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185 
(63) Karran E., Mercken M., De Strooper B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an 
appraisal for the development of therapeutics. Nature reviews Drug discovery 10:698-712 
(64) Kim J., Lee H.J., Lee K.W. (2010) Naturally occurring phytochemicals for the prevention of Alzheimer's 
disease. J Neurochem 112:1415-1430 
(65) LaFerla F.M., Green K.N., Oddo S. (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev 
Neurosci 8:499-509 
(66) Mattson M.P. (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic 
derivatives. Physiological reviews 77:1081-1132 
(67) Pagani L., Eckert A. (2011) Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis 2011:925050 
(68) Manczak M., Park B.S., Jung Y. et al. (2004) Differential expression of oxidative phosphorylation genes in 
patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. 
Neuromolecular Med 5:147-162 
(69) Gibson G.E., Sheu K.F., Blass J.P. (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J 
Neural Transm 105:855-870 
(70) Mosconi L., Pupi A., De Leon M.J. (2008) Brain glucose hypometabolism and oxidative stress in preclinical 
Alzheimer's disease. Ann N Y Acad Sci 1147:180-195 
(71) Schmitt K., Grimm A., Kazmierczak A. et al. (2012) Insights into mitochondrial dysfunction: aging, amyloid-
beta, and tau-A deleterious trio. Antioxid Redox Signal 16:1456-1466 
(72) Casley C.S., Canevari L., Land J.M. et al. (2002) Beta-amyloid inhibits integrated mitochondrial respiration 
and key enzyme activities. J Neurochem 80:91-100 
(73) Eckert A., Schmitt K., Gotz J. (2011) Mitochondrial dysfunction - the beginning of the end in Alzheimer's 
disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimers Res Ther 3:15 
(74) Perry G., Nunomura A., Hirai K. et al. (2000) Oxidative damage in Alzheimer's disease: the metabolic 
dimension. Int J Dev Neurosci 18:417-421 
(75) Devi L., Prabhu B.M., Galati D.F. et al. (2006) Accumulation of amyloid precursor protein in the mitochondrial 
import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J 
Neurosci 26:9057-9068 
(76) Keil U., Bonert A., Marques C.A. et al. (2004) Amyloid beta-induced changes in nitric oxide production and 
mitochondrial activity lead to apoptosis. J Biol Chem 279:50310-50320 
(77) Pavlov P.F., Wiehager B., Sakai J. et al. (2011) Mitochondrial gamma-secretase participates in the 
metabolism of mitochondria-associated amyloid precursor protein. FASEB J 25:78-88 
(78) Caspersen C., Wang N., Yao J. et al. (2005) Mitochondrial Abeta: a potential focal point for neuronal 
metabolic dysfunction in Alzheimer's disease. FASEB J 19:2040-2041 
(79) Lustbader J.W., Cirilli M., Lin C. et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in 
Alzheimer's disease. Science 304:448-452 
(80) Manczak M., Anekonda T.S., Henson E. et al. (2006) Mitochondria are a direct site of A beta accumulation in 
Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease 
progression. Hum Mol Genet 15:1437-1449 
(81) Rhein V., Baysang G., Rao S. et al. (2009) Amyloid-beta leads to impaired cellular respiration, energy 
production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol 
Neurobiol 29:1063-1071 
(82) Rhein V., Giese M., Baysang G. et al. (2010) Ginkgo biloba extract ameliorates oxidative phosphorylation 
performance and rescues abeta-induced failure. PLoS One 5:e12359 
(83) Lim Y.A., Rhein V., Baysang G. et al. (2010) Abeta and human amylin share a common toxicity pathway via 
mitochondrial dysfunction. Proteomics 10:1621-1633 
(84) Eckert A., Hauptmann S., Scherping I. et al. (2008) Oligomeric and fibrillar species of beta-amyloid (A beta 
42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) 86:1255-1267 
(85) Eckert A., Hauptmann S., Scherping I. et al. (2008) Soluble beta-amyloid leads to mitochondrial defects in 
amyloid precursor protein and tau transgenic mice. Neurodegener Dis 5:157-159 
(86) Gillardon F., Rist W., Kussmaul L. et al. (2007) Proteomic and functional alterations in brain mitochondria 
from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7:605-616 
(87) Hauptmann S., Scherping I., Drose S. et al. (2009) Mitochondrial dysfunction: an early event in Alzheimer 
pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30:1574-1586 
REFERENCES 
72 
 
(88) Reddy P.H., McWeeney S., Park B.S. et al. (2004) Gene expression profiles of transcripts in amyloid 
precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an 
early cellular change in Alzheimer's disease. Hum Mol Genet 13:1225-1240 
(89) Rhein V., Song X., Wiesner A. et al. (2009) Amyloid-beta and tau synergistically impair the oxidative 
phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 
106:20057-20062 
(90) Grimm A., Lim Y.A., Mensah-Nyagan A.G. et al. (2012) Alzheimer's disease, oestrogen and mitochondria: an 
ambiguous relationship. Mol Neurobiol 46:151-160 
(91) Reddy P.H. (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and 
synaptic deprivation in Alzheimer's disease. Brain Res 1415:136-148 
(92) David D.C., Hauptmann S., Scherping I. et al. (2005) Proteomic and functional analyses reveal a 
mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 280:23802-23814 
(93) DuBoff B., Gotz J., Feany M.B. (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. 
Neuron 75:618-632 
(94) Eckert A., Schulz K.L., Rhein V. et al. (2010) Convergence of amyloid-beta and tau pathologies on 
mitochondria in vivo. Mol Neurobiol 41:107-114 
(95) Gotz J., Chen F., van Dorpe J. et al. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice 
induced by Abeta 42 fibrils. Science 293:1491-1495 
(96) Gotz J., Chen F., Barmettler R. et al. (2001) Tau filament formation in transgenic mice expressing P301L tau. 
J Biol Chem 276:529-534 
(97) Lewis J., Dickson D.W., Lin W.L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice 
expressing mutant tau and APP. Science 293:1487-1491 
(98) Yao J., Irwin R.W., Zhao L. et al. (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in 
female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106:14670-14675 
(99) Swerdlow R.H., Khan S.M. (2004) A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. 
Medical hypotheses 63:8-20 
(100) Kalous M., Drahota Z. (1996) The role of mitochondria in aging. Physiological research / Academia 
Scientiarum Bohemoslovaca 45:351-359 
(101) Lee H.C., Wei Y.H. (1997) Mutation and oxidative damage of mitochondrial DNA and defective turnover of 
mitochondria in human aging. Journal of the Formosan Medical Association = Taiwan yi zhi 96:770-778 
(102) Swerdlow R.H., Burns J.M., Khan S.M. (2014) The Alzheimer's disease mitochondrial cascade hypothesis: 
progress and perspectives. Biochim Biophys Acta 1842:1219-1231 
(103) Moreira P.I., Zhu X., Wang X. et al. (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim 
Biophys Acta 1802:212-220 
(104) Dimauro S., Rustin P. (2009) A critical approach to the therapy of mitochondrial respiratory chain and 
oxidative phosphorylation diseases. Biochim Biophys Acta 1792:1159-1167 
(105) Smith R.A., Adlam V.J., Blaikie F.H. et al. (2008) Mitochondria-targeted antioxidants in the treatment of 
disease. Ann N Y Acad Sci 1147:105-111 
(106) Swerdlow R.H. (2007) Treating neurodegeneration by modifying mitochondria: potential solutions to a 
"complex" problem. Antioxid Redox Signal 9:1591-1603 
(107) McManus M.J., Murphy M.P., Franklin J.L. (2011) The mitochondria-targeted antioxidant MitoQ prevents 
loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's 
disease. J Neurosci 31:15703-15715 
(108) Smith R.A., Hartley R.C., Murphy M.P. (2011) Mitochondria-targeted small molecule therapeutics and 
probes. Antioxid Redox Signal 15:3021-3038 
(109) Mensah-Nyagan A.G., Do-Rego J.L., Beaujean D. et al. (1999) Neurosteroids: expression of steroidogenic 
enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacological reviews 
51:63-81 
(110) Plassart-Schiess E., Baulieu E.E. (2001) Neurosteroids: recent findings. Brain Research Review 37:133-
140 
(111) Corpechot C., Robel P., Axelson M. et al. (1981) Characterization and measurement of 
dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci U S A 78:4704-4707 
(112) Do Rego J.L., Seong J.Y., Burel D. et al. (2009) Neurosteroid biosynthesis: enzymatic pathways and 
neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 30:259-301 
(113) Patte-Mensah C., Kibaly C., Boudard D. et al. (2006) Neurogenic pain and steroid synthesis in the spinal 
cord. Journal of Molecular Neuroscience 28:17-31 
(114) Tsutsui K. (2008) Neurosteroids in the Purkinje cell: biosynthesis, mode of action and functional 
significance. Molecular Neurobiology 37:116-125 
REFERENCES 
73 
 
(115) Miller W.L., Auchus R.J. (2011) The molecular biology, biochemistry, and physiology of human 
steroidogenesis and its disorders. Endocrine reviews 32:81-151 
(116) Patte-Mensah C., Mensah-Nyagan A.G. (2008) Peripheral neuropathy and neurosteroid formation in the 
central nervous system. Brain Res Rev 57:454-459 
(117) Haberland M.E., Reynolds J.A. (1973) Self-association of cholesterol in aqueous solution. Proc Natl Acad 
Sci U S A 70:2313-2316 
(118) Issop L., Rone M.B., Papadopoulos V. (2013) Organelle plasticity and interactions in cholesterol transport 
and steroid biosynthesis. Molecular and cellular endocrinology 371:34-46 
(119) Rone M.B., Fan J., Papadopoulos V. (2009) Cholesterol transport in steroid biosynthesis: role of protein-
protein interactions and implications in disease states. Biochimica et Biophysica Acta 1791:646-658 
(120) Gwynne J.T., Strauss J.F., 3rd (1982) The role of lipoproteins in steroidogenesis and cholesterol 
metabolism in steroidogenic glands. Endocrine reviews 3:299-329 
(121) Papadopoulos V., Lecanu L., Brown R.C. et al. (2006) Peripheral-type benzodiazepine receptor in 
neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138:749-756 
(122) Duarte A., Poderoso C., Cooke M. et al. (2012) Mitochondrial fusion is essential for steroid biosynthesis. 
PLoS One 7:e45829 
(123) Miller W.L. (2008) Steroidogenic enzymes. Endocrine development 13:1-18 
(124) Lim Y.A., Grimm A., Giese M. et al. (2011) Inhibition of the Mitochondrial Enzyme ABAD Restores the 
Amyloid-beta-Mediated Deregulation of Estradiol. PLoS One 6:e28887 
(125) Foryst-Ludwig A., Clemenz M., Hohmann S. et al. (2008) Metabolic actions of estrogen receptor beta 
(ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS genetics 4:e1000108 
(126) Frye C.A., Koonce C.J., Walf A.A. (2014) Novel receptor targets for production and action of 
allopregnanolone in the central nervous system: a focus on pregnane xenobiotic receptor. Frontiers in 
cellular neuroscience 8:106 
(127) Irwin R.W., Brinton R.D. (2014) Allopregnanolone as regenerative therapeutic for Alzheimer's disease: 
translational development and clinical promise. Prog Neurobiol 113:40-55 
(128) Lamba V., Yasuda K., Lamba J.K. et al. (2004) PXR (NR1I2): splice variants in human tissues, including 
brain, and identification of neurosteroids and nicotine as PXR activators. Toxicology and applied 
pharmacology 199:251-265 
(129) Belelli D., Lambert J.J. (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev 
Neurosci 6:565-575 
(130) Maurice T., Gregoire C., Espallergues J. (2006) Neuro(active)steroids actions at the neuromodulatory 
sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection. 
Pharmacology, biochemistry, and behavior 84:581-597 
(131) Mellon S.H. (2007) Neurosteroid regulation of central nervous system development. Pharmacology & 
therapeutics 116:107-124 
(132) Melcangi R.C., Garcia-Segura L.M., Mensah-Nyagan A.G. (2008) Neuroactive steroids: state of the art and 
new perspectives. Cell Mol Life Sci 65:777-797 
(133) Stanisic V., Lonard D.M., O'Malley B.W. (2010) Modulation of steroid hormone receptor activity. Progress in 
brain research 181:153-176 
(134) Schaeffer V., Meyer L., Patte-Mensah C. et al. (2010) Progress in dorsal root ganglion neurosteroidogenic 
activity: basic evidence and pathophysiological correlation. Progress in Neurobiology 92:33-41 
(135) Maki P.M., Dumas J. (2009) Mechanisms of action of estrogen in the brain: insights from human 
neuroimaging and psychopharmacologic studies. Seminars in Reproductive Medicine 27:250-259 
(136) Longone P., di Michele F., D'Agati E. et al. (2011) Neurosteroids as neuromodulators in the treatment of 
anxiety disorders. Front Endocrinol (Lausanne) 2:55 
(137) Schumacher M., Weill-Engerer S., Liere P. et al. (2003) Steroid hormones and neurosteroids in normal and 
pathological aging of the nervous system. Prog Neurobiol 71:3-29 
(138) Feldman H.A., Longcope C., Derby C.A. et al. (2002) Age trends in the level of serum testosterone and 
other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J 
Clin Endocrinol Metab 87:589-598 
(139) Vallee M., Rivera J.D., Koob G.F. et al. (2000) Quantification of neurosteroids in rat plasma and brain 
following swim stress and allopregnanolone administration using negative chemical ionization gas 
chromatography/mass spectrometry. Anal Biochem 287:153-166 
(140) Caruso D., Barron A.M., Brown M.A. et al. (2013) Age-related changes in neuroactive steroid levels in 3xTg-
AD mice. Neurobiol Aging 34:1080-1089 
(141) Brown R.C., Han Z., Cascio C. et al. (2003) Oxidative stress-mediated DHEA formation in Alzheimer's 
disease pathology. Neurobiol Aging 24:57-65 
REFERENCES 
74 
 
(142) Smith C.D., Wekstein D.R., Markesbery W.R. et al. (2006) 3alpha,5alpha-THP: a potential plasma 
neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. 
Psychopharmacology (Berl) 186:481-485 
(143) Brown R.C., Cascio C., Papadopoulos V. (2000) Pathways of neurosteroid biosynthesis in cell lines from 
human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid 
peptide. Journal of Neurochemistry 74:847-859 
(144) Griffin L.D., Gong W., Verot L. et al. (2004) Niemann-Pick type C disease involves disrupted 
neurosteroidogenesis and responds to allopregnanolone. Nat Med 10:704-711 
(145) Schaeffer V., Meyer L., Patte-Mensah C. et al. (2008) Dose-dependent and sequence-sensitive effects of 
amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochem Int 52:948-
955 
(146) Schaeffer V., Patte-Mensah C., Eckert A. et al. (2006) Modulation of neurosteroid production in human 
neuroblastoma cells by Alzheimer's disease key proteins. Journal of neurobiology 66:868-881 
(147) Yao J., Irwin R., Chen S. et al. (2012) Ovarian hormone loss induces bioenergetic deficits and mitochondrial 
beta-amyloid. Neurobiol Aging 33:1507-1521 
(148) Compagnone N.A., Mellon S.H. (1998) Dehydroepiandrosterone: a potential signalling molecule for 
neocortical organization during development. Proc Natl Acad Sci U S A 95:4678-4683 
(149) Karishma K.K., Herbert J. (2002) Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the 
hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced 
suppression. Eur J Neurosci 16:445-453 
(150) Koenig H.L., Schumacher M., Ferzaz B. et al. (1995) Progesterone synthesis and myelin formation by 
Schwann cells. Science 268:1500-1503 
(151) Magnaghi V., Cavarretta I., Galbiati M. et al. (2001) Neuroactive steroids and peripheral myelin proteins. 
Brain Res Brain Res Rev 37:360-371 
(152) Borowicz K.K., Piskorska B., Banach M. et al. (2011) Neuroprotective actions of neurosteroids. Front 
Endocrinol (Lausanne) 2:50 
(153) Pike C.J., Carroll J.C., Rosario E.R. et al. (2009) Protective actions of sex steroid hormones in Alzheimer's 
disease. Front Neuroendocrinol 30:239-258 
(154) Paganini-Hill A., Henderson V.W. (1996) Estrogen replacement therapy and risk of Alzheimer disease. 
Archives of Internal Medicine 156:2213-2217 
(155) Tang M.X., Jacobs D., Stern Y. et al. (1996) Effect of oestrogen during menopause on risk and age at onset 
of Alzheimer's disease. Lancet 348:429-432 
(156) Anderson G.L., Limacher M., Assaf A.R. et al. (2004) Effects of conjugated equine estrogen in 
postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. 
Journal of the American Medical Association 291:1701-1712 
(157) Rossouw J.E., Anderson G.L., Prentice R.L. et al. (2002) Risks and benefits of estrogen plus progestin in 
healthy postmenopausal women: principal results From the Women's Health Initiative randomized 
controlled trial. Journal of the American Medical Association 288:321-333 
(158) Irwin R.W., Yao J., Hamilton R.T. et al. (2008) Progesterone and estrogen regulate oxidative metabolism in 
brain mitochondria. Endocrinology 149:3167-3175 
(159) Castellani R.J., Rolston R.K., Smith M.A. (2010) Alzheimer disease. Dis Mon 56:484-546 
(160) Amtul Z., Wang L., Westaway D. et al. (2010) Neuroprotective mechanism conferred by 17beta-estradiol on 
the biochemical basis of Alzheimer's disease. Neuroscience 169:781-786 
(161) Carroll J.C., Rosario E.R., Chang L. et al. (2007) Progesterone and estrogen regulate Alzheimer-like 
neuropathology in female 3xTg-AD mice. Journal of Neuroscience 27:13357-13365 
(162) Frye C.A., Walf A.A. (2008) Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation 
for cognitive performance of mid-aged mice. Neurobiol Learn Mem 89:17-26 
(163) Frye C.A., Walf A.A. (2009) Progesterone reduces depression-like behavior in a murine model of 
Alzheimer's Disease. Age 31:143-153 
(164) Simpkins J.W., Yi K.D., Yang S.H. et al. (2010) Mitochondrial mechanisms of estrogen neuroprotection. 
Biochimica et Biophysica Acta 1800:1113-1120 
(165) Nilsen J. (2008) Estradiol and neurodegenerative oxidative stress. Frontiers in Neuroendocrinology 29:463-
475 
(166) Borras C., Sastre J., Garcia-Sala D. et al. (2003) Mitochondria from females exhibit higher antioxidant gene 
expression and lower oxidative damage than males. Free Radical Biology and Medicine 34:546-552 
(167) Brinton R.D. (2008) Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic 
implications for prevention of Alzheimer's disease. Advanced Drug Delivery Reviews 60:1504-1511 
(168) Rosario E.R., Carroll J., Pike C.J. (2010) Testosterone regulation of Alzheimer-like neuropathology in male 
3xTg-AD mice involves both estrogen and androgen pathways. Brain Res 1359:281-290 
REFERENCES 
75 
 
(169) Rosario E.R., Carroll J.C., Oddo S. et al. (2006) Androgens regulate the development of neuropathology in 
a triple transgenic mouse model of Alzheimer's disease. J Neurosci 26:13384-13389 
(170) Papasozomenos S.C. (1997) The heat shock-induced hyperphosphorylation of tau is estrogen-independent 
and prevented by androgens: implications for Alzheimer disease. Proc Natl Acad Sci U S A 94:6612-
6617 
(171) Overk C.R., Perez S.E., Ma C. et al. (2013) Sex steroid levels and AD-like pathology in 3xTgAD mice. 
Journal of neuroendocrinology 25:131-144 
(172) Verdile G., Laws S.M., Henley D. et al. (2014) Associations between gonadotropins, testosterone and beta 
amyloid in men at risk of Alzheimer's disease. Mol Psychiatry 19:69-75 
(173) Chen S., Wang J.M., Irwin R.W. et al. (2011) Allopregnanolone promotes regeneration and reduces beta-
amyloid burden in a preclinical model of Alzheimer's disease. PLoS One 6:e24293 
(174) Singh C., Liu L., Wang J.M. et al. (2012) Allopregnanolone restores hippocampal-dependent learning and 
memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging 33:1493-1506 
(175) Vaze K.M., Sharma V.K. (2013) On the adaptive significance of circadian clocks for their owners. 
Chronobiology international 30:413-433 
(176) Circadian clocks (2013). Springer, New York 
(177) Hastings M.H., Reddy A.B., Maywood E.S. (2003) A clockwork web: circadian timing in brain and periphery, 
in health and disease. Nat Rev Neurosci 4:649-661 
(178) Lowrey P.L., Takahashi J.S. (2011) Genetics of circadian rhythms in Mammalian model organisms. 
Advances in genetics 74:175-230 
(179) Albrecht U. (2012) Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 
74:246-260 
(180) Preitner N., Damiola F., Lopez-Molina L. et al. (2002) The orphan nuclear receptor REV-ERBalpha controls 
circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110:251-260 
(181) Takahashi J.S. (1995) Molecular neurobiology and genetics of circadian rhythms in mammals. Annual 
review of neuroscience 18:531-553 
(182) Dibner C., Schibler U., Albrecht U. (2010) The mammalian circadian timing system: organization and 
coordination of central and peripheral clocks. Annual review of physiology 72:517-549 
(183) Moore R.Y., Eichler V.B. (1972) Loss of a circadian adrenal corticosterone rhythm following 
suprachiasmatic lesions in the rat. Brain Res 42:201-206 
(184) Stephan F.K., Zucker I. (1972) Circadian rhythms in drinking behavior and locomotor activity of rats are 
eliminated by hypothalamic lesions. Proc Natl Acad Sci U S A 69:1583-1586 
(185) Lehman M.N., Silver R., Gladstone W.R. et al. (1987) Circadian rhythmicity restored by neural transplant. 
Immunocytochemical characterization of the graft and its integration with the host brain. J Neurosci 
7:1626-1638 
(186) Lowrey P.L., Shimomura K., Antoch M.P. et al. (2000) Positional syntenic cloning and functional 
characterization of the mammalian circadian mutation tau. Science 288:483-492 
(187) Bos N.P., Mirmiran M. (1990) Circadian rhythms in spontaneous neuronal discharges of the cultured 
suprachiasmatic nucleus. Brain Res 511:158-162 
(188) Welsh D.K., Takahashi J.S., Kay S.A. (2010) Suprachiasmatic nucleus: cell autonomy and network 
properties. Annual review of physiology 72:551-577 
(189) Mohawk J.A., Takahashi J.S. (2011) Cell autonomy and synchrony of suprachiasmatic nucleus circadian 
oscillators. Trends in neurosciences 34:349-358 
(190) Schibler U. (2007) The daily timing of gene expression and physiology in mammals. Dialogues in clinical 
neuroscience 9:257-272 
(191) Lopez-Molina L., Conquet F., Dubois-Dauphin M. et al. (1997) The DBP gene is expressed according to a 
circadian rhythm in the suprachiasmatic nucleus and influences circadian behavior. The EMBO journal 
16:6762-6771 
(192) Takumi T., Matsubara C., Shigeyoshi Y. et al. (1998) A new mammalian period gene predominantly 
expressed in the suprachiasmatic nucleus. Genes to cells : devoted to molecular & cellular mechanisms 
3:167-176 
(193) Zylka M.J., Shearman L.P., Weaver D.R. et al. (1998) Three period homologs in mammals: differential light 
responses in the suprachiasmatic circadian clock and oscillating transcripts outside of brain. Neuron 
20:1103-1110 
(194) Akhtar R.A., Reddy A.B., Maywood E.S. et al. (2002) Circadian cycling of the mouse liver transcriptome, as 
revealed by cDNA microarray, is driven by the suprachiasmatic nucleus. Current biology : CB 12:540-
550 
(195) Wirz-Justice A. (2007) Chronobiology and psychiatry. Sleep medicine reviews 11:423-427 
REFERENCES 
76 
 
(196) Verwey M., Robinson B., Amir S. (2013) Recording and analysis of circadian rhythms in running-wheel 
activity in rodents. Journal of visualized experiments : JoVE 
(197) Bae K., Jin X., Maywood E.S. et al. (2001) Differential functions of mPer1, mPer2, and mPer3 in the SCN 
circadian clock. Neuron 30:525-536 
(198) van der Horst G.T., Muijtjens M., Kobayashi K. et al. (1999) Mammalian Cry1 and Cry2 are essential for 
maintenance of circadian rhythms. Nature 398:627-630 
(199) Vitaterna M.H., Selby C.P., Todo T. et al. (1999) Differential regulation of mammalian period genes and 
circadian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci U S A 96:12114-12119 
(200) Zheng B., Larkin D.W., Albrecht U. et al. (1999) The mPer2 gene encodes a functional component of the 
mammalian circadian clock. Nature 400:169-173 
(201) Balsalobre A., Damiola F., Schibler U. (1998) A serum shock induces circadian gene expression in 
mammalian tissue culture cells. Cell 93:929-937 
(202) Pagani L., Schmitt K., Meier F. et al. (2011) Serum factors in older individuals change cellular clock 
properties. Proc Natl Acad Sci U S A 108:7218-7223 
(203) Pagani L., Semenova E.A., Moriggi E. et al. (2010) The physiological period length of the human circadian 
clock in vivo is directly proportional to period in human fibroblasts. PLoS One 5:e13376 
(204) Welsh D.K., Yoo S.H., Liu A.C. et al. (2004) Bioluminescence imaging of individual fibroblasts reveals 
persistent, independently phased circadian rhythms of clock gene expression. Current biology : CB 
14:2289-2295 
(205) Nagoshi E., Saini C., Bauer C. et al. (2004) Circadian gene expression in individual fibroblasts: cell-
autonomous and self-sustained oscillators pass time to daughter cells. Cell 119:693-705 
(206) Balsalobre A., Brown S.A., Marcacci L. et al. (2000) Resetting of circadian time in peripheral tissues by 
glucocorticoid signaling. Science 289:2344-2347 
(207) Balsalobre A., Marcacci L., Schibler U. (2000) Multiple signaling pathways elicit circadian gene expression 
in cultured Rat-1 fibroblasts. Current biology : CB 10:1291-1294 
(208) Depner C.M., Stothard E.R., Wright K.P., Jr. (2014) Metabolic consequences of sleep and circadian 
disorders. Current diabetes reports 14:507 
(209) Bass J., Takahashi J.S. (2010) Circadian integration of metabolism and energetics. Science 330:1349-1354 
(210) Bellet M.M., Sassone-Corsi P. (2010) Mammalian circadian clock and metabolism - the epigenetic link. J 
Cell Sci 123:3837-3848 
(211) Marcheva B., Ramsey K.M., Peek C.B. et al. (2013) Circadian clocks and metabolism. Handbook of 
experimental pharmacology:127-155 
(212) Peek C.B., Affinati A.H., Ramsey K.M. et al. (2013) Circadian clock NAD+ cycle drives mitochondrial 
oxidative metabolism in mice. Science 342:1243417 
(213) Nakahata Y., Sahar S., Astarita G. et al. (2009) Circadian control of the NAD+ salvage pathway by CLOCK-
SIRT1. Science 324:654-657 
(214) Ramsey K.M., Yoshino J., Brace C.S. et al. (2009) Circadian clock feedback cycle through NAMPT-
mediated NAD+ biosynthesis. Science 324:651-654 
(215) Nakahata Y., Kaluzova M., Grimaldi B. et al. (2008) The NAD+-dependent deacetylase SIRT1 modulates 
CLOCK-mediated chromatin remodeling and circadian control. Cell 134:329-340 
(216) Li X., Kazgan N. (2011) Mammalian sirtuins and energy metabolism. International journal of biological 
sciences 7:575-587 
(217) Eckel-Mahan K., Sassone-Corsi P. (2009) Metabolism control by the circadian clock and vice versa. Nature 
structural & molecular biology 16:462-467 
(218) Rutter J., Reick M., Wu L.C. et al. (2001) Regulation of clock and NPAS2 DNA binding by the redox state of 
NAD cofactors. Science 293:510-514 
(219) O'Neill J.S., Reddy A.B. (2011) Circadian clocks in human red blood cells. Nature 469:498-503 
(220) O'Neill J.S., van Ooijen G., Dixon L.E. et al. (2011) Circadian rhythms persist without transcription in a 
eukaryote. Nature 469:554-558 
(221) Lamia K.A., Sachdeva U.M., DiTacchio L. et al. (2009) AMPK regulates the circadian clock by cryptochrome 
phosphorylation and degradation. Science 326:437-440 
(222) Um J.H., Yang S., Yamazaki S. et al. (2007) Activation of 5'-AMP-activated kinase with diabetes drug 
metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J 
Biol Chem 282:20794-20798 
(223) Langmesser S., Albrecht U. (2006) Life time-circadian clocks, mitochondria and metabolism. Chronobiology 
international 23:151-157 
   
 
77 
 
 
 
 
 
 
 
 
 
 
II. RESULTS 
RESULTS  Grimm A. et al. (2014) 
78 
 
 
A. Improvement of neuronal bioenergetics by neurosteroids: 
Implications for age-related neurodegenerative disorders. 
 
 
Amandine Grimm a,b,c,&; Karen Schmitt a,b,& ; Undine E. Lang b; Ayikoe Guy Mensah-Nyagan 
c; Anne Eckert a,b,* 
 
& These authors contributed equally to this work. 
 
a Neurobiology Laboratory for Brain Aging and Mental Health, Transfaculty Research 
Platform, Molecular & Cognitive Neuroscience, University of Basel, Wilhelm Klein-Str. 27 
CH-4012 Basel, Switzerland 
b Psychiatric University Clinics, University of Basel, Wilhelm Klein-Str. 27 
CH-4012 Basel, Switzerland 
c Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM 
U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de 
Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, 
France 
 
* Corresponding Author: Anne Eckert, anne.eckert@upkbs.ch  
 
 
 
Biochimica et Biophysica Acta, Molecular basis of disease 2014 
doi: 10.1016/j.bbadis.2014.09.013 
RESULTS  Grimm A. et al. (2014) 
79 
 
 
Abstract 
 
 The brain has high energy requirements to maintain neuronal activity. Consequently 
impaired mitochondrial function will lead to disease. Normal aging is associated with several 
alterations in neurosteroid production and secretion. Decreases in neurosteroid levels might 
contribute to brain aging and loss of important nervous functions, such as memory. Up to 
now, extensive studies only focused on estradiol as a promising neurosteroid compound that 
is able to ameliorate cellular bioenergetics, while the effects of other steroids on brain 
mitochondria are poorly understood or not investigated at all. Thus, we aimed to characterize 
the bioenergetic modulating profile of a panel of seven structurally diverse neurosteroids 
(progesterone, estradiol, estrone, testosterone, 3α-androstanediol, DHEA and 
allopregnanolone), known to be involved in brain function regulation. Of note, most of the 
steroids tested were able to improve bioenergetic activity in neuronal cells by increasing ATP 
levels, mitochondrial membrane potential and basal mitochondrial respiration. In parallel, 
they modulated redox homeostasis by increasing antioxidant activity, probably as a 
compensatory mechanism to a slight enhancement of ROS which might result from the rise 
in oxygen consumption. Thereby, neurosteroids appeared to act via their corresponding 
receptors and exhibited specific bioenergetic profiles. Taken together, our results indicate 
that the ability to boost mitochondria is not unique to estradiol, but seems to be a rather 
common mechanism of different steroids in the brain. Thus, neurosteroids may act upon 
neuronal bioenergetics in a delicate balance and an age-related steroid disturbance might be 
involved in mitochondrial dysfunction underlying neurodegenerative disorders. 
 
Keywords: Mitochondria, Neurosteroid, Bioenergetics, Amyloid-β peptide, tau protein. 
 
Abbreviations:  
3α-A, 3α-androstanediol; AD, Alzheimer’s disease; APP, amyloid-β precursor protein; AP, 
allopregnanolone; D, DHEA (dihydroepiandrosterone); DHR, dihydrorhodamine 123; DMSO, 
dimethylsulfoxide; E1, estrone; E2, 17β-estradiol; E3, estriol; ECAR, extracellular 
acidification rate; ETC, electron transport chain; MAS, mitochondrial assay solution; MPP, 
mitochondrial membrane potential; mtROS, mitochondrial reactive oxygen species; OCR, 
oxygen consumption rate; OXPHOS, Oxidative phosphorylation; P, progesterone; PD, 
Parkinson’s disease; PMP, plasma membrane permeabilizer; RCR, respiratory control ratio; 
roGFP, redox sensitive green fluorescent protein; ROS, reactive oxygen species; SRA, 
steroid receptor antagonist; T, testosterone; TCA, tricyclic acid. 
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1. Introduction 
 
 The brain is a highly differentiated organ with high energy requirements, mainly in the 
form of adenosine triphosphate (ATP) molecules. Despite its small size, it accounts for about 
20% of the body’s total basal oxygen consumption (1). As a result, the brain is more sensitive 
to neuronal damage during hypometabolic states and impaired redox homeostasis, as 
observed in normal aging and in neurodegenerative diseases associated with a decline in 
energy production and changes in the redox status (2). In this context, mitochondria, small 
organelles that are present in almost all cell types playing a predominant role in cellular 
bioenergetics, are particularly important in the nervous system because of its high energy 
demand. Mitochondria are not only the “powerhouses of the cell”, providing the main source 
of cellular energy via ATP generation through oxidative phosphorylation, but they also 
contribute to plenty of cellular functions, including apoptosis, intracellular calcium 
homeostasis, alteration of the cellular reduction–oxidation (redox) state and synaptic 
plasticity (3; 4). Thus, it is more and more recognized that mitochondrial dysfunction is a 
significant and early event of neurodegeneration, and that the pathophysiological 
mechanisms of a range of neurodegenerative diseases, including Alzheimer’s (AD) and 
Parkinson’s disease (PD), are associated with a decline in bioenergetic activity and an 
increase in oxidative stress, particularly in mitochondria themselves (5-10). 
 Steroid hormones are molecules involved in the control of many physiological 
processes in the periphery, from reproductive behavior to the stress response. They are 
mainly produced by endocrine glands, such as the adrenal glands, gonads and placenta, but 
in 1981 Baulieu and co-workers were the first to demonstrate the production of steroids 
within the nervous system itself (11). This last category of molecules is now called 
“neurosteroids” and is defined as steroids that are synthetized within the nervous system 
independently of peripheral endocrine glands. Neurosteroid levels remain elevated even after 
adrenalectomy and castration (12; 13) and are involved in brain-specific functions. Since the 
ability to produce neurosteroids is conserved during vertebrate evolution, one can suggest 
that this family of molecules is important for living things and that the modulation of their 
biosynthesis plays an important role in the pathophysiology of neurodegenerative disorders.  
 Studies performed in humans, animals, and cellular models have shown alterations in 
the synthesis of neurosteroids that declined during brain aging paralleled by a loss of 
important nervous functions, such as memory, and were further associated with PD and AD 
(14-16). Thus, several neurosteroids have been quantified in various brain regions of aged 
AD patients and aged non-demented controls. This showed a general trend toward lower 
steroid levels in AD patients compared to controls, associated with a negative correlation 
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between neurosteroid levels and amyloid-β (Aβ) and phospho-tau in some brain regions (17). 
In accordance with these observations, previous data from our groups provided first evidence 
that, vice versa, Aβ and hyperphosphorylated tau differentially impacted 
neurosteroidogenesis (Fig. 1) (18-20). Indeed, a decrease of progesterone and 17-
hydroxyprogesterone production was observed in amyloid precursor protein (APP)/Aβ-
overexpressing cells, while 3α-androstanediol and estradiol levels were increased (19). 
Moreover, in vitro treatment of human neuroblastoma cells with “non-toxic” Aβ concentrations 
(within the nanomolar range) revealed an increase in estradiol production, whereas toxic Aβ 
concentrations (within the micromolar range) showed the opposite effect (18). 
Overexpression of human wild type tau (hTau40) protein induced an increase in production 
of progesterone, 3α-androstanediol, and 17-hydroxyprogesterone, in contrast to the 
abnormally hyperphosphorylated tau bearing the P301L mutation that led to decreased 
production of these neurosteroids (19).  
 Moreover, a growing body of evidence has highlighted neuroprotective effects of 
steroids, particularly estradiol, against AD-related injury (reviewed in (21)). Because the drop 
of estrogen in a post-menopausal woman is considered as a risk factor in AD (two-thirds of 
AD patients are women), the neuroprotective action of estrogen has been widely investigated 
(reviewed in (22)). One in vivo study showed that estradiol treatment of ovariectomized 
female rats up-regulated enzymes involved in glycolysis and oxidative phosphorylation, and 
increased ATP synthase expression which was translated into an increased mitochondrial 
respiration (23). These findings were additionally confirmed in an AD mouse model by Yao 
and coworkers (24). 
 However, there is little evidence that other steroids are also able to act on 
mitochondrial function, and to our knowledge, no study has aimed to compare the effects of 
neurosteroids besides estradiol on cellular bioenergetics and redox environment in neuronal 
cells. Thus, the objective of our study was to investigate the effects of different neurosteroids 
on bioenergetic activity in vitro. For this purpose, we selected seven neurosteroids - 
progesterone, estradiol and estrone, belonging to the estrogen family; testosterone and 3α-
androstanediol, belonging to androgen family; and DHEA and allopregnanolone - known to 
be involved in brain function regulation (12; 13; 25; 18; 19; 17). Neurosteroid effects on ATP 
production, mitochondrial membrane potential (MMP), mitochondrial respiration, glycolysis 
and the consequences on the modulation of the redox environment were investigated in 
neuronal cells.  
 
2. Materials and methods 
 
2.1. Chemicals and reagents 
RESULTS  Grimm A. et al. (2014) 
82 
 
 Dulbecco’s-modified Eagle’s medium (DMEM), RPMI-1640 medium, fetal calf serum 
(FCS), penicillin/streptomycin, progesterone, 17β-estradiol, estrone, 3α-androstanediol, 
DHR, TMRM, ADP, pyruvate, succinate and malate were from Sigma-Aldrich (St. Louis, MO 
USA). Glutamax, MitoSOX, DPBS, Neurobasal medium and B27 were from Gibco Invitrogen 
(Waltham, MA, USA). DHEA and allopregnanolone were from Calbiochem (Billerica, MA, 
USA). PMP and XF Cell Mitostress kit were from Seahorse Bioscience (North Billerica, MA, 
USA). Testosterone was from AppliChem (Darmstadt, Germany). Horse serum (HS) was 
from Amimed, Bioconcept (Allschwil, Switzerland). RU-486, ICI-187.780, and 2-hydroxy 
flutamide were from Cayman Chemical (Ann Arbor, MI, USA). 
 
2.2. Cell culture 
 
 Human SH-SY5Y neuroblastoma cells were grown at 37 °C in a humidified incubator 
chamber under an atmosphere of 7.5% CO2 in DMEM supplemented with 10% (v/v) heat-
inactivated FCS, 5% (v/v) heat-inactivated HS, 2 mM Glutamax and 1% (v/v) 
penicillin/streptomycin. Cells were passaged 1-2 times per week, and plated for treatment 
when they reached 80–90% confluence.  
  
2.3. Primary neuronal cultures 
 
 Mouse cortical neurons were prepared from E15 embryos according to the French 
guidelines, as previously described (26). Cells were plated in poly-L-lysine-coated plates at a 
density of 1.5 × 104 cells/well for ATP measurement (white 96-well plate) or 5 × 104 cells/well 
for measurement with the Seahorse XF24 Analyser (XF24 cell culture microplate). After 7 
days at 37 °C, 50% of the medium was replaced with fresh medium every third day. ATP 
level, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were 
investigated in this primary neuronal culture after a 24 h treatment with the different 
neurosteroids. 
 
2.4.  Treatment paradigm  
 
 Assessment of cell viability was performed on SH-SY5Y neuroblastoma cells to 
determine the potential toxic concentration range of neurosteroids (from 10 nM to 1000 nM, 
data not shown) and steroid receptor antagonists (SRA, from 1 nM to 1 μM, data not shown) 
using a MTT reduction assay (Roche, Basel, Switzerland). On the basis of the MTT results, 
the concentrations 10 nM and 100 nM of steroids were then selected and used in all assays. 
SH-SY5Y cells were treated one day after plating either with DMEM (untreated control 
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condition) or with a final concentration of 10 nM and 100 nM of progesterone, 17β-estradiol, 
estrone, testosterone, 3α-androstanediol, DHEA or allopregnanolone made from a stock 
solution in DMSO for 24 h (final concentration of DMSO < 0.002%, no effect of the vehicle 
solution (DMSO) alone compared to the untreated condition). In the experiment using SRA, 
cells were pre-treated for 1 h. with 100 nM of RU-486 and ICI-187.780, and 1 μM of 2-
hydroxy flutamide (2OH-flutamide), and then treated for 24 h with the corresponding 
neurosteroids. To limit cell growth and to optimize mitochondrial respiration, treatment 
medium contained only a low amount of fetal calf serum (5% FCS) as well as glucose (1 g/l) 
and was supplemented with 4 mM pyruvate. Each assay was repeated at least 3 times. 
 
2.5. ATP levels 
 
 Total ATP content of SH-SY5Y cells was determined using a bioluminescence assay 
(ViaLighTM HT, Cambrex Bio Science, Walkersville, MD, USA) according to the instruction of 
the manufacturer, as previously described (27). SH-SY5Y cells were plated in 5 replicates 
into a white 96-wells cell culture plate at a density of 1.5 × 104 cells/well. The bioluminescent 
method measures the formation of light from ATP and luciferin by luciferase. The emitted 
light was linearly related to the ATP concentration and was measured using the multilabel 
plate reader VictorX5 (Perkin Elmer). 
  
2.6.  Cell proliferation assay  
 
 To verify if our treatment had an impact on cell cycle and induced proliferation, the 
BrdU Cell Proliferation Assay (Calbiochem, Darmstadt, Germany) was used following the 
instructions of the manufacturer. Briefly, SH-SY5Y cells were plated in 6 replicates into a 96-
wells cell culture plate at a density of 1 × 104 cells/well. During the final 12 h of neurosteroid 
treatment, BrdU was added to the wells and incorporated into the DNA of dividing cells. The 
detection of BrdU was performed using an anti-BrdU antibody recognized by a horseradish 
peroxidase-conjugated anti-mouse. After addition of the substrate (TMB), the color reaction 
was quantified using the multilabel plate reader VictorX5 at 450nm. Values are proportional 
to the number of dividing cells.  
 
2.7. Determination of mitochondrial membrane potential 
 
 The MMP was measured using the fluorescent dye tetramethylrhodamine, methyl 
ester, and perchlorate (TMRM). SH-SY5Y cells were plated in 6 replicates into a black 96-
well cell culture plate at a density of 1.5 × 104 cells/well. Cells were loaded with the dye at a 
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concentration of 0.4 μM for 15 min. After washing twice with HBSS, the fluorescence was 
detected using the multilabel plate reader VictorX5 (PerkinElmer) at 530 nm (excitation)/590 
nm (emission). Transmembrane distribution of the dye was dependent on MMP.  
 
2.8. Oxygen consumption rate and extracellular acidification rate 
 
 The Seahorse Bioscience XF24 Analyser was used to perform a simultaneous real-
time measurement of oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR). XF24 cell culture microplates (Seahorse Bioscience) were coated with 0.1% 
gelatine and SH-SY5Y cells were plated at a density of 2.5 × 104 cells/well in 100 μl of the 
treatment medium containing 5% FCS, 1 g/l glucose and 4 mM pyruvate. After neurosteroid 
treatment, cells were washed with PBS and incubated with 500 μl of assay medium (DMEM, 
without NaHCO3, without phenol red, with 1g/l glucose, 4 mM pyruvate, and 1% L-glutamine, 
pH 7.4) at 37 °C in a CO2-free incubator for 1 h. The plate was placed in the XF24 Analyser 
and basal OCR and ECAR were recorded during 30 min. For primary neuronal culture, the 
same conditions were kept, except the medium; here DMEM was replaced by RPMI-1640 
medium. 
 
2.9.  Mitochondrial respiration 
 
 The investigation of mitochondrial respiration was performed using the Seahorse 
Bioscience XF24 analyser. XF24 cell culture microplates were coated with 0.1% gelatine and 
cells were plated at a density of 2.5 × 104 cells/well in 100 μl of treatment medium containing 
5% FCS, 1 g/l glucose and 4 mM pyruvate. After neurosteroid treatment, cells were washed 
with 1× pre-warmed mitochondrial assay solution (MAS; 70 mM sucrose, 220 mM mannitol, 
10 mM KH2PO, 4.5 mM MgCl2, 2 mM HEPES, 1 mM EGTA and 0.2% (w/v) fatty acid-free BSA, 
pH 7.2 at 37 °C) and 500 μl of  pre-warmed (37 °C) MAS containing 1 nM XF plasma 
membrane permeabilizer (PMP, Seahorse Bioscience), 10 mM pyruvate, 10 mM succinate 
and 2 mM malate was added to the wells. The PMP was used to permeabilize intact cells in 
culture, which circumvents the need for isolation of intact mitochondria and allows the 
investigation of the OCR under different respiratory states induced by the sequential injection 
of: i) ADP (4 mM) to induce state 3; ii) Oligomycin (0.5 μM) to induce state 4o; iii) FCCP (2 
μM) to induce state 3 uncoupled (3u); and iv) Antimycin A/rotenone (0.5 μM and 1 μM 
respectively) to shut down mitochondrial respiration. Data were extracted from the Seahorse 
XF24 software and the respiratory control ratio (RCR: State 3/State 4o), which reflects the 
mitochondrial respiratory capacity, was calculated. 
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2.10. GABAA receptor expression 
 
 Cells were lysed and total RNA was extracted using the RNeasy Mini Kit from Qiagen 
(Venlo, Netherlands), according to the instructions of the manufacturer to measure GABAA 
receptor (subunits α1 and β2) mRNA levels. The first cDNA strand was synthesized using all 
RNA extracted by reverse transcription in a final volume of 30 μl using the Ready-to-Go You-
Prime First-Strand Bead cDNA synthesis kit (GE Healthcare, Little Chalfont, UK) according to 
the supplied protocol. After reverse transcription, the cDNA was diluted 1:3 and 3 μl were 
amplified by real-time PCR (StepOne™ System) in 20 μl using DyNAmy Flash Probe qPCR 
Kit (Thermo Scientific, Waltham, MA, USA) with conventional Applied Biosystems cycling 
parameters (40 cycles of 95°C, 5 s, and 60°C, 1 min). Primers for human and mouse GABAA 
receptor subunit α1 and β2 were obtained from Life Technologies (Waltham, MA, USA). 
References of the primers are: GABRA1: Hs00971228_m1; GABRB2: Hs00241451_m1; 
gabra1: Mm00439046_m1; and gabrb2: Mm00433467_m1. After amplification, the size of 
the quantitative real-time PCR products was verified by electrophoresis on 2% (wt/vol) 
ethidium bromide-stained agarose gel. CDK4 was used as control housekeeping gene to 
assess the validity of the cDNA mixture and the PCR reaction. The gene expression of CDK4 
was clearly detected in SH-SY5Y (data not shown), but not that of GABAA receptor. 
 
2.11. Reactive oxygen species detection 
 
 Total level of mitochondrial reactive oxygen species (mtROS) and specific level of 
mitochondrial superoxide anion radicals were assessed using the fluorescent dye 
dihydrorhodamine 123 (DHR) and the Red Mitochondrial Superoxide Indicator (MitoSOX), 
respectively. SH-SY5Y cells were plated in 6 replicates into a black 96-well cell culture plate 
at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells were loaded with 10 μM 
of DHR for 15 min or 5 μM of MitoSOX for 90 min at room temperature in the dark on an 
orbital shaker. After washing twice with HBSS (Sigma), DHR, which is oxidized to cationic 
rhodamine 123 localized within the mitochondria, exhibits a green fluorescence that was 
detected using the multilabel plate reader VictorX5 at 485 nm (excitation)/538 nm (emission). 
MitoSOX, which is specifically oxidized by mitochondrial superoxide, exhibits a red 
fluorescence detected at 535 nm (excitation)/595 nm (emission). The intensity of 
fluorescence was proportional to mtROS levels or superoxide anion radicals in mitochondria.  
 
2.12. MnSOD activity  
 
RESULTS  Grimm A. et al. (2014) 
86 
 
 The DetectX Superoxide Dismutase (SOD) Activity Kit (Ann Arbor, MI, USA) was 
used to quantitatively measure manganese SOD (MnSOD) activity following the instructions 
of the manufacturer. Briefly, 1 × 106 SH-SY5Y cells were collected for protein extraction. 
After a short sonication in PBS, the cellular homogenate was centrifuged at 1.500 × g for 10 
min at 4 °C. The supernatant was then centrifuged at 10,000 × g for 15 min and the obtained 
cell pellet was treated with 2 mM potassium cyanide, and assayed for MnSOD activity. 
 
2.13. Mitochondrial redox environment  
 
 To investigate changes in mitochondrial redox environment, SH-SY5Y cells were 
transfected with a plasmid coding for a redox sensitive green fluorescent protein with a 
mitochondrial targeting sequence (pRA305 in pEGFP-N1). In an oxidized environment the 
absorption increases at short wavelengths (390 nm) at the expense of absorption at longer 
wavelengths (485 nm). The fluorescence ratio indicates oxidation/reduction, i.e., the redox 
environment in the mitochondria (28). Cells were plated in 6 replicates into a black 96-well 
cell culture plate at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells were 
washed twice with PBS and placed in a HEPES buffer (130 mM NaCl, 5 mM KCl, 1 mM 
CaCl2, 10 mM D-glucose, and 20 mM HEPES). The ratio 390 nm/485 nm was measured 
using the multilabel plate reader VictorX5 detecting fluorescence at 390 nm or 485 nm 
(excitation)/510 nm (emission). An increase of the ratio indicates a more oxidized 
environment. 
 
2.14. Statistical Analysis 
 
 Data are given as the mean ± SEM, normalized to the untreated control group 
(=100%). Statistical analyses were performed using the Graph Pad Prism software. For 
statistical comparisons of more than two groups, One-way ANOVA was used, followed by a 
Dunnett's multiple comparison test versus the control. For statistical comparisons of two 
groups, Student unpaired t-test was used. P values < 0.05 were considered statistically 
significant. Statistical correlations were determined using Pearson’s correlation coefficients. 
 
3. Results 
 
3.1. Neurosteroids modulate mitochondrial bioenergetics 
 
 To investigate the effects of neurosteroids on cellular bioenergetic activity, we first 
studied the SH-SY5Y cell line, a commonly used neuronal culture in vitro model that 
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expresses a variety of neuronal receptors, including steroid receptors (progesterone, 
estrogen and androgen receptors) (29; 30). Cells were treated with different neurosteroids: 
progesterone (P), estradiol (E2), estrone (E1), testosterone (T), 3α-androstanediol (3α-A), 
DHEA (D) or allopregnanolone (AP), at two physiologically relevant concentrations, 10 nM 
and 100 nM (31-35) , and ATP level was measured after 24 h of treatment. All neurosteroids, 
except allopregnanolone, were able to significantly increase ATP level (Fig. 2A), ranging 
from a 10% increase after 3α-A treatment (10 nM) up to a 22% increase induced by 
progesterone (100 nM) compared to the untreated control.  
 A pre-treatment for 1 h with different steroid receptor antagonists (SRA) including the 
progesterone receptor antagonist RU-486 (assay concentration 100 nM), the estrogen 
receptor antagonist ICI-182.780 (assay concentration 100 nM), and the androgen receptor 
antagonist 2OH-flutamide (assay concentration 1 μM) completely abolished the action of P, 
E2 and E1, as well as T and 3α-A, respectively (Fig. 2B). The SRAs alone were devoid of 
the effects of ATP production. These results indicate that the action of neurosteroids may be 
mediated by nuclear receptors via gene regulation, at least for those neurosteroids that act 
via these receptors (progesterone, estrogens, and androgens).  
 To exclude that this rise in ATP was due to enhanced cell proliferation, we 
investigated the effects of the different neurosteroids. Of note, only allopregnanolone at 100 
nM induced a significant increase of cell division by about 6% compared to the control (Table 
1). Thus, our results indicate that the neurosteroid-induced up-regulation of cellular energy 
levels was independent of cell proliferation demands. 
 To verify whether the increase of ATP levels was directly linked to mitochondrial 
activity, we investigated the effects of neurosteroids on MMP, an indicator of the proton 
motive force necessary for ATP synthesis by the mitochondrial ATP synthase (36). Our 
results show that, at least for one of the two concentrations tested, neurosteroids induced a 
significant increase in MMP (Fig. 2C). The low concentration of 10 nM was particularly 
effective, ranging from an 18% increase after estradiol treatment up to a 32% increase 
induced by DHEA. Again, allopregnanolone was not able to significantly modulate the MMP. 
Thus, the observed increase in ATP is consistent with the finding of a slight hyperpolarization 
of the MMP. 
 Because molecules of ATP are produced by two main pathways, the cellular 
glycolysis and oxidative phosphorylation (OXPHOS) in mitochondria, we determined whether 
and which of those neurosteroids were able to modulate one or both pathways. For this 
purpose, we simultaneously monitored in real-time the extracellular acidification rate (ECAR), 
an indicator of glycolysis, and the oxygen consumption rate (OCR), an indicator of basal 
respiration, using a Seahorse Bioscience XF24 Analyser (Fig. 3A-C). On the one hand, 
despite a slight general increase, only estradiol and DHEA were able to significantly 
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modulate the ECAR after 24 h of treatment (about 16.4% and 19.4% respectively) (Fig. 3A). 
On the other hand, our findings demonstrate that estradiol, estrone, testosterone, 3α-A and 
DHEA significantly increased the OCR, with the most pronounced effect detected after a 
testosterone treatment at 100 nM (+26.5% compared to the control) (Fig. 3B). To compare 
the action of neurosteroids on glycolysis and basal respiration, we characterized the 
bioenergetic profile of SH-SY5Y neuroblastoma cells, representing OCR versus ECAR under 
the different treatment conditions (Fig. 3C). Notably, after treatment with the neurosteroid 
panel cells were switched to a metabolically more active state, with a tendency to increase 
both, glycolytic activity (ECAR) and basal respiration (OCR).  
 A Pearson correlation was performed to study whether the ATP levels correlated with 
OCR, ECAR or MMP (Fig. 4). A positive linear correlation between ATP level and OCR (Fig. 
4A), but not between ATP and ECAR (Fig. 4B) or MMP (Fig. 4C) was detected, suggesting 
that the improvement in ATP production was preferentially linked to an increase of 
mitochondrial respiration (oxygen consumption). 
 To investigate more deeply the effects of neurosteroids on mitochondrial OXPHOS, 
OCR was measured using permeabilized SH-SY5Y cells, which allows the evaluation of 
different respiratory states and the respiratory control ratio (RCR=state 3/state 4) (Fig. 5). 
Especially testosterone significantly up-regulated the mitochondrial respiratory capacity by 
increasing the respiratory state 3 (ADP-dependent), state 3 uncoupled (in the absence of 
proton gradient after injection of FCCP) and the RCR (Fig. 5A-C). The treatment with DHEA 
(10 nM) showed a similar effect on the RCR under these experimental conditions (Table 1), 
while the rest of the tested steroid compounds had no beneficial effect on RCR. Thus, our 
findings suggest that neurosteroids primarily act on basal respiration in neuroblastoma cells, 
and that testosterone and DHEA are additionally able to increase the capacity for substrate 
oxidation (high RCR), which is important when cells have specific or high energy demands. 
 
 Since SH-SY5Y cells and other cell lines are not as highly dependent on OXPHOS as 
primary cell cultures to produce ATP (37), we investigated the action of neurosteroids on 
primary cell cultures from mouse brain cortex. Data demonstrate that, except for the 
treatment with progesterone, the level of ATP was significantly increased with at least one of 
the two concentrations tested, ranging from a 27% increase after treatment with estrone (100 
nM) up to a 59% induced increase by DHEA (10 nM) (Fig 6A). Compared to the data 
obtained with SH-SY5Y neuroblastoma cells (Fig. 2A), the magnitude of the rise in ATP 
concentration was higher in the primary cortical cell culture (maximal increase of 22.6% in 
SH-SH5Y cells versus 59.2% in primary neurons). This result implies that primary cell 
cultures have a greater capacity to produce ATP than neuroblastoma cells. Moreover, both 
concentrations of allopregnanolone were able to increase ATP level in primary cells, which 
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was not the case in SH-SY5Y cells. Allopregnanolone mainly acts as an allosteric positive 
modulator of GABAA receptor (GABAA-R). To verify the implication of this receptor, we first 
investigated whether it was expressed in both cell types. We found that SH-SY5Y cells do 
not express the GABAA-R subunits α1 and β2 that are involved in the allopregnanolone 
binding site (38), in contrast to primary cortical neurons (Suppl. Fig. 1), indicating that 
GABAA-R may be involved in the modulation of bioenergetics by allopregnanolone in 
neurons. 
 To determine whether the increase in ATP level was due to an improvement of 
glycolytic activity or mitochondrial respiration in this cellular model, we again performed a 
simultaneous real-time monitoring of the ECAR and the OCR (Fig. 6B-D). We measured a 
significant effect on the OCR for most of the neurosteroids tested, starting with a 59% 
increase after treatment with testosterone (10 nM) up to a 128% increase induced by 3α-A 
(10 nM) (Fig. 6B). Again, the magnitude of change was higher compared to the 
neuroblastoma cell line (maximal increase of 26.5%). In parallel, we measured a slight, but 
not significant, decrease in the glycolytic activity, except for the treatment with progesterone 
at 100 nM which in contrast induced a huge increase in the ECAR (+51.% compared to the 
control condition) (Fig. 6C). The bioenergetic profile (OCR versus ECAR) revealed that after 
treatment with neurosteroids, the primary cortical neurons had the general tendency to 
switch to a more aerobic state (Fig. 6D) by increasing their oxygen consumption (OCR) and 
decreasing their glycolytic activity (ECAR), especially at the low concentration of 10 nM. 
 Taken together, these data indicate that in primary mouse neurons, most of the 
neurosteroids from the tested panel were able to increase ATP production via improvement 
of mitochondrial respiration. 
 
3.2.  Neurosteroids modulate the redox homeostasis  
 
 The increase of OXPHOS is often coupled with an increase in mitochondrial reactive 
oxygen species (mtROS) production (39; 40). Since neurosteroids were able to significantly 
increase mitochondrial respiration, we investigated whether ROS levels were also increased 
within mitochondria (mtROS) by measuring the oxidation of the fluorescent dye 
dihydrorhodamine 123 (DHR). All neurosteroids induced a significant dose-dependent 
increase in mtROS levels, ranging from a 43% increase after DHEA treatment (10 nM) up to 
a 111.3% increase induced by testosterone (100 nM) (Fig. 7A). Moreover, the specific 
measure of mitochondrial superoxide anion radicals revealed that some of the ROS 
produced were indeed superoxide anions (Table 1). However, the extent of mtROS 
production, which in excess can lead to massive oxidative stress, and finally cell death, did 
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not seem to be sufficient to trigger cell death under those experimental conditions (data not 
shown).  
 Therefore, we next tested the antioxidant defense system in mitochondria. We 
quantitatively measured the activity of the manganese superoxide dismutase activity 
(MnSOD), which is present within the mitochondrial matrix. Indeed, MnSOD activity was 
significantly increased (Fig. 7B) after treatment with the whole panel of neurosteroids, 
ranging from a 28.6% (progesterone, 100 nM) up to a 49.3% increase (testosterone, 100 
nM). The increase in mtROS was paralleled by an increase of antioxidant activity. In addition, 
mtROS level and MnSOD activity correlated with one another (Fig. 7C), suggesting that the 
increase of MnSOD activity was substrate-dependent.  
 Finally, to verify whether the mitochondrial redox environment was impacted by this 
increase of ROS versus increase of antioxidant defenses, SH-SY5Y cells stably transfected 
with a reporter gene coding for a redox sensitive green fluorescent protein (AR305 roGFP) 
located within mitochondria were treated with our panel of neurosteroids (28). Figure 7D 
displays the oxidation/reduction state in mitochondria, and indicates that, despite a slight 
switch toward a more oxidized state, only testosterone (100 nM) and DHEA (100 nM) 
significantly modified the redox environment in mitochondria.  
 Taken together, our data indicate that neurosteroids increased mitochondrial activity, 
which was paralleled by an enhancement in mtROS levels. However, cell viability was still 
unchanged and the raise of mtROS appeared to be at least in part compensated by an 
increase in antioxidant activity, which in turn led to a slight switch to an oxidized state within 
mitochondria. 
 
4. Discussion 
 
 The aim of our study was to investigate the effects of seven neurosteroids on cellular 
bioenergetics and redox homeostasis in neuronal cells. The key findings were that: i) the 
majority of these steroids increased energy metabolism, mainly via an up-regulation of the 
mitochondrial activity and at least in part via receptor activation, and ii) neurosteroids 
regulated redox homeostasis by increasing the antioxidant activity as a compensatory 
mechanism to the ROS level enhancement which might result from the acceleration in 
oxygen consumption accompanied by a greater electron leakage from the electron transport 
chain. Additionally, each neurosteroid seems to have a specific bioenergetic profile. The 
single profiles are delineated as pie charts for SH-SY5Y (Fig. 8A) and mouse primary 
cortical neurons (Fig. 8B).  
 Remarkably, each steroid doesn’t seem to act in the same way on both cell types. For 
example, allopregnanolone, which had no effects on ATP level and basal respiration in SH-
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SY5Y cells, appeared to increase those two parameters in primary neuronal cells. On the 
contrary, progesterone was able to increase ATP production in SH-SY5Y cells, but showed a 
significant effect only on glycolysis in primary cells. One explanation could be that SH-SY5Y 
cells and primary neuronal culture may exhibit steroid receptor expression profiles that are 
slightly different. Steroid receptor expression, such as that of progesterone, estrogen and 
androgen receptors, has already been demonstrated in both SH-SY5Y cells (29; 30) and in 
mouse neurons (41-43), respectively. It is known that allopregnanolone doesn’t bind to a 
conventional steroid receptor but mainly acts as a positive GABAA receptor (GABAA-R) 
allosteric modulator that strengthens the effects of GABA. We found that SH-SY5Y cells do 
not express GABAA-R unlike in primary neurons (Suppl. Fig. 1). This indicates that 
allopregnanolone may act via GABAA-R to increase ATP level especially in primary neurons 
and explains the lack of effect on ATP in SH-SY5Y cells. Furthermore, other signaling 
pathways and receptors may be involved in the effects of allopregnanolone upon 
bioenergetics in primary cortical neurons, such as the newly characterized pregnane 
xenobiotic receptor (44). 
 Moreover, it is known that proliferative cells and tumors have a net tendency to use 
the cellular glycolysis to produce ATP instead of the OXPHOS system. This phenomenon is 
called “Warburg effect” (37). On the contrary, primary neurons, which are differentiated cells, 
rely almost exclusively on the OXPHOS system to produce ATP and glycolysis is really low 
(raw data not shown). Indeed, in the latter model, ATP level appeared to be strictly coupled 
with the basal respiration. The bioenergetic profile of primary cortical cells revealed that 
neurosteroids preferentially increased mitochondrial respiration and not the glycolytic 
pathway, while both pathways were increased in SH-SY5Ycells (Fig. 3C, Fig. 6D). 
 
  In the recent years, neurosteroids have emerged as new potential therapeutic tools 
against neurodegeneration (45). Among the steroids, the family of sex steroid hormones is 
the most widely studied. They are in the focus of research on neurodegenerative diseases 
since cognitive decline and the risk to develop AD appear to be associated with an age-
related loss of sex hormones (e.g. estradiol, testosterone but also progesterone) in both, 
women and men (46; 25), a hypothesis largely supported by epidemiological evidence (47). 
In vitro and in vivo studies demonstrated neuroprotective effects of sex hormones, 
particularly with mitochondria proposed as the primary site of action of estradiol (48; 32; 49; 
24). Indeed, estrone (E1), estradiol (E2), and estriol (E3), are known to play a fundamental 
role in the regulation of the female metabolic system (50). It has been reported that 
estrogens can regulate mitochondrial metabolism by increasing the expression of glucose 
transporter subunits and by regulating some enzymes involved in the tricarboxylic acid cycle 
(TCA cycle) and glycolysis, which leads to an improvement in glucose utilization by cells 
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(reviewed in (21)). Estrogens seem also able to up-regulate genes coding for some electron 
transport chain components such as subunits of mitochondrial complex I (CI), cytochrome c 
oxidase (complex IV), and the F1 subunit of ATP synthase. In line with these findings, our 
data demonstrated that both female sex hormones, estradiol (E2) and estrone (E1), were 
able to increase ATP levels, basal respiration, and MMP in neuroblastoma cells (Fig. 8A). Of 
note, the increase of ATP levels induced by E2 and E1 was abolished in the presence of ICI-
182.780, an estrogen receptor (α and β) antagonist (Fig. 2B) suggesting that estrogens, 
such as E2 and E1, may act via these receptors to up-regulate genes involved in cellular 
bioenergetics, as mentioned above. Estradiol seemed to be more potent that estrone, 
because both concentrations (10 nM and 100 nM) were effective to increase ATP levels and 
mitochondrial respiration. In addition, estradiol was able to regulate glycolysis. This 
difference can be explained by the observation that, despite estrone’s capability as an 
estrogenic compound, it is about 10 times less estrogenic than estradiol (21). The same 
finding was observed in primary neurons (Fig. 8B).  
 
 Regarding the predominantly male hormone testosterone, we witnessed an increase 
in ATP levels, basal respiration and mitochondrial membrane potential in neuroblastoma 
cells (Fig. 8A). Moreover, testosterone was also the only steroid besides DHEA inducing an 
acceleration of the respiratory control ratio (RCR), an indicator of the capacity for substrate 
oxidation (high RCR), which is important when cells have specific or high energy demands. 
The role of androgens on mitochondrial function, especially testosterone, has received little 
attention up to now, compared to the estrogens. Only one study demonstrated a similar 
effect of testosterone on MMP (51). Furthermore, it has been proposed that estradiol and 
testosterone can regulate energy production by inducing nuclear and mitochondrial OXPHOS 
genes, since the subunits of mitochondrial chain complexes are encoded by the nuclear and 
the mitochondrial genome, respectively, and both contain hormone responsive elements 
(52). Again, those findings are in line with our results, since we have shown that the increase 
of ATP levels was blocked in the presence of estrogen and androgen receptor antagonists 
(Fig. 2B). 
 
 Progesterone is the second main female sex hormone but it is also a precursor for 
estrogens and androgens. Progesterone, and its 3α-5α-derivate allopregnanolone (or 3α, 5α-
tetrahydroprogesterone) as well as 3α-androstanediol, seem to play a role in mood 
modulation. Their therapeutic potential for the treatment of depression, anxiety (53-55) and 
more recently AD is currently under investigation (35). In the present study, we demonstrated 
that progesterone increased ATP levels and MMP without significant effects on basal 
respiration in neuroblastoma cells (Fig. 8A). An increase in glycolysis was also observed 
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after treatment in the primary neurons (Fig. 8B). Again, the up-regulatory effect of 
progesterone on ATP levels was shut down in the presence of the progesterone receptor 
antagonist RU-486 (Fig. 2B), suggesting that progesterone also modulates cellular 
bioenergetics by regulating gene expression via a progesterone nuclear receptor. Studies 
performed on ovariectomized rats revealed that a 24 h treatment with progesterone 
(subcutaneous injection, 30 μg/kg) increased OXPHOS capacity in isolated mitochondria, in 
part by enhancing cytochrome c oxidase activity and expression (32). Interestingly, the 
increase of OXPHOS capacity was suppressed by a co-treatment with estradiol and 
progesterone, suggesting a competitive mode of action between both steroids. Another study 
using wobbler ALS (amyotrophic lateral sclerosis) model mice showed that progesterone was 
able to normalize the deficits in mitochondrial complex I activity observed in motor neurons of 
the cervical spinal cord (56). Because progesterone seems to have different functional 
effects, one can speculate that its action on mitochondrial respiration may be distinct to 
specific nerve cell populations.  
 
 Allopregnanolone and 3α-androstanediol have a distinct mode of action compared to 
sex hormones because they mainly act on membrane receptors (allosteric modulator of 
GABAA-R) and not nuclear receptors (57). Their effects on mitochondrial bioenergetics 
cannot be explained by a direct regulation of genes involved in the OXPHOS system as 
previously proposed for sex hormones. In our study, 3α-androstanediol showed a similar 
effect compared to progesterone in the neuronal cell line, but was also able to significantly 
increase the basal respiration (at 100 nM) (Fig. 8A). Both concentrations were effective to 
increase ATP and respiration in primary cells (Fig. 8B). Allopregnanolone significantly 
regulated ATP levels and basal respiration only in primary neurons, whereas no effect was 
detected in the neuroblastoma cell line. Based on those observations, we can speculate that: 
i) GABAA-R is involved in the up-regulatory effect of allopregnanolone on ATP levels in 
primary cells because no increase was observed in SH-SY5Y cells lacking of this receptor 
(Suppl. Fig. 1); and ii) 3α-androstanediol could act via androgen receptor because its effect 
on ATP levels was abolished in the presence of an androgen receptor antagonist (Fig. 2B). 
However, further investigations will be required to understand the exact underlying 
mechanisms. Besides, due to the high complexity of the neurosteroid pathway synthesis, it is 
difficult to conclude that the effect which we observed on bioenergetics is due to the tested 
neurosteroid itself, or to one of its metabolites, because they all belong to crisscross 
pathways (Fig. 1). However, since blocking progesterone, estrogen and androgen receptors 
abolishes the effects of their respective agonists, we have good evidence that the 
neurosteroids themselves exhibit the mode of action. In the same way, we can exclude that 
progesterone is acting via its metabolite allopregnanolone because the latter has no effects 
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on bioenergetics in SH-SY5Y cells. Nevertheless, it is also possible that 3α-androstanediol 
doesn’t act directly on androgen receptors but is converted in dihydrotestosterone, another 
testosterone metabolite which has high affinity for this receptor. In a similar way, DHEA can 
be converted in androgens and estrogens and may act via the corresponding steroid nuclear 
receptor. 
 
 DHEA (dehydroepiandrosterone) was the first neurosteroid identified in 1981 (11), 
and its physiological action involves both genomic and non-genomic mechanisms, in part via 
activation of androgen/estrogen receptors and allosteric modulation of NMDA receptors, 
respectively (58). Human studies showed an age-related decrease in DHEA levels in the 
brain and in the blood in relation to the age-associated cognitive decline (59; 17). In vitro, we 
showed that DHEA enhanced ATP levels and basal respiration in primary neurons (Fig. 8B). 
A similar effect was observed in the neuronal cell line with an additional increase in MMP, 
glycolysis and RCR (Fig. 8A, Table 1). In agreement with our findings, DHEA was able to 
improve mitochondrial respiration in the brain of old rats (18-24 months) which exhibited a 
decline in mitochondrial function when compared to young rats (8-10 weeks) (60). More 
specifically, DHEA stimulated the respiratory state 3 in old rats which consequently was 
similar to that of untreated young rats. Furthermore, DHEA increased cytochrome c content 
in young and old mouse brains and enhanced mitochondrial dehydrogenase activities.  
 Thus, the different bioenergetic profiles we observed after treatment with our panel of 
steroids could be explained by their distinct abilities to directly or indirectly regulate the 
transcription of genes involved in glycolysis and oxidative phosphorylation (probably, via 
steroid nuclear receptors), but also the content and activity of mitochondrial respiratory 
complexes. Further investigations are required to determine in more detail which genes are 
involved in these processes. 
 
 Mitochondria are known to be paradoxical organelles. They can be compared to a 
double-edged sword that, on one hand, produces the energy necessary for cell survival, and 
on the other hand, induces the formation of ROS that can be harmful for cells when produced 
in excess with mitochondria as the first target of toxicity (39; 40). In our study, the increase in 
ATP appeared to be coupled to an increase in MMP and improved basal respiration (Fig. 
8A). In parallel, we detected higher mitochondrial ROS levels, supporting the hypothesis that 
increased mitochondrial activity generates more ROS. The only exception was observed 
after treatment with allopregnanolone where we detected more ROS but no increase in ATP 
level, MMP, or basal respiration. We can speculate that, in this model, allopregnanolone 
might be able to increase ROS-producing metabolic functions via other mechanisms. But 
with regard to the other neurosteroids, the increase of mitochondrial ROS was paralleled by 
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an increase in MnSOD activity. The MnSOD is located in the mitochondrial matrix and 
represents one of the first antioxidant defenses against ROS produced by OXPHOS (61). Its 
improved activity could be in part explained by an up-regulation of gene expression and 
protein level of MnSOD. Indeed, in studies which focused on antioxidant effects of steroids in 
ovariectomized female rats, an increase of MnSOD protein level has been observed after 
treatment with estradiol or progesterone (32), whereas DHEA preferentially up-regulated the 
expression of Cu/ZnSOD (31). In orchiectomized male rats, testosterone was also able to 
increase MnSOD protein level compared to the control (sham operated) (62). A similar 
observation was made in the wobbler ALS mouse model, where MnSOD expression was 
elevated after treatment with progesterone (56).  
 
 In our study, the correlation between mitochondrial ROS level and MnSOD activity 
implies that the increase of enzymatic SOD activity might be preferentially substrate-
dependent, but can be explained, at least in part, by an up-regulation of gene expression.  
 Based on our observation, one can speculate that pre-treatment with neurosteroids 
may exert a protective action against oxidative stress, possibly through a preconditioning 
mechanism via their ability to increase antioxidant defenses (i.e. MnSOD activity). However, 
in an already oxidized environment, the presence of neurosteroids may be deleterious for 
cells because they also appear to further increase ROS production. This observation 
reinforces the “critical window hypothesis” of the therapeutic use of steroids as debated 
recently with regard to the hormone replacement therapy in post-menopausal women (63) 
and implies that this kind of therapy should begin at an age when the redox system is still 
balanced, thus favoring the reference postulating early onset administration. 
 
 It is known that some neurosteroid levels decline during aging and are further 
modified in neurodegenerative conditions (i.e. AD and PD). In addition, mitochondrial 
dysfunction has been well-documented in aging and age-related neurodegenerative diseases 
(64). Steroids offer interesting therapeutic opportunities for promoting successful aging 
because of their pleiotropic effects in the nervous system. Our findings highlight, for the first 
time, up-regulatory effects of neurosteroids upon the neuronal bioenergetic activity via up-
regulation of the mitochondrial oxygen consumption as a common mechanism underlying 
neurosteroid action. In addition, these steroids can modulate the redox homeostasis, by 
balancing the increase of ROS production via improved mitochondrial antioxidant activity 
(Fig. 9). Thus, our results provide new insights in re-defining the biological model of how 
neurosteroids control neuronal functions. Because each steroid appeared to have a specific 
profile in bioenergetic outcome and redox homeostasis, the underlying mechanisms have to 
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be elucidated in more details in the future, as well as those in models of neurodegenerative 
diseases, such as AD. 
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Table 1: Effects of neurosteroids on cellular bioenergetics in neuroblastoma cells. 
  
Progesterone Estradiol Estrone Testosterone 
3α-
androstanediol 
DHEA 
Allo-
pregnanolone 
  
10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 
ATP level 113.9* 122.6* 113.4* 114.6* 116* 120.4* 110.7* 118* 110.1* 111.4* 107.6* 112.4* 95.8 100.3 
Cell proliferation 98.7 100.9 98.2 100.3 97.2 99.2 97.9 102.1 100.1 103.8 97.6 103.7 101.7 106.2* 
MMP 120* 108.2 118.5* 118.8* 120* 119.2* 128.1* 119.9* 123.2* 109.8 132.2* 119.9* 111.5 114.2 
Glycolysis 115.4 102.7 119.4* 116.1* 113.8 111.1 108.1 105.5 105.7 106.6 106.2 116.4* 102.2 101.6 
Mitochondrial 
respiration 
Basal 111 105.9 118.3* 123.2* 110.9 118.1* 115.1* 126.5* 106.9 114.1* 110.8* 106.7 99.6 109.6 
RCR 97.9 98.7 93.7 89.6 100.6 102.8 132.7* 116.5* 95.3 104 120.3* 97.81 105.7 102.1 
Mitochondrial 
ROS 
Total 108.4 151.7* 122.9 160.8* 121.8 171.3* 145.2* 211.3* 148.4* 182.8* 143.9* 200.6* 151* 207.2* 
Superoxide 100.7 104* 103 106.2* 102.8 108* 103.6* 105.8* 103.8* 105.9* 105* 106.4* 103.6* 107.4* 
MnSOD activity 110.6 128.6* 120.7 136.6* 128.7 141.9* 137.4* 149.3* 134.7* 127.6 135.3* 128.1* 128.7* 147.4* 
Mitochondrial redox state 105.7 110.6 108.1 108.9 104.1 109.2 109.9 113.6* 109.8 109.1 104.2 113.3* 91.7 102.5 
 
Values represent the mean normalized on 100% of the control group (untreated). * indicates when the percentage is significantly different from the control group. MMP; 
mitochondrial membrane potential, RCR; respiratory control ration, ROS; reactive oxygen species, MnSOD; manganese superoxide dismutase. 
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Fig. 1: Schematic representation of the main biochemical pathways for neurosteroidogenesis in the vertebrate 
brain. Boxes represent neurosteroids tested in our study. * indicates neurosteroids whose synthesis is impacted in 
AD. PREG; pregnenolone, PROG; progesterone, 17OH-PREG; 17-hydroxypregnenolone, 17OH-PROG; 17-
hydroxyprogesterone, DHEA; dehydroepiandrosterone, DHP; dihydroprogesterone, ALLOPREG; 
allopregnanolone, DHT; dihydrotestosterone, P450scc; cytochrome P450 cholesterol side chain cleavage, 
P450c17; cytochrome P450c17, 3β-HSD; 3β-hydroxysteroid dehydrogenase, 5α-R; 5α-reductase, Arom.; 
aromatase, 21-OHase; 21-hydroxylase, 3α-HSOR; 3α-hydroxysteroid oxydoreductase, 17β-HSD; 17β- 
hydroxysteroid dehydrogenase  
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Fig. 2. Neurosteroids increase ATP level in SH-SY5Y neuroblastoma cells. (A) ATP level was significantly 
increased after neurosteroid treatment for 24 h at a concentration of 10 nM (white boxes) or 100 nM (gray 
boxes).(B) ATP level was measured after pre-treatment of cells for 1 h with either progesterone receptor 
antagonist RU-486 (100 nM), or estrogen receptor antagonist ICI-182.780 (100 nM), or androgen receptor 
antagonist 2OH-flutamide (1 μM) and then treated for 24 h with the corresponding steroid agonist. (C) 
Mitochondrial membrane potential (MMP) was significantly increased after neurosteroid treatment for 24 h at a 
concentration of 10 nM (white boxes) or 100 nM (gray boxes). (A-C) Values represent the mean ± SEM; n=12-18 
replicates of three independent experiments. One-way ANOVA and post hoc Dunnetts' multiple comparison test 
versus control (untreated), *P<0.05; **P<0.01; ***P<0.001. Student unpaired t-test, && P<0.01; &&&P<0.001. P; 
progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 3α-androstanediol, D; dihydroepiandrostanedione 
(DHEA), AP; allopregnanolone, RU; RU-486, ICI; ICI-182.780, flut.; 2OH-flutamide. 
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Fig. 3. Neurosteroids positively regulate bioenergetic activity in SH-SY5Y neuroblastoma cells. (A) Extracellular 
acidification rate (ECAR) and (B) oxygen consumption rate (OCR) were measured simultaneously using a 
Seahorse Biosciences XF24 Analyser in the same experimental conditions. (C) Bioenergetic profiling of SH-SY5Y 
cells (OCR versus ECAR) revealed increased metabolic activity after treatment with neurosteroids. Values 
represent the mean of each group (mean of the ECAR in abscissa/mean of the OCR in ordinate) normalized to 
the untreated control group (=100%). (A-C) Values represent the mean ± SEM; n=12-18 replicates of three 
independent experiments. One-way ANOVA and post hoc Dunnetts' multiple comparison test versus control 
(untreated), *P<0.05; **P<0.01; ***P<0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 
3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone. 
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Fig. 4. ATP levels did correlate with basal mitochondrial respiration. Graph representing ATP levels in abscissa 
versus (A) OCR or (B) ECAR or (C) MMP in ordinate. Values represent the mean of each treatment group 
normalized to the control group (=100%). Pearson correlation r=0.5074, R2=0.2575, P=0.0032. OCR; oxygen 
consumption rate, ECAR; extracellular acidification rate; MMP; mitochondrial membrane potential. 
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Fig. 5. Testosterone increased mitochondrial respiratory capacity. (A) Oxygen consumption rate (OCR), was 
measured on permeabilized SH-SY5Y cells after treatment with testosterone for 24 h, using a XF24 Analyser 
(Seahorse Bioscience). The sequential injection of mitochondrial inhibitors is indicated by arrows (see details in 
the Materials and Methods section). (B) Values corresponding to the different respiratory states are represented 
as mean ± SEM (n= 15-18 replicate of three independent experiments/group) and were normalized to the basal 
respiration of the control group (=100%). (C) The respiratory control ratio (RCR= State 3/State 4o), which reflects 
the mitochondrial respiratory capacity, was increased by testosterone. Student unpaired t-test, *P<0.05. T 10 nM; 
testosterone at a concentration of 10 nM, T 100 nM; testosterone at a concentration of 100 nM, O; oligomycin, F; 
FCCP, R/A; rotenone/antimycin A. 
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Fig. 6. Neurosteroids up-regulated the bioenergetic activity in primary cortical cells. (A) ATP level was significantly 
increased after neurosteroid treatment (24 h) at a concentration of 10nM (white boxes) and 100nM (gray boxes). 
(B) Oxygen consumption rate (OCR) and (C) extracellular acidification rate (ECAR) were measured 
simultaneously using a Seahorse Biosciences XF24 Analyser under the same experimental conditions. (D) 
Bioenergetic profile of primary cortical cells (OCR versus ECAR) revealed an increased aerobic activity (O2 
consumption) after treatment with neurosteroids. Values represent the mean of each group (mean of the ECAR in 
abscissa / mean of the OCR in ordinate) and were normalized to the control group (100%). (A-C) Values 
represent the mean ± SEM, n=4-6 replicates of three independent experiments / group, and were normalized to 
the control group (=100%). One-way ANOVA and post hoc Dunnetts' multiple comparison test versus control 
(untreated), *P<0.05; **P<0.01; ***P<0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 
3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone. 
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Fig. 7. Neurosteroids modulate the mitochondrial redox environment in SH-SY5Y neuroblastoma cells. (A) 
Mitochondrial reactive oxygen species (mtROS) levels were significantly increased after neurosteroid treatment 
(24 h) at a concentration of 10 nM (white boxes) and 100 nM (gray boxes). (B) This increase was accompanied by 
an up-regulation of manganese superoxide dismutase activity (MnSOD). (C) A positive correlation was observed 
between ROS levels and MnSOD activity. (D) Using a reporter gene coding for a redox sensitive green 
fluorescent protein (AR305 roGFP) located within mitochondria, the mitochondrial redox state underwent a switch 
to a more oxidized state after neurosteroid treatment compared to the untreated control. (A, B) Values represent 
the mean ± SEM and were normalized to the corresponding untreated control group (=100%). (C) Values 
represent the mean of each group (mean of the mitochondrial ROS level in abscissa / mean of the MnSOD 
activity in ordinate) normalized to the untreated control group (=100%). Pearson correlation r=0.7096, R2=0.5035, 
P=0.0022. (D) Values represent the mean ± SEM of the ratio “oxidized state/reduced state”, n=8-15 replicates of 
three independent experiments/group. Values were normalized to the control group (=100%). One-way ANOVA 
and post hoc Dunnett’s multiple comparison test versus control (untreated), *P<0.05; **P<0.01; ***P<0.001; P; 
progesterone, E2; estradiol, E1; estrone, T; testosterone, 3a-A; 3a-androstanediol, D; dihydroepiandrostanedione 
(DHEA), AP; allopregnanolone, Ox.; oxidized environment, Red.; reduced environment.  
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Fig. 8. Different action profile of neurosteroids on cellular bioenergetics. Representative diagrams of the effects of 
neurosteroids on the bioenergetic activity (ATP level, basal respiration, glycolysis, MMP) and the modulation of 
mitochondrial redox environment (mtROS levels, MnSOD activity, redox state) in SH-SH5Y neuroblastoma cells 
(A), and the bioenergetic activity in primary cortical cells (B). No effect is represented in white color. A significant 
increase of the respective parameter is marked either in yellow (significant only at 10 nM), blue (significant only at 
100 nM), or green (significant at both concentrations). mtROS; mitochondrial reactive oxygen species, MMP; 
mitochondrial membrane potential, MnSOD; manganese superoxide dismutase activity.  
RESULTS  Grimm A. et al. (2014) 
106 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Schematic representation of the effects of neurosteroids on mitochondrial bioenergetics and redox 
environment in SH-SH5Y neuroblastoma cells. * indicates that the effect was similar to that observed in primary 
cortical cells. ETC; electron transport chain, TCA; tricyclic acid, MnSOD; manganese superoxide dismutase, 
ROS; reactive oxygen species, MMP; mitochondrial membrane potential.  
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Suppl. Fig. 1. PCR analysis of GABAA receptor in SH-SY5Y human neuroblastoma cells and mouse primary 
cortical cells. Total RNA obtained from both cell types was amplified with the corresponding primers for human 
and mouse GABAA receptor subunits α1 and β2. GABRA1; human subunit α1 (82 bp), GABRB2; human subunit 
β2 (143 bp), gabra1; mouse subunit α1 (98 bp), mouse; gabrb2; mouse subunit β2 (115 bp). 
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Abstract: 
 
 Alzheimer’s disease (AD) is an age-related neurodegenerative disease marked by a 
progressive physical and cognitive decline. Metabolic and mitochondrial impairments are 
common hallmarks of AD, and amyloid-β (Aβ) peptide and hyperphosphorylated tau protein – 
the two foremost histopathological signs of AD - have been implicated in mitochondrial 
dysfunction. Neurosteroids have recently shown promise in alleviating cognitive and neuronal 
sequelae of AD. The present study evaluates the impact of neurosteroids belonging to the 
sex hormone family (progesterone, estradiol, estrone, testosterone, 3α-androstanediol) on 
mitochondrial dysfunction in cellular models of AD. For that purpose, we treated human 
neuroblastoma cells (SH-SY5Y) stably transfected with the human amyloid precursor protein 
(APP) that overexpress APP and Aβ, wild-type tau protein (wtTau), or mutant tau (P301L), 
that induces abnormal tau hyperphosphorylation for 24 hrs with neurosteroids. We showed 
that APP and P301L cells both display a drop in ATP levels but they present distinct 
mitochondrial impairments with regard to their bioenergetic profiles. The P301L cells 
presented a decreased maximal respiration and spare respiratory capacity, while APP cells 
exhibited, in addition, a decrease in basal respiration, ATP turnover and glycolytic reserve. 
All the neurosteroids tested showed beneficial effects on ATP production and mitochondrial 
membrane potential in APP/Aβ overexpressing cells while only progesterone and estradiol 
increased ATP levels in mutant tau cells. Of note, testosterone was more efficient to alleviate 
Aβ-induced mitochondrial deficits, and progesterone and estrogen were more effective in 
rising bioenergetic outcomes in our model of AD-related tauopathy. Our findings lend further 
evidence to the neuroprotective effects of neurosteroids in AD pathology and may open new 
avenues for the development of gender-based therapeutic approaches in AD. 
 
Key words: Mitochondria, Neurosteroid, Bioenergetics, Amyloid-β peptide, tau protein. 
 
Abbreviations:  
3α-A, 3α-androstanediol; Aβ, Amyloid-β peptide; AD, Alzheimer’s disease; APP, amyloid-β 
precursor protein; DMSO, dimethylsulfoxide; E1, estrone; E2, 17β-estradiol; ECAR, 
extracellular acidification rate; ETC, electron transport chain; MMP, mitochondrial membrane 
potential; OCR, oxygen consumption rate; OXPHOS, Oxidative phosphorylation; P, 
progesterone; P301L, tau mutation; PD, Parkinson’s disease; ROS, reactive oxygen species; 
T, testosterone; wtTau, wild-type tau. 
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Introduction 
 
 Alzheimer’s disease (AD) is an age-related neurodegenerative disease that accounts 
for more than 60% of all dementia cases. AD will become increasingly burdensome and 
costly in the coming years as prevalence is expected to double within the next two decades 
(1). The disease is characterized by cognitive deficits and memory loss and, from a 
histopathological point of view, by the presence of amyloid-β (Aβ) plaques and neurofibrillary 
tangles (NFT) composed of abnormally hyperphosphorylated tau protein in the brain. Genetic 
studies link mutations in the amyloid-β protein precursor (APP) to familial AD (FAD) cases. 
These mutations lead to an increased Aβ production in the brain of AD patients (2). 
Interestingly no mutations in the tau coding gene have been identified so far in FAD. 
However, such mutations were detected in familial frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17) leading to NFT formation (3). Both 
histopathological hallmarks of AD, Aβ and abnormal tau protein, generate problems with 
synaptic integration, oxidative stress, disrupting Ca2+ homeostasis that inexorably lead to 
neurodegeneration (4-6).  
 Mitochondria are essential components of metabolic function and serve as the 
“powerhouses” of cells, providing energy in the form of adenosine triphosphate (ATP) that is 
used by cells to power a variety of cellular processes including apoptosis, intracellular 
calcium homeostasis, alteration of the cellular reduction–oxidation (redox) state and synaptic 
plasticity (7; 8). Mounting evidence suggests that mitochondrial dysfunction serves as a 
catalyst in AD, since the disease is associated with a decline in bioenergetic activity and an 
increase in oxidative stress that can already be detected at early stages of the disease (9-
11). Indeed, brain glucose hypometabolism could be observed in living AD patients even 
before the onset of clinical symptoms (12). This disease characteristic was also observed in 
AD mouse models in which mitochondrial dysfunction is already obvious before the 
appearance of Aβ deposits, NFT and cognitive impairments (reviewed in (13)). With regard to 
their critical role in the early pathogenesis of AD, mitochondria therefore represent interesting 
targets for the development of novel treatment avenues. 
 Based on recent breakthroughs, interventions that concentrate on mitochondrial 
deficits, such as neurosteroids, may serve as potential strategies for the treatment of AD (14-
16). In 1981, Baulieu and colleagues characterized a new category of steroids that are 
synthesized within the nervous system and are still present in substantial amounts after 
removal of the peripheral steroidogenic glands (17). This category of molecules was dubbed 
“neurosteroids”. In a recent study, we characterized the bioenergetic modulating profile of 
seven structurally diverse neurosteroids that are known to be involved in the regulation of 
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brain functions (18-21), namely progesterone, estradiol, estrone, testosterone, 3α-
androstanediol, DHEA and allopregnanolone. We found that most of the steroids we tested 
were able to improve bioenergetic activity in neuronal cells by increasing ATP levels, 
mitochondrial membrane potential (MMP) and mitochondrial respiration (16). Our results 
provide new insights in re-defining the biological model of how neurosteroids control 
neuronal functions and further emphasize the role of neurosteroids in neuroprotection.  
 In line with our study, a growing body of evidence attests to the neuroprotective 
effects of neurosteroids, especially estrogenic compounds, against AD-related cellular injury 
(reviewed in (15)). However, little is known about the influence of neurosteroids on AD-
related mitochondrial dysfunction. Additionally, the primary focus of neurosteroid treatment in 
AD has centered in the past on Aβ plaques rather than tau-related NFT.  
 
 Thus, the aim of our study was to assess whether neurosteroids of the sex hormone 
family could attenuate the toxic effects of Aβ and/or abnormal tau on mitochondria and also 
to differentiate the influence of neurosteroids on tau-related deficits independent of Aβ. For 
this purpose, we investigated the effects of progesterone, estradiol, estrone, testosterone 
and 3α-androstanediol on bioenergetics in SH-SY5Y neuroblastoma cells stably transfected 
with wild type human APP (APP cells) or the empty vector (Mock cells), and wild type human 
tau (wtTau cells) or mutated tau (P301L cells), respectively. Of note, both AD cell culture 
models, APP and P301L cells, exhibit the characteristics of a mitochondrial malfunction when 
compared to their respective controls. They had in common decreased ATP levels as well as 
impaired mitochondrial respiration (22; 23), but differed in underlying mechanisms. Thus, 
APP cells presented a defect in complex IV activity (22), whereas complex I activity was 
impacted by mutant tau in P301L cells (23). On the basis of our previous findings, it was 
therefore of utmost interest to examine whether neurosteroids are able to alleviate 
mitochondrial deficits manifested in these AD cellular models. In particular, their impact on 
ATP production, mitochondrial membrane potential (MMP), mitochondrial respiration and 
glycolysis was investigated. 
 
Materials and methods 
 
Chemicals and reagents 
 
 Dulbecco’s-modified Eagle medium (DMEM), foetal calf serum (FCS), 
penicillin/streptomycin, progesterone, 17β-estradiol, estrone, 3α-androstanediol and pyruvate 
were from Sigma-Aldrich (St. Louis, MO USA). Glutamax was from Gibco Invitrogen 
(Waltham, MA USA). XF Cell Mitostress kit was from Seahorse Bioscience (North Billerica, 
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MA USA). Testosterone was from AppliChem (Darmstadt, Germany). Horse serum (HS) was 
from Amimed, Bioconcept (Allschwil, Switzerland).  
 
Cell culture 
 
 APP cells were obtained by transfecting the human neuroblastoma SH-SY5Y with 
cDNAs (pCEP4 vector) containing either vector alone (Mock cells) or the entire coding region 
of human APP (APP695, APP cells) as previously described (22; 24). Stably transfected 
human SH-SY5Y neuroblastoma cells with wild-type (wtTau cells) and P301L mutant tau 
(P301L cells) were kindly provided by Jürgen Götz, Queensland Brain Institute (QBI), 
Brisbane, Queensland, Australia (25). Cells were grown at 37 °C in a humidified incubator 
chamber under an atmosphere of 7.5% CO2 in DMEM supplemented with 10% (v/v) heat-
inactivated FCS, 5% (v/v) heat-inactivated HS, 2 mM Glutamax and 1% (v/v) 
penicillin/streptomycin. Cells were passaged 1-2 times per week, and plated for treatment 
when they reached 80–90% confluence.  
  
Treatment paradigm 
 
 Assessment of cell viability was performed on SH-SY5Y neuroblastoma cells (Mock, 
APP, wtTau and P301L cells) to determine the potential toxic concentration range of 
neurosteroids (from 10 nM to 1000 nM, data not shown) using a MTT reduction assay 
(Roche, Basel, Switzerland) on the basis of the MTT results, and according to previous data 
obtained in untransfected SH-SY5Y neuroblastoma cells (16) the concentration 100 nM was 
then selected and used in all assays. Cells were treated one day after plating either with 
DMEM (untreated control condition) or with a final concentration of 100 nM of progesterone, 
17β-estradiol, estrone, testosterone or 3α-androstanediol made from a stock solution in 
DMSO for 24 hrs (final concentration of DMSO < 0.002%, no effect of the vehicle solution 
(DMSO) alone compared to the untreated condition). To limit cell growth and to optimize 
mitochondrial respiration, treatment medium contained only a low amount of fetal calf serum 
(5% FCS) as well as glucose (1 g/l) and was supplemented with 4 mM pyruvate. Each assay 
was repeated at least 3 times. 
 
ATP levels 
 
 Total ATP content was determined using a bioluminescence assay (ViaLighTM HT; 
Cambrex Bio Science) according to the instructions of the manufacturer, as previously 
described (22). Cells were plated in 5 replicates into a white 96-well cell culture plate at a 
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density of 1.5 x 104 cells/well. The bioluminescent method measures the formation of light 
from ATP and luciferin by luciferase. The emitted light was linearly related to the ATP 
concentration and was measured using multilabel plate reader VictorX5 (Perkin Elmer). 
  
Determination of mitochondrial membrane potential 
 
 The MMP was measured using the fluorescent dye tetramethylrhodamine, methyl 
ester, perchlorate (TMRM) (16). Cells were plated in 6 replicates into a black 96-well cell 
culture plate at a density of 1.5 x 104 cells/well. Cells were loaded with the dye at a 
concentration of 0.4 μM for 15 min. After washing twice with HBSS, the fluorescence was 
detected using the multilabel plate reader VictorX5 (PerkinElmer) at 530 nm (excitation)/590 
nm (emission). Transmembrane distribution of the dye was dependent on MMP.  
 
Mitochondrial respiration 
 
 The investigation of mitochondrial respiration and cellular glycolysis was performed 
using the Seahorse Bioscience XF24 analyser. XF24 cell culture microplates were coated 
with 0.1% gelatin and cells were plated at a density of 2.5 x 104 cells/well in 100 μl of 
treatment medium containing 5% FCS, 1 g/l glucose and 4 mM pyruvate. After neurosteroid 
treatment, cells were washed with 1X pre-warmed PBS and 500 μl of DMEM containing 1 g/l 
of glucose and 4 mM of pyruvate were added in each well. The oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) were recorded simultaneously before and 
after the sequential injection of i) Oligomycin (0.5 μM), ii) FCCP (2 μM), iii) Antimycin A and 
rotenone (0.5 μM and 1 μM respectively). Data were extracted from the Seahorse XF-24 
software and bioenergetic parameters (basal respiration, ATP turn over, maximal respiration, 
spare respiratory capacity and glycolytic reserve) were calculated according to the guideline 
of the company. 
 
Statistical Analysis 
 
 Data are given as the mean ± S.E.M. Statistical analyses were performed using 
Graph Pad Prism software. For statistical comparisons of more than two groups, one-way 
ANOVA was used, followed by a Dunnett's multiple comparison tests versus the control. For 
statistical comparisons of two groups, student unpaired t-tests were used. P values < 0.05 
were considered statistically significant. 
 
Results 
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 APP and hyperphosphorylated tau differentially impair mitochondrial 
bioenergetics  
 
 To measure efficiency of mitochondrial respiration and cellular bioenergetics in 
APP/Aβ overexpressing cells, we simultaneously monitored in real-time the oxygen 
consumption rate (OCR) (Fig. 1A), an indicator of mitochondrial respiration, as well as the 
extracellular acidification rate (ECAR) (Fig. 1B), an indicator of glycolysis, using a Seahorse 
Bioscience XF24 Analyzer. We first performed experiments on untreated control and APP 
cells to record AD-related differences in OCR and ECAR readouts. A significant decrease 
(about 50 %) in basal respiration, ATP turnover, maximal respiration, as well as glycolytic 
reserve was observed in APP cells when compared to control cells (Fig. 1C), paralleled by a 
reduction in ATP levels (-20% compared to control cells) (Fig. 1D). Surprisingly, a slight 
increase in MMP was observed in APP cells (Fig. 1E), translating to a hyperpolarization of 
the mitochondrial membrane potential. 
 The same experiments were conducted to characterize wtTau cells and P301L cells 
(Fig. 2). No significant difference in basal respiration, ATP turnover and glycolytic reserve 
was found between the two cell lines (Fig. 2A-C). However, wtTau cells had higher maximal 
respiration and spare respiratory capacity than P301L-transfected cells, indicating that 
mutant cells have some level of metabolic impairment, especially with regard to their 
mitochondrial reserve capacity (Fig. 2C). ATP levels were also significantly reduced in 
P301L cells (-27% compared to wtTau cells) (Fig. 2D), paralleled by a depolarization of 
mitochondrial membrane potential (decreased MMP, -10% compared to wtTau cells) (Fig. 
2E). 
 Taken together, these results confirm that APP/Aβ and hyperphosphorylated tau 
exhibit negative impacts on mitochondrial function leading to mitochondrial respiration 
deficiency and diminished ATP outcome. Since different bioenergetic parameters are 
impaired between APP and P301L cells, Aβ and abnormal tau appear to exert a different 
degree of toxicity on mitochondrial function.  
 
 Sex steroid hormones distinctively increase mitochondrial bioenergetics in 
APP/Aβ and tau-overexpressing cells 
 
 To address whether treatment with neurosteroids can improve mitochondrial function 
in AD cell culture models, ATP levels and MMP were analyzed in APP/Aβ and tau-
overexpressing cells after 24 hrs of treatment (concentration 100 nM) with different steroids: 
progesterone (P), estradiol (E2), estrone (E1), testosterone (T) and 3α-androstanediol (3α) 
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(Fig. 3). In APP cells, all steroids tested were able to significantly increase ATP levels (Fig. 
3A) as well as MMP (Fig. 3B). However, in P301L cells, only P and E2 induced a significant 
increase in ATP levels (Fig. 3C). P was particularly efficient since ATP levels in P301L were 
even higher (+6%) compared to those of the untreated wtTau cells. In addition, all the tested 
steroids, except testosterone, significantly increased MMP in P301L cells (Fig. 3D) with 
estrogens (E2 and E1) having the highest effect (+8% compared to untreated P301L cells). 
 To characterize the bioenergetic modulating profile of sex steroids on APP/Aβ and tau 
overexpressing cells, measurements with a Seahorse Bioscience XF24 analyzer were 
performed after 24 hrs of treatments (concentration 100 nM) (Fig. 4-5). In APP/Aβ 
overexpressing cells, only the testosterone treated group exhibited a higher basal respiration 
(Fig. 4A), ATP turnover (Fig. 4B), maximal respiration (Fig. 4C), spare respiratory capacity 
(Fig. 4D) and glycolytic reserve (Fig. 4E) compared to the untreated control group. In 
addition, 3α-androstanediol induced an improvement in the spare respiratory capacity (Fig. 
4D) and progesterone significantly increased glycolytic reserve (Fig. 4E). These data 
suggest that especially testosterone, the main male sex hormone, exhibits a beneficial 
impact on mitochondrial malfunction in AD cells modeling Aβ pathology.  
 Regarding the bioenergetic modulating profile of sex steroids on P301L cells, no 
significant changes were present in basal respiration (Fig. 5A). Nevertheless, the two main 
female sex hormones, P and E2, significantly enhanced ATP turnover (Fig. 5B), maximal 
respiration (Fig. 5C) as well as spare respiratory capacity (Fig. 5D) compared to the 
untreated P301L cells. Estrone (E1), another estrogen, was also able to significantly increase 
spare respiratory capacity (Fig. 5D) and 3α-androstanediol was the only steroid able to grow 
the glycolytic reserve (Fig. 5E) in P301L cells. Together, these data suggests that mainly 
female sex steroid hormones, P and E2/E1, improve mitochondrial bioenergetics in cells 
modeling tau pathology. 
 A full analysis of preference for oxidative phosphorylation as indicated by percent of 
OCR dedicated to ATP turnover (Fig. 6A, C) or spare respiratory capacity (Fig. 6B, D), 
versus the use of glycolytic reserves was performed in both APP/Aβ and tau-overexpressing 
cells. Tendency for greater or lesser metabolic activity is displayed on a second axis. Overall, 
APP cells were switched to a metabolically more active state after treatment with androgenic 
compounds (T and 3α), with a tendency to increase both glycolytic reserve (ECAR) and ATP 
turnover/spare respiratory capacity (OCR) (Fig. 6A-B). In P301L cells, ATP turnover and 
spare respiratory capacity were enhanced by progesterone (P) and estrogenic compounds 
(E1 and E2), leading to a more aerobic state (Fig. 6C-D). 
 Taken together, these results indicate that distinct sex steroid hormones are able to 
improve mitochondrial bioenergetics in APP/Aβ and tau-overexpressing cells by increasing 
RESULTS  Grimm A. et al. (in preparation) 
119 
 
ATP levels, MMP and mitochondrial respiration which contribute to the alleviation of 
mitochondrial deficits observed in those cell lines. 
 
Discussion 
 
 In this study, we distinguished the effects of several neurosteroids on ATP synthesis, 
MMP, mitochondrial respiration and glycolysis in two AD cellular models. Key findings were 
that: i) APP/Aβ and mutant tau-overexpressing cells present distinct bioenergetic 
impairments, with APP/Aβ having the strongest deleterious effect on mitochondrial function; 
ii) the male steroid hormone, testosterone, was more efficient to alleviate mitochondrial 
deficits in a model of AD-related amyloidopathy, whereas female steroid hormones, 
progesterone and estrogen, were more efficient to increase bioenergetic outcomes in a 
model of AD-related tauopathies.  
 
 Remarkably, bioenergetic profiles were differentially impacted in APP/Aβ-
overexpressing cells and abnormally hyperphosphorylated tau-overexpressing cells. Only the 
maximal respiration and spare respiratory capacity were reduced in P301L cells, while APP 
cells presented, in addition, a decrease in basal respiration, ATP turnover and glycolytic 
reserve. A drop in ATP levels was observed in both cell lines as well as a decreased MMP in 
P301L. Interestingly, APP cells presented a slight hyperpolarized mitochondrial membrane 
compared to the control Mock cells. This characteristic was previously observed in PC12 
cells overexpressing APP bearing the Swedish mutation (APPsw), another cellular model 
mimicking Aβ pathology (26). The authors hypothesized that this hyperpolarization may be 
due to the increased nitric oxide levels present in this cell line where Aβ production is 
enhanced. Of note, Aβ secretion was similar in wild type APP-overexpressing human SH-
SY5Y cells used in the present study and in APPsw-overexpressing PC12 cells within the 
low nanomolar range (26; 24), whereas higher Aβ levels obviously lead to MMP 
depolarization (26). 
 
 The different bioenergetic output observed between APP/Aβ and abnormal tau 
overexpressing cells can be explained by the fact that Aβ and tau differentially target 
mitochondria. Indeed, previous data of our group showed that APP cells present a decreased 
mitochondrial complex IV activity (22), whereas complex I activity was impacted in P301L 
cells (23). Moreover, we showed that Aβ peptide and abnormally hyperphosphorylated tau 
protein may act synergistically to trigger mitochondrial dysfunction in a triple transgenic 
mouse model of AD (tripleAD) obtained after crossing P301L tau transgenic mice with 
APPswPS2 double-transgenic mice (27). The investigation of oxidative phosphorylation 
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(OXPHOS) activity revealed that deregulation of complex I activity was related to tau, 
whereas deregulation of complex IV activity was dependent on Aβ.  
 Thus, on one hand, the lower complex I activity observed in P301L cells may lead to 
a decreased ability to reach maximal respiration, which reduces the spare respiratory 
capacity of the cells. On the other hand, the reduced complex IV activity, which is directly 
involved in oxygen consumption, may decrease additional respiratory parameters, including 
ATP turnover in APP cells. 
 
 A treatment with sex steroid hormones was able to alleviate bioenergetic impairments 
observed in APP and P301L cells in general. More precisely, the male hormone testosterone 
was able to enhance all the bioenergetic parameters that were impaired in APP/Aβ 
overexpressing cells, namely basal respiration, ATP turnover, maximal respiration and 
cellular glycolysis. In contrast, treatment with female hormones improved maximal respiration 
and spare respiratory capacity, two bioenergetic parameters that were disturbed in P301L 
cells. ATP turnover is an indication of the coupling efficiency that is directly linked to ATP 
production in mitochondria. Bioenergetic profile revealed that male and female steroid 
hormones were able to differentially increase ATP synthesis in APP and P301L cells 
respectively. The spare respiratory capacity and glycolytic reserve give an indication of the 
ability of cells to respond to stress under conditions of increased energy demand (28). Spare 
respiratory capacity was increased by estrogens and progesterone in P301L cells, whereas 
both parameters were enhance after treatment with androgen in APP cells. Together, data 
indicated that the cells were switched to a metabolically more active state, with a tendency to 
increase both ATP synthesis and metabolic reserves.  
 The ability of neurosteroids to modulate cellular bioenergetics was the focus of a 
recent study in our group. In particular, we showed that neurosteroids, including steroids that 
were investigated in the present study, were able to increase ATP levels and mitochondrial 
respiration in native SH-SY5Y neuroblastoma cells and mouse cortical neurons (16). 
Moreover, we showed that the effects we observed were, at least in part, mediated by steroid 
(progesterone, estrogen and androgen) receptor activation since the inhibition of those 
receptors by specific antagonists shut down the effects of the corresponding steroid ligand 
on ATP production.  
 Steroid receptors are nuclear receptors involved in the regulation of gene expression. 
With regards to bioenergetics, estrogens have been shown to up-regulate genes coding for 
some electron transport chain components such as subunits of mitochondrial complex I (CI), 
cytochrome c oxidase (complex IV), and the F1 subunit of ATP synthase, but also glucose 
transporter subunits, enzymes involved in the tricarboxylic acid cycle (TCA cycle) and 
glycolysis, leading to increased glucose utilization and mitochondrial respiration (reviewed in 
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(15)). Of note, since mitochondrial genome itself contains hormone responsive elements, it 
has been proposed that estradiol and testosterone can regulate energy production by 
inducing mitochondrial oxidative phosphorylation (OXPHOS) genes encoded in the 
mitochondrial DNA (29). In a similar way, progesterone has been shown to increase complex 
IV and V (ATP synthase) expression, paralleled by enhanced mitochondrial respiratory 
activity (30). With regards to the results obtained in the present study, we can speculate that 
the underlying mechanisms are similar and that the effects we observed are mediated, at 
least in part, by an increased expression of genes involved in OXPHOS and glycolysis. 
Further investigations will be needed to identify in detail which genes are concerned. 
 It is interesting to observe that sex steroid hormones didn't have the same modulating 
profile upon bioenergetic in presence of Aβ-related or tau-related mitochondrial dysfunction. 
Estrogens and progesterone seem to confer beneficial effects on mitochondrial-related 
dysfunction in tau pathology, whereas testosterone was more efficient alleviating 
mitochondrial deficits in APP/Aβ overexpressing cells. These findings may imply that women 
and men differentially answer to mitochondrial insults mediated either by Aβ or by abnormal 
tau. Epidemiological studies revealed that two thirds of AD patients are women and the 
sudden drop of estrogen levels after the menopause has been proposed to be one risk factor 
in Alzheimer's disease (AD) (31; 32). Indeed, estradiol is the major product of estrogen 
biosynthesis and it remains the most abundant estrogen in a woman’s pre-menopausal life. 
After menopause, women have comparable levels of estradiol compared to men, and it is at 
this time that women become more susceptible to AD. Thus, the precipitous decline of 
estrogens during menopause may contribute to AD onset as well as a greater vulnerability to 
the disease in women (15). Men, in contrast, present with a gradual reduction in testosterone 
over the life course eliminating approximately 2% of circulating testosterone every year (33). 
However, human and animal studies also suggested that androgen deprivation represents a 
risk factor for AD pathogenesis (34-36). Notably, in a triple transgenic mouse model of AD 
(3xTgAD), it has been shown that orchiectomized males presented an increased Aβ 
accumulation in the brain, coupled with impaired cognitive performances compared to sham 
operated mice (37). Treatment with androgens significantly attenuated the increase in AD 
pathology (37; 35). Further studies have indicated that advancing age in men enhances tau 
hyperphosphorylation consistent with AD pathology (38). These findings confirm that steroid 
influence on tau remains a promising, but understudied research avenue in AD. Of note, no 
sex predilection has been identified in patients with FTDP-17, a disease characterized by a 
strictly tau-dependent pathology (39; 40). This might suggest that the relationship between 
hormonal loss, in both women and men, and the risk to develop AD may be preferentially 
linked to Aβ pathology and not tau. 
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 A few studies have focused on the impact of steroids on abnormal tau. Liu and 
colleagues (41) discovered that protein kinase A may initiate phosphorylation of tau, and 
estradiol treatment of human embryonic kidney cells attenuated protein kinase A activity and 
reduced tau phosphorylation. Estradiol also exhibited rescue of aberrant tau in primary rat 
cortical neurons and SH-SY5Y neuroblastoma cells (42). Additional studies showed that both 
estrogen and progesterone were able to modulate activities of kinases and phosphatases 
involved in the regulation of tau phosphorylation, possibly by modulating glycogen synthase 
kinase (GSK) pathway (34). Specifically, estrogen appeared to reduce GSK-3β activity and 
progesterone decreased the expression of both GSK-3β (42; 34). These results imply that 
estrogen and progesterone can function along the same or disparate molecular pathways to 
modify abnormal tau protein. Regarding AD-linked Aβ pathology, studies have focused on 
the impact of estrogen on the deposition and clearance of Aβ (43; 44). Both estrone and 
estradiol decreased polymerization and stabilization of Aβ (45; 44). Other studies indicate 
that deficiencies in estrogen-related steroids can exacerbate Aβ plaques in AD mouse 
models and that treatment with estradiol was able to reduce Aβ burden, possibly via the 
increase of non-amyloidogenic pathways of APP processing (43; 46). The effects of 
progesterone on Aβ deposition and clearance are less investigated, but a recent study 
showed that progesterone and estradiol encouraged an increase in the expression of Aβ 
clearance factors in vitro and in vivo (47). 
 
 In the present study, testosterone ameliorated the effects of mitochondrial dysfunction 
caused by APP/Aβ but not abnormal tau. In our previous study investigating neurosteroid 
effects on bioenergetics in physiological conditions, the testosterone metabolite, 3α-
androstanediol, presented an effect similar to its precursor and was able to increase MMP, 
ATP levels and mitochondrial respiration in untransfected neuroblastoma cells and primary 
cortical cells (16). Here, 3α-androstanediol was less efficient to alleviate bioenergetic deficits 
in APP cells, suggesting a distinct mode of action compared to testosterone. Neuroprotective 
effects of testosterone on hyperphosphorylated tau are less well-characterized in the 
literature. Testosterone appears to prevent tau hyperphosphorylation in an in vivo model of 
heat shock induced phosphorylation through GSK-3β signaling inhibition (38). Interestingly, 
Rosario and colleagues (2010) (36) revealed less abnormal tau accumulation in 
gonadectomized male 3xTgAD mice treated with testosterone or estradiol, but not the 
testosterone metabolite dihydrotestosterone (DHT) (36). This implies that testosterone may 
exert indirect effects on tau hyperphosphorylation via its conversion to estradiol by the 
enzyme aromatase and by acting on estrogen receptors. In the same model, testosterone 
and DHT were able to decrease Aβ deposits with a higher efficiency than estradiol, 
suggesting an androgen receptor-dependent mechanism. Overk and colleagues (2013) (48) 
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examined basal levels of serum and brain testosterone in male 3xTgAD mice and found that 
testosterone levels rise with disease progression. This increase in testosterone in aged male 
3xTgAD mice was correlated with reduced Aβ plaque pathology. This suggests that 
testosterone may have some neuroprotective benefits on the AD disease course, but that 
testosterone administration is associated more with lesser Aβ protein burden rather than 
abnormal tau protein. In fact, testosterone has been shown to alter processing of amyloid 
precursor protein and enhances expression of neprilysin, an enzyme responsible for Aβ 
degradation (49). 
 
 The decrease in sex steroid hormones was proposed to be one risk factor of AD in 
both men and women. However, there is little information concerning changes of steroid 
levels in the human brain during ageing and under dementia conditions. Steroid hormone 
originate from the endocrine glands can freely pass through the blood brain barrier and act 
on nervous tissues. Since steroids can also be synthesized within the nervous system, 
changes in blood levels of steroids with increasing age do not necessarily reflect changes in 
brain levels. Schumacher and colleagues (2003) have quantified the level of different 
neurosteroids in various brain regions of aged AD patients and aged non-demented controls 
(21). They showed a general trend towards lower neurosteroid levels in AD patients. 
Additionally, neurosteroid levels were negatively correlated with Aβ and abnormal tau in 
some brain regions, suggesting a link between neurosteroid homeostasis and AD 
pathogenesis. Our experiments have shown a rescue of metabolic dysfunction in models of 
AD-linked tauopathies and amyloidopathies with neurosteroids belonging to the sex hormone 
family. Taking into account the data available in the literature and in our previous study, this 
rescue may possibly occur at two levels: i) neurosteroids can directly boost mitochondrial 
function via gene regulation; ii) neurosteroids can act to decrease Aβ accumulation and NFT 
formation, which alleviates mitochondrial impairments induced by Aβ and tau. An interaction 
between these mechanisms cannot be excluded. Experiments dissecting the mechanistic 
pathways of neurosteroid function underlying the gender differences in AD are further 
potential research paths for the better understanding of how neurosteroids impact 
mitochondrial function in AD. Ultimately, our research will potentially open new avenues for 
the development of gender-based therapeutic approaches in AD. 
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Fig. 1: Characterization of bioenergetic deficits in APP cells. (A) Oxygen consumption rate (OCR) and (B) 
extracellular acidification rate (ECAR) of Mock and APP cells were simultaneously measured using a XF24 
Analyser (Seahorse Bioscience). The sequential injection of mitochondrial inhibitors is indicated by arrows (see 
details in the Materials and Methods section). (C) Values corresponding to the different bioenergetic parameters 
are represented as mean ± SEM (n= 8-10 replicates). (A-C) Values were normalized to the basal OCR and ECAR 
of Mock cells (=100%). (D) ATP levels and (E) mitochondrial membrane potential (MMP) in Mock and APP cells. 
Values represent the mean ± SEM (n=12-18 replicates of three independent experiments) and were normalized to 
100% of Mock cells. Student unpaired t-test, *P<0.05; ***P<0.001. O; oligomycin, F; FCCP, R/A; 
rotenone/antimycin A. 
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Fig. 2: Characterization of bioenergetic deficits in P301L cells. (A) Oxygen consumption rate (OCR) and (B) 
extracellular acidification rate (ECAR) of wtTau and P301L cells were simultaneously measured using a XF24 
Analyser (Seahorse Bioscience). The sequential injection of mitochondrial inhibitors is indicated by arrows (see 
details in the Materials and Methods section). (C) Values corresponding to the different bioenergetic parameters 
are represented as mean ± SEM (n= 8-10 replicates). (A-C) Values were normalized to the basal OCR and ECAR 
of wtTau cells (=100%). (D) ATP levels and (E) mitochondrial membrane potential (MMP) in Mock and APP cells. 
Values represent the mean ± SEM (n=12-18 replicates of three independent experiments) and were normalized to 
100% of wtTau cells. Student unpaired t-test, *P<0.05; ***P<0.001. O; oligomycin, F; FCCP, R/A; 
rotenone/antimycin A. 
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Fig. 3: Neurosteroids increase ATP level and MMP in APP and P301L cells. ATP levels and MMP were 
measured after neurosteroid treatment for 24 hrs at a concentration of 100 nM in APP cells (A-B) and P301L cells 
(C-D) respectively. Values represent the mean ± SEM (n=12-18 replicates of three independent experiments) and 
were normalized to 100% of untreated Mock cells (A-B) or untreated wtTau cells (C-D). One-way ANOVA and 
post hoc Dunnett’s multiple comparison test versus untreated Mock or wtTau, *P<0.05; **P<0.01; ***P<0.001. P; 
progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α; 3α-androstanediol. 
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Fig. 4: Effects of neurosteroids on bioenergetic parameters in APP cells. (A) Basal respiration, (B) ATP turnover, 
(C) maximal respiration, (D) spare respiratory capacity and (E) glycolytic reserve were measured after 
neurosteroid treatment for 24 hrs at a concentration of 100 nM in APP cells, using a XF24 Analyzer (Seahorse 
Bioscience). Values represent the mean ± SEM (n=8-10 replicates) and were normalized to 100% of the control 
group (untreated APP cells). One-way ANOVA and post hoc Dunnett’s multiple comparison test versus control, 
*P<0.05; ***P<0.001. P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α; 3α-androstanediol. 
RESULTS  Grimm A. et al. (in preparation) 
128 
 
 
Fig. 5: Effects of neurosteroids on bioenergetic parameters in P301L cells. (A) Basal respiration, (B) ATP 
turnover, (C) maximal respiration, (D) spare respiratory capacity and (E) glycolytic reserve were measured after 
neurosteroid treatment for 24 hrs at a concentration of 100 nM in P301L cells, using a XF24 Analyzer (Seahorse 
Bioscience). Values represent the mean ± SEM (n=8-10 replicates) and were normalized to 100% of the control 
group (untreated P301L cells). One-way ANOVA and post hoc Dunnett’s multiple comparison test versus control, 
*P<0.05; ***P<0.001. P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α; 3α-androstanediol. 
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Fig. 6: Neurosteroids differentially regulate bioenergetic profile in APP/Aβ and abnormal tau-overexpressing cells. 
(A-B) Characterization of bioenergetic profiles of APP cells after neurosteroid treatment along two axes. Degree 
of (A) ATP turnover or (B) spare respiratory capacity is shown (in ordinate) in function of glycolytic reserve (in 
abscissa). The same parameters are displayed for P301L (C-D) respectively. Values represent the mean of each 
group normalized to the control group (untreated APP or P301L cells =100%). Significant changes upon 
respiratory parameters are highlighted by dashed circles. P; progesterone, E2; estradiol, E1; estrone, T; 
testosterone, 3α; 3α-androstanediol. 
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Abstract 
 
 Circadian clocks are self-sustained cellular oscillators that are tightly connected to 
metabolic processes through reciprocal regulation from metabolites to transcription factors. 
Within the cell, metabolism is a highly dynamic process where mitochondria network is a 
prominent actor in regulation of both energy metabolism and apoptotic pathways. We found 
that mitochondrial bioenergetic homeostasis, including mitochondrial respiration and 
consequently generation of its own byproducts as adenosine triphosphate (ATP) and reactive 
oxygen species (ROS), is directly coupled to mitochondrial network which is, at least in part, 
regulated by clock-controlled phosphorylation of Drp1, the main factor involved in 
mitochondrial fission. The time-dependent reorganization of mitochondrial architecture in turn 
regulates the clock through circadian oscillation of mitochondrial ATP which can act as input 
signal through activation of AMP-activated protein kinase (AMPK). Our findings highlight new 
insights in the understanding of the reciprocal temporal crosstalk that governs the molecular 
interplay between the coupling of mitochondrial dynamics and metabolism and circadian 
rhythms. 
 
Keywords: mitochondria, bioenergetics, dynamics, Drp1, circadian clock 
 
Abbreviations: 
2DG, 2 deoxy-D-glucose; AMPK, AMP-activated protein kinase; AraC, Cytosine β-D-
arabinofuranoside; ATP, adenosine tri-phosphate; cROS, cytosolic reactive oxygen species; 
DRP1, dynamin-related protein 1; ECAR, extracellular acidification rate; hFIS1, human 
fission protein 1; MEF, mouse embryonic fibroblast; MFN1/2, mitofusin 1/ 2; mROS, 
mitochondrial reactive oxygen species; NAD+(H), nicotinamide adenine dinucleotide 
(oxidized/reduced form); OCR, oxygen consumption rate; OXPHOS, Oxidative 
phosphorylation; OPA 1, optic atrophy 1; Per, clock gene Period; ROS, reactive oxygen 
species; SCN, suprachiasmatic nuclei; Ser637, residue serine 637; VDAC, voltage-
dependent anionic channels. 
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Introduction 
 
 The circadian clock is a hierarchical network of oscillators which coordinate a wide 
variety of endocrine, physiological and metabolic functions to the optimal time of day 
anticipating the periodical changes of the external environment for all living organisms, from 
cyanobacteria and fungi (1) to insects (2) and mammals (3). 
 Over the years, a growing body of evidences suggested particularly that energy 
metabolism (i.e. ATP release, reactive oxygen species (ROS)) and cellular defense 
mechanisms are coordinated by circadian clock (4; 5). The disruption of the clock impairs 
metabolic homeostasis among the living organisms (6; 7). This close relationship between 
circadian and metabolic cycles has been described in studies showing that the circadian 
clock exerts its control over metabolism by (i) controlling the expression of ascertained genes 
and enzymes involved in metabolic processes, (ii) intertwining nuclear receptors and nutrient 
sensors (e.g. SIRT1 and CLOCK, AMPK and CRY1) with the clock machinery, and/ or (iii) 
regulating metabolite levels (e.g. NAD+, cAMP) (8-12). While the regulation of metabolic 
pathways is well known to be achieved by the circadian clock, it has also been suggested 
that various hormones, nutrient sensors, redox sensors and metabolites are not only clock 
output but can also regulate in turn the biological clock by acting as an input signal (13; 14). 
While several studies showed diurnal oscillations in key bioenergetic parameters including 
expression of genes involved in mitochondrial respiration, mitochondrial membrane potential, 
cytochrome c oxidase activity in the SCN (15; 16), the whole mechanisms behind the 
relationship between the clock and the mitochondrial network remains mostly elusive. 
 Mitochondria are highly dynamic cellular organelles known to play a major role in 
cellular energy metabolism and maintenance of cell steadiness. These organelles are, 
among others, the place of synthesis of the main source of energy from nutritional sources in 
cells via ATP generation which is mainly accomplished through oxidative phosphorylation 
(17). To achieve the integrity of a healthy mitochondrial population within the cells but also 
the integrity of the cell itself, mitochondrial shape has to be modified to meet changing 
requirements in energy production and other mitochondrial functions. This requires a tightly 
regulated equilibrium between opposing mitochondrial fusion and fission activities (18; 19).  
 
 Thus, we have addressed the question of whether mitochondrial dynamics and 
metabolism are coupled events that may exhibit circadian oscillations and whether the 
mitochondrial network and the mitochondrial metabolism themelves may be able to influence 
the circadian clock by acting as retrograde signaling. For this purpose, the latest state-of-art 
approaches have been engaged in order to dissect the multilevel relationship between the 
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clock and mitochondrial function. Our findings are consistent with the hypothesis of the 
existence of crosstalk between the clock and mitochondrial network in order to maintain the 
bioenergetic homeostasis through the day in response to metabolic changes. 
 
Materials and Methods 
 
Mice 
 
 Drp1flx/flx mice (20) were crossed with mice expressing an inducible Cre recombinase 
transgene under the control of the CamKIIα promoter (Cre+) which is active in the 
hippocampus and the cortex of adult mice (from the European Mouse Mutant Archive EMMA 
strain 02125) (21). At 8 weeks of age the resulting Drp1flx/flx Cre+ mice were injected i.p. with 
1 mg tamoxifen (Sigma; 10 mg/ml tamoxifen dissolved in a 9:1 ratio of sunflower seed oil to 
ethanol) twice daily on five consecutive days to induce recombination of the Drp1 locus 
(Oettinghaus et al, submitted). 
 For the constant darkness (DD) experiments, all the mice were maintained for one 
week on a 12:12 light dark cycle prior to placement in DD 5 days before the beginning of the 
experiment with free access to food and water. 
 
Brain Homogenate Preparation  
 
 Brain homogenate preparations were obtained to determine nucleotides levels and 
AMPK activation. For that, brains were quickly dissected on ice and washed in an ice-cold 
buffer (210 mM mannitol, 70 mM sucrose, 10 mM Hepes, 1 mM EDTA, 0.45% BSA, 0.5 mM 
DTT, and Complete Protease Inhibitor mixture tablets (RocheDiagnostics). After removing 
the cerebellum, the tissue sample was homogenized in 2 ml of buffer with a glass 
homogenizer (10–15 strokes, 400 rpm). We used 10μl of the suspension for protein 
determination. All brain homogenate samples were normalized on 5 mg/ml of protein before 
ATP content, on 1 mg/ml for NAD+ and NADH level and for activated AMPK determination. 
 
Human Skin Fibroblast  
 
 Fibroblasts were isolated from biopsies, infected with the lentiviral circadian reporter 
mice Bmal1::luciferase and cultured in DMEM/1% penicillin streptomycin (Sigma)/1% 
Glutamax (Sigma) (DMEMc)/20% FBS (Sigma) as described previously (Brown, Fleury-Olela 
et al. 2005, Pagani PNAS 2009). For nucleotides level, ROS content, activated AMPK 
determination, oxygen consumption rate and mitochondrial morphology in human skin 
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fibroblasts, circadian rhythms were synchronized by serum shock treatment (50% horse 
serum supplemented DMEMc) for 2 hours at 37 °C.For the period length determination, 
circadian rhythms were synchronized by 100 nM dexamethasone (Sigma) in DMEMc + 20% 
FBS. DMEMc without phenol red was supplemented with 0.1 mM luciferin (Molecular 
Probes) and 10% FBS to obtain the counting medium (CM). 
 
Mouse Embryonic Fibroblast (MEF) 
 
 Drp1 lox/lox were prepared from E13.5 Drp1 lox/lox embryos as previously described 
(20). Drp1 -/- MEFs were subsequently generated by the expression of Cre recombinase in 
Drp1 lox/lox MEFs. The MEFs were cultured in DMEM/1% penicillin streptomycin 
(Sigma)/1% Glutamine (Sigma) (DMEMc)/10% FBS (Sigma)/1% non-essential amino acids. 
MEFs lacking mPer1−/−; mPer2−/− isolated from double knockout mice were generously 
provided by U. Albrecht (University of Fribourg) (22). MEF cultures were established from 
day 12 embryos as previously described (23) and the dissociated cells were plated in DMEM 
containing 10% FCS. 
 
Mitochondrial Morphology 
 
 For determination of mitochondrial dynamics in synchronized fibroblasts, cells were 
seeded on collagen - coated coverslip (0.05 mg/ml) at cell density sufficient to reach 50% of 
confluence the next day. After serum shock treatment, the medium was exchanged to 
DMEMc without phenol red + 2% FBS containing 75 nM Mitotracker® Red CMX ROS 
(579/599, Life technologies) which is a red-fluorescent dye that stains mitochondria in live 
cells and its accumulation is dependent upon membrane potential. From 8 hours post-
synchronization time point and at 8 hours intervals over the course of 24 hours, the stained 
cells were fixed with 4% paraformaldehyde/PBS for 30 minutes at room temperature. After 
extensive wash, the fixed cells were permeabilized with 0.15% Triton 100x prior staining 
nuclei with Sytox Green (Invitrogen) according to the manufacturer’s recommendation. After 
mounting the coverslips, images were processed by using a confocal microscope (60x oil 
objective, Leica). 
 To assess structure of the mitochondrial network in brain and liver slices from wild-
type mice at CT0 (onset of subjective day or rest period) and CT12 (onset of subjective night 
or activity period), samples were subjected to immunohistochemistry against Voltage-
Dependent Anionic Channels (VDAC, Cell Signaling), an outer mitochondrial membrane 
porin, followed by addition of anti-rabbit IgG, FITC (Sigma, 490/525). Prior to mounting the 
coverslips, brain and liver slices were nuclei-stained using TO-PRO-3iode (1uM, Invitrogen 
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642/661) according to the manufacturer’s recommendation. Images were obtained with 
confocal microscope (60x oil objective, Leica). 
 
Protein Gel Electrophoresis and Immunoblotting 
 
 After DC protein Assay (Biorad) quantification, equal amounts (50 μg from human 
skin fibroblasts protein lysates and 20 μg from mice brain lysates) were loaded on a 4-12% 
acrylamide gel (Invitrogen) to perform SDS-PAGE at 100V for 90 min and then transferred to 
PVDF membrane (Amersham Biosciences). We used primary antibodies to DRP1 (Cell 
Signaling), ser637-phosphorylated DRP1 (Cell Signaling) and VDAC (Cell Signaling). PVDF 
membranes were then treated with anti-IgG, horseradish-coupled secondary antibody. The 
bands were specifically detected by enhanced chemiluminescence reaction using 
SuperSignal™ West Dura Chemiluminescent Substrate (Thermo Scientific). Experiments 
were performed starting from 12 hours post-synchronization time point and measured at 4 
hours intervals for 6 time points. 
 
Nucleotides Measurements 
 
 Total ATP content from synchronized human skin fibroblasts, Drp1 lox/lox and Drp1 -
/- MEFs, Per1/2+/+ and Per1/2-/- MEFs and mice brain homogenates was determined using 
bioluminescence assay (ViaLighTM HT; Cambrex Bio Science) according to the instruction of 
the manufacturer. The enzyme luciferase, which catalyzes the formation of light from ATP 
and luciferin was used. The emitted light is linearly related to the ATP concentration and is 
measured using a luminometer (VictorX5, Perkin Elmer). To define the origin of ATP 
oscillation, DMEMc without phenol red + 2% FBS supplemented with 2-Deoxy-D-glucose (4.5 
g/l) a glycolysis inhibitor or oligomycin (2 μM), an ATP synthase inhibitor was added on 
synchronized human skin fibroblasts. To test the possibility that rhythmic ATP is a byproduct 
of rhythmic cell division, pharmacological disruption of the cell cycle was accomplished with 
the inhibitor AraC, an anticancer drug that prevents cell division (100 μm; Sigma). AraC was 
added to human skin fibroblasts cultures 3 hours after the seeding, directly after the medium 
exchange following the synchronization and then every 24 hours to assure continued block of 
cell division. To investigate the role of clock- regulated Drp1 in mitochondrial 
bioenergenetics, mitochondrial fission was abolished by selectively inhibition of mitochondrial 
division dynamin, Drp1, in presence of mdivi-1 (50 μM, Sigma). 
 For measurement of NAD+ and NADH from synchronized fibroblasts and mice brain 
homogenates, NAD+ and NADH were separately extracted using an acid-base extraction 
(HCL 0.1 mol/l – NAOH 0.1 mol/l). The determination of both NAD+ and NADH was 
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performed using an enzyme cycling assay based on passing the electron from ethanol trough 
reduced pyridine nucleotides to MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) in a PES (phenazine ethosulfate) coupled reaction resulting in a purple formazan 
product that can be quantitatively measured at a wavelength of 595 nm (VictorX5, Perkin 
Elmer). Experiments were performed starting from 12 hours post-synchronization time point 
and measured at 4 hours intervals for 6 time points. 
 
Oxygen Consumption Rate (OCR) Measurements 
 
 OCR was measured in synchronized fibroblasts as recommended as previously 
described (24). Briefly, human skin fibroblasts were seeded at the density of 3x104 cells/100 
μl per well on Seahorse Biosciences 24-well culture plates one day prior to the beginning of 
assay. After serum shock synchronization, medium was exchanged to 500 μl of assay 
medium (glucose-free RPMI-1640 medium containing 2% FBS, 2 mM sodium pyruvate, pH ~ 
7.4). Prior to measurements the microplates were equilibrated in a CO2 free incubator at 37 
°C for 60 minutes. The drug injections ports of the XF Assay Cartridge were loaded with the 
assay reagents at 10X in assay medium. 55 μl of oligomycin (10 μM), 62 μl of FCCP (7 μM), 
68μl of a mix of antimycin A (40 μM) and rotenone (20 μM) were added to ports A, B and C 
respectively. Experiments were performed at 16 hours post-shock and 28 hours post-shock. 
 
U2OS Cells Metabolome 
 
 Metabolic profiles also were obtained from dexamethasone-synchronized U2OS cells 
beginning at the 12 hour post synchronization time point and sampled at 4 hour intervals for 
6 time points. For metabolic profiles dexamethasone-synchronized U2OS cells beginning at 
the 12hr post synchronization time point and sampled at 4 hour intervals for 6 time points. 
Small-Molecule Determination. Metabolon analyzed metabolites in dexamethasone-
synchronized U2OS cells, as described previously (25; 26). 
 
Circadian period length determination 
 
 In transfected fibroblast, light output was measured in homemade light-tight 
atmosphere-controlled boxes for at least 5 days. To measure the fibroblast basal circadian 
rhythms, CM was supplemented with 10% FBS; to determine the influence of ATP on 
circadian period length, CM was supplemented with mitochondrial respiration inhibitors: 
rotenone, an complex I inhibitor (1 μM), oligomycin, ATP synthase inhibitor (2 μM) or 
carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), an uncoupler of proton 
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gradient (4 μM). To determine the role of Drp1-regulated mitochondrial bioenergenetics, CM 
was supplemented with mdivi-1 (50 μM, Sigma), a mitochondrial division inhibitor. 
 
Activated AMPK Quantification 
 
 The quantification of endogenous activated-AMPK was determined in lysates from 
synchronized fibroblasts and from brain homogenates by using PathScan® phospho-AMPKα 
(Thr172) sandwich ELISA (Cell Signaling) according to the instruction of the manufacturer. 
Briefly, AMPKα (phospho and nonphospho) is captured by the coated AMPKα rabbit antibody 
in the microplate. Then, a phospho-AMPKα (Thr172) mouse detection antibody is added to 
detect phosphorylation of Thr172 on the captured AMPKα protein. Anti-mouse IgG, HRP-
linked antibody is then used to recognize the bound detection antibody. HRP substrate, TMB, 
is added to develop color. The absorbance is measured at 450 nm within 30 minutes using a 
luminometer (VictorX5, Perkin Elmer) and is proportional to the quantity of AMPKα 
phosphorylated at Thr172. Experiments were performed starting from 12 hours post-
synchronization time point and measured at 4 hours intervals for 6 time points in fibroblasts 
and every 4 hours over the course of 24 hours in wild-type mice brain. 
 
ROS level 
 
 The formation of cytosolic (cROS) and mitochondrial (mROS) reactive oxygen 
species in synchronized fibroblasts were measured using, respectively, the fluorescent probe 
H2DCF-DA (DCF) and the non-fluorescent dihydrorhodamine-123 (DHR). Synchronized 
fibroblasts were loaded for 15 min with 10 μM DCF or 15 min with 10 μM DHR at 37 °C. After 
washing twice with HBSS, the formation of the reduced fluorescent product 
dichlorofluorescein was detected using the VictorX5 multilabel reader (PerkinElmer Life 
Sciences) at 485 nm (excitation)/535 nm (emission). DHR, which is oxidized to cationic 
rhodamine 123 which localizes in the mitochondria and exhibits green fluorescence, was 
detected using the VictorX5 multilabel reader at 490 nm (excitation)/590 nm (emission). The 
levels of superoxide anion radical were also assessed using the Red Mitochondrial 
Superoxide Indicator (MitoSOX, 5 μM, 30 min). MitoSOX, which is specifically oxidized by 
mitochondrial superoxide, exhibits a red fluorescence detected at 535 nm (excitation)/595 nm 
(emission). The intensity of fluorescence was proportional to mROS levels or superoxide 
anion radicals in mitochondria. Experiments were performed starting from 12 hours post-
synchronization time point and measured at 4 hours intervals for 6 time points. 
 
Quantitative Real-Time PCR 
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 Total RNA was extracted from lysates of synchronized fibroblasts using RNeasy Mini 
KIT (Qiagen). cDNA was generated using Ready-to-Go You-Prime First-Strand Beads (GE 
Healthcare). For data analysis, human Cdk4 was used as an endogenous control. Data are 
expressed as relative expression for each individual gene normalized to their corresponding 
controls using the comparative CT method. The primers used were purchased from Applied 
Biosystems (Probe ID: see Primers section for details). Data are expressed as relative 
expression for each individual gene normalized to their corresponding controls. 
 
Primer sequences 
 
 Primer Probe ID (Applied Biosystems) 
Fusion MFN1 Hs00250475_m1 
 MFN2 Hs00208382_m1 
 OPA1 Hs00323399_m1 
Fission DRP1 Hs00247147_m1 
 FIS1 Hs00211420_m1 
OXPHOS NDUFA2 (complex I) Hs00159575_m1 
 NDUFB5 (complex I) Hs00159582_m1 
 NDUFC1 (complex I) Hs00159587_m1 
 NDUFV2 (complex I) Hs00221478_m1 
 COX4I1 (complex IV) Hs00971639_m1 
 COX6A1 (complex IV) Hs01924685_g1 
 COX7A2 (complex IV) Hs01652418_m1 
 COX7B (complex IV) Hs00371307_m1 
 ATP5G2 (ATP synthase) Hs01096582_m1 
 ATP5C1 (ATP synthase) Hs01101219_g1 
 ATP5L (ATP synthase) Hs00758883_s1 
 
 
Statistical Analysis 
 
 Data were presented as mean ± S.E.M. For statistical comparisons, unpaired and 
paired Student's t-test, respectively, or Two-way ANOVA was used. Rhythmicity of 
metabolites was assessed using an algorithm previously described for rhythmic transcripts. 
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The JTK-cycle algorithm was used as implemented in R by Kronauer as previously described 
(26). P values less than 0.05 were considered statistically significant. 
 
Results 
 
Mitochondrial oxidative metabolism is driven by circadian clock. 
 
 To investigate whether the clock influences the cellular bioenergetic activity, we first 
monitored whole cell ATP content in synchronized human skin fibroblasts (Fig. 1A). Total 
ATP content exhibited a circadian rhythmicity with a peak occurring at 16 hours post-shock 
and a trough at 28 hours post- shock in synchronized fibroblasts (Fig. 1A). Similar 
observations were made in brain homogenates from wild-type mice kept in constant 
darkness where total ATP displayed ~24hours oscillations with a peak occurring at CT4, near 
the beginning of the rest period and a trough occurring at CT16, the beginning of the activity 
period (Fig. 1B). 
 
 As ATP molecules are produced by two main pathways, the cellular glycolysis and 
mitochondrial oxidative phosphorylation (OXPHOS), we monitored ATP content in 
synchronized fibroblasts in the presence of an ATP synthase inhibitor (oligomycin) or 
glycolysis inhibitor (2-deoxy-glucose) in order to determine which pathway is causative of 
ATP oscillation (Fig. 1A). We observed that the circadian oscillations in ATP were 
significantly dampened in the presence of oligomycin. In contrast, only the amplitude was 
decreased in the presence of 2-deoxy-glucose, suggesting that the circadian rhythm of ATP 
is primarily generated from mitochondrial oxidative phosphorylation. 
 
 In order to confirm that the observed ATP oscillations are not associated with 
synchronous cell cycle (27), we evaluated ATP content in Cytosine β-D-arabinofuranoside 
(AraC)-treated fibroblasts to induce disruption of cell cycle (Fig 1C). While AraC treatment 
decreased significantly cell proliferation (data not shown), pharmacological disruption of cell 
division with AraC led to a decreased level in rhythmic ATP content compared to untreated 
cells but no alteration in the period was observed in parallel as the ATP peak was occurring 
at 16 hours post-shock in AraC-treated cultures (Fig. 1C) which is consistent with 
observations made in astrocytes (28; 29). Together, these results demonstrate that circadian 
fluctuations in ATP levels mainly originated from mitochondrial oxidative metabolism (Fig. 
1A), independently of the cell cycle (Fig.1C). 
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 To further investigate whether expression of the core molecular clock transcription 
factors impact mitochondrial ATP generation, we evaluated ATP content in mouse embryonic 
fibroblasts (MEFs) isolated from mice deficient in the clock transcriptional repressors (PER1 
and PER2) (Fig. 1D). MEFs lacking the clock repressor genes Per1 and Per2 showed 
complete abolished ATP rhythm compared to control MEFs suggesting that circadian clock 
transcription repressors appear to influence, at least in part, oxidative metabolism. 
 
 To further investigate the clock-related regulation of mitochondrial oxidative 
metabolism, we monitored in real–time oxygen consumption rate (OCR) in synchronized 
fibroblast at 16 hours post-shock corresponding to total ATP peak and at 28 hours post-
shock related to total ATP trough (Fig. 2). For this purpose, OCR was assessed by using a 
Seahorse Bioscience XF24 Flux Analyzer by sequential injection of (i) the ATP synthase 
inhibitor oligomycin (1μM) to determine the OCR devoted to ATP synthesis counterbalancing 
against ATP consumption (also called ATP turnover), (ii) an uncoupling agent, FCCP 
[carbonyl cyanide p (trifluoromethoxy) phenylhydrazone] (0.7μM) to measure the maximal 
respiration in the absence of a proton gradient and (iii) inhibitors of activities of complexes I-
III, respectively rotenone (2μM) and antimycin A (4μM) to evaluate the OCR of non-
mitochondrial respiration (Fig. 2A). Consistent with the aforementioned ATP rhythms, we 
observed lower OCR in the basal respiration (~19%) as well as in ATP turnover (~24%) and 
maximal respiration (~14%) at 28 hours post-shock compared to OCR measured at 16 hours 
post- shock supporting the hypothesis of the clock-driven mitochondrial oxidative metabolism 
(Fig. 2B). The spare respiratory capacity corresponding to the ability of the cell to respond to 
an energetic demand as well as how closely the cell is to respiring to its theoretical maximum 
was higher (~48%) at 28 hours post-shock compared to OCR measured at 16 hours post- 
shock (Fig.2C). The rate of oxygen consumption due to non-mitochondrial sources (Fig. 2B), 
not coupled to ATP production but required to overcome the natural proton leak across the 
inner mitochondrial membrane (Fig. 2D) and related to glycolysis indicated by the 
extracellular acidification rate (ECAR) (Fig. 2E) was unchanged confirming the role of the 
oxidative phosphorylation in the generation and maintenance of ATP rhythm. Finally, we 
characterized the bioenergetic profile of synchronized human skin fibroblasts, representing 
OCR (basal respiration) versus ECAR (glycolysis) at 16 hours and 28 hours post-shock (Fig. 
2F). Remarkably, cells were switched between a metabolically active state corresponding to 
16 hours post-shock and a metabolically resting state corresponding to 28 hours post-shock, 
with only a variation of basal respiration (OCR). 
 
 To better understand the impact of the clock on mitochondrial respiration, we then 
investigated mitochondrial biogenesis around the clock by determining the gene expression 
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of subunits involved in oxidative phosphorylation, particularly in the electron transport chain 
(complex I and complex IV) and in ATP generation (ATP synthase or complex V) (Fig. S1) 
(15). RNA samples were isolated from synchronized human skin fibroblasts and relative 
quantification was performed by quantitative PCR (Fig. S1). Relative mRNA expression of 
complex I subunits exhibited a circadian rhythmicity with a peak occurring at 16 hours post-
shock and a trough at 28 hours post-shock (Fig. S1), while relative mRNA expression of 
complex IV subunits exhibited a circadian rhythmicity with a trough occurring at 16 hours 
post-shock and a peak at 28 hours post-shock (Fig. S1). Relative gene expression of ATP 
synthase (complex V) subunits displayed a circadian rhythmicity with a peak occurring at 20 
hours post-shock and a trough at 32 hours post-shock (Fig. S1). 
 
 Although oxidative phosphorylation (OXPHOS) is a vital part of metabolism, it 
produces in parallel reactive oxygen species (ROS). Since circadian ATP oscillation was 
correlated to mitochondrial respiration, we examined whether ROS levels within the cell 
followed a circadian pattern by measuring the fluoresecent probe H2DCF-DA and 
dihydrorhodamine 123 used respectively, for cytosolic (cROS) and mitochondrial (mROS) 
ROS in synchronized human skin fibroblasts (Fig. SI2). Remarkably, mROS levels displayed 
a circadian oscillation with a peak at 16 hours post-shock and a trough at 28 hours post-
shock while cROS level remained unchanged over the time. Moreover, the specific 
measurement of mitochondrial superoxide anion radicals revealed that a part of rhythmic 
ROS were indeed superoxide anions. 
 
 As important substrate in mitochondrial bioenergetics, we monitored NAD+ content in 
synchronized fibroblast (FIG S3) and in brain homogenate from wild-type non-fasted mice 
kept in constant darkness (FIG S3). We observed ~24hours oscillations of NAD+ with peak 
occurring at 16 hours post-shock in fibroblast culture (FIG S3) and near the beginning of the 
rest period (CT4) in mice brain homogenate (FIG S3). Both observations coincided with the 
rhythm of total ATP and thereby can be correlated to clock-driven mitochondrial metabolism. 
 
 To gain further insights into the signaling pathway between the clock and the 
mitochondrial network, we examined the metabolome in vitro to determine the key players of 
the metabolome in mitochondrial functions (FIG S4). Wide metabolic profiles were obtained 
from dexamethasone-synchronized U2OS cells over the course of 24 hours. All time points 
were subsequently analyzed by GC/LC-MS (26) (FIG S4). Overall, 228 metabolites were 
identified and ~29% of the identified metabolites (67 of 228) related amino acids, 
carbohydrates, cofactors, vitamins, energy, lipids, nucleotides and peptides metabolism 
displayed a circadian profile (FIG S4). Among the metabolites identified as rhythmic, the 
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largest group of compounds was represented by amino acids (33 of 67 rhythmic 
metabolites), which exhibited a restricted phase distribution around the clock (Fig S4). 
Remarkably, all others groups identified as rhythmic displayed an identical phase distribution 
(FIG S4). Interestingly, the majority of the rhythmic metabolites are likely related to numerous 
metabolomic pathways closely or remotely implicated in mitochondrial functions including 
energy metabolism and redox state (FIG S4). 
 
 Overall, these findings indicate a central role of the clock in the regulation of 
mitochondrial bioenergetic homeostasis, in part through mitochondrial biogenesis and in 
other part through the circadian modulation of metabolites connected to mitochondrial 
metabolism. 
 
Clock control of Drp1- dependent mitochondrial metabolism 
 
 Because mitochondria are known to be highly dynamic organelles, we investigated 
whether the circadian clock intervenes in the control and the maintenance of the 
mitochondrial network architecture (Fig. 3). Hence, we examined mitochondrial morphology 
using the red-fluorescent dye Mitotracker CMXROS in synchronized human primary skin 
fibroblasts and images were processed by confocal microscopy (Fig. 3A + SI5). We 
observed that mitochondrial network morphology displayed a circadian rhythmicity with three 
distinct states (tubular at 8 hours post-shock, intermediate at 16 hours post-shock and 
fragmented at 24 hours post-shock) in synchronized fibroblast culture. In parallel, we 
investigated the relationship between the clock and the mitochondrial architecture in brain 
and liver sections from wild-type mice at CT0 (onset of subjective day or rest period) and 
CT12 (onset of subjective night or activity period) by immunohistochemistry labeling VDAC 
(Voltage-Dependent Anionic Channels), an outer mitochondrial membrane porin (Fig 3B). 
Consistent with our in vitro observations, the mitochondrial network in both central and 
peripheral tissues exhibited a tubular morphology at CT0 corresponding to the beginning at 
the rest period while the shape network revealed a fragmented state at CT12 matching with 
the beginning of the activity period. 
 
 To further assess the relationship between the clock and mitochondrial shaping 
events, we analyzed the gene expression of the fusion proteins (mitofusins 1 and 2, MFN1 
and 2; optic atrophy 1, OPA1) and fission proteins (dynamin-related protein1, DRP1; human 
fission protein 1, hFIS1) required in the maintenance and regulation of mitochondrial system 
(30; 31) (Fig. 3C+ SI5). For this purpose, mRNA samples were isolated in synchronized 
human skin fibroblasts and relative quantification was performed by quantitative PCR (Fig. 
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3C+ SI5). Interestingly, none of the genes displayed a circadian pattern in their expression 
(Fig. 3C+ SI5), suggesting that 24-hour oscillations observed in the mitochondrial network 
architecture in vitro and in vivo may be controlled by post-transcriptional modifications of the 
mitochondrial shaping proteins. 
 
 To investigate whether regulation of the mitochondrial shaping trough activation/ 
inactivation of DRP1 protein, the main factor involved in mitochondrial fission, is under the 
control of the clock (Fig. 3D), we considered the potential contribution of the biological clock 
in the posttranslational modification of DRP1 by phosphorylation at a serine residue (Ser637) 
using immunoblotting against successively DRP1 and phosphorylated DRP1 at serine 637 in 
lysates (i) from synchronized human primary skin fibroblasts and (ii) from mouse brain of 
non-fasted wild-type mice maintained in constant darkness (Fig. 3D). While total DRP1 
protein did not display circadian oscillation in both (i) cell lysates and (ii) brain lysates, 
phosphorylated DRP1 at serine 637 exhibited ~24 hours rhythms with a peak occurring 
respectively, at (i) 16 hours post-shock and at (ii) CT12 (onset of the subjective night) (Fig. 
3D). Taken together, these results highlight that the remodeling events of the mitochondrial 
network in vitro and in vivo can be integrated into the biological clock network, partly through 
posttranslational modulation of DRP1 protein, suggesting a key role for the clock in 
mitochondrial network tasks to anticipate energetic requirements depending on the time of 
the day. 
 
 Because a growing body of evidence suggests a tight connection between 
mitochondrial shape changes and mitochondrial bioenergetic homeostasis, we investigated 
whether the circadian control of DRP1 is directly involved in the circadian ATP oscillation 
(Fig. 4). A treatment with a mitochondrial division inhibitor, mdivi-1, completely abolished 
ATP oscillation compared to untreated human skin fibroblasts (Fig. 4A). To further confirm 
whether inhibition or absence of DRP1 is able to impact ATP oscillation, we evaluated ATP 
content in mouse embryonic fibroblasts (MEFs) isolated from mice deficient in Drp1 as well 
as in Drp1-ablated hippocampus of adult mice kept in constant darkness (Fig.4B-C). MEFs 
lacking of Drp1 did not display ATP oscillation compared to control MEFs (Fig 4B). In 
addition, ATP content was evaluated at CT4, near the beginning of the rest period and at 
CT16, the beginning of the activity period accordingly to the aforementioned observation 
(Fig.1C). Consistent with our in vitro observations, ATP measured in Drp1 -/- hippocampi 
mice did not display a significant change between CT4 and CT16 compared to control 
hippocampi while the cerebrum from Drp1 -/- mice exhibited a circadian ATP changes 
equivalent to control cerebrum (Fig. 4C). Together, these findings provide new insights into 
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the control and maintenance of the mitochondrial metabolism connected to mitochondrial 
network changes through the clock modulation of DRP1. 
 
Crosstalk between Drp1- dependent mitochondrial metabolism and clock 
 
 To highlight the status of mitochondrial network and its signaling molecules in the 
regulation of the clock, we characterized the circadian period length of dexamethasone-
synchronized fibroblasts infected with a lentivirus that harbored a circadian reporter construct 
(the Bmal1 promoter driving expression of the firefly luciferase gene) by disturbing either 
mitochondrial respiration or mitochondrial network (Fig.5A-B). Rotenone, oligomycin or 
FCCP were used to inhibit mitochondrial respiration leading to a depletion in ATP content 
(FIG 5A). Notably, cells had a significantly longer period length in the presence of 
mitochondrial respiration inhibitors compared to the control cells. Moreover, disruption of 
mitochondrial division by mdivi-1 treatment significantly increased period length (Fig.5B). 
These findings suggest that Drp1-mediated mitochondrial ATP oscillations may play a key 
role in the retrograde signaling to the clock. 
 
 To better understand the underlying mechanisms in this retrograde signaling, we 
evaluated the activation of AMP-activated protein kinase (AMPK) via threonine 
phosphorylation, which is reported to transmit energy-dependent signals to the mammalian 
clock (FIG 5C-D) (32; 11). Activation of AMPK by phosphorylation was measured in 
synchronized human skin fibroblasts (FIG 5C) and in brain of non-fasted wild-type mice kept 
in constant darkness (FIG 5D). Relative phosphorylation on threonine 172 of AMPK 
displayed ~24 hours oscillations in both fibroblast culture and brain homogenate with a 
trough occurring respectively at 20 hours post- shock (FIG 5C) and a trough at CT 12 (FIG 
5D).  
 
 Together with the observations of the circadian ATP fluctuations, these data establish 
new insights in the multilevel regulation of the mitochondrial structure–function relationship 
by the biological clock, indicating a timekeeping system not only cyclic, but also outlining 
prior and upcoming events, in order to maintain energetic homeostasis in response to cellular 
metabolic change over the time. 
 
DISCUSSION 
 
 In our study, we aimed to investigate the clock-control on the coupling between 
mitochondrial network and bioenergetics to anticipate energetic requirements of diverse 
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cellular functions in response to cellular and environmental constraints. The major 
breakthroughs were that, (i) along rhythmic mitochondrial respiration, ATP, ROS and NAD+ 
as readouts of normal mitochondrial metabolism displayed circadian oscillation; (ii) these 
rhythmic byproducts were directly coupled with mitochondrial dynamics through the clock-
controlled Drp1 activity and (iii) both mitochondrial dynamics and bioenergetics might feed 
input signals back to the circadian clock. 
 
 Examination of the ATP content revealed that human skin fibroblasts and MEFs 
displayed circadian oscillations in ATP levels entirely coupled with rhythmic mitochondrial 
oxygen consumption in vitro. Remarkably, the bioenergetic profile showed that only 
mitochondrial respiration varied in a circadian manner over the time whereas the glycolysis 
remained unchanged. It indicated that this event is significantly dependent on mitochondrial 
respiration, consistent with the notion of mitochondria as major producers of ATP within the 
cell. Furthermore, when in resting state (low ATP), the cells exhibited a higher spare 
respiratory capacity indicating that the cells are more flexible to response to fluctuations in 
cellular energy demands than those cells which are already in high energy production state. 
The importance of a functional molecular clock in rhythmic ATP generation was confirmed in 
MEfs deficient in core clock repressors Per1 and Per2 consistent with the findings on 
depletion of ATP in astrocytes from both Per1 and Per2 -/-, as well as Cry1 and Cry2 -/- 
knock-out mice (28). Nevertheless, the opposite effect was observed in MEFs lacking of 
clock repressors in galactose-containing medium, where increased mitochondrial ATP 
production was consistent with increased mitochondrial oxidative metabolism (33). Similarly, 
mouse brain exhibited circadian oscillations in ATP levels in vivo according to the period of 
activity and rest. These findings can be explained, at least, with results from transcriptional 
profiling studies. Consistent with previous data in SCN2.2 cells and the SCN in vivo (15; 34; 
35), the expression of several subunits involved in the electron transport chain as well as in 
the ATP synthase appeared to be clock-controlled in human skin fibroblasts. In addition, 
numerous key bioenergetic parameters, including mitochondrial membrane potential and 
cytochrome c oxidase activity (16) as well as extracellular ATP accumulation (29), seem to 
follow circadian oscillations in SCN as well as in astrocytes. Moreover, the ATP breakdown 
product adenosine is known as crucial for the transition from wakefulness to sleep (36). 
Accumulation of adenosine in the basal forebrain induces the release of GABA, one of the 
inhibitory neurotransmitters involved in this transition, which eventually initiates the sleep 
phase. Overall, these findings support the concept of temporal organization of mitochondrial 
bioenergetic metabolism generating rhythmic mitochondrial ATP which in turn, along its 
metabolites, represents a physiological output of the mammalian cellular clock, especially in 
the brain, one of the highest energy demanding tissues of the human body. 
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 Along the rhythmic ATP coupled with rhythmic mitochondrial respiration, we also 
observed that several metabolites, including ROS and NAD+, remotely or closely connected 
to mitochondrial functions exhibited circadian oscillation in vitro and in vivo, suggesting a 
direct effect of the endogenous circadian clock on multiple metabolic pathways. In addition, 
our global circadian metabolomic analysis demonstrated that half of all rhythmic compounds 
were amino acids and associated metabolites known to be engaged in mitochondrial 
energetic homeostasis through branched-chain amino acids metabolism, glycolysis and TCA 
cycle to provide the energetic substrates such as pyruvate for the generation of ATP through 
oxidative phosphorylation, exhibited circadian profile in vitro. Furthermore, numerous 
rhythmic metabolites are also engaged in redox homeostasis through glutathione 
metabolism, which is one major endogenous defense system to combat cellular oxidative 
stress. Overall, the major circadian pathway signatures of the cellular metabolome that we 
have identified are consistent with those previously described in rodents (37) and humans 
(26). Moreover, it was recently suggested that clock control over mitochondrial activity is 
mediated, in part, by cycling metabolites (e.g: NAD+) and protein acetylation (33; 38). Taken 
together, these findings support the hypothesis that the circadian clock synchronizes 
mitochondrial ATP production in a time-of-day-dependent manner in response to daily 
fluctuations in cellular energy demands. The regulation of mitochondrial function appears to 
be achieved by the clock, among others potential pathways, through several rhythmic 
metabolites acting as upstream signals from the clock to mitochondria. 
 
 Once perceived as solitary structures, mitochondria are now recognized as highly 
mobile along cytoskeletal tracks and dynamic organelles that continually fuse and divide in 
response of cellular energy requirements (39). Our findings highlight, on the one hand, that 
mitochondrial bioenergetics are coupled to mitochondrial network changes in physiological 
conditions in vivo and in vitro, and, on the other hand, this coupling is under the control of the 
circadian clock. Interestingly, expression of genes involved in fusion and fission did not 
exhibit any oscillations whereas, in accordance with the circadian variations of ATP, the 
mitochondrial network showed significant circadian changes in its architecture in vitro and in 
vivo, suggesting that clock-controlled post-transcriptional modifications might be involved in 
the regulation of the mitochondrial network. Drp1, the only known mammalian mediator of 
mitochondrial fission, is one of the proteins that ensures the integrity of a healthy 
mitochondrial population within the cell but also the integrity of the cell itself. Analysis of 
regulation of Drp1 by the couple PKA/ Calcineurin at the phosphorylation site serine 637 
revealed that this process followed a circadian pattern. Moreover, it has been described that 
the activity of calcineurin, but not its protein expression, is under circadian regulation (40) 
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suggesting that the oscillation of Drp1 phosphorylation may be dependent of the 
dephosphorylation activity of calcineurin. Likewise, when Drp1 activity is pharmacologically 
or genetically impaired, we revealed that the circadian fluctuations in ATP content were 
abolished in vitro and in vivo confirming the clock control of Drp1-dependent mitochondrial 
metabolism. Altogether, the data showed for the first time that the regulation of mitochondrial 
function is achieved by the clock-controlled mitochondrial network, in part, through the post-
transcriptional regulation of Drp1. 
 
 While the extensive roles of mitochondria in maintaining cellular homeostasis and 
activity have created the need for diverse means of communication to and from the 
mitochondrial network, the underlying signaling mechanisms between the biological clock 
and mitochondrial network remain mostly unclear. When both mitochondrial respiration and 
fission are pharmacologically inhibited, we observed the dampening of mitochondrial ATP 
rhythm as well as the increase of circadian period in human skin fibroblasts. Interestingly, 
these findings can be explained by the well-established nutrient sensors such as AMPK 
involved in the crosstalk between metabolism and the biological clock (11). According to this 
study, the activation of AMPK followed a circadian pattern in vitro and in vivo, partially in 
antiphase to cycling ATP confirming that rhythmic mitochondrial ATP has a key role in 
retrograde signaling to the clock via the activation of AMPK, which in turn mediates the 
phosphorylation of CRY leading to proteolytic degradation of the negative arm of the central 
oscillator (32). 
 
 Overall, along the growing body of evidence stating the importance to integrate the 
cellular metabolism to circadian clocks (41), our findings establish a detailed molecular link 
among circadian control of the mitochondrial architecture and mitochondrial oxidative 
metabolism suggesting the key role of the clock-controlled mitochondrial network to 
anticipate energetic requirements of diverse cellular functions in response to cellular and 
environmental constraints (FIG S6). The events of mitochondrial morphological transitions as 
central actor in coupling circadian and mitochondrial metabolic cycles through metabolic 
retrograde signaling strengthen the still elusive understanding of the crosstalk between 
cellular systems and the biological clock. Thus, our findings could have multiple implications 
in the context of metabolic homeostasis in human health and diseases linked to impairment 
in circadian clock and/ or mitochondrial function. Perturbations in the clock may be a key 
initiating factor in diseases linked to mitochondrial weakening including neurodegenerative 
diseases as Alzheimer’s disease. 
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Fig. 1. Circadian clock control of mitochondrial ATP. (A) Relative total ATP level measured from 12 hours 
post-synchronization time point every 4 hours for 6 time points in human skin fibroblasts treated with 2 - deoxy-D-
glucose (2DG, 4.5g/L) or oligomycin (OLIGO, 2 μM) compared to non-treated cells (CTRL) (n=4). Left panel 
displays relative total ATP level at 16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP 
content) in control and treated conditions. (B) Relative total ATP level measured in brain of non-fasted wild-type 
mice kept in constant darkness every 4 hours for 24 hours (n= 4). Left panel displays relative total ATP level at 
CT4 (peak of ATP content) and at CT16 (trough of ATP content) in control and treated conditions. (C) Relative 
total ATP content measured from 12 hours post-synchronization time point with 4 hours intervals for 6 time points 
in AraC- treated fibroblasts (100 μM) compared to non-treated cells (CTRL) (n= 8). Left panel displays relative 
total ATP level at 16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content) in control 
and treated conditions. (D) Relative total ATP level measured from 12 hours post-synchronization time point every 
4 hours for 6 time points in Per1/2 −/− MEFs compared to controls. Left panel displays relative total ATP level at 
16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content) in control and Per1−/− and 
Per2−/− MEFs. **/## P < 0.01, ***/### P < 0.001 for Student’s two-tailed t test comparing single time points of 16 
hours versus 28 hours. Data are represented as average ± SEM. 
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Fig. 2. Circadian modulation of mitochondrial respiration. (A) Oxygen Consumption Rate (OCR) evaluated in 
synchronized fibroblasts treated sequentially with oligomycin (Oligo, 2 μM), FCCP (0.7 μM), rotenone (ROT, 2 
μM) and antimycin A (AA, 4 μM) at 16 hours post-shock and at 28 hours post-shock (n= 2). (B) Bioenergetic 
profile of synchronized fibroblasts at 16 hours post-shock and at 28 hours post-shock (n= 2). Basal respiration, 
ATP turnover and maximal respiration are determined after normalization to non-mitochondrial respiration. (C) 
Percentage of Oxygen Consumption Rate (OCR) linked to spare respiratory capacity (SRC) at 16 hours post-
shock and 28 hours post-shock in human skin fibroblast (n= 2). (D) OCR related to the proton leak (independent 
to ATP production) at 16 hours post-shock and 28 hours post-shock in human skin fibroblast (n= 2). (E) 
Extracellular Acidification Rate (ECAR) corresponding to glycolytic rate at 16 hours post-shock and 28 hours post-
shock in human skin fibroblast (n= 2). (F) Cellular bioenergetic profile of human skin fibroblast at 16 hours post-
shock and 28 hours post-shock (n= 2). *P < 0.05, **P < 0.01, ***P < 0.001 for Student’s two-tailed t test 
comparing single time points. Data are represented as average ± SEM. 
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Fig. 3. Circadian clock regulation of mitochondrial dynamics. (A and B) Mitochondrial network morphology 
assessed in (A) synchronized human skin fibroblasts at 8 hours intervals for 3 time points and in (B) (i) brain and 
(ii) liver from non-fasted wild-type mice kept in darkness condition at CT0 and CT12. White arrows indicate the 
tubular network and yellow arrows designate the fragmented network. Scale bars, (A) fibroblast, 7.5 μm, (B) 
brain, 50 μm; liver, 25 μm. (C) Relative mRNA expression of nuclearly-encoded genes related to mitochondrial 
fusion (MFN1, MFN2 and OPA1) and fission (DRP1 and hFIS1) measured at 16 hours and 28 hours post-
synchronization in human skin fibroblasts (n = 5 per time points). (D) Right: Phosphorylation of DRP1 (P-DRP1) 
on serine 637 and total DRP1 evaluated  in (i) human skin fibroblasts 12 hours post-synchronization time point at 
4 hours intervals for 6 time points and in (ii) brain homogenate of non-fasted wild-type mice kept in constant 
darkness every 4 hours over the course of 24 hours. Left: Relative DRP1 phosphorylation (ser637) measured in 
(i) human skin fibroblasts and in (ii) brain homogenate of non-fasted wild-type mice kept in constant darkness (n = 
3). Data are represented as average ± SEM. 
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Fig. 4. Clock control of Drp1-dependent mitochondrial metabolism. (A and B) Relative total ATP level 
measured from 12 hours post-synchronization time point every 4 hours for 6 time points in (A) human skin 
fibroblasts treated with Mdivi-1 (50 μM) compared to non-treated cells (CTRL) and (B) in Drp1 -/- MEFs (n=4). Left 
panel displays relative total ATP level at 16 hours post-shock (peak of ATP content) and at 28 hours (trough of 
ATP content) in control and treated conditions. (C) Total ATP level measured in cortex and hippocampi of non-
fasted Drp1 -/- mice kept in constant darkness at CT4 (peak of ATP content) and at CT16 (trough of ATP content) 
(n= 4). *P < 0.05, **P < 0.01, ***P < 0.001 for Student’s two-tailed t test comparing single time points. Data are 
represented as average ± SEM. 
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Figure 5. Retrograde signaling from mitochondrial network to the clock. (A and B) Circadian period length 
was determined in dexamethasone - synchronized human skin fibroblasts transfected with Bmal1::luciferase 
reporter in presence of (A) rotenone (ROT, 1 μM), oligomycin (OLIGO, 2 μM) or FCCP (4 μM) and (B) Mdiv-1 (50 
μM ) compared to control (CRTL). Bars represent the mean of three independent measurements ± SEM. (C-D) 
Activation of AMPK by phosphorylation was assessed from 12 hours post-synchronization time point at 4 hours 
intervals for 6 time points in (C) human skin fibroblasts (n = 4) and from (D) brain of non-fasted wild-type mice 
kept in constant darkness every 4 hours for 24 hours (n = 4). Quantification of activated AMPK is normalized on 
(C) values at 12 hours post-shock and on (D) value at CT 0. Insets in (C-D) represent the amount of 
phosphorylated AMPK at (C) 20 hours post-shock (trough) and at 32 hours (peak) and at (D) CT 0, 12 and 24. *P 
< 0.05, **P < 0.01, ***P < 0.001 for Student’s two-tailed t test comparing single time points. Data are represented 
as average ± SEM. 
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Figure S1. Circadian control of gene expression related to mitochondrial oxidative metabolism. (A-C) 
Circadian profiles of relative mRNA expression of (A) complex I, (B) complex IV and (C) complex V subunits 
involved in the electron transport chain and oxidative phosphorylation from 12 hours post-synchronization time 
point every 4 hours for 6 time points in human skin fibroblasts. (D-F) Relative mRNA expression of (D) complex I 
subunits, (E) complex IV subunits at 16 hours post-shock (corresponding respectively to the peak and trough) and 
28 hours post-shock (corresponding respectively to the trough and peak) and (F) complex V subunits at 20 hours 
post-shock and 32 hours post-shock (corresponding respectively to the peak and trough) in synchronized 
fibroblast. *P < 0.05, **P < 0.01, ***P < 0.001 for Student’s two-tailed t test comparing single time points. Data are 
represented as average ± SEM. 
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Figure S2. Mitochondrial ROS are driven by the clock. (A) Cytosolic (cROS) and mitochondrial (mROS) 
reactive oxygen species levels were evaluated from 12 hours post-synchronization time point with 4 hours 
intervals for 6 time points in human skin fibroblasts (n= 4). Left panel displays cROS and mROS levels at 16 
hours post-shock (peak) and at 28 hours (trough). (B) Superoxide anions level was evaluated from 12 hours post-
synchronization time point with 4 hours intervals for 6 time points in human skin fibroblasts (n= 4). Left panel 
displays superoxide anions level at 16 hours post-shock (peak) and at 28 hours (trough). *P < 0.05, **P < 0.01, 
***P < 0.001 for Student’s two-tailed t test comparing single time points. Data are represented as average ± SEM. 
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Figure S3. NAD+ content is clock-driven in vitro and vivo. (A) Total NAD+ measured 12 hours 
post-synchronization time point with 4 hours intervals for 6 time points in human skin fibroblasts (n=4 
per time points). Inset in (D): Relative total NAD+ level at 16 hours post-shock (peak) and at 28 hours 
(trough). (B) Total NAD+ content measured every 4 hours for 24 hours from brain of non-fasted wild-
type mice kept in constant darkness (n= 4). Inset in (E): Relative total NAD+ level at CT4 (peak) and at 
CT16 (trough). *P < 0.05, **P < 0.01, ***P < 0.001 for Student’s two-tailed t test comparing single time 
points. Data are represented as average ± SEM. 
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Figure S3. Rhythmic metabolites involved in mitochondrial metabolism. (A) Heat plots for all 
identified metabolites in synchronized human U2OS cells. High levels of metabolites are shown in red 
and low levels are shown in blue. (B) Percentage of non-circadian and circadian metabolites in 
synchronized U2OS cells. (C-D) Pathway analyses (C) and time-of-day distribution (D) of peak phases 
of rhythmic metabolites in synchronized human U2OS cells. Pathways are color-coded as follows: 
amino acids, blue; carbohydrates, red; cofactors & vitamins, violet; energy, brown; lipids, orange; 
nucleotides, pink; peptides, green. (E-H) Rhythmic profiles of ascertained metabolites previously 
described as engaged in (E) branched-chain amino acids metabolism, in (F) GSH/GSSG metabolism, 
in (G) glycolysis  and (H) TCA cycle (n= 2). 
 
RESULTS                                     Schmitt K., Grimm A. et al. (in preparation) 
 
160 
 
 
 
 
 
Figure S5. Clock- controlled mitochondrial structural network organization. (A) Number of cells 
displaying one of the mitochondrial network states (tubular, intermediate and fragmented) determined 
from 8 hours post-shock every 8 hours over the course of 48 hours (mean of 3 independent 
experiments, 100 cells counted per conditions). (B, C) Profile of relative mRNA expression of 
nuclearly-encoded genes related to (B) mitochondrial fusion (MFN1, MFN2 and OPA1) and (C) fission 
(DRP1 and hFIS1) was evaluated from 12 hours post-shock every 4 hours for 6 time points in human 
skin fibroblasts without displaying circadian oscillations. Data are represented as average ± SEM. 
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Figure S6. Schematic representation of the relationship between the core molecular clock and 
mitochondrial dynamics. 
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 The fine understanding of how mitochondria function is a major field of research since 
it is becoming increasingly apparent that mitochondrial dysfunction is involved in a broad 
range of metabolic and degenerative diseases, and aging (1). Mitochondria are particularly 
important in the brain which has high energy requirements since neurons need a lot of 
energy in form of ATP molecules to fulfill their roles (2). Increasing evidences showed that 
reduced energy metabolism together with mitochondrial dysfunction, oxidative stress, and 
impaired mitochondrial fusion/fission activity, constitutes a prominent and early event in 
neurodegenerative diseases, including AD (3; 1). Thus, current pharmacological concepts 
aim to boost mitochondrial bioenergetics, especially by improving cellular respiration and by 
increasing ATP production.  
 In the last decade, neurosteroids have emerged as new potential therapeutic tools in 
degenerative diseases as peripheral neuropathies and AD (4; 5). For instance, 
neurosteroids, such as estradiol and allopregnanolone, were able to alleviate deficits 
manifested in AD by inducing neurogenesis, reducing Aβ generation and neuroinflammation, 
and decreasing cognitive impairments in AD transgenic mice (6-9). However, except for 
estradiol, the effects of neurosteroids on mitochondrial function remained unresolved. 
 
 In the present PhD work, we demonstrated that not only estradiol but also other 
neurosteroids were able to boost mitochondrial function in neuronal cells. In physiological 
(healthy) conditions, most of the neurosteroids were able to improve mitochondrial 
bioenergetics by increasing ATP levels, MMP and basal respiration (see section II.A). Each 
of them appeared to have a specific action profile upon bioenergetic outcomes, possibly 
because they are acting via different steroid receptors. These observations are in line with 
other studies showing that some neurosteroids regulated the expression of different genes 
coding for proteins involved in the bioenergetic metabolism, such as enzymes involved in 
glycolysis, the Krebs cycle, and mitochondrial complexes (reviewed in (10), see APPENDIX 
4). 
 In pathological conditions, more specifically in cellular models mimicking certain 
histopathological aspects of AD - namely the presence of Aβ peptide and abnormally 
hyperphosphorylated tau – we showed that neurosteroids belonging also to the family of sex 
hormones were able to alleviate bioenergetic deficits occurring in these cellular models (see 
section II.B). Interestingly, female hormones (estradiol and progesterone) were more 
efficient to alleviate mitochondrial deficits induced by abnormal tau, whereas testosterone, 
the male hormone, increased bioenergetic output in cell overexpressing APP/Aβ. In 
agreement with these findings, previous studies showed that neurosteroids may exert their 
neuroprotective action, at least in part by modulating Aβ clearance/accumulation and tau 
hyperphosphorylation, but also by protecting neurons against oxidative stress and apoptosis 
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(11). Here, we showed that their protective action may be mediated by an improvement of 
mitochondrial function that is impacted by Aβ and abnormal tau, possibly via the regulation of 
genes involved in the bioenergetic metabolism, as hypothesized in section II.A.  
 
 The decrease of blood steroid levels (e.g. the drop of estradiol in women after the 
menopause) and brain neurosteroid levels with increasing age – a phenomenon even more 
pronounced in AD – are believed to impact neuronal and cognitive functions (12-14). Indeed, 
studies showed that the decrease in brain steroid levels was paralleled by Aβ accumulation 
and tau hyperphosphorylation in some brain regions, as well as cognitive deficits (12; 14), 
suggesting that neurosteroid protective effects play a role in maintaining proper brain 
function during aging. In line with these observations, numerous studies attest the protective 
effects of neurosteroids in vitro and in vivo, with a major focus on sex steroid hormones, 
especially estradiol, the main female hormone, due to the fact that one-third of AD patients 
are woman (see APPENDICES 4 and 5). However, clinical trials showed contradictory 
results: on the one hand, hormonal replacement therapy (HRT) was shown to have beneficial 
effects in postmenopausal women by decreasing the risk to develop AD (15; 16). On the 
other hand, results from the “Woman's health initiative memory study” (WHIMS) showed that 
long term HRT aggravate cognitive symptoms with, in addition, diverse side effects, including 
increased risks for breast cancer, pulmonary embolism and stroke (17; 18). The synthetic 
nature of the tested hormones has been implicated in the failure of the WHIMS trial but also 
the “critical time windows” in which steroid hormones, like estrogens, might exert a 
neuroprotective effect. Indeed, a recent study performed on ovariectomized rats shows that 
only early onset estrogen replacement therapy was able to prevent oxidative stress and 
metabolic alteration induced by the loss of sex steroid hormones after ovariectomy (19). In 
our study (section II.A), we showed that the improvement of mitochondrial respiration 
induced by neurosteroids in neuronal cells was coupled with an increase of ROS levels, 
probably resulting from a greater electron leakage by the electron transport chain. 
Nevertheless, neurosteroids were able to regulated redox homeostasis by increasing the 
antioxidant activity to compensate this rise of ROS. Based on these observations, we can 
hypothesize that, to be protective, a neurosteroid-based therapy has to be administrated at 
an age when the redox system is still balanced, because one can assume that if the 
treatment starts too late, the presence of neurosteroids might be potentially deleterious due 
to increased ROS production when antioxidant defense mechanisms function insufficiently.  
 
 Taken together, our results provide a potential molecular basis for the beneficial and 
neuroprotective effects of neurosteroids, which may open new avenues for drug 
development with regard to targeting mitochondria in prevention of neurodegeneration. 
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Because each neurosteroid appeared to have a specific action profile on bioenergetic 
outcomes in healthy condition or in the presence of Aβ or tau, the underlying molecular 
mechanisms still need to be elucidated in more detail, such as their ability to regulate the 
expression and activity of mitochondrial complexes involved in oxidative phosphorylation. 
 
 To improve our understanding of the mechanisms regulating mitochondrial function, 
we additionally focused our research on the relationship between mitochondrial bioenergetics 
and dynamics, and their potential regulation by the circadian system. A growing body of 
evidences shows that the metabolic homeostasis and the circadian clock are connected in 
numerous ways through reciprocal regulation (20-22). In addition, circadian disruptions, 
which can occur during shift work, disturbed sleep/wake cycle, and dietary alterations were 
shown to impair metabolic homeostasis, leading to adverse health effects (reviewed in (23)). 
Although mitochondria play a central role in cellular metabolic processes, the relationship 
between the circadian clock and mitochondrial function (dynamics and bioenergetics) 
remains mostly elusive.  
 
 In our work, we showed that mitochondrial bioenergetics, namely mitochondrial 
respiration and its byproducts (ATP, NAD+ and ROS), oscillate with a period length of about 
24 hours in fibroblasts, an in vitro model of peripheral clock (see section II.C). These 
rhythmic oscillations in bioenergetics were consistent with the rhythms of mitochondrial 
changes in fusion/fission that are under the clock-controlled activity of the fission protein 
Drp1. The latter results could be confirmed also in vivo in mouse brains. A recent study is in 
line with our findings showing that the circadian clock controls mitochondrial oxidative 
function through rhythmic regulation of NAD+ biosynthesis in mice (24). Other studies 
addressed the question of circadian regulation of ATP production (25; 26) but no underlying 
mechanisms were described. Here, we established a detailed molecular link among the 
circadian control of mitochondrial bioenergetics and dynamics. More precisely, our findings 
suggest that the circadian clock is able to regulate mitochondrial ATP production in a time-
dependent manner in order to anticipate the energy demand in response to cellular and 
environmental constraints. In addition, we showed that mitochondria may, directly or 
indirectly, send signals back to the circadian clock (e.g. NAD+ or activation of AMPK), which 
might, in turn, regulate the expression/activity of molecular clock components (e.g. PER, 
CRY).  
 
 Together, these findings shed new light on the circadian regulation of mitochondrial 
function, and vice versa, and could have multiple implications in the context of metabolic 
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homeostasis in human health and disease states linked to impairment in biological rhythm 
and/or mitochondrial function. 
 
 Altogether, our findings improved the knowledge about the modulation of 
mitochondrial bioenergetics in heath and disease states by: i) neurosteroids which constitute 
new therapeutic options to overcome bioenergetic deficits in neurodegenerative diseases, 
and ii) the biological clock which anticipates daily fluctuations in cellular energy demands 
(Fig. 31). Further investigations need to be performed to enlighten the underlying 
mechanisms in more details. 
 
 
Fig. 31: Hypothetical links between mitochondrial function and the circadian clock and their regulation by 
neurosteroids. On the one hand, we showed that neurosteroids can increase mitochondrial bioenergetics which 
can alleviate mitochondrial dysfunction manifested in Alzheimer’s disease (AD). On the other hand we showed 
that the circadian clock controls mitochondrial dynamics, which in turn modulate bioenergetic activity. In addition, 
mitochondria can send signals back to the clock that regulates mitochondrial dynamics and bioenergetics. 
  
CONCLUSION   
 
169 
 
 
References 
 
(1) Yin F., Boveris A., Cadenas E. (2014) Mitochondrial energy metabolism and redox signaling in brain aging and 
neurodegeneration. Antioxid Redox Signal 20:353-371 
(2) Raichle M.E., Gusnard D.A. (2002) Appraising the brain's energy budget. Proc Natl Acad Sci U S A 99:10237-
10239 
(3) Schmitt K., Grimm A., Kazmierczak A. et al. (2012) Insights into mitochondrial dysfunction: aging, amyloid-
beta, and tau-A deleterious trio. Antioxid Redox Signal 16:1456-1466 
(4) Panzica G.C., Balthazart J., Frye C.A. et al. (2012) Milestones on Steroids and the Nervous System: 10 years 
of basic and translational research. Journal of neuroendocrinology 24:1-15 
(5) Schaeffer V., Meyer L., Patte-Mensah C. et al. (2010) Progress in dorsal root ganglion neurosteroidogenic 
activity: basic evidence and pathophysiological correlation. Progress in Neurobiology 92:33-41 
(6) Brinton R.D. (2013) Neurosteroids as regenerative agents in the brain: therapeutic implications. Nature 
reviews Endocrinology 9:241-250 
(7) Irwin R.W., Brinton R.D. (2014) Allopregnanolone as regenerative therapeutic for Alzheimer's disease: 
translational development and clinical promise. Prog Neurobiol 113:40-55 
(8) Irwin R.W., Solinsky C.M., Brinton R.D. (2014) Frontiers in therapeutic development of allopregnanolone for 
Alzheimer's disease and other neurological disorders. Frontiers in cellular neuroscience 8:203 
(9) Yao J., Brinton R.D. (2012) Estrogen regulation of mitochondrial bioenergetics: implications for prevention of 
Alzheimer's disease. Advances in pharmacology 64:327-371 
(10) Grimm A., Lim Y.A., Mensah-Nyagan A.G. et al. (2012) Alzheimer's disease, oestrogen and mitochondria: an 
ambiguous relationship. Mol Neurobiol 46:151-160 
(11) Pike C.J., Carroll J.C., Rosario E.R. et al. (2009) Protective actions of sex steroid hormones in Alzheimer's 
disease. Front Neuroendocrinol 30:239-258 
(12) Caruso D., Barron A.M., Brown M.A. et al. (2013) Age-related changes in neuroactive steroid levels in 3xTg-
AD mice. Neurobiol Aging 34:1080-1089 
(13) Frye C.A., Walf A.A. (2008) Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for 
cognitive performance of mid-aged mice. Neurobiol Learn Mem 89:17-26 
(14) Schumacher M., Weill-Engerer S., Liere P. et al. (2003) Steroid hormones and neurosteroids in normal and 
pathological aging of the nervous system. Prog Neurobiol 71:3-29 
(15) Paganini-Hill A., Henderson V.W. (1996) Estrogen replacement therapy and risk of Alzheimer disease. 
Archives of Internal Medicine 156:2213-2217 
(16) Tang M.X., Jacobs D., Stern Y. et al. (1996) Effect of oestrogen during menopause on risk and age at onset 
of Alzheimer's disease. Lancet 348:429-432 
(17) Anderson G.L., Limacher M., Assaf A.R. et al. (2004) Effects of conjugated equine estrogen in 
postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. 
Journal of the American Medical Association 291:1701-1712 
(18) Rossouw J.E., Anderson G.L., Prentice R.L. et al. (2002) Risks and benefits of estrogen plus progestin in 
healthy postmenopausal women: principal results From the Women's Health Initiative randomized 
controlled trial. Journal of the American Medical Association 288:321-333 
(19) Lopez-Grueso R., Gambini J., Abdelaziz K.M. et al. (2014) Early, but not late onset estrogen replacement 
therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. Antioxid Redox 
Signal 20:236-246 
(20) Bass J., Takahashi J.S. (2010) Circadian integration of metabolism and energetics. Science 330:1349-1354 
(21) Bellet M.M., Sassone-Corsi P. (2010) Mammalian circadian clock and metabolism - the epigenetic link. J Cell 
Sci 123:3837-3848 
(22) Eckel-Mahan K., Sassone-Corsi P. (2009) Metabolism control by the circadian clock and vice versa. Nature 
structural & molecular biology 16:462-467 
(23) Marcheva B., Ramsey K.M., Peek C.B. et al. (2013) Circadian clocks and metabolism. Handbook of 
experimental pharmacology:127-155 
(24) Peek C.B., Affinati A.H., Ramsey K.M. et al. (2013) Circadian clock NAD+ cycle drives mitochondrial 
oxidative metabolism in mice. Science 342:1243417 
(25) Marpegan L., Swanstrom A.E., Chung K. et al. (2011) Circadian regulation of ATP release in astrocytes. J 
Neurosci 31:8342-8350 
(26) Womac A.D., Burkeen J.F., Neuendorff N. et al. (2009) Circadian rhythms of extracellular ATP accumulation 
in suprachiasmatic nucleus cells and cultured astrocytes. Eur J Neurosci 30:869-876 
 
 
170 
 
 
 
 
 
 
 
 
 
 
IV. DESCRIPTIF SYNTHETIQUE EN FRANCAIS 
DES TRAVAUX DE LA THESE 
Descriptif synthétique en français des travaux de la thèse 
171 
 
Les mitochondries sont de minuscules organelles qui génèrent néanmoins la quasi-
totalité de l’énergie cellulaire sous la forme de molécules d’adénosine triphosphate (ATP). 
Elles exercent un rôle fondamental au sein des cellules eucaryotes car elles orchestrent à la 
fois le métabolisme énergétique et les voies apoptotiques qui contrôlent la survie et la mort 
cellulaire. Il est maintenant largement admis que les mitochondries sont le produit de 
l’endosymbiose d’une α-proteobactérie avec l’ancêtre des cellules eucaryotes (1). De ce fait, 
elles possèdent encore un génome résiduel ainsi qu’une double membrane (Fig. 1). 
 
 
Fig. 1: Représentation classique de l’ultrastructure mitochondrial (courtoisie de M. Wanner Fabio). 
 
 Les mitochondries sont des organelles extrêmement dynamiques dont la taille et 
l’aspect varient selon les espèces et organes, mais aussi en fonction de l’environnement 
cellulaire. Afin de maintenir une population mitochondriale homogène, les mitochondries se 
divisent et fusionnent de manière cyclique pour mélanger leur contenu en métabolites et 
protéines, mais aussi pour éviter l’apparition de mutation dans l’ADN mitochondrial (mtDNA). 
Ce phénomène est appelé « fusion / fission » mitochondriale et permet la redistribution des 
organelles au sein des cellules en fonction des besoins énergétiques (2; 3). 
 Les mitochondries remplissent plusieurs rôles qui incluent notamment la régulation du 
calcium intracellulaire et l’homéostasie de l’état réduit/oxydé (redox) des cellules, la plasticité 
synaptique et la neurotransmission (1). Elles sont surtout considérées comme les “usines 
énergétiques” des cellules et une de leur fonction essentielle est la production de molécules 
d’ATP, qui est la source universelle d’énergie cellulaire, synthétisées pendant la 
phosphorylation oxydative (OXPHOS) à partir des sources nutritionnelles. En effet, l’ATP est 
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principalement produite via deux voies métaboliques : la glycolyse et l’OXPHOS (ou 
respiration cellulaire). La première voie fournie un gain net de deux molécules d’ATP, ainsi 
que deux molécules de nicotinamide adénine dinucleotides (NADH) et deux molécules de 
pyruvate. Ce dernier est ensuite transféré dans la matrice mitochondriale et rejoint le cycle 
de Krebs qui permet de produire les principaux donneurs d’électrons (NADH et flavine 
adénine dinucléotides (FADH2)) utilisés pendant l’OXPHOS. 
 La deuxième voie de synthèse d’ATP, l’OXPHOS, utilise les donneurs d’électrons 
synthétisés par le cycle de Krebs pour générer une différence de potentiel au niveau de la 
membrane mitochondriale interne (Fig. 2). En effet, les électrons apportés par NADH et 
FADH2 sont transportés au sein de la chaîne de transport d’électrons (electron transport 
chain : ETC) composés de quatre complexes protéiques (complexe I à IV) responsables du 
transfert de protons (H+) de la matrice vers l’espace intermembranaire. La différence de 
potentiel ainsi générée servira de moteur à l’ATP synthase (ou complexe V), l’enzyme 
responsable de la synthèse d’ATP. Comparé à la glycolyse qui ne produit que deux 
molécules d’ATP, l’OXPHOS génère entre 30 et 32 ATP par molécules de glucose (4).  
 
Fig. 2: Bioénergétique de la chaîne de transport d'électrons. Après le cycle de Krebs, le NADH généré est 
transféré au complexe I et  converti en NAD+. Le transfert d'électrons à travers la chaîne maintient le potentiel de 
membrane mitochondriale en pompant des protons de la matrice vers l'espace intermembranaire. Au final, l’ADP 
est phosphorylée pour former l'ATP par le complexe V (ATP synthase). UQ; coenzyme Q, Cyt c; cytochrome c 
(adapté de (5) et (6)). 
 Paradoxalement, alors qu’elles produisent la principale énergie vitale des cellules 
(ATP), les mitochondries produisent aussi des molécules toxiques dérivées de l’oxygène 
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(reactive oxygen species : ROS). Ces ROS sont en partie produites au cours de l’OXPHOS 
et, en temps normal, sont détoxifiées par le système de défenses antioxydant présent dans 
les cellules, comme par exemple les superoxydes dismutases (SOD) (7). Il arrive cependant 
que ce système de défense antioxydants soit dépassé, et l’accumulation des ROS peut 
engendrer un stress oxydant qui va perturber le bon fonctionnement des cellules et, au final, 
conduit à la mort cellulaire. Les neurones sont particulièrement sensibles face au stress 
oxydant et, étant des cellules postmitotiques et différenciées, leur mort engendrera des 
dysfonctionnements cérébraux et des troubles cognitifs, tels que ceux observé dans les 
maladies neurodégénératives.  
 En effet, le cerveau est un organe particulièrement énergivore qui, malgré sa petite 
taille, a besoin d’environ 20% de l’oxygène présent dans l’organisme pour fonctionner 
normalement (8). Ceci s’explique par le fait que les neurones sont des cellules excitables qui 
requièrent beaucoup d’ATP pour permettre la fusion et le recyclage des vésicules 
nécessaires à la sécrétion de neurotransmetteurs, mais aussi pour maintenir le potentiel de 
membrane des cellules (9). Ainsi, une perturbation de la fonction mitochondriale mènera 
inévitablement à un état pathologique pouvant aller d'une subtile altération des activités 
neuronales jusqu’à la mort cellulaire et à la neurodégénérescence, comme c’est le cas par 
exemple dans la maladie d’Alzheimer (MA). 
 Dans ce contexte, la compréhension des mécanismes intrinsèques qui contrôlent la 
dynamique et le métabolisme énergétique mitochondrial (ou bioénergétique) représente un 
enjeu majeur pour lutter efficacement contre les déficits métaboliques et les maladies 
neurodégénératives, telles que la MA. 
 
 Dans le cadre de ce travail de thèse, notre principal objectif a été d'approfondir nos 
connaissances sur la régulation de la fonction mitochondriale et d'identifier des facteurs clés 
(endogènes et/ou exogènes) qui sont déterminants dans le contrôle de l'activité 
mitochondriale. Ces facteurs pourraient alors servir d'outils pour élaborer des stratégies 
contre les pathologies impliquant des dysfonctionnements mitochondriaux. Pour atteindre cet 
objectif, nous avons organisé notre travail en deux parties:  
1) En tenant compte des données bibliographiques qui suggèrent que les neurostéroïdes 
possèdent un fort potentiel neuroprotecteur, nous avons décidé d'évaluer leur capacité à 
améliorer la fonction mitochondriale en situation normale (physiologique) et dans des 
modèles cellulaires mimant les caractéristiques de la MA, telles que l'accumulation du 
peptide amyloïde-β (Aβ) et l'hyperphosphorylation de la protéine tau.  
2) Dans la deuxième partie, nous avons cherché à déterminer si l’horloge biologique, qui 
coordonne tout un panel de comportements journaliers et de processus physiologiques, est 
impliquée dans la régulation de la fonction mitochondriale.  
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 Ainsi, dans la première partie de cette thèse, nous avons étudié in vitro la capacité de 
différents neurostéroïdes à réguler la bioénergétique mitochondriale. Plus particulièrement, 
nous avons voulu savoir s’ils étaient capables de compenser ou d’alléger les déficits 
bioénergétiques observés dans des modèles cellulaires présentant l’une ou l’autre des 
protéines impliquées dans la physiopathologie de la MA, à savoir le peptide amyloïde-β (Aβ) 
et la protéine tau hyperphosphorylée. 
 
 La MA est une maladie neurodégénérative liée à l’âge qui affecte près de 2% de la 
population dans les pays industrialisés et représente environ 60% des cas de démence à 
travers le monde (10). En 2006, près de 26.6 millions de cas ont été diagnostiqués, et les 
études prédisent que le nombre de patients devrait quadrupler d’ici 2050, ce qui en fait une 
des maladies les plus coûteuses pour la société dans les pays développés (11). La maladie 
touche en général les individus de plus de 65 ans, excepté dans les rares cas familiaux 
(<1%) (12), et se traduit par un progressif déclin physique et cognitif, en particulier pour les 
tâches sollicitant la mémoire, le langage ou l’orientation spatiale (13; 14). À ce jour, aucun 
traitement n’est en mesure de prévenir, guérir ou même de ralentir la progression de la 
maladie (14).  
 D’un point de vue histopathologique, le MA est caractérisée par la présence de 
plaques extracellulaires et d’une dégénérescence neurofibrillaire intracellulaire (DNF) qui 
apparaissent dans certaines zones du cerveau, notamment dans l’hippocampe, une 
structure qui joue un rôle central dans la mémoire et l’apprentissage (15; 16; 14). Ces 
plaques extracellulaires (aussi appelées plaques séniles) sont formées par l’accumulation du 
peptide Aβ issue de la protéolyse de la protéine précurseur de l’amyloïde β (APP), par la β et 
la γ sécrétase (17). La DNF est quant à elle générée par l’hyperphosphorylation anormale de 
tau, une protéine associée aux microtubules, qui se détache et forme des agrégats 
intracellulaires (18). Bien que ces deux phénomènes soient au cœur des recherches contre 
la MA depuis de nombreuses années, les causes de la formation des plaques séniles et de 
la DNF n’ont pas encore été élucidés. 
 Des études plus récentes ont montré que les stades précoces de la MA sont associés 
à un déclin de l’activité bioénergétique cérébrale et une augmentation du stress oxydant (en 
particulier dans les mitochondries) (16; 19). Plus précisément, il a été montré que des 
patients atteints de la MA présentaient un hypométabolisme cérébral (baisse de 
consommation de glucose) et ceci avant même l’apparition des symptômes cliniques (19). 
Cette caractéristique est retrouvée chez l’animal, dans des modèles de souris transgéniques 
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de la MA, où un dysfonctionnement mitochondrial a pu être détecté avant les plaques 
séniles, la DNF et les troubles cognitifs ((20) voir ANNEXE 1).  
 
 Les recherches ciblant les dysfonctionnements mitochondriaux dans la MA ont révélé 
que le peptide Aβ et la protéine tau hyperphosphorylée avaient tous deux un impact négatif 
sur la fonction mitochondriale (métabolisme bioénergétique et dynamique mitochondrial) et 
pouvait agir soit de manière séparé soit de manière synergétique pour induire leurs effets 
toxiques ( (21; 20) voir ANNEXE 1 et 2). Pris séparément, Aβ et tau hyperphosphorylée 
engendrent tous deux une baisse de la production d’ATP, de la respiration cellulaire, 
augmentent la production de ROS et perturbent le potentiel de  membrane mitochondriale 
(21; 22; 20) (voir Fig. 3). Notamment, il a été montré que l’Aβ pouvait réduire l’activité du 
complexe IV mitochondrial (23; 24), alors que la présence de tau hyperphosphorylée 
diminuait l’activité du complexe I (25).  
 Les deux protéines ont également un impact négatif sur la dynamique mitochondriale 
(activité de fusion/fission). En effet, les cellules surexprimant l’APP présentent un réseau 
mitochondrial fragmenté (27; 28), alors que la surexpression de tau engendre une élongation 
anormale des mitochondries dans des neurones de drosophiles et de souris (29).  
 
 Des études effectuées sur les souris triples transgéniques (tripleAD : APPxPS2xpR5) 
ont permis de montrer que Aβ et tau hyperphosphorylée peuvent agir de manière 
synergétique sur la mitochondrie ((30) voir aussi ANNEXE 3). En effet, les 
dysfonctionnements mitochondriaux étaient déjà apparents à 8 mois chez les souris tripleAD 
alors qu’ils n’apparaissaient qu’à 12 mois chez les souris doubles transgéniques (APPxPS2). 
De plus, ces souris présentaient des déficits exacerbés au niveau de l’OXPHOS et la 
synthèse d’ATP, ainsi qu’une augmentation de la production de ROS. 
 En résumé, ces données indiquent fortement que les dysfonctionnements 
mitochondriaux jouent un rôle clef dans la pathogenèse de la MA. La mitochondrie 
représente donc une cible intéressante pour élaborer des stratégies thérapeutiques dans les 
stades encore précoces de la maladie. C’est pourquoi, les concepts pharmacologiques 
actuels visent à : stimuler la respiration mitochondriale, augmenter la production d’ATP et 
réduire le stress oxydant (niveaux de ROS). 
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Fig. 3 : Convergence pathogène de la protéine tau hyperphosphorylée et le peptide Aß sur les mitochondries. Aß 
et la protéine tau sont capables d'altérer la respiration mitochondriale en inhibant le complexe IV et complexe I 
respectivement. Ceci induit une diminution de la consommation d'oxygène, de la production d'ATP et une 
augmentation des niveaux de ROS. Le stress oxydant induit par le dysfonctionnement de la chaîne de transport 
des électrons peut surpasser les défenses antioxydantes des cellules (MnSOD, Cu/ZnSOD) et impacter le 
potentiel de membrane (ΔΨ) ainsi que l'ADN mitochondrial (mtDNA). Dans les mitochondries, le peptide Aß peut 
se lier à des protéines comme l’ABAD et CypD, ce qui génère plus de ROS et mène à l'ouverture des pores de 
transition de perméabilité mitochondriale (mPTP), déclenchant les voies apoptotiques par la libération de Cyt C 
dans le cytosol. En parallèle, le peptide Aß peut également être responsable des altérations métaboliques en 
inhibant les enzymes impliquées dans la glycolyse et du cycle de Krebs, de même que l'excitotoxicité induite par 
le calcium dans les neurones. Enfin, l’Aß et la protéine tau peuvent perturber l'activité de fusion / fission 
mitochondriale, conduisant à une mauvaise répartition des mitochondries dans les neurones. CI complexe I, CII 
complexe II , CIII complexe III, CIV complexe IV, CV complexe V, cyt c cytochrome c, Cu/Zn SOD cuivre/zinc 
superoxyde dismutase, MnSOD manganèse superoxyde dismutase, ROS espèces réactives de l'oxygène, 
mtDNA ADN mitochondrial, TOM / TIM translocases des membranes mitochondriales interne / externe, ABAD Aß 
binding alcohol dehydrogenase, FIS, protéine fission 1, CypD cyclophiline D (adapté de (26) et (22)). 
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Dans les travaux de thèse présentés ici, nous avons fait l’hypothèse que les 
neurostéroïdes pourraient être de nouveaux candidats capables de stimuler la respiration 
mitochondriale. 
 Les neurostéroïdes sont des stéroïdes synthétisés par les neurones et/ou les cellules 
gliales du système nerveux central ou périphérique. Pour être considéré comme un 
neurostéroïde, une concentration substantielle du stéroïde doit persister dans le système 
nerveux après ablation des glandes endocrines périphériques qui sécrètent les hormones 
stéroïdiennes (31; 32). Il est possible de distinguer 3 catégories de neurostéroïdes: (i) les 
neurostéroïdes non-exclusifs tels que l'estradiol, la testostérone et la progestérone, qui sont 
des hormones stéroïdiennes synthétisées par les glandes endocrines mais également par 
les neurones et les cellules gliales; ii) les neurostéroïdes semi-exclusifs comme 
l'alloprégnanolone qui est principalement synthétisée dans le système nerveux mais aussi en 
faible quantité par les glandes endocrines; iii) les neurostéroïdes exclusifs comme 
l'épialloprégnanolone qui ne sont produits que dans le système nerveux (35). 
 La mitochondrie est un organite qui joue un rôle crucial dans la biosynthèse des 
stéroïdes périphériques ou hormones stéroïdiennes (stéroïdogenèse) et des neurostéroïdes 
(neurostéroïdogenèse). En effet, la mitochondrie est le siège de la première étape des voies 
enzymatiques de la stéroïdogenèse et de la neurostéroïdogenèse (31; 33; 34) (Fig. 4).  
 
Fig. 4: Représentation schématique des principales voies de biosynthèse des neurostéroïdes dans le cerveau 
des vertébrés. TSPO ; translocator protein, 17OH-PREG; 17-hydroxypregnenolone, 17OH-PROG; 17-
hydroxyprogesterone, DHEA; dehydroepiandrosterone, DHP; dihydroprogesterone, ALLOPREG; 
allopregnenolone, DHT; dihydrotestosterone, P450scc; cytochrome P450 cholesterol side chain cleavage, 
P450c17;cytochrome P450c17, 3β-HSD; 3β-hydroxysteroid dehydrogenase, 5α-R; 5α-reductase, Arom.; 
aromatase, 21-OHase; 21-hydroxylase, 3α-HSOR; 3α-hydroxysteroid oxydoreductase,17β-HSD; 17β-
hydroxysteroid dehydrogenase. 
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 Contrairement aux hormones stéroïdiennes qui agissent par un mode d'action 
endocrine (effet sur des cibles lointaines par rapport aux glandes endocrines sécrétrices), les 
neurostéroïdes ont une action autocrine et paracrine. Ils modulent plusieurs processus 
physiologiques tels que: la neurotransmission, la viabilité neuronale, la myélinisation, 
l'apprentissage, la cognition et la mémorisation (36; 37; 32). 
 
 Divers travaux réalisés dans des modèles expérimentaux de maladies 
neurodégénératives et de neuropathies périphériques suggèrent que les neurostéroïdes ont 
un fort potentiel neuroprotecteur (38-45). Par ailleurs, des études post-mortem ont révélé 
une baisse des concentrations endogènes de neurostéroïdes dans le cerveau des patients 
Alzheimer comparés aux sujets contrôles (46). Cette baisse est négativement corrélée à 
l’accumulation du peptide Aβ et à l’hyperphosphorylation de la protéine tau dans les 
structures cérébrales limbiques. Des données similaires ont été mises en évidence dans le 
cerveau de souris transgéniques modélisant la MA (47). Collectivement, ces résultats 
suggèrent que la neurodégénérescence et/ou les dysfonctionnements neuronaux évoqués 
par la toxicité Aβ et l'hyperphosphorylation de tau pourraient résulter, au moins en partie, de 
la diminution des concentrations cérébrales de neurostéroïdes neuroprotecteurs. 
 En ce qui concerne les déficits mitochondriaux observés dans la MA, de nombreuses 
études sont axées sur l'estradiol (voir ANNEXE 4) qui est également connu pour stimuler le 
métabolisme bioénergétique dans les cellules. Cependant, aucune étude n’a testé les effets 
d'autres neurostéroïdes sur la bioénergétique mitochondriale et l'homéostasie redox dans les 
cellules neuronales. 
 
 Par conséquent, dans le but d’élargir nos connaissances sur les effets 
neuroprotecteurs des neurostéroïdes et leurs mécanismes sous-jacents, nous avons 
sélectionné un panel de neurostéroïdes (progestérone, estradiol, l'estrone, testostérone, 3α-
androstanediol, DHEA et alloprégnanolone) comme candidats potentiels capables de 
moduler la fonction mitochondriale. 
 Pour choisir le panel à tester, nous nous sommes appuyés sur des travaux antérieurs 
qui ont révélé, d'une part, que l’Aβ et tau hyperphosphorylée modulent la production 
endogène de neurostéroïdes (48; 49), et d'autre part, que l’homéostasie de l’estradiol dans 
les mitochondries est perturbée par les peptides Aβ qui inhibent l’amyloid-β binding alcohol 
dehydrogenase (ABAD) connue également sous l'appellation de 17β-hydroxystéroïde 
déshydrogénase (Fig. 3-4) ( (50) voir aussi ANNEXE 5 et 6). Avant de caractériser le mode 
d'action des neurostéroïdes sur la bioénergétique mitochondriale dans des conditions 
pathologiques (MA), nous avons d'abord cherché à comprendre leurs effets per se en 
utilisant des cellules de neuroblastome humains, SH-SY5Y, traitées pendant 24 heures. Les 
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effets des 7 neurostéroïdes sélectionnés ont été testés sur la production d’ATP, le potentiel 
de membrane mitochondriale (MMP), la respiration mitochondriale, la glycolyse et 
l’environnement redox des cellules. 
 Nos résultats montrent que la progestérone, l’estradiol, l’estrone, la testostérone, la 
3α-androstanediol et la DHEA stimulent l’activité bioénergétique cellulaire après 24 heures 
de traitement (10 nM et 100 nM), en augmentant les niveaux d’ATP, le MMP et la respiration 
basale, sans effets significatifs sur la glycolyse. La testostérone et la DHEA améliorent en 
plus le respiratory control ratio (RCR), un indicateur de la capacité respiratoire des 
mitochondries. Il apparaît donc que les neurostéroïdes agissent principalement sur la 
respiration basale en augmentant les niveaux énergétiques des cellules déjà à l’état de 
repos, et lorsque les cellules ont une forte demande énergétique, la testostérone et la DHEA 
sont capables d’améliorer le RCR pour répondre à cette demande.  
 Les neurostéroïdes sont des molécules lipophiles et peuvent donc traverser les 
membranes plasmiques des cellules pour activer des récepteurs nucléaires, régulant ainsi la 
transcription de gènes. Afin de voir si les récepteurs nucléaires des stéroïdes étaient 
impliqués dans la modulation de la bioénergétique mitochondriale, nous avons utilisé des 
antagonistes spécifiques (RU 486 : antagoniste des récepteurs à la progestérone, ICI 
182.780 : antagoniste des récepteurs aux estrogènes, dihydroxy-flutamide : antagoniste des 
récepteurs aux androgènes) et évalués leurs effets sur la production d’ATP en présence de 
l’agoniste stéroïdien correspondant. Les résultats montrent qu’en présence de la molécule 
antagoniste, l’effet des neurostéroïdes sur la production d’ATP est complètement aboli, 
suggérant que la modulation de la bioénergétique se fait, au moins en partie, par l’activation 
de la transcription de gènes codant pour des protéines impliquées dans la glycolyse ou 
l'OXPHOS.  
 D’autre part, nous avons observé que l’augmentation de l’activité mitochondriale 
induite par les neurostéroïdes était parallèle à une élévation des niveaux de ROS dans les 
mitochondries, sans pour autant affecter la survie des cellules. Cette élévation résulte 
probablement d'une fuite d'électrons par la chaîne de transport d'électrons car, comme 
expliqué précédemment, si les mitochondries produisent de l’ATP, elles produisent 
également des ROS. Les neurostéroïdes sont cependant capables de compenser cette 
augmentation des ROS mitochondriaux par une hausse de l’activité antioxydante (ici, 
l’activité de la manganèse superoxydes dismutase), ce qui fait que l’état redox 
intramitochondrial n’en ressort que légèrement oxydé. 
 
 Ainsi, ces premières données indiquent que les neurostéroïdes sont en effet en 
mesure de stimuler la fonction mitochondriale en condition physiologique. Nos principales 
conclusions sont que: i) la majorité de ces stéroïdes induisent une augmentation du 
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métabolisme énergétique, principalement par l'intermédiaire d'une hausse de l'activité 
mitochondriale; ii) les neurostéroïdes testés sont capables de réguler l’homéostasie redox en 
augmentant l'activité antioxydante pour compenser l’élévation des niveaux de ROS produit 
lors de l’OXPHOS. De plus, chaque neurostéroïde semble avoir un profil bioénergétique 
spécifique. Les résultats obtenus après l’utilisation d’antagonistes des récepteurs nucléaires 
aux stéroïdes suggèrent qu’ils agissent, au moins en partie, par l'intermédiaire de leur 
récepteur correspondant pour réguler l'expression de gènes impliqués dans la glycolyse et 
l’OXPHOS, mais peut-être aussi sur l'activité des complexes respiratoires mitochondriaux. 
D'autres études sont maintenant nécessaires pour déterminer plus en détail les mécanismes 
moléculaires qui sont impliqués dans ces processus.(mettreplus haut) 
 
 En nous appuyant sur ces premiers résultats, nous avons cherché à savoir si les 
neurostéroïdes avaient un effet bénéfique pour contrecarrer les déficits mitochondriaux 
observés dans la MA.  
 Nous avons donc traité des cellules de neuroblastome humain (SH-SY5Y) 
transfectées de manière stable, soit avec la protéine précurseur de l'amyloïde humaine 
(APP) qui surexpriment l'APP et l’Aß (23; 24), soit avec la protéine tau « normale » (wild-type 
tau : wtTau), ou la protéine tau mutante (P301L), qui induit une hyperphosphorylation 
anormale de tau (25), pendant 24 heures avec différents neurostéroïdes appartenant à la 
famille des hormones sexuelles (progestérones, estradiol, estrone, testostérone, 3α-
androstanediol). Plusieurs paramètres bioénergétiques ont ensuite été mesurés, à savoir : 
les niveaux d’ATP, le MMP, la respiration basale, le renouvellement de l’ATP (ATP turnover), 
la respiration mitochondriale maximale, la capacité respiratoire de réserve ainsi que la 
réserve glycolytique. 
 En accord avec les données bibliographiques mentionnées précédemment, nous 
avons d’abord démontré que la présence de l'APP/Aß ou la protéine tau mutante avait une 
incidence différente sur la bioénergétique mitochondriale dans ces modèles cellulaires (23; 
25). La surexpression de l’une ou l’autre de ces protéines induisait une diminution similaire 
des niveaux d’ATP. Cependant, alors que la protéine tau mutante n’affectait que la 
respiration mitochondriale maximale et la capacité respiratoire de réserve, la surexpression 
de l'APP/Aß induisait en plus une diminution de la respiration basale, du renouvellement de 
l'ATP (ATP turnover) et de la réserve glycolytique. Tous les neurostéroïdes que nous avons 
testés étaient en mesure d’augmenter les niveaux d'ATP et le MMP dans les cellules 
surexprimant l’APP/Aß. En revanche, seules la progestérone et l'estradiol induisaient une 
augmentation de l’ATP dans les cellules exprimant la protéine tau mutante.  
 De plus, nous avons pu montrer que l'hormone stéroïdienne mâle, la testostérone, 
était plus efficace pour réduire les déficits mitochondriaux induits l’APP/Aß. En effet, elle était 
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la seule molécule capable d’augmenter la respiration basale, le renouvellement d’ATP, la 
respiration mitochondriale maximale et la capacité respiratoire de réserve dans les cellules 
surexprimant l’APP/Aß. Les hormones stéroïdiennes femelles, la progestérone et les 
estrogènes (l’estradiol et l’estrone), étaient quant à elles plus efficaces pour augmenter ces 
différents paramètres bioénergétiques dans le modèle cellulaire de tauopathies liés à la MA. 
 En résumé, nos résultats apportent de nouvelles évidences attestant des effets 
neuroprotecteurs des neurostéroïdes dans la MA. Ces molécules représentent donc des 
candidats prometteurs capables d'augmenter la bioénergétique cellulaire en conditions 
pathologiques. 
 
 L'ensemble des résultats de la première partie de cette thèse fournit une base 
moléculaire potentielle pour les effets bénéfiques et neuroprotecteurs des neurostéroïdes, et 
ouvrent de nouvelles voies pour le développement de médicaments ciblant les mitochondries 
dans la neurodégénérescence. Nos résultats indiquent fortement que les neurostéroïdes 
représentent des molécules prometteuses capables d'augmenter l’activité bioénergétique via 
l'amélioration de la respiration mitochondriale, dans des conditions saines et pathologiques. 
Comme chaque neurostéroïde semble avoir un profil d'action spécifique sur la 
bioénergétique cellulaire, que ce soit  en conditions normales ou en présence de Aß ou tau, 
il est maintenant nécessaire d’élucider plus en détail quels sont les mécanismes 
moléculaires sous-jacents, comme par exemple leurs capacités individuelles à réguler 
l'expression et l'activité des complexes mitochondriaux impliquée dans l’OXPHOS. 
 
 Dans la deuxième partie de cette thèse, nous avons cherché à comprendre comment 
la fonction mitochondriale est régulée de manière endogène au sein des cellules. Plus 
précisément, nous avons cherché à déterminer si, et surtout comment, la dynamique 
mitochondriale (activité de fusion/fission) ainsi que la bioénergétique était modulées par 
l'horloge biologique de manière circadienne. 
 
 L’horloge circadienne (du latin « circa diem» : environ un jour) représente un réseau 
hiérarchique d’oscillateurs qui coordonnent toute une variété de comportements journaliers 
et de processus physiologiques à un moment optimal de la journée, dans le but d’anticiper 
les changements de l’environnement extérieur chez tous les êtres vivants (51).  
 Pour être considéré comme circadien, un rythme (ou oscillation) doit remplir trois 
critères essentiels (52). Tout d’abord, il doit être endogène, avec une période d’environ 24 
heures, et persister en condition constante, par exemple quand l’individu ou l’animal sont 
placés dans l’obscurité, sans stimuli lumineux. Deuxièmement, le rythme doit être 
entrainable (ou synchronisable) par des stimuli externes appelés « Zeitgebers » comme par 
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exemple les cycles jour/nuit ou les prises alimentaires. Enfin, la période du rythme (le temps 
que met une oscillation pour se répéter) ne doit pas être affectée par les changements de 
température dans des limites physiologiquement acceptables. 
 Dans l'ensemble, les rythmes circadiens permettent à l'organisme de coordonner 
divers processus physiologiques et comportementaux au cours de la journée. Le rythme 
circadien le plus évident observé chez les humains, et d'autres animaux, est le cycle veille-
sommeil. 
 
 L’une des principales propriétés du système circadien est sa capacité à synchroniser 
l’horloge circadienne à tous les niveaux (de l’horloge moléculaire à l’organisme entier). 
Virtuellement, toutes les cellules de l’organisme sont dotées d’horloges endogènes qui 
fonctionnent en phase les unes avec les autres afin de maintenir un fonctionnement cohérent 
entre les différents organes du corps (53). Pour orchestrer tous ces oscillateurs individuels, 
le système circadien possède une horloge centrale, située dans les noyaux 
suprachiasmatiques (SCN) du cerveau (54; 55), qui remplit un rôle clef et permet de: i) 
percevoir les signaux environnementaux (ex : la lumière) ; ii) intégrer les informations 
temporelles (ex : le moment de la journée (jour/nuit)) ; iii) transmettre des signaux pour 
synchroniser les horloges périphériques situées dans différents tissus ou organes (foie, 
estomac, muscles, pancréas…) qui à leur tour transmettant des signaux rétroactifs au SCN 
(Fig. 5). 
 
Fig. 5: Subdivisions du système circadien: entrée, effecteurs d'horloge et sortie d'horloge. Cette division peut être 
faite au niveau cellulaire ainsi qu'au niveau systémique. SCN noyaux suprachiasmatiques, CNS système nerveux 
central (adapté de (53)). 
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Au niveau moléculaire, le maintien d’un rythme avec une période de 24 heures est 
rendu possible grâce à des boucles rétroactives de transcription/traduction composées 
d’éléments trans-activateurs (positifs) ou trans-inhibiteurs (négatifs) (Fig.6). BMAL1 et 
CLOCK font partie des éléments activateurs de transcription qui régulent les gènes sous le 
contrôle de l’horloge (CCG : Clock-controlled genes) ainsi que la transcription des éléments 
inhibiteurs : Cryptochrome (CRY) et Period (PER) (56). Ces derniers inhibent la transcription 
de BMAL1, et donc leur propre transcription, et la boucle peut recommencer. D’autres 
éléments peuvent venir réguler l’expression ou la stabilité des composants de cette l’horloge 
moléculaire, comme par exemple REV-ERBα (reverse orientation c-erb α) ou ROR (orphan 
nuclear receptor genes).  
 
Fig. 6: Liens entre l’horloge moléculaire et le métabolisme. L'horloge moléculaire peut directement ou 
indirectement synchroniser divers processus métaboliques en activant la transcription de gènes qui sont sous le 
contrôle de l’horloge (CCG : clock-controlled genes). Vice versa, les flux métaboliques ainsi générés peuvent 
renvoyer des signaux à l’horloge moléculaire (via SIRT1 ou l’AMPK) à la manière d’un rhéostat afin de 
coordonner les processus métaboliques avec les cycles jour/nuit ou les périodes de jeûne et de prise alimentaire. 
NAMPT; nicotinamide phosphoribosyltransferase, SIRT1; sirtuines 1, AMPK; protéine kinase dépendante de 
l’adénosine monophosphate (adapté de (57)). 
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 Les rythmes circadiens apparaissent de plus en plus comme une adaptation 
évolutive, notamment au niveau métabolique, qui permet la séparation temporelle des 
réactions cataboliques et anaboliques pour les aligner avec les rythmes jour/nuit ou les 
périodes de jeûne ou de prise alimentaire (58). Bien qu’il soit de plus en plus admis que 
l’horloge moléculaire est étroitement liée au métabolisme (59; 53), les mécanismes sous-
jacents n’ont pas encore été clairement élucidés. Certaines pistes sont actuellement à 
l’étude et impliquent des molécules telles que le NAD+, NAMPT (nicotinamide 
phosphoribosyltransferase), SIRT1 (sirtuines 1) ou encore l’AMPK (protéine kinase 
dépendante de l’adénosine monophosphate) (60-64) (Fig. 6). 
 
 De nouvelles évidences suggèrent que le métabolisme énergétique (libération d'ATP, 
ROS et mécanismes de défense cellulaire) serait lui aussi coordonné par l'horloge 
circadienne (65; 66). Bien qu’’il semble probable que la mitochondrie, véritable machinerie 
métabolique des cellules, soit étroitement liée de plusieurs façons à travers une régulation 
réciproque avec l’horloge circadienne, la relation entre le système circadien et la fonction 
mitochondriale reste encore très floue. 
 Ainsi, nous avons voulu savoir, d'une part, si l’horloge circadienne exerçait un 
contrôle sur la fonction mitochondriale, notamment sur la dynamique et la bioénergétique, et 
d’autre part, si la mitochondrie pouvait elle-même influencer des paramètres de l’horloge.  
 Pour ce faire, nous avons utilisé des cultures primaires de fibroblastes humains 
comme modèles d'horloge périphérique (67; 68). Après synchronisation des cellules, nous 
avons étudié la dynamique (morphologie mitochondriale, activité de fusion/fission) ainsi que 
la bioénergétique mitochondriale (production d’ATP et respiration). 
 
 Nos données ont révélé que la forme des mitochondries et le métabolisme 
bioénergétique (OXPHOS) sont sous le contrôle de l'horloge et oscillent avec une période de 
24 heures environ. Plus précisément, nous avons constaté que les niveaux d'ATP présentent 
une rythmicité circadienne avec un pic et un creux survenant respectivement 16 heures et 28 
heures après synchronisation. Ces données ont pu être confirmées in vivo, dans des 
cerveaux de souris maintenues en obscurité constante, où les taux d’ATP présentaient 
également une oscillation de 24 heures, avec un pic survenant au début de la période de 
repos. De plus, l'étude de la respiration mitochondriale in vitro a également fourni des 
résultats en corrélation avec les oscillations d’ATP. Nous avons observé que les taux de 
consommation d’oxygène (OCR) sont plus bas 28 heures postsynchronisation comparés à 
16 heures, supportant l’hypothèse que le métabolisme oxydatif de la mitochondrie est 
contrôlé par l’horloge biologique. 
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 L’étude de la dynamique mitochondriale a quant à elle révélé que l’activité de 
fusion/fission des mitochondries présente aussi un rythme d’environ 24 heures en corrélation 
avec la synthèse d’ATP. En effet, le réseau mitochondrial était dans un état : i) tubulaire (ou 
fusionné) 8 heures après synchronisation, quand les taux d’ATP augmentent; ii) 
intermédiaire 16 heures après synchronisation, au pic d’ATP ; iii) fragmenté 24 heures après 
synchronisation, au début du creux d’ATP. Cette rythmicité semble être dépendante de 
l'activité de DRP1, une protéine impliquée dans la fission mitochondriale. En effet, l’utilisation 
de fibroblastes DRP1 K.O ou le traitement des cellules avec un inhibiteur de fission a 
complètement aboli l'oscillation de l’ATP in vitro. De plus, la forme phosphorylée de DRP1 
(correspondant ici à la forme inactive de cette protéine) présente une oscillation circadienne 
au niveau protéique, suggérant que la fission mitochondrial, dépendant de DRP1, est sous le 
contrôle de l’horloge biologique. À nouveau, ces derniers résultats ont pu être confirmés in 
vivo dans les cerveaux de souris.  
 Nous avons également montré que des sous-produits dérivés de l'activité 
mitochondriale, comme les ROS et les niveaux NAD+, tous deux indicateurs de 
l'environnement redox, présentent aussi une oscillation circadienne en phase avec les 
niveaux d’ATP et la respiration mitochondriale.  
 Pour finir, nous avons également constaté que les mitochondries peuvent eux-
mêmes agir sur le rythme circadien via plusieurs signaux rétrogrades, dont l'activation de 
l’AMPK par phosphorylation (dépendant du ratio AMP/ATP) qui peuvent réguler l’activité des 
composants de l’horloge moléculaire tels que PER et CRY. 
 
 L'ensemble des résultats de la seconde partie de cette thèse nous ont permis 
d’établir un lien moléculaire entre le contrôle circadien de la dynamique mitochondriale et la 
bioénergétique, et vice versa. Ces données suggèrent que l’horloge circadienne joue un rôle 
clé dans le contrôle du métabolisme mitochondrial pour anticiper les besoins énergétiques 
nécessaires à la réalisation de diverses fonctions cellulaires en réponse aux exigences 
environnementales et/ou intracellulaires.  
 
 En conclusion, les résultats de ces travaux de thèse contribuent fortement à accroître 
nos connaissances sur la modulation de la fonction mitochondriale en conditions 
physiologiques et pathologiques (Fig. 7). Notre travail permet d'identifier les neurostéroïdes 
comme étant des molécules très prometteuses à exploiter pour contrecarrer les déficits 
bioénergétiques dans les maladies neurodégénératives, en particulier dans la MA. De plus, 
nous démontrons que la dynamique et la bioénergétique mitochondriales sont contrôlées par 
l'horloge biologique, ce qui pourrait avoir de multiples implications dans la régulation de 
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l'homéostasie métabolique chez le sujet sain ou chez les patients atteints de pathologies 
liées à une altération des rythmes biologiques et/ou des fonctions mitochondriales. 
 Des recherches complémentaires doivent maintenant être effectuées pour élucider 
plus en détail quels sont les mécanismes sous-jacents. 
 
 
Fig. 7 : Liens hypothétiques entre la fonction mitochondriale et l’horloge circadienne, et leur régulation par les 
neurostéroïdes. D'une part, nous avons montré que les neurostéroïdes peuvent augmenter la bioénergétique 
mitochondriale, ce qui peut partiellement pallier la dysfonction mitochondriale observée dans la maladie 
d'Alzheimer (MA). D'autre part nous avons montré que l'horloge circadienne contrôle la dynamique 
mitochondriale, qui à son tour module l'activité bioénergétique. De plus, la mitochondrie peut envoyer des signaux 
rétrogrades à l'horloge, ce qui influence à nouveau la dynamique et la bioénergétique mitochondriale. 
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ABBREVIATIONS 
 
3α-HSOR 3α-hydroxysteroid oxydoreductase 
3β-HSD 3β-hydroxysteroid dehydrogenase 
5α-R 5α-reductase 
17β-HSD 17β-hydroxysteroid dehydrogenase 
17OH-PREG 17-hydroxypregnenolone 
17OH-PROG 17-hydroxyprogesterone 
21-OHase 21-hydroxylase  
α-KGDH α-ketoglutarate dehydrogenase 
Aβ Amyloid-beta peptide 
ABAD Aβ binding protein alcohol dehydrogenase 
ACBD3 Acyl-CoA binding domain-containing 3  
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
AICD Aβ intracellular cytoplasmic domain 
AIF Apoptosis-inducing factor 
ALLOPREG Allopregnenolone 
AMPK AMP-activated protein kinases 
ANT Adenine nucleotide transporter  
APOE Apolipoprotein E 
APP Amyloid precursor protein 
AR Androgen receptor 
Arom. Aromatase 
ATP Adenosine triphosphate 
BACE β-site of APP cleaving enzyme 
C83 83-amino-acid Ct APP fragment 
C99 99-amino-acid Ct APP fragment 
CaMKII Calcium-calmodulin dependent protein kinase II 
CCG Clock-controlled gene 
cdk5 Cyclin-dependent kinase 5 
CK1ε casein kinase 1ε  
COX Cytochrome c oxidase 
Cry 1-2 Cryptochrome 1-2 
CT Circadian time 
Cu/Zn SOD Copper/zinc superoxide dismutase 
Cyp D cyclophilin D 
DD Dark/dark 
DHEA(S) Dehydroepiandrosterone (sulphate) 
DHP Dihydroprogesterone 
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DHT Dihydrotestosterone 
Drp1 Dynamin-related protein 1 
ER Endoplasmic reticulum  
ERα/β Estrogen receptors α and β  
ERK2 Extracellular signal-regulated kinase 2 
ETC Electron transport chain 
FAD Familial Alzheimer’s disease form 
FAD+ Flavin adenine dinucleotide 
FIS1 Fission protein 1  
FTDP-17 Fronto-temporal dementia with Parkinsonism linked to chromosome 17 
GDP Guanosine diphosphate 
GPX Glutathione peroxidase 
GR Glutathione reductase 
GSH Glutathione 
GSK-3β Glycogen synthase kinase-3β  
GTP Guanosine triphosphate 
H2O2 Hydrogen peroxide 
HST Hydroxysteroid sulfotransferase 
IMM Inner mitochondrial membrane 
IMS Intermembrane space 
iTRAQ Isobaric tags for relative and absolute quantitation 
LD Light/dark 
MAO Monoamine oxidase A 
MAP Microtubule-associated protein  
MFN1/2 Mitofusin 1 and 2 
MnSOD Manganese superoxide dismutase 
MMP Mitochondrial membrane potential 
mPTP mitochondrial permeability transition pore  
mtDNA Mitochondrial DNA 
NADH Nicotine adenine dinucleotide 
nDNA Nuclear DNA 
NFT Neurofibrillay tangles 
NMDA N-methyl-D-aspartate 
NO. Nitric oxide 
NOS Nitric oxide synthase 
eNOS/iNOS/nNOS  endothelial/inducible/neuronal nitric oxide synthase 
O2-. Superoxide anion 
OH. Hydroxyl radical 
OMM Outer mitochondrial membrane 
ONOO- Peroxynitrite 
OPA1 Optic atrophy 1 
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OXPHOS Oxidative phosphorylation system 
P301L mice/cells mutant tau mice/cells 
P450scc Cytochrome P450 cholesterol side chain cleavage 
P450c17 Cytochrome P450c17 
PDH Pyruvate dehydrogenase 
PER 1-3 Period 1-3 
PET Positron emission tomography 
PINK1 PTEN-induced putative kinase 1 
PKA-RIα protein kinase A regulatory subunit I alpha  
PKC Protein kinase C 
PR progestins receptors 
PROG Progesterone 
PS1/2 Presenelin 1 and 2 
REV-ERBα Reverse orientation c-erb α  
RNS Reactive nitrogen species 
ROR Orphan nuclear-receptor  
ROS Reactive oxygen species 
SAD Sporadic Alzheimer’s disease form 
SCN Suprachiasmatic nucleus 
SIRT1 Sirtuin 1 
SRE Steroid responsive elements  
STAR Steroidogenesis acute regulatory protein  
STS Steroid sulfatase 
TIM Translocator inner membrane 
TOM Translocator outer membrane 
triple
AD mutated Tau (P301L), PS2 (N141l) and APPSwe (KM670/671NL) triple transgenic mouse 
model 
TSPO Translocator protein 
UQ˙- Ubisemiquinone anion radicals  
UQ Coenzyme Q 
VDAC Voltage-dependant anion channels 
wtTau Wild type tau  
ZT Zeitgeber time 
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Insights into mitochondrial dysfunction:  
Aging, amyloid-beta, and tau-A deleterious trio. 
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Insights into Mitochondrial Dysfunction:
Aging, Amyloid-b, and Tau–A Deleterious Trio
Karen Schmitt,1 Amandine Grimm,1 Anna Kazmierczak,1,2 Joanna B. Strosznajder,2
Ju¨rgen Go¨tz,3 and Anne Eckert1
Abstract
Significance: Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder mainly af-
fecting elderly individuals. The pathology of AD is characterized by amyloid plaques (aggregates of amyloid-b
[Ab]) and neurofibrillary tangles (aggregates of tau), but the mechanisms underlying this dysfunction are still
partially unclear. Recent Advances: A growing body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated event that contributes to synaptic abnormalities and,
ultimately, selective neuronal degeneration in AD. Critical Issues: In this review, we discuss on the one hand
whether mitochondrial decline observed in brain aging is a determinant event in the onset of AD and on the
other hand the close interrelationship of this organelle with Ab and tau in the pathogenic process underlying
AD. Moreover, we summarize evidence from aging and Alzheimer models showing that the harmful trio ‘‘aging,
Ab, and tau protein’’ triggers mitochondrial dysfunction through a number of pathways, such as impairment of
oxidative phosphorylation (OXPHOS), elevation of reactive oxygen species production, and interaction with
mitochondrial proteins, contributing to the development and progression of the disease. Future Directions: The
aging process may weaken the mitochondrial OXPHOS system in a more general way over many years pro-
viding a basis for the specific and destructive effects of Ab and tau. Establishing strategies involving efforts to
protect cells at the mitochondrial level by stabilizing or restoring mitochondrial function and energy homeostasis
appears to be challenging, but very promising route on the horizon. Antioxid. Redox Signal. 16, 1456–1466.
Introduction
Aging is an inevitable biological process that results in aprogressive structural and functional decline, as well as
biochemical alterations that altogether lead to reduced ability
to adapt to environmental changes. Although aging is almost
universally conserved among all organisms, the molecular
mechanisms underlying this phenomenon still remain un-
clear. There are several theories of aging, in which free radical
(oxidative stress), DNA, or protein modifications are sug-
gested to play the major causative role (54, 72). A growing
body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated
event that contributes to synaptic abnormalities in aging and,
ultimately, increased susceptibility to age-related disorders
including Alzheimer’s disease (AD) (58). AD is the most
common neurodegenerative disorder among elderly indi-
viduals. It accounts for up to 80% of all dementia cases and
ranks as the fourth leading cause of death among those above
65 years of age. With the increasing average life span of hu-
mans, it is highly probable that the number of AD cases will
dangerously raise. The pathology of AD characterized by
abnormal formation of amyloid plaques (aggregates of amy-
loid-b [Ab]) and neurofibrillary tangles (NFT; aggregates
of tau) was shown to be accompanied by mitochondrial
dysfunction. However, the mechanisms underlying this dys-
function are poorly understood. There remain several open
questions: Is age-related oxidative stress accelerating the NFT
andAb pathologies? Are these lesions causing oxidative stress
themselves? Or are there other mechanisms involved? Within
the past years, several mouse models have been developed
that reproduce the aging process and diverse aspects of AD.
These models help in understanding the age-related patho-
genic mechanisms that lead to mitochondrial failure in AD,
and in particular the interplay of AD-related cellular modifi-
cations within this process (17, 18).
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Mitochondrial Aging—the Beginning of the End in AD?
Mitochondria play a pivotal role in cell survival and death
by regulating both energy metabolism and apoptotic path-
ways; they contribute to many cellular functions, including
intracellular calcium homeostasis, the alteration of the cellular
reduction-oxidation (redox) potential, cell cycle regulation,
and synaptic plasticity (47). They are the ‘‘powerhouses of
cells,’’ providing energy from nutritional sources via ATP
generation, which is accomplished through oxidative phos-
phorylation (OXPHOS) (65). However, when mitochondria
fulfill their physiological function, it is as if Pandora’s box has
been opened, as this vital organelle contains potentially
harmful proteins and biochemical reaction centers; mito-
chondria are the major producers of reactive oxygen species
(ROS) at the same time being susceptible targets of ROS tox-
icity. Unstable ROS are capable of damaging many types of
mitochondrial components; this includes oxidative deterio-
ration of mitochondrial DNA (mtDNA), lipids of the mito-
chondrial membrane, and mitochondrial proteins, and it is
thought that this damage thatmay accumulate over time from
ROS generated from aerobic respiration may play a signifi-
cant role in aging (Fig. 1). Moreover, it was previously dem-
onstrated that nitrosative stress evoked by increased nitric
oxide synthesis also leads to protein oxidation as well as mi-
tochondrial and DNA damage, which are common mecha-
nisms occurred in elderly (13, 34, 70).
Although most mitochondrial proteins are encoded by the
nuclear genome, the mitochondrial genome encodes proteins
required for 13 polypeptide complexes of the respiratory
chain involved in ATP synthesis. Given that mtDNA exists in
the inner matrix and this is in close proximity to the inner
membrane where electrons can form unstable compounds,
mtDNA, unlike nuclear DNA (nDNA), is not protected by
histones (4) making it more vulnerable to oxidative stress and
its mutation rate is about 10-fold higher than that of nDNA,
especially in tissues with a high ATP demand like the brain
(54). These mtDNA mutations occur in genes encoding elec-
tron transport chain (ETC) subunits including NADH dehy-
drogenase, cytochrome c oxidase (COX), and ATP synthase
(83). Eventually, ROS-related mtDNAmutations can result in
the synthesis of mutant ETC proteins that, in turn, can lead to
the leakage of more electrons and increased ROS production.
This so-called ‘‘vicious cycle’’ is hypothesized to play a critical
role in the aging process according to the mitochondrial the-
ory of aging. In addition to age-associated increase in mtDNA
mutations, the amount of mtDNA also declines with age in
various human and rodent tissues (2, 68). Furthermore,
abundance of mtDNA correlates with the rate of mitochon-
drial ATP production (68), suggesting that age-related mito-
chondrial dysfunction inmuscle is related to reducedmtDNA
abundance. However, age-associated change in mtDNA
abundance seems to be tissue specific, as several studies have
reported no change in mtDNA abundance with age in other
than muscular tissues in both man and mouse (20, 46).
How does the somatic mtDNA involved in aging pheno-
types contribute to AD development? As only a small fraction
of AD is caused by autosomal dominant mutations, this
comes down to the question of what is causing the prevalent
sporadic cases in the first place. Somatic mutations in mtDNA
could cause energy deficiency, increased oxidative stress, and
accumulation of Ab, which act in a vicious cycle reinforcing
mtDNA damage and oxidative stress (45). Indeed, defects in
mtDNA associated with decreased cytochrome oxidase
activity have been found in AD patients (9). Although a
similarly impaired mitochondrial function and subsequent
compensatory response have been observed in both non-
demented aged andAD subjects, no clear causativemutations
in the mtDNA have been correlated to AD; although some
variations have functional consequences, including changes
in enzymatic activity (40). Perhaps the main differences are
that, in AD brains, defects are more profound due to Ab and
tau accumulation, because of decreased compensatory re-
sponse machinery (Fig. 1).
Many investigators have developed models for studying
mitochondrial-related aging (36). Among them senescence-
acceleratedmice (SAM) strains are especially useful models to
understand the mechanisms of the age-related mitochondrial
decline. Behavioral studies showed that learning andmemory
deficits already started as early as 6 months and worsened
with aging in SAMP8 mice (accelerated senescence-prone 8)
(53, 77). Moreover, Omata and collaborators showed age-
related changes in cerebral energy production in the 2-month-
old SAMP8 followed by a decrease in mitochondrial function
compared with SAMR1 mice (accelerated senescence-resis-
tant 1) (51). Aging is not only connected with increased mi-
tochondrial ROS production due to ETC impairment but also
with a dysbalance of the protective antioxidant machinery
inside mitochondria. For instance, age-related changes in
levels of antioxidant enzymes, such as copper/zinc superox-
ide dismutase (Cu/Zn-SOD) andmanganese SOD (Mn-SOD),
have been found in liver and cortex of SAMP8 mice when
compared with age-matched SAMR1 mice, supporting in-
creased oxidative stress as a key mechanism involved in the
aging process (37). More recently, Yew and collaborators have
shown an impairment of mitochondrial functions including a
decrease of COX activity, mitochondrial ATP content, and
mitochondrial glutathione (GSH) level at a relatively early age
in SAMP8 mice compared with SAMR1 mice (67, 78). Fur-
thermore, the biochemical consequences of aging have been
investigated using proteomic analysis in the brain of SAMP8
and SAMR1 mice at presymptomatic (5-month old) and
symptomatic (15-month old) stages (84), revealing differen-
tially expressed proteins with age in both mouse strains,
such as Cu/Zn-SOD. Besides the progressive mitochondrial
decline and increased oxidative stress, tau hyperpho-
sphorylation was also observed at an early age in the brain of
SAMP8mice (1, 71). In addition, SAMP8mice showed an age-
related increase in mRNA and protein levels of amyloid-b
precursor protein (APP). The cleavage product Ab was sig-
nificantly increased at 9 months in SAMP8 and amyloid pla-
ques started to form at around 16 months of age (48, 73).
Altogether, these data indicate that mitochondrial dysfunc-
tion is a highly relevant event in the aging process, which is
also known as the primary risk factor for AD and other
prevalent neurodegenerative disorders.
Age-Related Ab and Tau Effects on Mitochondria in AD
AD is a progressive, neurodegenerative disorder, charac-
terized by an age-dependent loss of memory and an impair-
ment of multiple cognitive functions. From a genetic point of
view, AD can be classified into two different forms: rare fa-
milial forms (FAD) where the disease onset is at an age below
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60 years (< 1% of the total number of AD case) and the vast
majority of sporadic AD cases where onset occurs at an age
over 60 years. Genetic studies in FAD patients have identified
autosomal dominant mutations in three different genes, en-
coding theAPP (over 20 pathogenic mutations identified) and
the presenilins PS1 and PS2 (more than 130 mutations iden-
tified) (26). These mutations are directly linked to the in-
creased production of Ab from its precursor protein APP,
suggesting a direct and pathological role for Ab accumulation
in the development of AD.
Mitochondrial dysfunction has been proposed as an un-
derlying mechanism in the early stages of AD, since energy
deficiency is a fundamental characteristic feature of AD brains
(44) as well as of peripheral cells derived from AD patients
(22). Understanding the molecular pathways by which the
various pathological alterations including Ab and tau com-
promise neuronal integrity, leading to clinical symptoms, has
been a long-standing goal of AD research. The successful
development of mouse models that mimic diverse aspects of
the AD process has facilitated this effort and assisted in
FIG. 1. Aging, Ab, and tau: toxic consequence on mitochondria. The aging process may weaken the mitochondrial
OXPHOS (oxidative phosphorylation) system in a more general way by the accumulation of ROS-induced damage over
many years thereby sowing the seeds for specific and destructive effects of Ab and tau. ROS induce peroxidation of several
mitochondrial macromolecules, such as mtDNA and mitochondrial lipids, contributing to mitochondrial impairment in the
mitochondrial matrix. In AD, mitochondria were found to be a target of Ab toxicity, which may act directly or indirectly on
several proteins, leading to mitochondrial dysfunction. Indeed, Ab was found in the OMM and IMM as well as in the matrix.
The interaction of Ab with the OMM might affect the transport of nuclear-encoded mitochondrial proteins, such as subunits
of the ETC CIV, into the organelle via the TOM import machinery. Ab seems to be able to enter into the mitochondrial matrix
through TOM and TIM or could be derived from mitochondria-associated APP metabolism. The interaction of Ab with the
IMM would bring it into contact with respiratory chain complexes with the potential for myriad effects on cellular metab-
olism. It may be that Ab by these interactions affects the activity of several enzymes decreasing the ETC enzyme CIV,
reducing the amount of hydrogen that is translocated from the matrix to the intermembrane space, thus impairing the MMP.
The dysfunction of the ETC leads to a decreased CV activity and so to a lower ATP synthesis, in addition to an increased ROS
production. Interestingly, deregulation of CI is mainly tau dependent, while deregulation of CIV is Ab dependent, at both the
protein and activity level. Ab, amyloid-b; AD, Alzheimer’s disease; APP, amyloid precursor protein; CI, complex I; CII,
complex II; CIII, complex III; CIV, complex IV; CV, complex V, Cu/Zn-SOD, copper/zinc superoxide dismutase; cyt c,
cytochrome c; ETC, electron transport chain; IMM, inner mitochondrial membrane; MMP, mitochondrial membrane po-
tential; MnSOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; OMM, outer mitochondrial membrane;
ROS, reactive oxygen species; TIM, translocase of the inner membrane; TOM, translocase of the outer membrane. (To see this
illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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understanding of the age-dependent interplay of Ab and tau
on bioenergetics processes in vivo (Figs. 2 and 3).
Separate modes of Ab and tau toxicity on mitochondria
Mitochondria were found to be a target for APP toxicity as
both the full-length protein and Ab accumulate in the mito-
chondrial import channels, and both lead to mitochondrial
dysfunction (7, 42, 55, 56). Several evidences from cellular and
animal AD models indicate that Ab triggers mitochondrial
dysfunction through a number of pathways such as impair-
ment of OXPHOS, elevation of ROS production, interaction
with mitochondrial proteins, and alteration of mitochondrial
dynamics (52). Indeed, abnormal mitochondrial dynamics
have been identified in sporadic and familial AD cases (43, 76)
as well as in AD mouse model (6); a distortion probably me-
diated by altered expression of dynamin-like protein 1
(DLP1), a regulator of mitochondrial fission and distribution,
due to elevated oxidative and/or Ab-induced stress. This
modification can disturb the balance between fission and fu-
sion of mitochondria in favor of mitochondrial fission fol-
lowed by mitochondrial depletion from axons and dendrites
and, subsequently, synaptic loss.
Success in developing mouse models that mimic diverse
facets of the disease process has greatly facilitated the un-
derstanding of physiopathological mechanisms underlying
AD. Thus, in 1995, Games and collaborators established the
first APP mice model (called PDAPP) bearing the human
‘‘Indiana’’ mutation of the APP gene (V171F). They observed
the accumulation of Ab in the brain and subsequent amyloid
plaque formation as well as astrocytosis and neuritic dystro-
phy (21). Interestingly, in this model cognitive deficits, such as
spatial learning impairment, occur before the formation of Ab
plaques and increase with age (8). This phenomenon was also
observed in Tg2576 transgenic mice bearing the human
Swedishmutation of theAPP gene (K670N,M671L). In fact, in
most of the APP mouse models, the cognitive impairment
begins concomitantlywithAb oligomer formation in the brain
(around 6 months of age), while neuritic amyloid deposits
become visible only between 12 and 23 months and then the
amount of deposits increases (23, 31, 35). Thus, memory def-
icits seem to directly correlate with the accumulation of in-
tracellular Ab oligomers and not with amyloid plaque
formation. Crossing APP transgenicmice with those bearing a
mutation in presenilin 1 gene enabled an earlier onset of
amyloid plaques compared with APPmice. In one of the most
FIG. 2. Age-dependent appearance of histopathological hallmarks in transgenic AD mouse model.
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aggressive models, double-transgenic APPS/L/PS1
(APPSwedish/London/PS1M141L) mice, Ab accumulation begins
very soon at 1–2 months of age while cognitive deficits and
amyloid plaque formation are already observed at 3 months
(3, 16). A stronger decrease of mitochondrial membrane po-
tential as well as ATP level was also found in these mice.
Mitochondrial dysfunctions also appear to a very early
stage in these transgenic mouse models. For example, in the
APPSw transgenic strain Tg2576, an upregulation of genes
related to mitochondrial energy metabolism and apoptosis
was observed already at 2 months of age. Alterations in
composition of the mitochondrial respiratory chain com-
plexes I and III protein subunit as well as impairment of mi-
tochondrial respirationwere detected around 6months, when
soluble Ab accumulated in the brain without plaque forma-
tion (10, 23, 59). To test the hypothesis that oxidative stress can
underlie the deleterious effects of PS mutations, Schuessel
and collaborators analyzed lipid peroxidation products (4-
hydroxynonenal [HNE] and malondialdehyde) and antioxi-
dant defense mechanisms in brain tissue and ROS levels in
splenic lymphocytes from transgenic mice bearing the human
PS1 M146L mutation (PS1M146L) compared with those from
mice transgenic for wild-type human PS1 (PS1wt) and non-
transgenic littermate control mice (66). In brain tissue,
HNE levels were increased only in aged (19–22 months)
PS1M146L transgenic animals compared with PS1wt mice
and not in young (3–4 months) or middle-aged mice (13–15
months). Similarly, in splenic lymphocytes expressing the
transgenic PS1 proteins, mitochondrial and cytosolic ROS
levels were significantly elevated compared with controls
only in cells from aged PS1M146L animals. Antioxidant
defense mechanisms (activities of antioxidant enzymes in-
cluding Cu/Zn-SOD, GSH peroxidase, and GSH reductase)
as well as susceptibility to oxidative stress in vitro were
unaltered. In summary, these results demonstrate that the
PS1M146L mutation increases mitochondrial ROS formation
and oxidative damage selectively in aged mice. Consistent
with this observation, in Swedish amyloid precursor protein
(APPSw)/PS2 double-transgenic mice, mitochondrial im-
pairment was first detected at 8 months of age, before am-
yloid plaque deposition, but after soluble Ab accumulation
(60, 61). Taken together, these findings are consistent with
the recently proposed hypothesis of the age-related Ab
toxicity cascade that suggests that the most toxic Ab species
that cause majority of molecular and biochemical abnor-
malities are in fact intracellular soluble oligomeric
FIG. 3. Age-dependent mitochondrial dysfunction in senescence-accelerated and transgenic AD mouse models. (Star:
start of the experiments).
1460 SCHMITT ET AL.
aggregates rather than the extracellular, insoluble plaques
that may comprise the form of cellular defense against tox-
icity of oligomers (19). Interestingly, human amylin that
aggregates in type 2 diabetic pancreas and shares with Ab
its amyloidogenic properties also causes an impaired com-
plex IV activity, whereas nonamyloidogenic rat amylin did
not (39).
How does tau interfere with mitochondrial function? In its
hyperphosphorylated form, tau, which forms the NFTs, the
second hallmark lesion in AD, has been shown to block mi-
tochondrial transport, which results in energy deprivation
and oxidative stress at the synapse and, hence, neurodegen-
eration (27, 33, 57). Till now, no mutations in microtubule-
associated protein tau (MAPT) coding genes have been
detected in relation to familial forms of AD. However, in
familial frontotemporal dementia (FTD) with parkinsonism,
mutations in the MAPT gene were identified on chromosome
17. This was the basis for creating a robust mouse model for
tau pathology in 2001. These P301L tau–expressing pR5 mice
(longest four-repeat 4R2N) show an accumulation of tau as
soon as 3 months of age and develop NFTs around 6 months
of age (24). A mass spectrometric analysis of the brain
proteins from these mice revealed mainly a deregulation of
mitochondrial respiratory chain complex components (in-
cluding complex V), antioxidant enzymes, and synaptic
protein space (11). The reduction in mitochondrial complex V
levels in the P301L tau mice that was revealed using pro-
teomics was also confirmed as decreased in human P301L
FTDP-17 (FTD with parkinsonism linked to chromosome 17)
brains. The functional analysis demonstrated age-related
mitochondrial dysfunction, together with reduced NADH-
ubiquinone oxidoreductase (complex I) activity as well as
age-related impaired mitochondrial respiration and ATP
synthesis in pR5 mice model. Mitochondrial dysfunction was
also associated with higher levels of ROS in aged transgenic
mice. Increased tau pathology resulted in modification of
lipid peroxidation levels and the upregulation of antioxidant
enzymes in response to oxidative stress (11). Thus, this
evidence demonstrated for the first time that not only Ab but
also tau pathology leads to metabolic impairment and
oxidative stress by distinct mechanisms from that caused by
Ab in AD.
Synergistic modes of Ab and tau toxicity
on mitochondria
Although Ab and tau pathologies are both known hall-
marks of AD, the mechanisms underlying the interplay be-
tween plaques and NFTs (or Ab and tau, respectively) have
remained unresolved. However, a close relationship between
mitochondrial impairment and Ab on the one hand and tau
on the other hand has been already established. How do both
AD features relate to each other? Is it possible that these two
molecules synergistically affect mitochondrial integrity?
Several studies suggest that Ab aggregates and hyperpho-
sphorylated tau may block the mitochondrial carriage to the
synapse leading to energy deficiency and neurodegeneration
(28). Moreover, the enhanced tau levels may inhibit the
transport of APP into axons and dendrites, which suggests a
direct link between tau and APP in axonal failure (14, 69).
Remarkably, intracerebral Ab injections amplify a preexisting
tau pathology in several transgenic mouse models (5, 25, 29),
whereas lack of tau abrogates Ab toxicity (32, 33). Our find-
ings indicate that in tau transgenic pR5 mice, mitochondria
display an enhanced vulnerability toward an Ab insult in vitro
(12, 15, 16), suggesting a synergistic action of tau and Ab
pathology on this organelle (Figs. 2 and 3). The Ab caused a
significant reduction of mitochondrial membrane potential in
cerebral cells from pR5 mice (11). Furthermore, incubation of
isolated mitochondria from pR5 mice with either oligomeric
or fibrillar Ab species resulted in an impairment of the mito-
chondrial membrane potential and respiration. Interestingly,
aging particularly increased the sensitivity of mitochondria to
oligomeric Ab insult compared with that of fibrillar Ab (15).
This suggests that while both oligomeric and fibrillar Ab
species are toxic, they exert different degrees of toxicity.
Crossing P301L mutant tau transgenic JNPL3 mice (shortest
four-repeat [4R0N] tau together with the P301L mutation)
with APPSw transgenic Tg2576 mice revealed the presence of
NFT pathology in spinal cord and pons already at 3months of
age (38). Ab plaques were detected at the age of 6 months and
had the samemorphology and distribution than in the 1-year-
old Tg2576 mice. Taken together, these studies illustrate the
existence of a complex interplay between the two key proteins
in AD.
Additionally, in recent years triple-transgenic mouse models
have been established that combineAb and taupathologies (Figs.
2 and 3). In these models the contribution of both AD-related
proteins on the mitochondrial respiratory machinery and energy
homeostasis has been investigated in vivo. Indeed, our group
demonstrated a mitochondrial dysfunction in a novel triple-
transgenic mouse model (pR5/APPSw/PS2 N141I)—tripleAD
mice—using proteomics followed by functional validation
(60). Particularly, deregulation of activity of complex I was
found to be tau dependent, whereas deregulation of complex
IV was Ab dependent, in 10-month-old tripleAD mice. The
convergent effects of Ab and tau led already at the age of
8 months to a depolarization of mitochondrial membrane
potential in tripleAD mice. Additionally, we found that age-
related oxidative stress also plays a significant part in the
deleterious vicious cycle by exaggerating Ab- and tau-
induced disturbances in the respiratory system and ATP
synthesis, finally leading to synaptic failure.
Our data complement those obtained in another triple-
transgenic mouse model 3xTg-AD (P301Ltau/APPSw/PS1
M146L) (50). In these studies, mitochondrial dysfunction was
evidenced by an age-related decrease in the activity of regu-
latory enzymes ofOXPHOS such as COX, or of the Krebs cycle
such as pyruvate dehydrogenase, analyzing 3xTg-AD mice
aged from 3 to 12 months (82). Besides, these mice also ex-
hibited increased oxidative stress and lipid peroxidation.
Most of the effects on mitochondria were seen at the age of 9
months, whereas mitochondrial respiration was significantly
decreased at 12 months of age. Importantly, mitochondrial
bioenergetics deficits were found to precede the development
of AD pathology in the 3xTg-AD mice. Figure 4 nicely shows
that AD-specific changes including cognitive impairments,
Ab accumulation, Ab plaques, andmitochondrial dysfunction
seem to occur at an earlier onset from single, double up to
triple AD transgenic mice models. Together, our studies
highlight the key role of mitochondria in AD pathogenesis
and consolidate the notion that a synergistic effect of tau and
Ab enhances the pathological weakening of mitochondria at
an early stage of AD.
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Ab-Binding Alcohol Dehydrogenase: A New Lead
to Decode the Mechanisms of Ab-Induced
Mitochondrial Dysfunction
A few years ago, Yan and collaborators showed that the Ab
peptide can directly bind a mitochondrial enzyme called Ab-
binding alcohol dehydrogenase (ABAD) that is overexpressed
in the brains of Alzheimer’s patients and AD mouse models
(79). The interaction of Ab with this enzyme exacerbates mi-
tochondrial dysfunction induced by Ab (decrease of mito-
chondrial complex IV activity, diminution ofO2 consumption,
and increase of ROS), as shown in double-transgenic mice
overexpressing mutant APP and ABAD (81). Furthermore,
these mice presented an earlier onset of cognitive impairment
and histopathological changes when compared with APP
mice, suggesting that the Ab–ABAD interaction is an impor-
tant mechanism underlying Ab toxicity. The Ab–ABAD
complex could have a direct effect on the ETC because ABAD
was found to be one of three proteins that comprise the fully
functional mammalian mitochondrial RNAse P (63), a func-
tion that may not require dehydrogenase activity and that
links ABAD directly to the production of mitochondrial ETC
proteins and ROS generation.
Recently, it has been shown that inhibition of Ab–ABAD
interaction by a decoy peptide can restore mitochondrial
deficits and improve neuronal and cognitive function (81).
Our findings, using SH-SY5Y neuroblastoma cells treated
with Ab1-42, a cellular model of AD, seem to confirm these
observations (Lim et al., unpublished observations). We em-
ployed a novel small ABAD-specific inhibitor to investigate
the role of this enzyme in Ab toxicity. The inhibitor signifi-
cantly improved metabolic functions impaired by Ab, and
specifically reduced Ab-induced oxidative stress and cell
death. Furthermore, we have shown previously that the
production of estradiol, a well-known neuroprotective neu-
rosteroid and ABAD substrate, is increased after 24 h in the
presence of a ‘‘nontoxic’’ concentration of Ab and is de-
creased when using a toxic concentration of this peptide (64),
suggesting that Ab is able to modulate (directly or indirectly)
neurosteroid levels. Accordingly, new findings from our
group demonstrate that the levels of estradiol in the cytosol
and in mitochondria can differently be influenced by Ab
peptide (500 nM, 5 days of treatment) (Fig. 5A, B). We ob-
served that cytosolic estradiol is reduced in the presence of
Ab, but at the same time mitochondrial estradiol load was
significantly increased. We suggest that this increase is due
to an Ab-induced decrease of ABAD activity, thus limiting
the conversion of estradiol in estrone within mitochondria
(Fig. 5C). Inhibition of ABAD activity by Ab peptide was
already demonstrated by Yan and collaborators (80) using
17b-estradiol as substrate of the enzyme. One mechanism
that could explain this inhibition is the fact that Ab–ABAD
interaction changes the conformation of the enzyme, avoid-
ing the binding of the cofactor NAD + , and this reduces the
metabolic activity of ABAD (41). However, the total amount
of estradiol is about 500-fold higher than in the mitochon-
drial fraction. Even if Ab induced an increase in estradiol
within mitochondria, the reduction of total estradiol level by
other enzymes of the complex steroidogenic pathway may
therefore be more relevant for cellular dysfunction. Besides,
FIG. 4. Age-dependent onset of AD-associated pathological changes in different AD mouse models (age in months). In
both triple Tg mouse models [TripleAD, (60); 3xTgAD, (50–82)] an earlier onset in the appearance of AD-related changes in the
brain can be detected when compared with double transgenic [APPSw/PS2 (60, 61)] and to mice bearing only APP mutations
[APPSw, (24)], suggesting again a synergistic effect of Ab and tau in the pathogenesis of AD. Age of the mice is given in
months. APPSw, APP Swedish transgenic mice; APPSw/PS2, APP Swedish/presenilin 2 transgenic mice; tripleAD, APP
Swedish/presenilin 2/P301L tau transgenic mice; 3xTgAD, APP Swedish/presenilin 1/P301L tau transgenic mice. (To see
this illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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it was also speculated that estradiol exhibits a ‘‘prooxidant
effect’’ in the presence of ongoing oxidative stress (49).
Thereby, estradiol is hydroxylated to catecholestrogens that
can enter a redox cycle generating superoxide radicals,
leading to a continuous formation of ROS that amplifies
oxidative stress.
Thus, inhibition of the Ab–ABAD interaction seems to be
an interesting therapeutic target to block or prevent Ab-
inducedmitochondrial toxicity because it could normalize the
imbalance between ROS and estradiol levels in mitochondria
and thereby help in improving mitochondrial and neuronal
function.
Conclusion
We discuss here the recent findings regarding the possible
shared mechanisms involving mitochondrial decline driven
by brain aging and the close interrelationship of this organelle
with the two main pathological features in the pathogenic
process underlying AD.
According to themitochondrial aging theory, ROS-induced
damage and mtDNA mutations accumulate over time in-
ducing ETC impairment and weaken mitochondria function
in a rather unspecific way; thus, laying the ground for the two
common hallmarks of AD, plaques and NFTs, or Ab and tau,
respectively, which destruct independently as well as syner-
gistically this vital organelle via specific mode of actions on
complexes I and IV.
Given the complexities of AD, the key role of mitochondrial
dysfunction in the early pathogenic pathways by which Ab
leads to neuronal dysfunction in AD is particularly chal-
lenging with respect to establishing therapeutic treatments.
Besides the modulation and/or removal of both Ab and tau
pathology, strategies involving efforts to protect cells at the
mitochondrial level by stabilizing or restoring mitochondrial
function or by interfering with energy metabolism appear to
be promising. Transgenic AD mice, and particularly triple-
transgenic models that combine both pathologies in an age-
dependent manner (Fig. 4), are valuable tools in monitoring
therapeutic interventions at the mitochondrial level. Even-
tually, this may lead to therapies that prevent the progression
of the age-related mitochondrial decline thereby reducing the
vulnerability to Ab and/or tau at an early stage of the disease.
Acknowledgments
This work has been supported by grants from the Swiss
National Science Foundation (#31000_122572), Sciex_NMSCH
and Synapsis Foundation.
References
1. Alvarez-Garcia O, Vega-Naredo I, Sierra V, Caballero B,
Tomas-Zapico C, Camins A, Garcia JJ, Pallas M, and Coto-
Montes A. Elevated oxidative stress in the brain of senes-
cence-accelerated mice at 5 months of age. Biogerontology 7:
43–52, 2006.
2. Barazzoni R, Short KR, and Nair KS. Effects of aging on
mitochondrial DNA copy number and cytochrome c oxidase
gene expression in rat skeletal muscle, liver, and heart. J Biol
Chem 275: 3343–3347, 2000.
FIG. 5. Ab–ABAD interaction and estradiol level in mitochondria. (A) Mitochondrial estradiol is very low compared with
total estradiol level in SH-SY5Y neuroblastoma cells. Unpaired t-test, ***p< 0.001. (B) Estradiol level is differently influenced
by Ab peptide in the cytosol and in mitochondria. Paired t-test, *p < 0.05, ***p< 0.0001. (C) Ab peptide is able to modulate
ABAD function by binding directly to this mitochondrial enzyme. This results in the decrease of ABAD-induced conversion
of estradiol into estrone with a concomitant increase of ROS levels and an impairment of the ETC in mitochondria. ABAD,
Ab-binding alcohol dehydrogenase. (To see this illustration in color the reader is referred to the Web version of this article at
www.liebertonline.com/ars).
AGING, AMYLOID-b, AND TAU–A DELETERIOUS TRIO 1463
3. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B,
Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA,
Langui D, Duyckaerts C, Tremp G, and Pradier L. Time
sequence of maturation of dystrophic neurites associated
with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol
184: 247–263, 2003.
4. Bohr VA. Repair of oxidative DNA damage in nuclear and
mitochondrial DNA, and some changes with aging in
mammalian cells. Free Radic Biol Med 32: 804–812, 2002.
5. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC,
Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, and
Jucker M. Induction of tau pathology by intracerebral infu-
sion of amyloid-beta -containing brain extract and by amy-
loid-beta deposition in APP x Tau transgenic mice. Am J
Pathol 171: 2012–2020, 2007.
6. Calkins MJ, Manczak M, Mao P, Shirendeb U, and Reddy
PH. Impaired mitochondrial biogenesis, defective axonal
transport of mitochondria, abnormal mitochondrial dy-
namics and synaptic degeneration in a mouse model of
Alzheimer’s disease. Hum Mol Genet 20: 4515–4529, 2011.
7. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader
JW, XuHW, SternD,McKhannG, andYan SD.Mitochondrial
Abeta: a potential focal point for neuronal metabolic dys-
function in Alzheimer’s disease. FASEB J 19: 2040–2041, 2005.
8. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ,
Justice A, McConlogue L, Games D, Freedman SB,
and Morris RG. A learning deficit related to age and beta-
amyloid plaques in a mouse model of Alzheimer’s disease.
Nature 408: 975–979, 2000.
9. Coskun PE, Beal MF, and Wallace DC. Alzheimer’s brains
harbor somatic mtDNA control-region mutations that sup-
press mitochondrial transcription and replication. Proc Natl
Acad Sci U S A 101: 10726–10731, 2004.
10. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barn-
ham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Mas-
ters CL, and Trounce IA. Copper-dependent inhibition of
human cytochrome c oxidase by a dimeric conformer of
amyloid-beta1-42. J Neurosci 25: 672–679, 2005.
11. David DC, Hauptmann S, Scherping I, Schuessel K, Keil U,
Rizzu P, Ravid R, Drose S, Brandt U, Muller WE, Eckert A,
and Gotz J. Proteomic and functional analyses reveal a mi-
tochondrial dysfunction in P301L tau transgenic mice. J Biol
Chem 280: 23802–23814, 2005.
12. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C,
Halliday G, and Gotz J. Beta-amyloid treatment of two
complementary P301L tau-expressing Alzheimer’s disease
models reveals similar deregulated cellular processes. Pro-
teomics 6: 6566–6577, 2006.
13. Domek-Lopacinska KU and Strosznajder JB. Cyclic GMP
and nitric oxide synthase in aging and Alzheimer’s disease.
Mol Neurobiol 41: 129–137, 2010.
14. Ebneth A, Drewes G, Mandelkow EM, and Mandelkow E.
Phosphorylation of MAP2c and MAP4 by MARK kinases
leads to the destabilization of microtubules in cells. Cell Motil
Cytoskeleton 44: 209–224, 1999.
15. Eckert A, Hauptmann S, Scherping I, Meinhardt J, Rhein V,
Drose S, Brandt U, Fandrich M, Muller WE, and Gotz J.
Oligomeric and fibrillar species of beta-amyloid (A beta 42)
both impair mitochondrial function in P301L tau transgenic
mice. J Mol Med (Berl) 86: 1255–1267, 2008.
16. Eckert A, Hauptmann S, Scherping I, Rhein V, Muller-Spahn
F, Gotz J, and Muller WE. Soluble beta-amyloid leads to
mitochondrial defects in amyloid precursor protein and tau
transgenic mice. Neurodegener Dis 5: 157–159, 2008.
17. Eckert A, Schmitt K, and Gotz J. Mitochondrial dysfunc-
tion—the beginning of the end in Alzheimer’s disease? Se-
parate and synergistic modes of tau and amyloid-beta
toxicity. Alzheimers Res Ther 3: 15, 2011.
18. Eckert A, Schulz KL, Rhein V, and Gotz J. Convergence of
amyloid-beta and tau pathologies on mitochondria in vivo.
Mol Neurobiol 41: 107–114, 2010.
19. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Ser-
rano J, Bentura ML, Martinez-Murillo R, Martinez A, and
Rodrigo J. Intra- and extracellular Abeta and PHF in clini-
cally evaluated cases of Alzheimer’s disease. Histol Histo-
pathol 19: 823–844, 2004.
20. Frahm T, Mohamed SA, Bruse P, Gemund C, Oehmichen M,
and Meissner C. Lack of age-related increase of mitochon-
drial DNA amount in brain, skeletal muscle and human
heart. Mech Ageing Dev 126: 1192–1200, 2005.
21. Games D, Adams D, Alessandrini R, Barbour R, Berthelette
P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F,
et al. Alzheimer-type neuropathology in transgenic mice
overexpressing V717F beta-amyloid precursor protein. Nat-
ure 373: 523–527, 1995.
22. Gibson GE, Sheu KF, and Blass JP. Abnormalities of mito-
chondrial enzymes in Alzheimer disease. J Neural Transm
105: 855–870, 1998.
23. Gillardon F, Rist W, Kussmaul L, Vogel J, Berg M, Danzer K,
Kraut N, and Hengerer B. Proteomic and functional alter-
ations in brain mitochondria from Tg2576 mice occur before
amyloid plaque deposition. Proteomics 7: 605–616, 2007.
24. Gotz J, Chen F, Barmettler R, and Nitsch RM. Tau filament
formation in transgenic mice expressing P301L tau. J Biol
Chem 276: 529–534, 2001.
25. Gotz J, Chen F, van Dorpe J, and Nitsch RM. Formation of
neurofibrillary tangles in P301l tau transgenic mice induced
by Abeta 42 fibrils. Science 293: 1491–1495, 2001.
26. Gotz J and Ittner LM. Animal models of Alzheimer’s disease
and frontotemporal dementia.NatRevNeurosci 9: 532–544, 2008.
27. Gotz J, Ittner LM, Fandrich M, and Schonrock N. Is tau
aggregation toxic or protective: a sensible question in the
absence of sensitive methods? J Alzheimers Dis 14: 423–429,
2008.
28. Gotz J, Ittner LM, and Kins S. Do axonal defects in tau and
amyloid precursor protein transgenic animals model ax-
onopathy in Alzheimer’s disease? J Neurochem 98: 993–1006,
2006.
29. Gotz J, Schild A, Hoerndli F, and Pennanen L. Amyloid-
induced neurofibrillary tangle formation in Alzheimer’s
disease: insight from transgenic mouse and tissue-culture
models. Int J Dev Neurosci 22: 453–465, 2004.
30. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR,
Weidensteiner C, von Kienlin M, and Ozmen L. Phosphor-
ylation of Tau at S422 is enhanced by Abeta in TauPS2APP
triple transgenic mice. Neurobiol Dis 37: 294–306, 2010.
31. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL,
Jendrach M, Leuner K, Eckert A, and Muller WE.
Mitochondrial dysfunction: an early event in Alzheimer
pathology accumulates with age in AD transgenic mice.
Neurobiol Aging 30: 1574–1586, 2009.
32. Ittner LM and Gotz J. Amyloid-beta and tau - a toxic pas de
deux in Alzheimer’s disease.Nat Rev Neurosci 12: 65–72, 2011.
33. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J,
Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A,
Staufenbiel M, Hardeman E, and Gotz J. Dendritic function
of tau mediates amyloid-beta toxicity in Alzheimer’s disease
mouse models. Cell 142: 387–397, 2010.
1464 SCHMITT ET AL.
34. Jesko H, Chalimoniuk M, and Strosznajder JB. Activation of
constitutive nitric oxide synthase(s) and absence of inducible
isoform in aged rat brain. Neurochem Int 42: 315–322, 2003.
35. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J,
Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier
L, Muller WE, and Eckert A. Amyloid beta-induced changes
in nitric oxide production and mitochondrial activity lead to
apoptosis. J Biol Chem 279: 50310–50320, 2004.
36. Kuro-o M. Disease model: human aging. Trends Mol Med 7:
179–181, 2001.
37. Kurokawa T, Asada S, Nishitani S, and Hazeki O. Age-
related changes in manganese superoxide dismutase activity
in the cerebral cortex of senescence-accelerated prone and
resistant mouse. Neurosci Lett 298: 135–138, 2001.
38. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P,
Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Ba-
ker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH,
Dickson DW, Davies P, and Hutton M. Neurofibrillary
tangles, amyotrophy and progressive motor disturbance in
mice expressing mutant (P301L) tau protein. Nat Genet 25:
402–405, 2000.
39. Lim YA, Rhein V, Baysang G, Meier F, Poljak A, Raftery MJ,
Guilhaus M, Ittner LM, Eckert A, and Gotz J. Abeta and
human amylin share a common toxicity pathway via mito-
chondrial dysfunction. Proteomics 10: 1621–1633, 2010.
40. Lu J, Wang K, Rodova M, Esteves R, Berry D, Lezi E, Crafter
A, Barrett M, Cardoso SM, Onyango I, Parker WD, Fontes J,
Burns JM, and Swerdlow RH. Polymorphic variation in cy-
tochrome oxidase subunit genes. J Alzheimers Dis 21: 141–
154, 2010.
41. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N,
Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu
S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P,
Zewier ZL, Arancio O, Stern D, Yan SS, and Wu H. ABAD
directly links Abeta to mitochondrial toxicity in Alzheimer’s
disease. Science 304: 448–452, 2004.
42. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, and
Reddy PH. Mitochondria are a direct site of A beta accu-
mulation in Alzheimer’s disease neurons: implications for
free radical generation and oxidative damage in disease
progression. Hum Mol Genet 15: 1437–1449, 2006.
43. Manczak M, Calkins MJ, and Reddy PH. Impaired mito-
chondrial dynamics and abnormal interaction of amyloid
beta with mitochondrial protein Drp1 in neurons from pa-
tients with Alzheimer’s disease: implications for neuronal
damage. Hum Mol Genet 20: 2495–2509, 2011.
44. Manczak M, Park BS, Jung Y, and Reddy PH. Differential
expression of oxidative phosphorylation genes in patients
with Alzheimer’s disease: implications for early mitochon-
drial dysfunction and oxidative damage. Neuromolecular Med
5: 147–162, 2004.
45. Mao P and Reddy PH. Aging and amyloid beta-induced
oxidative DNA damage and mitochondrial dysfunction in
Alzheimer’s disease: Implications for early intervention and
therapeutics. Biochim Biophys Acta 1812: 1359–1370, 2011.
46. Masuyama M, Iida R, Takatsuka H, Yasuda T, and Matsuki
T. Quantitative change in mitochondrial DNA content in
various mouse tissues during aging. Biochim Biophys Acta
1723: 302–308, 2005.
47. Mattson MP, Gleichmann M, and Cheng A. Mitochondria in
neuroplasticity and neurological disorders. Neuron 60: 748–
766, 2008.
48. Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tu-
mosa N, and Flood JF. Beta-amyloid precursor polypeptide
in SAMP8 mice affects learning and memory. Peptides 21:
1761–1767, 2000.
49. Nilsen J. Estradiol and neurodegenerative oxidative stress.
Front Neuroendocrinol 29: 463–475, 2008.
50. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE,
Kayed R, Metherate R, Mattson MP, Akbari Y, and LaFerla
FM. Triple-transgenic model of Alzheimer’s disease with
plaques and tangles: intracellular Abeta and synaptic dys-
function. Neuron 39: 409–421, 2003.
51. Omata N, Murata T, Fujibayashi Y, Waki A, Sadato N,
Yoshimoto M, Wada Y, and Yonekura Y. Age-related
changes in energy production in fresh senescence-accelerated
mouse brain slices as revealed by positron autoradiography.
Dement Geriatr Cogn Disord 12: 78–84, 2001.
52. Pagani L and Eckert A. Amyloid-Beta interaction with mi-
tochondria. Int J Alzheimers Dis 2011: 925050, 2011.
53. Pallas M, Camins A, Smith MA, Perry G, Lee HG, and Ca-
sadesus G. From aging to Alzheimer’s disease: unveiling
‘‘the switch’’ with the senescence-accelerated mouse model
(SAMP8). J Alzheimers Dis 15: 615–624, 2008.
54. Park CB and Larsson NG. Mitochondrial DNA mutations in
disease and aging. J Cell Biol 193: 809–818, 2011.
55. Pavlov PF, Hansson Petersen C, Glaser E, and Ankarcrona
M. Mitochondrial accumulation of APP and Abeta: signifi-
cance for Alzheimer disease pathogenesis. J Cell Mol Med 13:
4137–4145, 2009.
56. Pavlov PF, Wiehager B, Sakai J, Frykman S, Behbahani H,
Winblad B, and Ankarcrona M. Mitochondrial gamma-
secretase participates in the metabolism of mitochondria-
associated amyloid precursor protein. FASEB J 25: 78–88, 2011.
57. Reddy PH. Abnormal tau, mitochondrial dysfunction, im-
paired axonal transport of mitochondria, and synaptic dep-
rivation in Alzheimer’s disease. Brain Res 1415: 136–148, 2011.
58. Reddy PH and Beal MF. Amyloid beta, mitochondrial dysfunc-
tion and synaptic damage: implications for cognitive decline in
aging and Alzheimer’s disease. Trends Mol Med 14: 45–53, 2008.
59. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV,
Partovi D, Jung Y, Yau V, Searles R, Mori M, and Quinn J.
Gene expression profiles of transcripts in amyloid precursor
protein transgenic mice: up-regulation of mitochondrial
metabolism and apoptotic genes is an early cellular change
in Alzheimer’s disease. Hum Mol Genet 13: 1225–1240, 2004.
60. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F,
Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E,
Czech C, Gotz J, and Eckert A. Amyloid-beta and tau syn-
ergistically impair the oxidative phosphorylation system in
triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci
U S A 106: 20057–20062, 2009.
61. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew
JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H,
Czech C, Huber G, Bluethmann H, Jacobsen H, and Kemp
JA. PS2APP transgenic mice, coexpressing hPS2mut and
hAPPswe, show age-related cognitive deficits associated
with discrete brain amyloid deposition and inflammation. J
Neurosci 23: 8989–9003, 2003.
62. Rodriguez MI, Escames G, Lopez LC, Lopez A, Garcia JA,
Ortiz F, Sanchez V, Romeu M, and Acuna-Castroviejo D.
Improved mitochondrial function and increased life span
after chronic melatonin treatment in senescent prone mice.
Exp Gerontol 43: 749–756, 2008.
63. Sapra AK, Anko ML, Grishina I, Lorenz M, Pabis M, Poser I,
Rollins J, Weiland EM, and Neugebauer KM. SR protein
family members display diverse activities in the formation of
nascent andmaturemRNPs in vivo.Mol Cell 34: 179–190, 2009.
AGING, AMYLOID-b, AND TAU–A DELETERIOUS TRIO
64. Schaeffer V, Meyer L, Patte-Mensah C, Eckert A, and Men-
sah-Nyagan AG. Dose-dependent and sequence-sensitive
effects of amyloid-beta peptide on neurosteroidogenesis in
human neuroblastoma cells. Neurochem Int 52: 948–955, 2008.
65. Scheffler IE. A century of mitochondrial research: achieve-
ments and perspectives. Mitochondrion 1: 3–31, 2001.
66. Schuessel K, Frey C, Jourdan C, Keil U, Weber CC, Muller-
Spahn F, Muller WE, and Eckert A. Aging sensitizes toward
ROS formation and lipid peroxidation in PS1M146L trans-
genic mice. Free Radic Biol Med 40: 850–862, 2006.
67. Shi C, Xiao S, Liu J, Guo K, Wu F, Yew DT, and Xu J. Ginkgo
biloba extract EGb761 protects against aging-associated mi-
tochondrial dysfunction in platelets and hippocampi of
SAMP8 mice. Platelets 21: 373–379, 2010.
68. Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J,
Raghavakaimal S, and Nair KS. Decline in skeletal muscle
mitochondrial function with aging in humans. Proc Natl
Acad Sci U S A 102: 5618–5623, 2005.
69. Stamer K, Vogel R, Thies E, Mandelkow E, and Mandelkow
EM. Tau blocks traffic of organelles, neurofilaments, and
APP vesicles in neurons and enhances oxidative stress. J Cell
Biol 156: 1051–1063, 2002.
70. Strosznajder JB, Jesko H, Zambrzycka A, Eckert A, and
Chalimoniuk M. Age-related alteration of activity and gene
expression of endothelial nitric oxide synthase in different
parts of the brain in rats. Neurosci Lett 370: 175–179, 2004.
71. Sureda FX, Gutierrez-Cuesta J, Romeu M, Mulero M,
Canudas AM, Camins A, Mallol J, and Pallas M. Changes in
oxidative stress parameters and neurodegeneration markers
in the brain of the senescence-accelerated mice SAMP-8. Exp
Gerontol 41: 360–367, 2006.
72. Swerdlow RH. Brain aging, Alzheimer’s disease, and mito-
chondria. Biochim Biophys Acta 1812: 1630–1639, 2011.
73. Takemura M, Nakamura S, Akiguchi I, Ueno M, Oka N, Ishi-
kawa S, Shimada A, Kimura J, and Takeda T. Beta/A4 pro-
teinlike immunoreactive granular structures in the brain of
senescence-acceleratedmouse.Am J Pathol 142: 1887–1897, 1993.
74. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat
AC, Stern DM, Arancio O, and Yan SS. ABAD enhances
Abeta-induced cell stress via mitochondrial dysfunction.
FASEB J 19: 597–598, 2005.
75. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM,
and Arancio O. Progressive age-related development of
Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55:
801–814, 2004.
76. Wang X, Su B, Fujioka H, and Zhu X. Dynamin-like protein
1 reduction underlies mitochondrial morphology and dis-
tribution abnormalities in fibroblasts from sporadic Alzhei-
mer’s disease patients. Am J Pathol 173: 470–482, 2008.
77. Watanabe K, Tonosaki K, Kawase T, Karasawa N, Nagatsu I,
Fujita M, and Onozuka M. Evidence for involvement of
dysfunctional teeth in the senile process in the hippocampus
of SAMP8 mice. Exp Gerontol 36: 283–295, 2001.
78. Xu J, Shi C, Li Q, Wu J, Forster EL, and Yew DT. Mitochon-
drial dysfunction in platelets and hippocampi of senescence-
accelerated mice. J Bioenerg Biomembr 39: 195–202, 2007.
79. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Col-
lison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S,
Roher A, and Stern D. An intracellular protein that binds
amyloid-beta peptide and mediates neurotoxicity in Alz-
heimer’s disease. Nature 389: 689–695, 1997.
80. Yan SD, Shi Y, Zhu A, Fu J, Zhu H, Zhu Y, Gibson L, Stern E,
Collison K, Al-Mohanna F, Ogawa S, Roher A, Clarke SG,
and Stern DM. Role of ERAB/L-3-hydroxyacyl-coenzyme A
dehydrogenase type II activity in Abeta-induced cytotoxic-
ity. J Biol Chem 274: 2145–2156, 1999.
81. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D,
Stern DM, GunnMoore FJ, Xi Chen J, Arancio O, and Yan SS.
Inhibition of amyloid-beta (Abeta) peptide-binding alcohol
dehydrogenase-Abeta interaction reduces Abeta accumula-
tion and improves mitochondrial function in a mouse model
of Alzheimer’s disease. J Neurosci 31: 2313–2320, 2011.
82. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, and Brinton
RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s
pathology in female mouse model of Alzheimer’s disease.
Proc Natl Acad Sci U S A 106: 14670–14675, 2009.
83. Yen TC, Su JH, King KL, and Wei YH. Ageing-associated
5 kb deletion in human liver mitochondrial DNA. Biochem
Biophys Res Commun 178: 124–131, 1991.
84. ZhuL,Yu J, ShiQ,LuW,LiuB,XuS,WangL,Han J, andWang
X. Strain- and age-related alteration of proteins in the brain of
SAMP8 and SAMR1 mice. J Alzheimers Dis 23: 641–654, 2011.
Address correspondence to:
Dr. Anne Eckert
Neurobiology Laboratory for Brain Aging and Mental Health
Psychiatric University Clinics
University of Basel
CH-4012 Basel
Switzerland
E-mail: anne.eckert@upkbs.ch
Date of first submission to ARS Central, November 10, 2011;
date of acceptance, November 27, 2011.
Abbreviations Used
Ab¼ amyloid-b
ABAD¼Ab-binding alcohol dehydrogenase
AD¼Alzheimer’s disease
APP¼ amyloid precursor protein
APPSw¼ Swedish amyloid precursor protein
APPwt¼wild-type amyloid precursor protein
COX¼ cytochrome c oxidase
DLP1¼dynamin-like protein 1
ETC¼ electron transport chain
FTD¼ frontotemporal dementia
GSH¼ glutathione
HA¼human amylin
HNE¼ 4-hydroxynonenal
IMM¼ inner mitochondrial membrane
MAPT¼microtubule-associated protein tau
MMP¼mitochondrial membrane potential
mtDNA¼mitochondrial DNA
nDNA¼nuclear DNA
NFT¼neurofibrillary tangle
NO¼nitric oxide
OMM¼ outer mitochondrial membrane
OXPHOS¼ oxidative phosphorylation
PDH¼pyruvate dehydrogenase
PS¼presenilin
ROS¼ reactive oxygen species
SAM¼ senescence-accelerated mice
SOD¼ superoxide dismutase
TIM¼ translocase of the inner membrane
TOM¼ translocase of the outer membrane
1466 SCHMITT ET AL.
Appendix 2 
March separate, strike together - Role of phosphorylated 
TAU in mitochondrial dysfunction in Alzheimer's disease.  
Eckert A, Nisbet R, Grimm A, Götz J. 
Biochim Biophys Acta doi: 10.1016/j.bbadis.2013.08.013. (2013)
Review
March separate, strike together — Role of phosphorylated TAU in
mitochondrial dysfunction in Alzheimer's disease☆
Anne Eckert a, Rebecca Nisbet b, Amandine Grimm a, Jürgen Götz b,⁎
a Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Switzerland
b Centre for Ageing Dementia Research (CADR), Queensland Brain Institute (QBI), The University of Queensland, Australia
a b s t r a c ta r t i c l e i n f o
Article history:
Received 2 July 2013
Received in revised form 8 August 2013
Accepted 12 August 2013
Available online 17 September 2013
Keywords:
Alzheimer's disease
Axonal transport
DRP1
Mitochondrion
Tauopathy
The energydemand and calciumbuffering requirements of the brain aremet by thehighnumberofmitochondria
in neurons and in these, especially at the synapses. Mitochondria are themajor producer of reactive oxygen spe-
cies (ROS); at the same time, they are damaged by ROS that are induced by abnormal protein aggregates that
characterize human neurodegenerative diseases such as Alzheimer's disease (AD). Because synaptic mitochon-
dria are long-lived, any damage exerted by these aggregates impacts severely on neuronal function. Here we
review how increased TAU, a defining feature of AD and related tauopathies, impairs mitochondrial function
by following the principle: ‘March separate, strike together!’ In the presence of amyloid-β, TAU's toxicity
is augmented suggesting synergistic pathomechanisms. In order to restore mitochondrial functions in
neurodegeneration as a means of therapeutic intervention it will be important to integrate the various aspects
of dysfunction and get a handle on targeting distinct cell types and subcellular compartments. This article is
part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.
© 2013 Published by Elsevier B.V.
1. Introduction
The family of microtubule-associated proteins (MAPs) comprises
three major classes of polypeptides: MAP1 (N250 kDa), MAP2
(~200 kDa), and TAU (50–70 kDa) [1,2]. MAP2 and TAU are expressed
in most neurons, where they localize to separate subcellular compart-
ments. While MAP2 is largely found in dendrites, TAU is concentrated
in axons [3]. In the roundworm Caenorhabditis elegans, protein with
TAU-like repeats (PTL-1) is the sole MAP homolog [4,5], allowing for
studies into shared functions of TAU and MAP2 [6]. In the human
brain, TAU exists as six isoforms that have either three or four
microtubule-binding domains. In the adult mouse brain, there are only
isoforms with four microtubule-binding domains expressed. TAU has
been localized to cell-types other than neurons such as astrocytes and
oligodendrocytes although under physiological conditions expression
levels are relatively low [7]. When TAU was discovered in 1975 [8],
the subsequent years focused mainly on its tissue distribution and the
role TAU has in microtubule assembly and stabilization. With the iden-
tification of aggregates of TAU in the Alzheimer's disease (AD) brain, the
focus shifted to addressing pathological functions. Histopathologically,
AD is characterized by reduced synaptic density, neuronal loss in select-
ed brain areas, as well as amyloid-β (Aβ)-containing plaques and neu-
rofibrillary tangles (NFTs). It is the filamentous core of NFTs that is
composed of highly phosphorylated forms of TAU [9,10].
1.1. TAU phosphorylation
What is the role of TAUphosphorylation in disease? TAU is a remark-
able protein inasmuch as it contains 80 serine and threonine residues
and 5 tyrosine residues that can be potentially phosphorylated [11]. In
the normal brain there are 2–3 mol of phosphate per mole of TAU. In
the AD brain, TAU is hyperphosphorylated to a stoichiometry of at
least three-fold greater than normal supporting the notion that phos-
phorylation is a critical step in the aggregation process [12]. Whether
phosphorylation at distinct sites is required or whether a generally ele-
vated level of phosphorylation is sufficient is not known although the
latter possibility is suggested bywork inDrosophila [13].With the enter-
ing of a formulation of the TAU dye methylene blue (Rember) into clin-
ical trials a discussion has been initiated whether this putative drug is
truly an aggregation inhibitor [14] and more specifically whether TAU
in NFTs is massively phosphorylated (http://www.alzforum.org/new/
detail.asp?id=3410).
While one study claims that the filaments in the NFTs are entirely
composed of hyperphosphorylated TAU [15], another claims that
hyperphosphorylated TAU accounts for less than 10% of total TAU that
is moreover localized to the proteolytically susceptible fuzzy outer
coat of the filaments, and not to their structural core [16,17].
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1.2. MAPT mutations and TAU transgenic mice
The TAU field has received a major boost with the identification of
pathogenic mutations in the MAPT gene that encodes TAU in familial
cases (FTDP-17, frontotemporal dementia with Parkinsonism linked to
chromosome 17) of frontotemporal lobar degeneration (FTLD-TAU), a
disease that shares with AD the aggregation of TAU and NFT formation,
but lacks an overt Aβ pathology [18–20]. This enabled us and others to
express FTLD mutant forms of TAU in mice and thereby reproduce
TAU aggregation and NFT formation, and also to achieve a concomitant
behavioural impairment in transgenic mouse models [21]. One such
mouse strain generated in our laboratory is pR5 that expresses P301L
mutant TAU and because of the pattern of TAU aggregation in the
brain, displays amygdala- and hippocampus-dependent memory im-
pairments [22,23]. This and other mouse models were instrumental in
determining that manipulating phosphorylation by either inhibiting ki-
nases or activating phosphatases causes an amelioration of the TAU pa-
thology, including a restoration of behavioural impairments and
prevention of neuronal cell loss [24–26]. When TAU mutant pR5 mice
that progressively develop NFTs were crossed with phosphatase
(PP2A)-impaired mice, this caused 7-fold increased numbers of hippo-
campal neurons that specifically phosphorylated the pathological
Ser422 epitope of TAU, and 8-fold increased numbers of NFTs [27]. An-
other mouse strain generated by us expresses K369I mutant TAU and
because of a unique expression pattern that includes the substantia
nigra it is characterized by Parkinsonism [28]. Again, in these mice,
TAU is highly phosphorylated; however, different from the pR5 strain,
the 12E8 phospho-epitope Ser262/Ser356 is spared. Together this un-
derscores the importance of phosphorylation in disease. Importantly
and relevant to the topic of this article, TAU transgenic mouse models
have proven instrumental in highlighting mitochondrial dysfunction
as a central mechanism in neurodegeneration.
2. Mitochondrial dysfunction — cause or consequence
Mitochondria play a pivotal role in cell survival and death by regulat-
ing both energy metabolism and apoptotic pathways. They contribute
to many cellular processes including intracellular calcium homeostasis
and synaptic plasticity [29]. Maternally inherited, mitochondria are
compartmentalized organelles consisting of a matrix and two mem-
branes, an outer and an inner membrane with folded cristae, separated
by an intermembrane space. These organelles are the powerhouses of
all nucleated cells. They produce adenosine triphosphate (ATP) via the
combined efforts of the tricarboxylic cycle (TCA) and the oxidative
phosphorylation (OxPhos) system of the electron transport chain
(ETC). The respiratory chain comprises four biochemically linked
multi-subunit complexes I, II, III and IV, as well as two electron carriers,
ubiquinone/coenzyme Q and cytochrome C, that are localized at the
inner mitochondrial membrane (Fig. 1). By using the energy that is
stored in nutritional sources the respiratory chain generates a proton
gradient across the inner membrane to drive ATP synthesis via ATP
synthase (complex V), while at the same time transferring electrons
to oxygen and producing water [30]. Mitochondria are the major pro-
ducer of reactive oxygen species (ROS) and at the same time a target
of ROS toxicity [31]. The organelle has at its disposal a powerful quality
control system to dealwith these challenges:firstly intra-mitochondrial
proteases and molecular chaperones that maintain mitochondrial
proteostasis; secondly a dynamic network maintained by membrane
fission and fusion, a process termed mitochondrial dynamics, by
which damaged or defective mitochondrial components are isolated
and targeted for autophagy (mitophagy) [32]. Mitochondrial dynamics
cannot be discussed in isolation, as mitochondrial fission (i.e. biogene-
sis), fusion, motility/transport and turnover (by mitophagy) are highly
inter-dependent processes [33]. This is especially critical for highly
polarized cells such as neurons. The role of mitochondria in ageing
and in pathophysiological processes such as AD is constantly being
unravelled. Concomitant to ROSproduction an inefficientmitochondrial
base excision repair (BER) machinery has been postulated, with oxida-
tive damage to mitochondrial DNA (mtDNA) being a determining
event that occurs during ageing [34].
2.1. Manipulating fission and fusion genes
The question arises whether any form of chronic oxidative stress-
associated event would at an early stage contribute to the synaptic ab-
normalities and, ultimately, selective neuronal degeneration that char-
acterizes AD, as a growing body of evidence would suggest [35]. The
bulk of AD cases are sporadic, and only a small fraction is caused by au-
tosomal dominant mutations. Regarding the role of mitochondrial dys-
function in AD one can envisage several scenarios. Firstly, oxidative
stress could be a down-stream consequence of another pathogenic
event; secondly, it could be the cause of neurodegeneration; thirdly, it
might accelerate and/or augment the damage elicited by TAU and/or
Aβ [31]. By manipulating mitochondrial in vivo genes with a role in fu-
sion and fission, a process discussed in more detail below, neither an
AD-like TAU nor an Aβ pathology has been encountered [36–41],
which would place mitochondrial dysfunction down-stream of TAU
and Aβ toxicity. However, as most mouse strains that lack fission or fu-
sion genes show early lethality it has not been possible to study conse-
quences for TAU and Aβ and in particular the role ageing has in such an
impairment.
2.2. Senescence-accelerated mice
In studying mitochondrial functions and age-related mitochondrial
decline, senescence-accelerated mouse strains such as SAMP8 (senes-
cence accelerated prone 8) are useful, as themice displaymany features
known to occur early in the pathogenesis of AD, such as increased oxi-
dative stress andmemory impairment [42]. Together with a series of re-
lated senescence-acceleratedmice, the SAMP8 strain was established in
the mid 1970s by conventional inbreeding of AKR/J-derived mice that
displayed features of accelerated ageing such as hair loss, reduced activ-
ity, shortened life expectancy, lordokyphosis (increased curvature of the
spine), and periophthalmic (around the eye) problems [43]. Littermates
that did not show a senescence-associated phenotype were also inbred
and senescence-resistant, longer-lived SAMR strains were obtained
such as SAMR1 (senescence accelerated mouse resistant 1). To better
delineate the role of specific single nucleotide variants (SNVs) of these
multigenic strains with distinct phenotypes, two recent independent
studies used whole exome sequencing to make the strains more useful
for studies into ageing and neurodegeneration [44,45].
In SAMP8 mice learning and memory deficits were already evident
at 6 months of age and became more pronounced with advanced age
[46]. TAU was found to be hyperphosphorylated using a small set of
phosphorylation site-specific antibodies, but filament and NFT forma-
tion has not been reported indicating that the SAMP8 mice present
with an early rather than amore advanced TAU pathology [47]. Staining
with Aβ-specific antibodies suggested Aβ deposition [48,49], although,
because the murine protein differs from the human Aβ-precursor
protein (APP) and lacks the amino acids that are required to generate
Aβ, these deposits have been termed ‘Aβ-like’ [48]. Compared with
SAMR1 mice, age-related changes in cerebral energy production were
found in SAMP8 at 2 months followed by a decrease in mitochondrial
function [50,51]. More recent studies extended this finding by revealing
decreases in cytochrome C oxidase (COX) activity, mitochondrial ATP
content, and mitochondrial glutathione (GSH) levels in young SAMP8
compared with SAMR1 mice [52,53]. Ageing is accompanied not only
by increased mitochondrial ROS production due to ETC impairment
but also by an imbalance of the protective mitochondrial antioxidant
machinery. For instance, age-related changes in levels of antioxidant
enzymes, such as copper/zinc superoxide dismutase (Cu/Zn-SOD) and
manganese SOD (Mn-SOD) were found in the liver and cortex of
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SAMP8 mice compared with age-matched SAMR1 mice [54–56]. In-
creased lipid peroxidation and carbonyl damage is present as early
as two months of age [57]. Furthermore, SAMP8 mice reveal age-
dependent reductions of various receptors including the NMDA receptor
that has a role in excitotoxicity as discussed below [58]. Whereas SAMP
mice are certainly a better model for accelerated ageing rather than
neurodegeneration, they nonetheless support increased oxidative stress
as a keymechanism in the ageing process. Crossing TAU transgenicmice
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Fig. 1. Themitochondrion under physiological and pathological conditions. Under healthy conditions, fusion andfission are balanced, and damagedmitochondria are removed by a process
termedmitophagy. Both antero- and retrograde axonal transports are unimpaired providing the synapses with sufficient numbers of functional mitochondria to meet the special energy
requirement and calcium buffering of this cellular compartment. Under conditions of elevated TAU, the delicate balance of fission and fusion is deregulated. Fission is impaired and an
elongatedmitochondrial network results. Thismay ormay not affect mitophagy. Phosphorylated TAU also impairs anterograde transport of distinct cargoes, which include mitochondria.
As a consequence, less mitochondria are provisioned to the synapses, which leads to synaptic degeneration. In the scheme, key molecules with roles in mitochondrial transport are indi-
cated, with kinesin being the actual motor andMiro and Milton being adaptor proteins. Inset: Elevated levels of phosphorylated TAU selectively impair complex I of the electron transfer
chain, ultimately resulting in reduced levels of ATP and hence, energy deprivation of affected neurons. Hyperphosphorylated forms of TAU also cause an increased production of reactive
oxygen species (ROS) and reduced activities of detoxifying enzymes (detox. enz.) including superoxide dismutase (SOD).
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with mitochondrial impairment onto a SAMP8 genetic background
might establish a more advanced model of neurodegeneration com-
pared to one where the TAU transgene is expressed on a conventional
inbred background such as C57Bl/6.
2.3. The Harlequin model
Another, although less frequently, employed strain with mitochon-
drial dysfunction and oxidative stress is the Harlequin (Hq) mutant
mouse strain. Hq mice show an 80–90% depletion of the mitochondrial
apoptosis-inducing factor (AIF) resulting in reduced levels of complex I
of the ETC and increased oxidative stress [59]. Interestingly, although
AIF is reduced throughout the brain, neuronal loss is largely restricted
to distinct brain regions (cerebellum and retina), indicating selective
vulnerability. Because a mitochondrial dysfunction specifically of com-
plex I characterizes the P301L TAU transgenic pR5mice, the two strains
were crossed. This caused an increased TAU pathology (higher degree
of phosphorylation and more NFTs) and age-dependent cerebellar
neurodegeneration that was preceded by decreased activities of the
ETC and depletion of ATP levels [60]. Interestingly, low levels of TAU
in the cerebellar granule cell layer significantly increased cerebellar ap-
optosis and led to an aggravation of motor deficits even though only a
very small number of cerebellar granule neurons were positive for
TAU phospho-epitopes. This implies that in particularly vulnerable neu-
ronal populations such as the Hq cerebellar granule cells, even low
levels of non-hyperphosphorylated TAUmay be sufficient to induce ap-
optosis and cause functional neurological impairment [60]. Analysis of
the activities of complexes I–V revealed a complex picture: In the
TAU/Hq mice an additive effect of the two mutations was observed,
i.e. both a reduced complex I protein content caused by the Hq mouse
mutation and a functional reduction of the remaining complex I activity
caused by additional TAU expression. For complex III, for example, early
decreases in activity were observed in 1-month-old TAU transgenic and
TAU/Hq mice. However, while TAU single mutant mice were able to
compensate for this deficiency, complex III activity remained reduced
in the TAU/Hq double mutant mice at 7 months. Together this study
demonstrates a mutual reinforcement of the TAU pathology and mito-
chondrial dysfunction in vivo, proposing TAU/Hq double mutant mice
as a valuable model to study TAU-related neurodegenerative changes
in a setting of impaired mitochondrial function.
3. TAU specifically impairs complex I and Aβ complex IV
3.1. Proteomic and functional studies in P301L TAU transgenic mice
An unbiased approach to address TAU-mediated impairment in
model systems is by functional genomics that generally generates long
lists of deregulated transcripts and proteins, which can then be grouped
by category analysis [61]. P301L TAU expressing pR5 mice reveal a sig-
nificant aggregation of TAU at an early age, with NFTs developing
around the age of 6 months, and hence they represent a model suited
for the proteomic investigation of TAU-related changes in AD [62,63].
A mass spectrometric analysis of fractionated brain proteins derived
from these mice revealed mainly a deregulation of mitochondrial respi-
ratory chain complex components (including complex V), antioxidant
enzymes, and synaptic proteins [64]. The reduction in mitochondrial
complex V levels in the pR5 mice that was revealed using proteomics
was also confirmed as decreased in brains from human carriers of the
P301L FTDP-17 mutation. The functional analysis demonstrated age-
related mitochondrial dysfunction, together with reduced NADH ubi-
quinone oxidoreductase (complex I) activity as well as age-related im-
paired mitochondrial respiration and ATP synthesis in the pR5 mouse
model. Mitochondrial dysfunction was further associated with higher
ROS levels in aged transgenic mice, concomitant with the upregulation
of antioxidant enzymes in response to oxidative stress (Fig. 1). In-
creased TAU pathology resulted also in lipid peroxidation [64]. Because
prior studies had shown that Aβmainly impairs complex IV [65,66], the
finding that TAUmainly impairs complex I of the ETC demonstrated for
the first time that TAU pathology also leads to metabolic impairment
and oxidative stress, by mechanisms that are distinct from those
exerted by Aβ. How TAU affects complex activities is not understood
and TAUmaywell do so indirectly. For Aβ, interactionwith and binding
to mitochondrial proteins (such as Aβ-binding alcohol dehydrogenase,
ABAD; or the voltage-dependent anion channel 1 protein, VDAC) has
been postulated [67,68]. Intracellular localization of Aβ has been
questioned by a recent study, however, which highlights the use of
antibodies in these studies that bind not only to Aβ but also to its
precursor protein, APP [69]. Because VDAC was found to interact with
phosphorylated TAU it has been proposed that phosphorylated TAU
may block mitochondrial pores and that one of TAU's functions is to
maintain normal mitochondrial pore opening and closure [68].
3.2. P301L TAU transgenic mice crossed with Aβ-forming mice
While the focus of this review article is on TAU and not on Aβ, it is
still worthwhile looking into models that combine both pathologies.
When the triple transgenic tripleAD mouse model (pR5/APPsw/PS2
N141I) was subjected to quantitative proteomics, this revealed that
one-third of the proteins had functions in mitochondria, specifically
complexes I and IV. Therefore, mitochondrial functions were assessed
[70]. Again, deregulation of the activity of complex I was found to be
TAU-dependent, and deregulation of complex IV Aβ-dependent, when
analyzing 10-month-old tripleAD mice. The convergent effects of Aβ
and TAU led to a depolarization of themitochondrial membrane poten-
tial in tripleAD mice already at the age of 8 months. Additionally, we
found that age-related oxidative stress played a significant part in the
deleterious vicious cycle by exaggerating Aβ- and TAU-induced distur-
bances in the respiratory system and ATP synthesis, finally leading to
synaptic failure. Furthermore, synergistic effects of TAU andAβ onmito-
chondrial impairment were revealed.
These data complement those obtained in another triple transgenic
mouse model, 3xTg-AD (P301Ltau/APPSw/PS1 M146L) [71]. Mitochon-
drial dysfunctionwas evidenced by an age-related decrease in the activ-
ity of regulatory enzymes of the oxidative phosphorylation system such
as COX, or of the TCA cycle such as pyruvate dehydrogenase, analyzing
3xTg-AD mice between 3 and 12 months of age [72]. In addition,
these mice also exhibited increased oxidative stress and lipid pero-
xidation. Most of the effects on mitochondria were seen at the age of
9 months, whereas mitochondrial respiration was significantly de-
creased at 12 months of age. Importantly, mitochondrial bioenergetic
deficits were found to precede the development of AD pathology in
these mice. In a follow-up study, the 3xTg-AD mice were analyzed by
2D-DIGE, a quantitative proteomic profiling method [73]. Proteins that
were dysregulated in 3xTg-AD cortices functioned in a wide variety
of metabolic pathways, including the TCA cycle, oxidative phospho-
rylation, pyruvate metabolism, glycolysis, oxidative stress, fatty acid
oxidation, ketone body metabolism, ion transport, apoptosis, and mito-
chondrial protein synthesis. These alterations in themitochondrial pro-
teome of the cerebral cortices of 3xTg-ADmice occurredwell before the
development of significant Aβ plaques and NFTs, supporting the notion
that mitochondrial dysregulation is an early event in AD pathogenesis.
4. TAU impairs mitochondrial transport
Mitochondria can move in both anterograde and retrograde direc-
tions in one axon [74]. Early studies in wild-type TAU overexpressing
mice using pulse-chase experiments had already revealed that TAUme-
diates impaired anterograde transport [75]. In K369I mutant TAU trans-
genic K3 mice, it was then demonstrated that elevated TAU impairs
transport of distinct cargoes including mitochondria, both in the
nigrostriatal pathway and in the sciatic nerve [28]. More specifically,
by ligating the sciatic nerve proteins whose transport was impaired
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could be discriminated from those, whosewas not, indicating selectively
impaired axonal transport. It was found that complex V accumulated
proximally and distally of the ligation in wild-type nerves, representing
bidirectional transport of mitochondria. In ligated transgenic nerves,
however, complex V accumulated only in the distal part, suggesting im-
paired anterograde and unaffected retrograde transports of mitochon-
dria in K3 mice (Fig. 1). As an underlying pathomechanism, trapping of
the kinesin adaptor molecule JIP1 by phosphorylated forms of TAU in
the soma was identified. This trapping prevented JIP1 from loading dis-
tinct cargoes (including mitochondria) onto the kinesin machinery for
transport down the axon. Relocalization of JIP1 from the axon to the
soma was also found in the AD brain underscoring the validity of the
finding in the transgenic model [76]. Another pathomechanism was
identified in the squid axon, where filamentous, but not soluble, forms
ofwild-type TAUwere found to inhibit anterograde transport by activat-
ing axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3
(GSK3), independent of microtubule binding [77]. In a related study, in-
creased expression of GSK3β and the p25 activator of cyclin dependent
kinase 5 (cdk5) in neurons was shown to cause an increased pausing
ofmitochondria rather than changes to their velocities [78]. Competition
for binding to kinesin has been suggested by co-immunoprecipitation
experiments: The data indicate that TAU being a cargo of kinesin itself
may displace other kinesin-based cargo, including cytoskeletal proteins
and organelles such as mitochondria [79]. Also in C. elegans, perturbed
axonal transport of mitochondria was reported when so-called pro-
aggregant tau was expressed which causes TAU aggregation [80].
While TAU is often treated as if it were one protein, it is in fact sev-
eral proteins. Differential effects of three-repeat (3R) and four-repeat
(4R) TAU on mitochondrial axonal transport have been reported [81].
As 3R TAU is believed to be less tightly associated with microtubules
than 4R TAU [82,83], it was postulated that 4R TAUmay lead to greater
alterations of organelle transport than 3R TAU. Indeed, while both 3R
and 4R TAU changed the normal mitochondrial distribution within the
cell body and reduced mitochondrial localization to axons, the effects
of 4R TAU were more pronounced. Furthermore, 3R and 4R TAU caused
different alterations in retrograde and anterograde transport dynamics;
however, 3R TAU had a slightly stronger effect on axon transport dy-
namics. TAU over-expression in general increased the net movement
of axonal mitochondria towards the neuronal cell body [81]. Multiple
studies have shown that Aβ, the second key player in AD, impairs mito-
chondrial transport [84], while a recent study using oligomeric Aβ did
not find changes to mitochondrial motility [85]. However, reducing
TAU levels prevents Aβ toxicity as discussed below, andmore specifically
the defects in axonal transport induced by Aβ in APP mutant mice [86].
More recently, RNAi-mediated knockdown ofMilton orMiro, which
encodes adaptor proteins essential for axonal transport of mitochon-
dria, in human TAU transgenic flies was found to enhance the TAU-
induced neurodegeneration [87] (Fig. 1). Phosphorylation of TAU at
the 12E8 phospho-epitope Ser262 was increased when Milton or Miro
was reduced. Partitioning defective-1 (PAR-1), the Drosophila homolog
of mammalian microtubule affinity-regulating kinase (MARK) mediat-
ed this increase. Mutagenesis studies suggested that increased phos-
phorylation of the 12E8 epitope through PAR-1 contributes to TAU-
mediated neurodegeneration in a pathological context when axonal
mitochondria are depleted. Mitochondrial movement in the neuritic
processes of PC12 cells was inhibited when another phospho-epitope
of TAU, AT8 (comprised of three sites, Ser199, Ser202, and Thr205)
was changed to phosphomimetic aspartates [88]. These mutations also
caused an expansion of the space between microtubules in cultured
cells when membrane tension was reduced by disrupting actin fila-
ments. Thus, the authors concluded that TAU phosphorylation at the
AT8 sites may affect mitochondrial movement by controlling microtu-
bule spacing [88]. In human embryonic stem cell-derived neural stem
cells the consequences of an overexpression of the longest human tau
isoform, 2N4R tau versus pseudohyperphosphorylated tau (p-tau) was
studied. Interestingly, p-tau, but not 2N4R tau, readily leads to TAU
aggregation and impaired mitochondrial transport in human neurons.
Although these alterations did not induce cell death, p-tau-expressing
neurons cultured under non-redox-protected conditions underwent a
pronounced degeneration with the formation of axonal varicosities se-
questering transported proteins and progressive neuronal cell death
[89]. That tau can impair axonal transport of mitochondria in the ab-
sence of hyperphosphorylation has been shown in P301L tau knock-in
mice that did not develop a TAU pathology. In fact, the overall phos-
phorylation of tau in these mice was reduced (e.g., at epitopes PHF-1
or AT270), perhaps due to a reduced microtubule binding [90]. The im-
pact of impaired transport on TAU pathology has also been studied. In
mice lacking the kinesin light chain 1 (KLC1) subunit of the anterograde
motor kinesin-1, this caused an axonopathy, with dystrophic axons
exhibiting abnormal tau hyperphosphorylation and accumulation [91].
Together these studies illustrate that phosphorylated forms of TAU
alter mitochondrial transport.
5. TAU impairs mitochondrial dynamics
Mitochondria differ remarkably from each other in size depending
on cell-type and subcellular compartment [92,93]. Because axons and
dendrites have differential energy demands, themitochondrial network
is generally more elongated in the cell body and dendrites of a neuron,
and more fragmented in the axon [94,95] (Fig. 1). Moreover, a distinc-
tion is made between nonsynaptic and synaptic mitochondria [96–98].
To meet the specific subcellular demands, the mitochondrial network
is shaped by a set of proteins that regulates fusion and fission [99]. In
mammalian cells three large GTPases govern fusion: Mitofusins 1 and
2 (MFN1 and MFN2) dimerize on the outer membranes of adjacent mi-
tochondria to induce outer membrane fusion. This is followed by fusion
of the inner membranes, a process mediated by OPA1 (optic atrophy 1)
that resides in the intermembrane space [100,101]. Fission is under
control of yet another GTPase, DRP1 (dynamin-related protein 1, also
known as DLP1 andDNM1) [102]. A set of additional proteins, including
FIS1, mitochondrial fission factor (MFF), and mitochondrial dynamics
proteins of 49 and 51 kDa (MiD49 andMiD51), have a role in recruiting
and assembling DRP1 at the outer membrane [103]. Fission and fusion
need to be balanced. For example, knockdown of Drp1 leads to mito-
chondrial elongation, respiratory dysfunction and, ultimately, apoptosis
[104], whereas elevatedmitochondrial fusion is also a stress response in
certain situations, enhancing ATP production and resistance to apopto-
sis [105], as reviewed recently [99].
Not surprisingly, an impaired balance of fission and fusion has been
reported in AD, both at the transcript and protein levels [106,107]. Re-
duced levels of DRP1 and increased mitochondrial length were found
in one study [108], whereas another revealed reduced cytoplasmic
levels but (although not statistically significant) increasedmitochondri-
al levels of DRP1, indicative of increased fission [106,109]. This and
other recent studies suggest some degree of variability in the regulation
of mitochondrial dynamics. For a conclusive picture it will be crucial to
analyze the subcellular localization and post-translationalmodifications
of DRP1, rather than global changes.
Mitochondrial dynamics has also been studied in mouse models of
AD. Here, a significant body of data is available for the role of Aβ,
which overall suggests that its net effect is towards increased fragmen-
tation [106,108,110,111]. However, as discussed above, in addition to
Aβ, TAU also forms aggregates in the AD brain and it would not be sur-
prising if the observed differences in the impairment of complex activ-
ities would also extend to differences in the rates of fission and fusion.
While hyperphosphorylation of TAU is believed to be a precipitating
event in disease, recent data suggest that carboxy-terminal cleavage of
TAU, which impairs mitochondrial function may also be critical
[112,113]. Full-length TAU induced an increase in mitochondrial size,
whereas truncated TAU induced mitochondrial fragmentation [114]. In
neuroblastoma cells, P301L TAU impaired mitochondrial motility, to-
gether with a down-regulation of both fission and fusion [115]. When
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combined with Aβ, truncated TAU impaired mitochondrial transport,
enhanced oxidative stress, and caused a depletion of the mitochondrial
membrane potential in cortical neurons. These effects were eithermod-
est or absentwhen Aβwas combinedwith full-length TAU, suggesting a
specific synergistic cooperation of cleaved TAU with Aβ in disrupting
mitochondria [112,113]. An altered distribution of mitochondria, with-
out a change in size, was found in transgenic mice with high levels of
P301L mutant TAU expression [116]. In these mice, mitochondrial dis-
tribution was progressively disrupted with age, particularly in somata
and neurites that contained TAU aggregates. Apparently, the effects of
TAU on mitochondria, both independently and in cooperation with
Aβ, varywidely between TAU species, although the reasons for these di-
vergent effects remain to be determined.
New light on TAU's role in mitochondrial dynamics was shed by a
complementary study in TAU transgenic worms and flies. It has previ-
ously been found that TAU induces the stabilization and bundling of fil-
amentous (F)-actin [117]. Because localization of the fission protein
DRP1 to mitochondria is an actin-dependent process, whereby DRP1
and mitochondria (via myosin II) must interact with filamentous (F)-
actin prior to their colocalization, increased F-actin in humanTAU trans-
genic mice and flies disrupts the physical association of mitochondria
and DRP1, leading to mitochondrial elongation [118,119] (Fig. 1). This
causes neurotoxicity that can be rescued by reducing mitochondrial fu-
sion, enhancing fission, or reversing actin stabilization. The study fur-
ther found that elongation is not a secondary effect of impaired axonal
transport [118]. Despite those new highlights on the role of TAU in the
impairment of mitochondrial dynamics, there is no clear evidence of
its role in mitochondrial turnover. In fact, as mentioned above, fusion/
fission activity plays an important role in mitochondrial quality control.
It allows the exchange of materials such as lipids, proteins, metabolites
and mtDNA throughout the mitochondrial network, avoiding energetic
deficiencies. However, when mitochondria are extensively damaged,
they exit the fusion/fission cycle and are selectively eliminated by
mitophagy (Fig. 1). This process occurs when mitochondria are in a
fragmented state andwhen themitochondrial membrane is depolarized
after stress [120]. Mitochondria are degraded by engulfment into
autophagosomes, which fuse with lysosomes and break down the or-
ganelles. In the case where the process of mitophagy is disturbed, a
decreased cellular respiration has been observed, parallel to an accumu-
lation of oxidized proteins [33]. Nothing seems to be known about the
effect of TAU on mitochondrial turn-over but since new evidence
shows that TAU may lead to mitochondrial elongation (fused state),
we can speculate that it might decrease the elimination of damagedmi-
tochondria via the process of mitophagy (which requires mitochondrial
fragmentation). However, because AD is characterized by both TAU and
Aβ pathology, future studies into mitochondrial dynamics/mitophagy
need to take both molecules into consideration. More specifically, it
will be necessary to firstly analyze synaptosomal as well as total mito-
chondria, and secondly, human tissue that represents the full spectrum
of TAU and/or Aβ pathology, to dissect effects of Aβ onmitochondria dy-
namics from those of TAU.
6. TAU mediates excitotoxicity
TAU affectsmitochondrial dysfunction also because of its crucial role
inmediating excitotoxicity, a pathomechanism that has been implicated
in AD [121]. Under basal conditions, mild activation of theNMDA recep-
tor (NMDAR) results in physiological ROS production, while under neu-
rodegenerative conditions triggered by Aβ, over-activation of NMDARs
causes excessive calcium influx, nitric oxide (NO) activation, mitochon-
drial depolarization and superoxide formation that result in neuronal
damage and death [122–124]. Aβ is believed to exert excitotoxicity ei-
ther directly or indirectly, by over-activating the NMDAR [125]. NO ex-
erts themajority of its effects by reacting with a cysteine thiol on target
proteins, a process termed S-nitrosylation. This modifies enzymes with
a role in glycolysis, gluconeogenesis and oxidative phosphorylation,
indicating that this type of posttranslational modification may regulate
metabolism and mitochondrial bioenergetics [126]. In a recent study,
inhibition of Drp1 was found to prevent excitotoxic cell death in a hip-
pocampal cell culture system [127]. Calcium influx also stimulates ki-
nases, causing TAU to detach from microtubules and relocalize to the
somatodendritic domain, where it aberrantly interacts with proteins in-
cluding JIP1, thereby impairing mitochondrial transport [28].
Is there a more direct role for TAU in excitotoxicity? In a patho-
cascade, Aβ has been placed upstream of TAU [128]. This concept has
been proven in P301L mutant TAU transgenic mice that develop an in-
creased number of NFTs, either by crossing them with Aβ plaque-
forming transgenic mice [129], or by intracerebral injections of Aβ
[130]. While Aβ causes TAU aggregation, its toxicity is also dependent
on TAU as has been first shown in vitro [131] and subsequently
in vivo [132]. Removing TAU largely abrogates the pathological features
that characterize Aβ plaque-formingmice, namely prematuremortality,
high susceptibility to experimentally induced excitotoxic seizures and
memory deficits [132]. Mechanistically, this protection appeared to be
conferred by a reduced susceptibility to excitotoxicity either when
TAU was absent or when its levels were reduced [132,133]. Even
under physiological conditions, TAUwas found to be present in the den-
drite (although at low quantities compared with the axon), where it is
critically involved in postsynaptic NMDAR downstream signalling by lo-
calizing the SRC kinase FYN to the dendrite. FYN phosphorylates the
NMDAR that then recruits the postsynaptic scaffolding protein PSD-95
to form a complex [133]. The TAU axis hypothesis claims that as TAU ac-
cumulates in a phosphorylated form in the dendrite, it mediates the
toxic effects of Aβ by causing increased concentrations of FYN which is
then available to phosphorylate the excitotoxic NMDAR signalling com-
plex [134]. Aβ, Fyn and TAU therefore seem to orchestrate neuronal
damage [133,135,136]. It has been shown that synaptic NMDAR signal-
ling and extrasynaptic NMDAR signalling have opposite effects on cell
survival and that differentially located NMDARs are coupled to different
intracellular cascades. A recent study found that Aβ induces dendritic
spine loss via a pathway involving synaptic NR2A-containing NMDARs
whereas activation of extrasynaptic NR2B-containing NMDARs is re-
quired for neurodegeneration that is TAU-dependent [137]. Together
this suggests thatmanipulating components of theNMDAR or the inter-
action of TAU and FYN may be therapeutically beneficial. In fact,
disrupting the complex between NMDAR and PSD-95 pharmacological-
ly was found to protect Aβ plaque-formingmice from premature death,
memory impairment and the susceptibility to excitotoxic seizures [133].
In conclusion, TAU affects mitochondrial dysfunction also because of its
crucial role in mediating excitotoxicity, a pathomechanism that has
been implicated in AD.
7. Integration—mitochondria are key targets of Aβ and TAU toxicity
in AD
Mitochondria are key targets of Aβ and TAU toxicity in AD (Fig. 1). A
picture is emerging whereby these two molecules damage mitochon-
dria in multiple ways, by marching separately and striking together.
While the causes of sporadic AD are not known it is evident that Aβ
and TAU levels are elevated at an early stage. An impaired homeostasis
because of increased Aβ production and decreased clearance causes in-
creased levels, which acts on mitochondria by impairing complex IV
function, and by facilitating the fragmentation of mitochondria. Both in-
sults cause increases in ROS levels, decreased activities of detoxifying
enzymes such as superoxide dismutase (SOD), and an impaired mito-
chondrial membrane potential that results in reduced ATP levels. Ele-
vated Aβ levels also result in the overexcitation of neurons, which
leads to an influx of calcium ions, with the consequence of increased
COX levels, which then damages mitochondria. When Aβ levels are
increased this also activates distinct TAU kinases and/or inactivates
TAU phosphatases resulting in a massive hyperphosphorylation of
TAU. Hyperphosphorylated TAU specifically impairs complex I of the
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mitochondrial respiratory chain, again leading to increased ROS levels,
lipid peroxidation, decreased activities of detoxifying enzymes such as
superoxide dismutase (SOD), and an impaired mitochondrial mem-
brane potential. It also impairs anterograde transport of mitochondria
and other cargoes by trapping the kinesin adaptor molecule JIP1 in the
neuronal cell body, preventing it from executing its normal function.
In AD, hyperphosphorylated TAU not only accumulates in the axon,
but also relocalizes and accumulates in the cell body and dendrites of af-
fected neurons. In the dendritic compartment, it facilitates the toxic ef-
fects of Aβ that are mediated by the NMDAR. Elevated levels of TAU
have also functional consequences on mitochondrial dynamics. TAU
causes actin stress fibres to form. This blocks the proper execution of
DRP1-mediated fission with a net result of mitochondrial elongation.
This, similar to an augmented fragmentation caused by Aβ, causes in-
creased ROS levels, decreased activities of detoxifying enzymes and an
impaired mitochondrial membrane potential. In light of the apparently
opposing effects Aβ has on mitochondrial size it seems that either too
little or too much fission/fusion is detrimental for neurons. Obviously,
with TAU impairing axonal transport of mitochondria, the calcium buff-
ering requirements at the synapse are undermined. Together, TAU and
Aβ establish a vicious cycle of misregulated dynamics and transport of
the mitochondria, which together with alterations in mitochondrial
components such as complex proteins or mtDNA, causes mitochondrial
impairment in AD.
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Abstract: 
 
Alzheimers disease (AD) is characterized by the presence of amyloid plaques (aggregates 
of amyloid-! [A!]) and neurofibrillary tangles (aggregates of tau) in the brain, but the 
underlying mechanisms of the disease are still partially unclear. A growing body of evidence 
supports mitochondrial dysfunction as a prominent and early, chronic oxidative stress-
associated event that contributes to synaptic abnormalities, and, ultimately, selective 
neuronal degeneration in AD. Using a high-resolution respirometry system, we shed new 
light on the close interrelationship of this organelle with A! and tau in the pathogenic process 
underlying AD by showing a synergistic effect of these two hallmark proteins on the oxidative 
phosphorylation capacity of mitochondria isolated from the brain of transgenic AD mice. 
In the present chapter, we first introduce the principle of the A! and tau interaction on 
mitochondrial respiration, and secondly, we describe in detail the used respiratory protocol.  
 
Key words: mitochondria, Alzheimers disease, amyloid-!, tau, Oxygraph, oxidative 
phosphorylation. 
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1. Introduction 
 
With the increasing average life span of humans, Alzheimers disease (AD) is the most 
common neurodegenerative disorder among elderly individuals. It accounts for up to 80% of 
all dementia cases and ranks as the fourth leading cause of death amongst those above 65 
years of age (1). Although the hallmark lesions of the disease were already described by 
Alois Alzheimer in 1906 - amyloid-! (A!) containing plaques and microtubule-associated 
protein tau-containing neurofibrillary tangles (NFTs) , the underlying molecular mechanisms 
that cause the formation of these end-stage lesions are still poorly understood. However, a 
growing body of evidence supports mitochondrial dysfunction as a prominent and early 
chronic oxidative stress-associated event that contributes to synaptic abnormalities and, 
ultimately, selective neuronal degeneration in AD (2; 3). Within the last few years, several 
cell culture models as well as single, double, and more recently, triple transgenic mouse 
models have been developed to reproduce diverse aspects of AD. These models help in 
understanding the pathogenic mechanisms that lead to mitochondrial failure in AD, and in 
particular the interplay of AD-related cellular modifications within this process (4). 
In this chapter, we will highlight the critical key role of mitochondria and the close inter-
relationship of this organelle with the two main pathological features in the pathogenic 
process underlying AD. Particularly, we will emphasise on the recent insights showing 
independent as well as synergistic effects of A! peptide and hyperphosphorylated tau on 
mitochondrial function by using a high-resolution respirometry system (Oxygraph-2k). 
 
1.1 A! and tau induce mitochondrial toxicity 
 
Mitochondria play a pivotal role in cell survival and death by regulating both energy 
metabolism and apoptotic pathways. They are the powerhouses of cells providing energy 
via ATP generation which is accomplished through oxidative phosphorylation (OXPHOS) 
from nutritional sources (5) [Fig 1]. Neurons have particularly high numbers of mitochondria 
which are especially enriched in synapses. Due to the limited glycolytic capacity of neurons, 
those cells are highly dependent on mitochondrial function for energy production (6). Thus, 
deregulation of mitochondrial function leads to synaptic stress, disruption of synaptic 
transmission, apoptosis and ultimately, neurodegeneration (7; 8).  
Evidences from cellular and animal AD models indicate that A! triggers mitochondrial 
dysfunction through a number of pathways such as impairment of OXPHOS, elevation of 
ROS production, interaction with mitochondrial proteins, and alteration of mitochondrial 
dynamics (9; 10). Success in developing mouse models that mimic diverse facets of the 
disease process has greatly facilitated the understanding of pathophysiological mechanisms 
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underlying AD. In 1995, Games and collaborators established the first amyloid precursor 
protein (APP) mouse model (called PDAPP) bearing the human Indiana mutation of the 
APP gene (V171F). They observed the accumulation of A! in the brain and subsequent 
amyloid plaque formation, as well as astrocytosis and neuritic dystrophy (4). Interestingly, in 
most of the APP mouse models, the cognitive impairment begins concomitantly with A! 
oligomer formation in the brain (around 6 months of age), while neuritic amyloid deposits 
become visible only between 12 and 23 months and the amount of deposits increases in 
parallel (11). Thus, memory deficits seem to correlate directly with the accumulation of 
intracellular A! oligomers and not with amyloid plaque formation. When those mice were 
crossed with those bearing a mutation in presenilin 1 gene (PS1), coding for a gene involved 
in APP processing, an earlier onset of amyloid plaques was observed, alongside a stronger 
decrease of mitochondrial membrane potential as well as ATP level (12).  
Mitochondrial dysfunctions occur at a very early disease stage in AD transgenic 
mouse models. For example, in the APPsw transgenic strain Tg2576 (Swedish mutation), an 
upregulation of genes related to mitochondrial energy metabolism and apoptosis was 
observed already at 2 months of age. Alterations in composition of the mitochondrial 
respiratory chain complexes I and III protein subunit as well as impairment of mitochondrial 
respiration were detected around 6 months, when soluble A! accumulated in the brain 
without plaque formation (13; 14).  
Consistent with this observation, in APPsw / presenilin 2 (PS2) double-transgenic 
mice, mitochondrial impairment was first detected at 8 months of age, before amyloid plaque 
deposition, but after soluble A! accumulation (15). Taken together, these findings are 
consistent with the recently proposed hypothesis of an age-related A! toxicity cascade that 
suggests that the most toxic A! species that cause majority of molecular and biochemical 
abnormalities are in fact intracellular soluble oligomeric aggregates rather than the 
extracellular, insoluble plaques (16).  
How does tau, the second hallmark lesion in AD, interfere with mitochondrial 
function? In its abnormally hyperphosphorylated form, which forms the NFTs, tau has been 
shown to block mitochondrial transport. This results in energy deprivation and oxidative 
stress at the synapse, and, consequently, neurodegeneration (17; 18). Untill now, no 
mutations in microtubule-associated protein tau (MAPT) coding genes have been detected in 
relation to familial forms of AD. However, in familial frontotemporal dementia (FTD) with 
parkinsonism, mutations in the microtubule-associated protein tau gene (MAPT) were 
identified on chromosome 17. This was the basis for creating a robust mouse model for tau 
pathology in 2001. These P301L tauexpressing pR5 mice show an accumulation of tau as 
soon as 3 months of age and develop NFTs around 6 months of age (19). A mass 
spectrometric analysis of the brain proteins from these mice (aged from 8.5-10 months) 
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revealed mainly a deregulation of mitochondrial respiratory chain complex components 
(including complex V), antioxidant enzymes, and synaptic protein space (20). The reduction 
in mitochondrial complex V levels in the P301L tau mice was also confirmed in human P301L 
FTDP-17 (FTD with parkinsonism linked to chromosome 17) brains. The functional analysis 
demonstrated age-related mitochondrial dysfunction, together with reduced NADH 
ubiquinone oxidoreductase (complex I) activity as well as age-related impaired mitochondrial 
respiration and ATP synthesis in a pR5 mouse model. Mitochondrial dysfunction was also 
associated with higher levels of ROS in aged transgenic mice. Increased tau pathology 
resulted in modification of lipid peroxidation levels and the upregulation of antioxidant 
enzymes in response to oxidative stress (20). Thus, this evidence demonstrated for the first 
time that not only A! but also tau pathology weakens gradually mitochondrial function in a 
rather specific way leading to metabolic impairment and oxidative stress in AD. 
 
1.2 Synergistic mode of action of A! and Tau 
 
Although A! and tau pathologies are both known hallmarks of AD, the mechanisms 
underlying the interplay between plaques and NFTs (or A! and tau, respectively) have 
remained unclear. However, a close relationship between mitochondrial impairment and A! 
on the one hand and tau on the other hand has been already established. How do both AD 
features relate to each other? Several studies suggest that A! aggregates and 
hyperphosphorylated tau may block the mitochondrial transport to the synapse leading to 
energy deficiency and neurodegeneration (21).  
Remarkably, intracerebral A! injections amplify a pre-existing tau pathology in several 
transgenic mouse models (22; 23), whereas lack of tau abrogates A! toxicity (24; 18). Our 
findings indicate that in tau transgenic pR5 mice, mitochondria display an enhanced 
vulnerability toward A! insult in vitro (25; 2), suggesting a synergistic action of tau and A! 
pathology on this organelle. Thus, these studies provide the first evidence for the existence 
of a complex interplay between A! and Tau in AD whereby these two molecules damage 
mitochondria in multiple ways, but what about their specific effects on mitochondrial 
respiration? 
 
1.3 Using high-resolution respirometry system in isolated mitochondria to 
evaluate OXPHOS capacity. 
 
To address this question, we used a high-resolution respiratory system to evaluate the 
capacity of the entire oxidative phosphorylation system (OXPHOS) of cerebral mitochondria 
from mice bearing either an APP/PS2 mutation, P301L mutation (pR5 mice), or the triple 
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mutation APP/PS2/P301L (tripleAD mice) compared to wild-type mice (26). Measurement of 
oxygen (O2) flux and consumption was performed at 37 °C using an Oroboros Oxygraph-2k 
system on freshly isolated mitochondria from cortical brains of age-matched wild-type, 
APP/PS2, pR5 and tripleAD mice as follows. After detection of endogenous respiration, 
glutamate and malate were added to induce state 4 respiration [Fig 1 and 2A], then ADP was 
added to stimulate state 3 respiration. After determining coupled respiration, FCCP was 
added and the maximal respiratory capacity measured in the absence of a proton gradient. 
Cytochrome c (cyt c) injection was used to demonstrate mitochondrial membrane integrity. 
To inhibit activities of complexes IIII, rotenone (rot) and antimycine A (AA) were added. 
Complex IV activity was stimulated by ascorbate/TMPD (A/T) before terminating 
mitochondrial respiration by adding sodium azide (azide).O2 consumption was normalised to 
the corresponding citrate synthase activity.  
We determined flux control ratios to obtain information on metabolic states of respiration. 
The respiratory control ratio (RCR3/4) is an indicator of the state of coupling of mitochondria. 
State 3 is the rate of phosphorylating respiration in the presence of exogenous ADP, and 
state 4 is associated with proton leakage across the inner mitochondrial membrane in the 
absence of ADP. Our findings suggest a pronounced decrease of RCR3/4 in mitochondria 
from APP/PS2 and tripleAD compared with age-matched wild-type mice already at 8 months of 
age. This decrease was also found in the oldest mice (12 months of age). When we 
examined the ETS/ROX (electron transport system/residual oxygen consumption) ratio, 
which yields an index of the maximum oxygen consumption capacity relative to the 
magnitude of residual oxygen consumption, we found that it was also decreased in APP/PS2 
and tripleAD compared with age-matched wild-type mice at 8 and 12 months of age. 
Interestingly, in a previous study, the decreased respiration of mitochondria from pR5 mice 
compared with wild-type controls was not visible before the age of 24 months (20). In 
contrast, APP/PS2 mitochondria showed a decrease in OXPHOS compared with wild-type 
already at the age of 8 months. At this age, OXPHOS of brain mitochondria from tripleAD mice 
did not differ compared with that of age-matched APP/PS2 mitochondria , but it was 
significantly decreased in tripleAD mice at the age of 12 months [Fig 2B]. Taken together, with 
increasing age, the global failure of the mitochondrial respiratory capacity deteriorated the 
strongest in mitochondria from tripleAD mice, suggesting a synergistic destructive effect of tau 
and A! on mitochondria.   
In conclusion, our studies highlight the key role of mitochondria in AD pathogenesis and 
the close interrelationship of this organelle and the two main pathological features of the 
disease. We showed that disturbances in the respiratory and energy system of tripleAD mice 
seem to be due to a convergence of A! and tau on mitochondria, accelerating defects in 
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respiratory capacity, which consolidates the idea that a synergistic effect of tau and A! 
increase the pathological deterioration of mitochondria. 
 
 Now we will describe in detail the protocol which we followed previously (26). After 
listing the material needed, we will describe the isolation of mitochondria from mouse brains 
and the steps required to measure the mitochondrial respiration. It is important to note that 
this protocol assumes that the Oroboros Oxygraph-2k system is routinely used in the 
laboratory and does not include technical details about oxygraph maintenance or calibration, 
but only experimental procedure regarding the assessment of mitochondrial respiration. 
 
2. Materials 
 
Prepare all solutions using ultrapure water (prepared by purifying deionized water to attain a 
sensitivity of 18 M" cm at 25°C). 
 
2.1 Solutions for the Isolated Mitochondria Preparation 
 
1. Medium 1: NaCl 138 mM, KCl 5.4 mM, Na2HPO4 0.17 mM, KH2PO4 0.22 mM, 
glucose·H2O 5.5 mM, saccharose 58.4 mM, pH 7.35. To prepare 1 litre of medium 
1, weigh 8 g NaCl, 0.4 g KCl, 0.024 g Na2HPO4, 0.03 g KH2PO4, 1.1 g 
glucose·H2O, 20 g saccharose. Add water to a volume of 900 ml (using a 
graduated cylinder) and mix with magnetic stir bar at room temperature until all 
powders are dissolved. Adjust pH and make up to 1 l with water. Store at 4 #C. 
 
2. Isolated Mitochondria Buffer : mannitol 210 mM, saccharose (70 mM), HEPES  10 
mM, EDTA (tritriplex III) 1 mM, BSA 0.45 %, pH 7.4. To prepare 200 ml buffer, 
weigh 7.65 g mannitol, 4.79 g saccharose, 477 mg HEPES, 74.4 mg EDTA 
(tritriplex III) and 0.9 g BSA. Add water to a volume of 190 ml (using a graduated 
cylinder) and mix with magnetic stir bar at room temperature until all powders are 
dissolved. Adjust pH and make up to 200 ml with water. Prepare aliquots of 10 ml 
and keep at -20#C (see Note 1).  
 
2.2 Solutions for the Mitochondrial Respiration 
 
1. Mitochondrial Respiration Buffer: saccharose 65mM, potassium dihydrogen 
phosphate  10mM, Tris HCl 10mM, MgSO4 . 7 H2O  10mM, EDTA (tritriplex III). 2 
H2O 2 mM, pH 7. To prepare 200 ml, weigh 4.45 g saccharose, 0.272 g 
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potassium dihydrogen phosphate, 0.315 g Tris HCl, 0.493 g MgSO4 . 7 H2O, 
0.149 g EDTA (tritriplex III). 2 H2O. Add water to a volume of about 190 ml (using 
a graduated cylinder) and mix with magnetic stir bar at room temperature until all 
powders are dissolved. Adjust pH and make up to 200 ml with water. Prepare 
aliquots of 20 ml and keep at -20#C. 
 
2. Mitochondrial Respiration Medium (MiR05): EGTA  0.5 mM, MgCl2.6H2O  3 mM, 
K-lactobionate 60 mM, taurine 20 mM, KH2P04 10 mM, HEPES 20 mM, 
saccharose 110 mM, BSA 1 g/l,  pH = 7.1. Start to prepare the K-lactobionate 
stock solution (0.5 M) by dissolving 35.83 g lactobionic acid in 100 ml H2O and 
adjust the pH to 7.0 with KOH and bring the volume to 200 ml. To prepare 1 litre 
of MiR05, weigh 0.190 g EGTA, 0.610 g MgCl2.6H2O, 2.502 g taurine, 1.361 g 
KH2P04, 4.77 g HEPES, 37.65 g saccharose, 1 g BSA. Add about 750 ml water 
and 120 ml K-lactobionate stock solution (0.5 M). Mix with magnetic stir bar at 
room temperature, adjust the pH to 7.1 with KOH (5 N), and make up to 1 litre 
with water. Divide into 20 ml aliquots and store frozen at -20°C (see Note 2). 
 
3. Substrates: The substrates employed and details of preparation are summarised 
in Table 1. (see Notes 3-13) 
 
2.3 Oxygraph 
 
Mitochondrial oxygen consumption was measured at 37 °C using an Oroboros 
Oxygraph-2k system following the Gnaiger method (27). 
 
3. Method 
 
3.1 Isolated mitochondria preparation 
 
Before experiment: perform an instrumental and chemical background with the oxygraph. 
Prepare isolated mitochondria buffer (see Note 1) and keep on ice. Turn on the centrifuge 
(4°C). 
 
1. Kill the mice by decapitation and dissect one brain hemisphere on ice. Wash in 10 ml 
of ice-cold medium 1. 
2. Put the preparation in the Potter-tube to homogenise in 1 ml isolated mitochondria 
buffer. Pipette 10 to 15 times to homogenise the preparation (see Note 14).  
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3. Wash the Potters plug 3 times with 150 ul isolated mitochondria buffer and put the 
preparation in a 2 ml tube. Wash the Potters tube 3 times with 150 ul isolated 
mitochondria buffer and put the preparation in the same 2 ml tube. Vortex (see Note 
15).  
4. Centrifuge 7 min, 1450 rcf, at 4°C and recover the supernatant in a new 2 ml tube. 
This step removes nuclei and tissue particles. 
5. Centrifuge 3 min, 1450 rcf, at 4°C and recover the supernatant again in a new 2 ml 
tube. 
6. Centrifuge 5 min, 10 000 rcf, at 4°C, throw away the supernatant and recover the 
pellet. 
7. Put the pellet (mitochondria) in 1ml isolated mitotochondria buffer and mix 15 times 
using the pipette. 
8. Repeat step 7 and 8 to obtain the mitochondrial fraction and put the pellet in 100 ul 
isolated mitotochondria buffer. Keep on ice until the measurement (see Note 16).  
 
3.2 Mitochondrial respiration measurement 
 
Before experiment prepare the substrates (Table 1) and the oxygraph (see Note 17)  
 
1. Add 50 ul isolated mitochondria preparation to each chamber and close the chamber 
(see Note 18). Mark it as (01-state 1). 
2. Add 10 ul glutamate / 5 ul malate (stock concentration = 2 M / 0.8 M respectively, 
assay concentration = 10 mM / 2 mM). Mark it as (02-GM2). 
3. Add 8 ul ADP / chamber (stock concentration = 0.5M, assay concentration = 2 mM). 
Mark it as (03-GM3). 
4. Add 2.5 ul FCCP / chamber (stock concentration = 0.32 mM, assay concentration = 
0.4 uM). Mark it as (04-GP3u). 
5. Add 5 ul Cytochrome c / chamber (stock concentration = 4 mM, assay concentration 
= 10 uM). Mark it as (05-GM3c). 
6. Add 5 ul rotenone / chamber (stock concentration = 0.2 mM, assay concentration = 
0.5 uM). Mark it as (06-rot). 
7. Add 5 ul antimycine A / chamber (stock concentration = 1 mM, assay concentration = 
2.5 uM). Mark it as (07-AA). 
8. Add 5 ul ascorbate / chamber (stock concentration = 0.8 M, assay concentration = 2 
mM) and 5 ul TMPD / chamber (stock concentration = 0.2 M, assay concentration = 
0.5 mM). Mark it as (08-AT). 
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9. Add 20 ul sodium azide / chamber (stock concentration = 1 M, assay concentration = 
10 mM). Mark it as (09-azide). 
 
4. Analysis 
 
After the measurement, extract the raw data from the oxygraph software (DatLab) to an 
Excel file. Normalise the data on citrate synthase activity, which correlates with mitochondrial 
content (see Note 19). Perform the statistical analysis using GraphPad Prim software and a 
two-way ANOVA followed by Bonferroni post hoc tests to compare the different groups. 
Consider statistically significant only P values < 0.05. Represent data as means ± SEM. 
 
5. Notes 
 
1. Just before starting the experiment, warm up the isolated mitochondria buffer. For 2 
brain hemispheres, add 1 tablet of CompleteR Mini (protease inhibitor cocktail tablet) 
and 5 ul dithiothréitol (DTT: Stock solution = 1M in water, Final concentration in the 
buffer = 0.5mM) to 10 ml buffer. Prepare maximum 3h before use. 
2. The MiR05 is stable for about 2-3 months. The K-lactobionate must be prepared 
fresh. 
3. Solution stored at low temperature: mix carefully after rewarming, since phase 
separation may occur and compounds may precipitate in cold solutions. During the 
course of the experiment keep stock solutions on ice. Solutions which contain ethanol 
may have a problem of evaporation and subsequent increase of concentration of 
stock solutions. 
4. Adjust pH to 7.0 with 37% HCl and divide into 0.5 ml aliquots.Store frozen at -20#C. 
5. Neutralize with 10N KOH and divide into 0.5 ml aliquots. Store frozen at -20#C. 
6. Neutralize (pH 7.0) with 5 N KOH and divide into 100 ul aliquots. Store at -80#C. 
7. Divide into 0.2 ml aliquots. Store frozen at -20#C. 
8. To prevent autooxidation, prepare a solution of ascorbic acid (137.6 mg/ml, pH ca 2). 
Adjust the pH to ca 6 of the solution containing the ascorbate sodium salt with 
ascorbic acid. Divide into 0.2 ml aliquots. Store frozen at -20#C. Light sensitive$ 
9. To prevent autooxidation, neutralize with the solution containing 0.8 M of ascorbic salt 
(dilution 1:80, final concentration ascorbate: 10mM). Divide into 0.2 ml aliquots. Store 
frozen at -20#C.  
10. Difficult to dissolve, divide into 0.2 ml aliquots, store at -20#C. Light sensitive$ Very 
toxic! 
11. Divide into 0.2 ml aliquots, store at -20#C. Very toxic$ 
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12. Divide into 0.2 ml aliquots, store frozen at -20#C. Very toxic$ 
13. Divide into 0.5 ml aliquots, store frozen at -20#C. 
14.  Pipette gently up and down to avoid bubble formation and strong oxygenation of the 
sample. 
15. If you have several mice, stop the process at this step, put the preparation on ice and 
use the next mouse to perform the centrifugation steps with all the samples at the 
same time. Since the Oxygraph contains 2 chambers, it is possible to investigate the 
mitochondrial respiration for only a few animals per day (6-8 mice / day). 
16. 50 ul of the preparation will be used for the Oxygraph measurement. For protein 
determination, dilute 3ul of isolated mitochondria in PBS (dilution 1:5) and perform the 
protein assay (here, we use the Biorad DCTM Protein Assay and the bovine serum 
albumin (BSA) for the standard curve). 
17. The experiment requires an instrumental and chemical background following the 
protocol of the company. Calibration will determined the air saturation (R1) and the 
zero saturation (R0). 
18. When the oxygraph chambers are closed, check that there are no air bubbles left 
inside. 
19. Citrate synthase is an enzyme of the tricarboxylic acid cycle. Its activity is frequently 
used to normalise other mitochondrial enzymatic activities and mitochondrial 
respiration because it correlates to mitochondrial content. To measure citrate 
synthase activity, follow the reduction of 5, 5-dithiobis (2-nitrobenzoic acid) (DTNB) 
by citrate synthase at 412 nm (extinction coefficient of 13.6 mM-1·cm-1) in a coupled 
reaction with coenzyme A (CoA) and oxaloacetate. Briefly, incubate a reaction 
mixture of 0.2 M Tris-HCl (pH 8.0), 0.1 mM acetyl-CoA, 0.1 mM DTNB, n-dodecyl-!-
D-maltoside (20%), and 10 ug of mitochondrial protein at 30 °C for 5 min. Initiate the 
reaction by the addition of 0.5 mM oxaloacetate and monitor the absorbance change 
for 5 min with a Shimadzu MultiSpec-1501 diode array spectrophotometer. Calculate 
the enzymatic activity of citrate synthase using the slope of absorption by minute. 
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Table 1: Preparation and function of the substrates used to investigate mitochondrial respiration using the Oroboros Oxygraph-2k system. 
  
Name / Formula MW (g/mol) Stock solution Function Note # 
Mitochondrial 
substrates 
glutamate L-glutanic acide C5H8NO4Na 187.1 2 M 3.742 g/10 ml H2O Induce state 4 respiration 4 
malate L-malic acid C4H6O5 134.1 0.8 M 1.073 g/10 ml H2O Induce state 4 respiration 5 
ADP 
adenosine 5'-diphosphate 
C10H15N5O10P2K 
491.2 0.5 M 0.491 g/2 ml H2O Induce state 3 respiration 6 
cytC cytochrome C 12500 4 mM 50 mg/1 ml H2O 
Demonstrate mitochondrial membrane 
integrity 
7 
ascorbate 
ascorbate sodium salt 
C6H7O6Na 
198.1 0.8 M 1.584 g/10 ml H2O Stimulates complex IV activity 8 
TMPD 
N,N,N',N'-tetramethyl-p-
phenylenediaminedichloride 
C10H16N2·HCl 
237.2 0.2 M 47.4 mg/1 ml H2O Stimulates complex IV activity 9 
Mitochondrial 
inhibitors 
rotenone C23H22O6 394.4 1 mM 3.94 mg/10 ml Ethanol Inhibits complex I activity 10 
AA antimycin A 540 5 mM 11 mg/4 ml Ethanol Inhibits complex III activity 11 
azide sodium azide NaN3 65.01 1 M 65 mg/1 ml H2O Inhibits oxygen consumption 12 
Mitochondrial 
uncouplers 
FCCP 
carbonyl cyanide p-
(trifluoromethoxy) 
phenylhydrazone C10H5F3N4O 
254.2 0.32 mM 
2.54 mg/10 ml Ethanol to 
have 1mM. Dilute 1: 3.125 
in Ethanol 
Determine uncoupled respiration in 
absence of a proton gradient. 
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Fig. 1: The mitochondrial electron transport chain: impact of A! peptide, tau protein, and effects of mitochondrial 
substrates used during the measurement protocol with Oxygraph. Complexes I (NADH: ubiquinone 
oxidoreductase) and II (succinate dehydrogenase, belongs to the tricarboxylic acid (TCA) cycle) receive electrons 
from NADH and FADH2, respectively. Electrons are then driven from complexes by the mobile carrier molecules 
coenzyme Q/ubiquinone (UQ) and cytochrome c (Cyt c) to the final acceptor, molecular oxygen (O2). Electron 
flow is coupled to proton movement across the inner mitochondrial membrane (IMM) in complexes I, III and IV. 
The resulting proton gradient is harvested by complex V to generate ATP. In Alzheimers disease, abnormal 
mitochondrial electron activities have been observed, predominantly in complexes I and IV, leading to impaired 
mitochondrial membrane potential, decreased production of ATP (complex V), and enhanced reactive oxygen 
species (ROS) levels. Interestingly, deregulation of complex I is mainly tau-dependent, while deregulation of 
complex IV is amyloid-! (A!)-dependent, at both the protein and activity level. The targets of the different 
substrates used during the Oxygraph measurement are marked with * on the figure and their specific actions are 
summarized in Table 1. AA, antimycin A; AT, ascorbate/ TMPD; IMS, intermembrane space. 
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Fig. 2: Synergistic effects of A! and Tau on mitochondrial respiration. (A) Representative diagrams of O2 flux and 
consumption in mitochondria from 12-month-old wild-type, APP/PS2, and 
triple
AD mice in response to titrated 
substrates and inhibitors of mitochondrial complexes. (B) Two-way ANOVA revealed a significant effect of the 
transgene on the respiratory rates of mitochondria between 12-month-old wild-type and APP/PS2 mice and this 
impaired respiration was even more pronounced in 
triple
AD mice. Two-way ANOVA post-hoc Bonferroni. *, P<0.05; 
**, P<0.01; ***, P<0.001 vs. wild-type; 
+
, P<0.05; 
++
; P<0.01; 
+++
; P<0.001 vs. APP/PS2 (n=712 animals/group). 
Modified from Rhein et al., PNAS 2009 (26) with permission. 
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Abstract Hormonal deficit in post-menopausal women has
been proposed to be one risk factor in Alzheimer's disease
(AD) since two thirds of AD patients are women. However,
large treatment trials showed negative effects of long-term
treatment with oestrogens in older women. Thus, oestrogen
treatment after menopause is still under debate, and several
hypotheses trying to explain the failure in outcome are under
discussion. Concurrently, it was shown that amyloid-beta
(Aβ) peptide, the main constituent of senile plaques, as well
as abnormally hyperphosphorylated tau protein, the main
component of neurofibrillary tangles, can modulate the level
of neurosteroids which notably represent neuroactive steroids
synthetized within the nervous system, independently of pe-
ripheral endocrine glands. In this review, we summarize the
role of neurosteroids especially that of oestrogen in AD and
discuss their potentially neuroprotective effects with specific
regard to the role of oestrogens on the maintenance and
function of mitochondria, important organelles which are
highly vulnerable to Aβ- and tau-induced toxicity. We also
discuss the role of Aβ-binding alcohol dehydrogenase
(ABAD), a mitochondrial enzyme able to bind Aβ peptide
thereby modifying mitochondrial function as well as oestra-
diol levels suggesting possible modes of interaction between
the three, and the potential therapeutic implication of inhibit-
ing Aβ–ABAD interaction.
Keywords Alzheimer's disease . Neurosteroids .
Oestrogen . Mitochondria . ABAD
Introduction
Steroid hormones are molecules, mainly produced by endo-
crine glands such as the adrenal gland, gonads and placenta,
involved in the control of many physiological processes
mainly in the periphery, from reproductive behaviour to
stress response. In 1981, Baulieu and co-workers were the
first to demonstrate steroid production within the nervous
system itself [1]. They showed that the level of some ste-
roids, such as dehydroepiandrosterone (DHEA), was even
four times higher in the anterior brain of rats than in plasma
and nearly 18 times higher than in the posterior brain with
regard to its sulphated form (DHEAS). Of note, the level of
this steroid remained elevated in the brain even after adre-
nalectomy and castration. In the following decades, other
steroids were identified to be synthetized in situ in the brain,
and enzymatic activities of proteins involved in steroido-
genesis have been shown in many regions of the central and
peripheral nervous system, in neurons as well as in glial
cells [2–5]. Thus, this category of molecules is now called
“neurosteroids” and defines neuroactive steroids that are
synthetized within the nervous system, independently of
peripheral endocrine glands. While steroid hormones act at
a distance from their glands of origin in an endocrine way,
neurosteroids are synthetized by the nervous system and act
on the nervous system in an auto/paracrine configuration.
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Because of their lipophilic nature, peripheral steroid hor-
mones can freely cross cell membranes, including the
blood–brain barrier, and play an important role in the devel-
opment, maturation and differentiation of the central and
peripheral nervous system. However, since some steroids
are also synthetized within the nervous system, their blood
levels do not necessarily correspond to their brain concen-
trations [6]. Intra-cerebral steroid synthesis seems to play a
role in cognition, anxiety, depression, neuroprotection and
even nociception [7].
The ability to cross cellular membranes allows them to
act on nuclear receptors exhibiting genomic action by reg-
ulating gene transcription. This action seems to be important
during neonatal life where it has been shown that neuro-
steroids, such as progesterone (PROG) or oestradiol, are
able to promote dendritic growth, spinogenesis, synapto-
genesis and cell survival, particularly in the cerebellum
[5]. Some studies already demonstrated the role of neuro-
steroids, particularly oestrogens, in the regulation of glucose
homeostasis and lipid metabolism [8] as well as in neuro-
protection [9]. Risk for Alzheimer's disease (AD) is associ-
ated with age-related loss of sex steroid hormones in both
women and men [10, 11]. On the one hand, in post-
menopausal women, the precipitous depletion of oestrogens
and progestogens is hypothesized to increase susceptibility
to AD pathogenesis, a concept largely supported by epide-
miological evidence but refuted by some clinical findings,
above all, by results from the “Woman's health initiative
memory study” (WHIMS) (please see detailed discussion in
the “Conclusion” section). On the other hand, a growing
body of evidence indicates a more gradual age-related de-
cline in testosterone in men similarly associated with in-
creased risk to several diseases including AD. Since
testosterone is at least in part aromatized in the brain to
17β-oestradiol, a loss of it may also affect oestrogen-
mediated neuroprotective pathways. But also, the difference
between how rapidly and significantly the female versus
male primary sex hormones decline might partially contrib-
ute to higher AD incidences in women than in men [10].
Alzheimer's Disease, Oxidative Stress, Effect of Gender
and Neogenesis of Neurosteroids
AD is a neurodegenerative brain disorder and the most
common form of dementia among the elderly as shown by
the worldwide prevalence of the disease which was 26.6
million people in 2006 [12]. Clinical symptoms are charac-
terized by severe and progressive loss of memory, language
skills as well as spatial and temporal orientation. From a
cellular point of view, the pathological hallmark of AD is
the presence of extracellular senile plaques—composed of
aggregated amyloid-β peptide (Aβ)—and intracellular
neurofibrillary tangles (NFT)—consisting of aggregates of
abnormally hyperphosphorylated tau protein. A lot of efforts
have been made during the last years to understand the
pathogenesis of the disease, particularly the role of AD
key proteins, Aβ and tau, in oxidative stress and mitochon-
drial dysfunction [13].
Epidemiological and observational studies demonstrated
a higher prevalence and incidence of AD in women even
after adjusting for age—about two thirds of AD patients are
female—as well as a greater vulnerability to the disease
[14]. Thus, at early stages of neurofibrillary tangle develop-
ment, women exhibit greater senile plaque deposition than
men [15], and AD pathology is more strongly associated
with clinical dementia in female patients than in male [16].
The drop of oestrogen levels after menopause was proposed
to be one explanation to this phenomenon. However, there is
little information concerning changes of steroid levels in the
human brain during ageing and under dementia conditions.
As steroids present in nervous tissues originate from the
endocrine glands (steroid hormones) and from local synthe-
sis (neurosteroids), changes in blood levels of steroids with
age do not necessarily reflect changes in their brain levels.
The concentrations of a range of neurosteroids have recently
been measured in various brain regions of aged AD patients
and aged non-demented controls including both genders by
the very sensitive GC/MS methods [6]. Schumacher and
colleagues showed a general trend towards lower level of
steroids including oestrogen in AD patients compared to
controls. Notably, neurosteroid levels were negatively cor-
related with Aβ and phospho-tau in some brain regions [6].
Another study using radioimmunoassay for steroid quanti-
fication demonstrated a decrease in oestrogen level in post-
mortem brain from female AD patients aged 80 years and
older but no significant difference in the 60–79-year age
range compared to non-demented women [17]. However in
men, an age-dependent decrease of androgen level was
observed in the brain of non-demented subjects, which
was even more pronounced in the brain of male AD patients
[17]. Whereas large studies investigating systematically
gender differences with respect to Aβ and or tau pathology
in post-mortem brain tissue from AD patients are missing,
broad evidence emerged from transgenic mice models of
AD indicating an increased Aβ load burden and plaque
number in the female brain compared to age-matched male
mouse brain [11, 18]. Of note, consistent findings on greater
Aβ burden in females were found in different animal AD
models: Tg2576 (APPSWE) mice [19], APP/PS1 [20],
APP23 [21], as well as in triple transgenic mice, like
3xTg-AD mice [18, 22] and tripleAD mice ([23], with respect
to gender differences: unpublished observations). On the
basis that the estrous cycle in female mice is constantly
repeated until approximately 11 months of age and becomes
irregular between 12 and 14 months, the data demonstrating
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a significant enhancement of Aβ load in important brain
regions like the hippocampus from the female after the age
of 11 months are striking. Regarding tau pathology, no
gender differences have been observed in the latter triple
AD models. In agreement, NFT formation in Aβ-injected
tau transgenic mice (P301L) did not vary with gender [24].
Even though one single publication reported an enhanced
neurofibrillary pathology in female TAPP mice [25], all
together, these results point to the involvement of the Aβ
pathway, rather than the tau pathway, in the higher risk of
AD in women.
Interestingly, further supporting evidence comes from ox-
idative stress studies. Previous research of our group [26]
demonstrated a gender-specific partial up-regulation of anti-
oxidant defence in post-mortem brain regions from female
compared to male AD patients further indicating that oxida-
tive damage is caused rather by overproduction from reactive
oxygen species (ROS) than by insufficient detoxification of
ROS. Since mitochondria represent the major source of ROS,
the findings from Lloret and co-workers are of specific interest
showing that brain mitochondria from old female rats produce
higher levels of ROS after exposure to Aβ than age-matched
brain mitochondria from male rats [27].
A selection of studies attested neuroprotective effects of
neurosteroids against AD-related cellular and mitochondrial
injury, but the underlying mechanisms are still poorly
understood.
Findings of our group corroborated that AD key proteins
and oxidative stress are themselves able to modify neogenesis
of neurosteroids in a cellular AD model [28, 29] (Fig. 1). In
fact, treatment of human SH-SY5Y neuroblastoma cells with
H2O2 for 24 or 48 h led to a decrease of oestradiol synthesis.
This was paralleled by an increased cell death compared to
untreated controls and a down-regulation of the expression of
aromatase, an enzyme responsible for oestradiol formation
from testosterone. Interestingly, cell death was also observed
after inhibition of aromatase by treatment with letrozole,
suggesting that endogenous oestradiol formation plays a crit-
ical role in cell survival. Furthermore, if cells were pre-treated
with oestradiol, it was possible to protect them against H2O2
and letrozole-induced cell death. In agreement, a similar pro-
tective effect of oestradiol was observed in stress condition
experiments treating the same cell line with heavy metals,
such as cobalt and mercury [30].
In addition, modulation of neurosteroid production was
observed in SH-SY5Y cells overexpressing the human am-
yloid processor protein (APP) or human tau protein [28].
Indeed, overexpression of human wild-type Tau (hTau 40)
protein induced an increase in the production of PROG, 3α-
androstanediol and 17-hydroxyprogesterone, in contrast to
overexpression of the abnormally hyperphosphorylated tau
bearing the P301L mutation which led to a decrease in the
production of these neurosteroids. In parallel, a decrease of
PROG and 17-hydroxyprogesterone production was ob-
served in cells expressing human wild-type APP (wtAPP),
whereas 3α-androstanediol and oestradiol levels were in-
creased. These results provided first evidence that AD key
proteins are able to modulate, directly or indirectly, the
biological activity of the enzymatic machinery producing
neurosteroids. These findings were further confirmed by in
vitro experiments using native SH-SY5Y cells treated with
aggregated Aβ1-42 peptide for 24 h [31]. Since APPwt SH-
Fig. 1 Main biochemical pathways for neurosteroidogenesis in the ver-
tebrate brain. Boxes represent neurosteroids which are sensitive to modu-
lation by AD key proteins, Aβ and/or tau. Mitochondrial 17β-HSD
(marked by *) is equivalent to the ABAD in mitochondria. PREG preg-
nenolone, PROG progesterone, 17OH-PREG 17-hydroxypregnenolone,
17OH-PROG 17-hydroxyprogesterone, DHEA dehydroepiandrosterone,
DHP dihydroprogesterone, ALLOPREG allopregnanolone,DHT dihydro-
testosterone, P450scc cytochrome P450 cholesterol side chain cleavage,
P450c17 cytochrome P450c17, 3β-HSD 3β-hydroxysteroid dehydroge-
nase, 5α-R 5α-reductase, Arom. aromatase, 21-OHase 21-hydroxylase,
3α-HSOR 3α-hydroxysteroid oxydoreductase, 17β-HSD 17β-
hydroxysteroid dehydrogenase
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SY5Y cells secrete Aβ levels within nanomolar concentra-
tion range, treatment of native SH-SY5Y cells using a “non-
toxic” concentration range (100–1,000 nM, non-cell death-
inducing Aβ1-42 concentrations) revealed an increase in
oestradiol production, whereas toxic Aβ1–42 concentrations
within the micromolar range, leading to cell death, strongly
reduced oestradiol levels.
Modulation of steroid production was also shown in
other cell lines, for example in oligodendrocytes, where
DHEA production is up-regulated under oxidative stress
condition induced by treatment with Aβ peptide or Fe2+
[32]. Interestingly, similar results were found in Alzheimer
patients where DHEA was significantly elevated in brain
and cerebrospinal fluid when compared to control subjects
[33]. Finally, several reports propose the role of allopregna-
nolone (3α, 5α-THP) as a plasmatic biomarker for AD,
since it was shown that the level of this neurosteroid is
decreased by 25 % in the plasma of demented patients
compared with control subjects [34, 35].
The fact that the ability to produce neurosteroids is con-
served in the vertebrates' evolution suggests that this cate-
gory of molecules is important for living beings. Thus, we
could speculate that the modulation of their biosynthesis
plays an important role in the pathophysiology of neurode-
generative disorders, such as AD.
Neurosteroids, Especially Oestrogens,
and Neuroprotection in AD
Evidence of Neuroprotective Action of Steroids in Cellular
and Animal Studies
Neuroprotective effects of neurosteroids against a variety of
brain injuries have already been described for many years.
Numerous studies with the focus on oestrogens showed that
these molecules are able to enhance cerebral blood flow,
prevent atrophy of cholinergic neurons, and modulate the
effects of trophic factors in the brain [36]. Oestrogens are a
group of compounds known for their importance in the
estrous cycle including oestrone (E1), oestradiol (E2), and
oestriol (E3). Oestradiol is about ten times as potent as
oestrone and about 80 times as potent as oestriol in its
oestrogenic effect. Oestradiol is also present in males, being
produced as an active metabolic product of testosterone. The
serum levels of oestradiol in males (14–55 pg/mL) are
roughly comparable to those of post-menopausal women
(<35 pg/mL). Oestradiol in vivo is interconvertible with
oestrone, oestradiol to oestrone conversion being favoured;
however, evidence of metabolism is mainly derived from the
periphery.
Animal studies, especially in rodents and transgenic mice
models for AD, seem to confirm positive effects of oestrogen
treatment. It has been shown that a treatment with oestrogen in
mice expressing mutations in human APP (Swedish and Indi-
ana mutation) had an impact on APP processing decreasing
Aβ levels and so its aggregation into plaques [37]. Mecha-
nisms underlying this action of oestrogen are still poorly
understood, but as discussed by Pike et al. [11], it seems that
oestrogen amongst others is able to promote the α-secretase
pathway (non-amyloidogenic, meaning non-Aβ producing)
via activation of extracellular-regulated kinase 1 and 2 (ERK
1 and 2) and through the protein kinase C (PKC) signalling
pathway.
In triple transgenic AD mice, depletion in sex steroid
hormones induced by ovariectomy in adult females in-
creased significantly Aβ accumulation and had a negative
impact on cognitive performance [18, 38]. Treatment of
these ovariectomized mice with oestrogens was able to
prevent these effects vice versa. Of note, when PROG was
administrated in combination with oestrogens, the beneficial
effects on Aβ accumulation were blocked but not on cog-
nitive performance. However, oestrogen and PROG both
can modulate kinase and phosphatase activity involved in
tau phosphorylation, especially the glycogen synthase
kinase-3β (GSK-3β). Thus, oestrogen can induce the phos-
phorylation of GSK-3β which inactivates the enzyme and
reduces tau phosphorylation, whereas PROG can decrease
the expression of tau and GSK-3β [11, 39]. This suggests
that oestrogen and PROG not only can interact to regulate
APP processing and tau phosphorylation but can also act
independently on different AD pathways.
Cognitive effects of PROG were confirmed in mice bear-
ing the Swedish double mutation of APP and mutant pre-
seniline 1 (APPswe+PSEN1Δ9 mutant mice) which showed
decreased hippocampally mediated cognitive performances
compared to non-transgenic littermates [38]. In this AD
mouse model, PROG was able to improve the cognitive
performance in tasks involving the cortex but not in those
involving the hippocampus. Besides, APPswe+PSEN1Δ9
mice presented decreased 3α, 5α-THP levels (metabolite of
PROG) in the hippocampus, compared to wild-type mice,
suggesting that deficits in hippocampal function may be
due, at least in part, to reduced capacity to form 3α, 5α-
THP in the hippocampus. Furthermore, a more recent study
supported the role of 3α, 5α-THP in triple transgenic mice
model of AD (3xTgAD) by showing reduced Aβ generation
in the hippocampus, cortex and amygdala, coupled with an
increased cellular regeneration after treatment with 3α, 5α-
THP [40].
At the cellular level, oestrogen binds to nuclear receptors,
such as oestrogen receptor α and β (ER α/β), and acts as
transcription factor. It enhanced the expression of anti-
apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-
regulated the expression of Bim, a pro-apoptotic factor,
preventing the initialisation of cell death programme by
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mitochondria [11, 41]. Another way that oestrogen can
protect cells from apoptosis is the activation of antioxidant
defence systems by up-regulating the expression of manga-
nese superoxide dismutase (MnSOD) and glutathione perox-
idase [42]. Thus, oestrogen can have direct antioxidant effects
by increasing reduced glutathione levels and decreasing oxi-
dative DNA damage in mitochondria, as observed in a study
using ovariectomized female rats [43]. Of note, oestrogen can
also modulate the redox state of cells by intervening with
several signalling pathways, such as mitogen-activated
protein kinase (MAPK), G protein-regulated signalling,
NFκB, c-fos, CREB, phosphatidylinositol-3-kinase, PKC
and Ca2+ influx [41, 44]. On the basis of this complex
mode of action, oestrogens not only seem to be able to
decrease oxidative stress markers, including lipid peroxi-
dation, protein oxidation and DNA damage, but can also
directly act on the regulation of mitochondrial function
[42].
Neurosteroids and Mitochondria: Focus on Potential
Protective Effects of Oestrogen Against Aβ-Induced
Toxicity
Mitochondria are the “powerhouses of the cell”, providing
the main part of cellular energy via ATP generation, which
is accomplished through oxidative phosphorylation from
nutritional sources [45]. They control cell survival and death
by regulating both energy metabolism and apoptotic path-
ways and contribute to many cellular functions, including
intracellular calcium homeostasis, alteration of the cellular
reduction–oxidation potential, cell cycle regulation and syn-
aptic plasticity [46]. Mitochondrial dysfunction has been
proposed as an underlying mechanism in the early stages
of AD [47, 48]. We recently summarized evidence from
ageing and Alzheimer models showing that the harmful trio
“ageing, Aβ and tau protein” triggers mitochondrial dys-
function through a number of pathways, such as impairment
of oxidative phosphorylation, elevation of reactive oxygen
species production and interaction with mitochondrial pro-
teins, contributing to the development and progression of
the disease [13, 49].
Mitochondria and neurosteroidogenesis are also closely
linked since mitochondria contain the first enzyme involved
in steroidogenesis, the cytochrome P450 cholesterol side
chain cleavage enzyme (P450scc) located at the inner side
of the mitochondrial membrane which is responsible for the
conversion of cholesterol to pregnenolone (PREG). The first
step of neurosteroidogenesis is the transfer of cholesterol
from the outer to the inner mitochondrial membrane. It is
also the rate-limiting step in the production of neurosteroids
because the ability of cholesterol to enter into mitochondria
to be available to the P450scc will determine the efficiency
of steroidogenesis [50]. Free cholesterol accumulates
outside of mitochondria and binds to the steroidogenic acute
regulatory protein, a hormone-induced mitochondria-
targeted protein that initiates cholesterol transfer into mito-
chondria. Then, molecules are transported inside mitochon-
dria by a protein complex including translocator proteins
(TSPO), a cholesterol-binding mitochondrial protein also
known under the name of peripheral-type benzodiazepine
receptor, which permits cholesterol transfer into mitochon-
dria and subsequent steroid formation.
It has been shown that TSPO is up-regulated in the post-
mortem brain of AD patients, resulting in an increased level
of PREG in the hippocampal region of those brains [50].
Interestingly, the level of 22R-hydroxycholesterol, a steroid
intermediate in the conversion of cholesterol to PREG, was
found at lower levels in the AD brain compared to the
control, which suggests that TSPO does not function nor-
mally in Alzheimer patients [33, 51].
From an energetic point of view, it is known that steroids
such as oestrogen can regulate mitochondrial metabolism by
increasing the expression of glucose transporter subunits
and by regulating some enzymes involved in the tricarbox-
ylic acid cycle (TCA cycle) as well as glycolysis, such as the
hexokinase, phosphofructokinase, pyruvate and malate de-
hydrogenase [41, 52], which leads to improved glucose
utilization by cells [11, 44] (Fig. 2).
Oestrogens seem to be able to up-regulate genes coding
for some electron transport chain components present in
nuclear and in mitochondrial DNA [53, 54]. In fact, an
oestrogen-induced increased expression of some subunits
of mitochondrial complex I (CI), cytochrome c oxidase
(complex IV or CIV) and F1 subunit of ATP synthase was
observed [41, 42, 52]. Furthermore, treatment of ovariecto-
mized female rats with oestradiol induced an increase of
mitochondrial respiratory function in the brain with regard
to an enhancement of O2 consumption coupled to an in-
creased activity of cytochrome c oxidase [53]. Thus, oes-
trogen seems to enhance the general metabolism in cells, but
besides, it seems also able to directly protect mitochondria
against oxidative stress-induced injury [52]. Thus, incuba-
tion of isolated mitochondria from the rat brain with oestra-
diol leads to a decrease of H2O2 production by this organelle
coupled with an increase of the mitochondrial membrane
potential (MMP). Furthermore, it has been proposed that its
phenolic A ring could allow oestradiol to intercalate into the
mitochondrial membrane and to avoid lipid peroxidation
occurring in stress condition [54], which could be responsi-
ble for the stabilization of the MMP. Moreover, oestradiol
seems to prevent the release of cytochrome c by mitochon-
dria (a mechanism known to induce apoptosis of cells by
activating the caspase cascade in the cytoplasm), a mecha-
nism increasing the efficiency of the respiratory chain [52].
Finally, another oestrogen signalling pathway avoiding
the negative effects of oxidative stress is the one regulating
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calcium homeostasis by inducing mitochondrial sequestra-
tion of cytosolic calcium [42, 54]. In fact, an imbalance of
calcium regulation can lead to an increase of ROS produc-
tion by activating the enzyme nitric oxide synthase, which
can in turn sensitize neural cells to oxidative damage. It has
been shown that an oestradiol treatment of primary hippo-
campal neurons was able to potentiate glutamatergic re-
sponse via NMDA receptor which resulted in an increased
influx of calcium in cells. This effect was coupled to an
induction of mitochondrial sequestration of cytosolic calci-
um and an increase of the mitochondrial calcium load tol-
erability thereby avoiding calcium-induced excitotoxicity as
well as promoting cell survival.
Taken together, all those different findings indicate that
oestrogen might be able to compensate deficits and injuries
that occur in AD, namely mitochondrial respiration impair-
ments, enhanced ROS production, excitotoxicity and, more
generally, metabolic deficits (Fig. 2). More recently, new light
has been shed on a mitochondrial enzyme that is able to
directly bind Aβ peptide and in which one of the main
substrate is 17β-oestradiol [55]. This enzyme is known under
the name of 17β-hydroxysteroid dehydrogenase type 10
(17β-HSD) or Aβ-binding alcohol dehydrogenase (ABAD).
ABAD, Oestradiol and Aβ-Induced Mitochondrial
Impairment
ABAD belongs to the alcohol dehydrogenase family, and it is
responsible for the reversible oxido/reduction of several sub-
strates including linear alcohols and steroids, such as 17β-
oestradiol, using NAD+ as cofactor [56]. Under normal con-
ditions (without Aβ), this enzyme plays a role in the regulation
of metabolic homeostasis, and its overexpression improved
cell viability and ATP content [57]. It has been shown that
ABAD is up-regulated in brains of AD mice as well as AD
patients [57, 58], and it has been suggested that the binding of
Aβ changes the conformation of the enzyme, which seems to
exacerbate mitochondrial dysfunction induced by Aβ.
Fig. 2 Modulation of mitochondrial function by Aβ, hyperphosphory-
lated tau and oestradiol. In AD, mitochondrial dysfunction was found
to be a central pathological mechanism which occurs already at early
stages of the disease. On one hand, studies showed that amyloid-β
peptide (Aβ) can be responsible of metabolic impairments, such as the
decrease of glucose consumption observed in the AD brain as well as
the calcium-induced excitotoxicity in neurons. It has been found that
hyperphosphorylated tau and Aβ are able to impair mitochondrial
respiration by inhibiting the ETC CI and CIV, respectively, inducing
decreased oxygen consumption, decreased ATP production and in-
creased ROS level. This oxidative stress induced by ETC dysfunction
can surpass cellular and mitochondrial scavenger (MnSOD, Cu/
ZnSOD) and impacts on MMP as well as mitochondrial DNA
(mtDNA). On the other hand, it has been shown that oestradiol can
increase glucose utilization by cells as well as ETC activity, stabilize
the MMP and prevent ROS production and calcium-induced excitotox-
icity. In the graph, E2 designates where oestradiol potentially acts on
mitochondria to compensate Aβ-induced toxicity. In turn, Aβ seems to
be able to impact oestradiol metabolism in mitochondria, since it can
be directly linked to the mitochondrial enzyme ABAD and possibly
modulates its enzymatic activity (such as the reversible conversion of
oestradiol to oestrone) and non-enzymatic activity (mitochondrial RN-
Ase P). ABAD Aβ-binding alcohol dehydrogenase, CI complex I, CII
complex II, CIII complex III, CIV complex IV, CV complex V, cyt c
cytochrome c, Cu/Zn SOD copper/zinc superoxide dismutase, MnSOD
manganese superoxide dismutase, TCA tricyclic acid, E2 oestradiol,
ROS reactive oxygen species, mtDNA mitochondrial DNA, ER oestro-
gen receptor
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More recently, studies performed in transgenic micemodels
of AD showed that behavioural stress or depletion of ovarian
hormones by ovariectomy exacerbated mitochondrial dys-
function, aggravated plaque pathology and increased ABAD
expression in the brain [59, 60]. Furthermore, double trans-
genic mice overexpressing mutant APP and ABAD present an
earlier onset of cognitive impairment and histopathological
changes when compared to APP mice [49], suggesting that
Aβ–ABAD interaction is an important mechanism underlying
Aβ toxicity. This hypothesis is supported by a study from Yao
and collaborators who recently showed that inhibition of Aβ–
ABAD interaction by a decoy peptide can restore mitochon-
drial deficits (activity of mitochondrial respiratory complexes,
ROS level) and improve neuronal and cognitive function [60].
New interesting findings of our group seem to go in the
same way with regard to the use of a novel small ABAD-
specific compound inhibitor (AG18051) by investigating
the role of this enzyme in Aβ toxicity in human SH-SY5Y
cells treated for 5 days with Aβ1–42 0.5 uM [61]. The crystal
structure of human ABAD in presence of AG18051 showed
that the inhibitor formed a covalent link with the NAD+
cofactor and occupied the substrate-binding site of the en-
zyme [62]. Thus, the inhibitor was able to prevent Aβ-
induced cell death and significantly normalized metabolic
functions impaired by Aβ, such as cytosolic and mitochon-
drial ROS as well as mitochondrial respiration. Furthermore,
it was able to restore oestradiol levels which were reduced
after treatment with Aβ [31, 61]. What is interesting to note
is that the apparent protective effects of the ABAD inhibitor
seem to be independent on its interaction with Aβ. In fact, a
24-h pre-treatment with AG18051, before the incubation of
cells with Aβ1-42, was sufficient to prevent cell death, nor-
malize ROS production and restore mitochondrial respira-
tion. Regarding oestradiol level, we previously showed that
it decreased in the cytosol and increased in isolated mito-
chondria of SH-SY5Y cells after 5 days of treatment with
Aβ [49]. The ABAD inhibitor normalized the oestradiol
level in the cytosol [61], and preliminary data of our group
suggest a similar effect in isolated mitochondria (unpub-
lished data). Thus, we propose the following model of mode
of action: ABAD inhibitor is able to block Aβ toxicity by
changing ABAD configuration, which disables the binding
of Aβ thus preventing its toxic effects (Fig. 3). The action of
ABAD on the electron transport chain (ETC) is still unclear,
but the potential role of ABAD as mitochondrial RNAse P
directly links ABAD to the production of mitochondrial
ETC proteins and ROS generation [63]. Notably, AG18051
was able to normalize also this function of ABAD since
mitochondrial respiration was restored, but the underlying
mechanisms still remain unclear [61].
Thus, the interplay between ABAD, oestradiol and mito-
chondria may be a very interesting lead to follow in the
future to decode Aβ-induced mitochondrial toxicity and
explore therapeutic strategies of ABAD inhibition.
Conclusion
It is still debated whether oestrogen treatment after meno-
pause could result in improved cognitive function in wom-
en. This debate is based on many animal and cell culture
data showing that oestrogens can positively affect the ageing
and AD brain. It was recognized from former studies that
oestrogen depletion in post-menopausal women represents a
significant risk factor for the development of AD and that an
oestrogen replacement therapy may decrease this risk and
even delay disease progression [64, 65]. However, large
treatment trials showed negative effects of long-term
Fig. 3 Aβ, ABAD and mitochondria: modes of interactions. a Under
normal conditions, ABAD is responsible of the reversible oxido/reduc-
tion of linear alcohols and steroids, such as the reversible conversion
from oestradiol to oestrone. Its potential function as an RNAse P could
also be important for the good functioning of the mitochondrial ETC. b
Under AD-relevant pathological conditions, Aβ can directly bind the
mitochondrial enzyme ABAD, changing the configuration of the en-
zyme which seems to inhibit its activity and creates an imbalance
between oestradiol and oestrone. Aβ-induced ABAD misfolding can
impact ETC functioning and increase, directly or indirectly, ROS
production, which lead to cell death. c In the presence of AG18051
(AG), the binding of Aβ to ABAD is inhibited, normalizing oestradiol
level, ROS production, ETC activity, and improves cell survival.
ABAD Aβ-binding alcohol dehydrogenase, IMM inner mitochondrial
membrane, OMM outer mitochondrial membrane
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treatment with oestrogens in older women. Above all, results
from the WHIMS including 4,532 post-menopausal woman
aged over 68 years indicated a twofold increase in dementia
after 4.2 years of hormonal treatment (p.o. treatment with
premaxin plus medroxyprogesterone). In addition, the study
indicated potential risks for breast cancer, pulmonary embo-
lism and stroke [66, 67]. Some attribute this failure to the
synthetic nature of the hormones used in the WHIMS trial,
since in vitro studies support a beneficial role of oestradiol and
progesterone, but not of medroxyprogesterone used in the
WHIMS [68, 69]. Of note, medroxyprogesterone is not me-
tabolized to 3α, 5α-THP and can inhibit conversion of PROG
to 3α, 5α-THP [70]. Similarly, oestradiol, PROG or 3α, 5α-
THP, but not medroxyprogesterone, showed beneficial effects
in ageing, seizure, cortical contusion, ischaemia and diabetic
neuropathymodels [38]. Another theorywhich tries to explain
trial failure is the “critical window hypothesis”, asking for the
critical period where oestrogen might exert a neuroprotective
effect [71]. This hypothesis is substantiated by animal re-
search, e.g. mice which have undergone ovariectomy, but in
which oestrogen treatment was delayed substantially by
months (the equivalent of years in human terms), did not
benefit by this, as the animals did which received treatment
immediately after ovariectomy [72]. However, a recent meta-
analysis [73] indicated, contrary to expectations, that age of
women and duration of time relapsed when treatment was
initiated since menopause did not significantly affect treat-
ment outcome. Thus, natural oestradiol (E2) without a pro-
gestagen should represent the preferred treatment [73].
Furthermore, the oral route of drug delivery, being non-
invasive in nature, is by far the most convenient and preferred
route of administration in any acute or chronic treatment.
Though oestradiol itself from conventional oral oestradiol
formulations has the ability to cross the blood–brain barrier
(BBB) and reach the brain, but a large oral dose is required to
achieve therapeutic levels of oestradiol due to its non-
specificity for the brain. This non-specificity increases the
peripheral drug burden and subsequently potentiates the risk
of peripheral adverse effects. Furthermore, with specific re-
gard to the brain-specific action of oestradiol as a neuroste-
roid, independently of its action in the periphery, other modes
of administration (cyclical, nasal, polymer nanoparticles for
oral delivery) need to be sought and investigated [74]. Alter-
natively, the true potential of phyto-oestrogens, like the soy
isoflavones genistein, daidzein and glycitein, which activate
the same neuroprotective pathways than oestrogens but with
weak oestrogenic cellular effects that might be responsible for
the lower prevalence of AD in Japanese living in their ethnic
homeland compared to Japanese living in the USA [75], to
beneficially modify disease processes should be studied in
clinical trials [27]. In addition, the field could strongly benefit
from the successful development of oestrogen derivates that
have no unfavourable oestrogenic side effects. The successful
use of oestrogen or oestrogen-analogue therapies to delay,
prevent and/or treat AD will require additional research to
optimize key parameters of therapy.
In this context, the interplay between ABAD, oestradiol
and mitochondria and accordingly ABAD inhibition might
represent a further interesting lead to follow in the future.
Knowledge acquired from these studies will eventually be
applied to unravel the pathophysiology and to inform pre-
vention and intervention strategies of AD.
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8.1 INTRODUCTION
The brain is considered to be especially vulnerable to
oxidative stress due to high levels of prooxidant factors
and relatively low antioxidant defence. Putative proox-
idant factors consist of a high metabolic rate, high levels
of unsaturated fatty acids that readily undergo lipid
peroxidation reactions, and relatively high levels of iron
in some brain regions that facilitate hydroxyl radical
formation from Fenton reactions [1]. Furthermore,
neuronal activity results in high levels of intracellular
calcium ions after depolarization that are linked to
activation of phospholipase A2, release of arachidonic
acid, and subsequent formation of reactive oxygen
species (ROS) from cyclooxygenase and lipoxygenase
reactions (Fig. 8.1). Calcium ions also facilitate mito-
chondrial depolarization with release of mitochondrial
factors that promote ROS formation. Furthermore,
calcium ions are required for nitric oxide synthesis via
endothelial and neuronal nitric oxide synthases (eNOS
and nNOS). The brain contains relatively high levels of
nitric oxide that can give rise to formation of highly
reactive peroxynitrite. Also, catecholamine metabolism
involves increased ROS formation: Superoxide can be
generated from semiquinone formation, and hydrogen
peroxide is released as a by-product of catecholamine
synthesis by tyrosine hydroxylase and degradation by
monoamine oxidases.
Despite these prooxidant factors, the brain possesses
only relatively low levels of antioxidant defenses. Cata-
lase activity is extremely low in brain tissue, and gluta-
thione peroxidase as well as superoxide dismutase show
low activity compared with other organs such as liver,
heart, and kidney [2]. As a consequence, increased levels
of ROS can be especially detrimental to brain tissue.
Oxidative stress has accordingly been suggested to be a
primary factor in the pathogenesis of several chronic
neurodegenerative disorders, most prominently Alzhei-
mer disease (AD), Parkinson disease (PD), and Hun-
tington disease (HD).
Several studies, mainly in animals, suggest neuroster-
oid involvement in neuroprotection [3]. However in
humans, the role of neurosteroidogenesis in the regula-
tion of degenerative mechanisms is unknown. Since the
process of neurosteroid biosynthesis is a pivotal mecha-
nism intervening in the protection or viability of nerve
cells, it might be regulated or significantly affected under
oxidative stress conditions. However, the key factors
interacting with neurosteroid biosynthesis under patho-
physiological conditions are poorly understood. New
findings demonstrate an amino acid sequence-dependent
action of amyloid-β (Aβ) on neurosteroidogenic path-
ways [4]. The data also indicate that, unlike progesterone
neosynthesis, regulation of endogenous estradiol forma-
tion by pathogenic factors may be a deciding process
controlling cell death mechanisms. Targeting estradiol
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biosynthetic pathways in nerve cells may therefore be
interesting in development of neuroprotective strategies.
8.2 EVIDENCE FOR A PATHOLOGICAL ROLE
FOR OXIDATIVE STRESS IN AD
AD is a neurodegenerative brain disease and the most
common form of dementia among the elderly. It is
characterized by clinical symptoms of severe and pro-
gressive loss of memory, language skills, as well as
spatial and temporal orientation. The pathology of
AD is characterized by extracellular senile plaques,
composed of aggregated amyloid-β peptide, and intra-
cellular neurofibrillary tangles, consisting of aggregates
of abnormally hyperphosphorylated Tau protein, and is
accompanied by mitochondrial dysfunction, but the
mechanisms underlying AD-related dysfunction and
neurodegeneration are poorly understood.
Identification of factors that contribute to the pathol-
ogy of AD comes from epidemiological as well as genetic
studies: AD can be classified into two different forms,
rare familial forms (FAD), in which the disease onset is
at an age younger than 60 years, and the vast majority of
sporadic AD cases, in which onset occurs at an age over
60. Both forms of AD show the same clinical symptoms
and neuropathology. Genetic studies in FAD patients
have identified mutations in the genes encoding for the
amyloid precursor protein (APP) and for the presenilins
PS1 and PS2 that cause an autosomal inherited form of
AD with 100% penetrance. These FAD mutations
consistently lead to increased production of Aβ from
its precursor protein APP, which prompted Hardy and
Higgins [5] to suggest a direct and pathological role for
Aβ accumulation in the development of AD. In the
sporadic form of the disease, several risk factors have
been found that increase the risk to develop the disease
but—unlike FAD mutations—do not necessarily lead to
development of AD. Aging is by far the most important
risk factor for AD, but the apolipoprotein E4 allele and
female sex also predispose to the development of AD.
Immunohistochemical studies of postmortem AD
brains have established that neurons undergo apoptotic
cell death. Since ROS can elicit apoptotic signaling, the
hypothesis that oxidative stress is involved in the patho-
genic steps that lead to the development of AD was
proposed in the 1990s by several groups [6—9]. There is
a large body of evidence in support of this hypothesis:
Oxidative stress has been repeatedly shown to be associ-
ated with Aβ toxicity and with risk factors for sporadic
AD—mostly aging and the apolipoprotein E4 genotype.
8.2.1 Evidence for a Role for Oxidative Stress
in Sporadic AD
Oxidative stress has been associated with the risk factors
for sporadic AD, most prominently with aging [10],
suggesting that an age-associated rise in accumulation
of ROS can render the brain more vulnerable to the
development of AD. Consequently, increased markers of
oxidative stress have been found in AD patients: Several
studies have reported elevated levels of lipid peroxida-
tion products, oxidatively modified proteins, and oxi-
dized DNA and RNA bases in brains and cerebrospinal
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Fig. 8.1 Factors contributing to the accumulation of reactive oxygen species (ROS) in brain tissue and their implications in
Alzheimer disease. See text for details. MAO, monoamine oxidase; COX, cyclooxygenase; LOX, lipoxygenase; AA, arachidonic acid;
eNOS/nNOS, endothelial/neuronal nitric oxide synthase; Aβ, amyloid-β peptide
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fluid from AD patients compared to age-matched non-
demented control subjects [11–13]. Furthermore, tissue
samples from AD brains display a higher susceptibility
to in vitro oxidation [14], suggesting an impairment of
antioxidant defense in AD patients. Reports on antioxi-
dant parameters in AD brains have, however, been
contradictory so far. Several antioxidant enzymes have
been studied in AD brains with inconsistent results, but
the majority of reports found elevations in antioxidant
enzymes, suggesting an upregulation of antioxidant
defense in response to increased ROS levels [15]. Inter-
estingly, upregulation of antioxidant defence was more
pronounced in female patients, and levels of 4-hydro-
xynonenal (HNE), a neurotoxic aldehyde derived from
lipid peroxidation reactions, were elevated in female
compared to male patients. These findings suggest that
brains from female AD patients are under higher oxida-
tive pressure [15], consistent with epidemiological find-
ings that AD is more frequent in postmenopausal
women compared to age-matched men. This observation
can possibly be linked to the lack of sexual hormones,
especially estrogens, that can modulate cognitive func-
tion and nonreproductive behaviours in humans and
other mammalian species [16]. Potential sources of ROS
in AD brains include ROS derived from impaired
mitochondrial function [17, 18] and secondary ROS
formation due to inflammatory reactions. Furthermore,
increased monoamine oxidase B activity and increased
levels of potentially pro-oxidative heavy metals like iron
have been identified in AD brains [19, 20] and in patients
with mild cognitive impairment (MCI), the “clinical
precursor of AD,” suggesting that oxidative stress is an
early event of the disease [21].
Apart from aging, the apolipoprotein E4 allele is the
second most important risk factor for the development
of AD. Apolipoprotein E seems to play a role in brain
lipid metabolism and neuronal and glial development.
It can exist in three different alleles, E2, E3, and E4,
which differ in only two amino acids: The E2 isoform
contains two and the E3 isoform one cysteine residue,
while the E4 isoform contains none. Carriers of the
apolipoprotein E4 are at increased risk to develop
sporadic AD, especially when they are homozygous
carriers. The apolipoprotein E4 allele has been associ-
ated with increased oxidative damage in AD brains,
with the greatest impact in homozygotic carriers [22]
and an increased susceptibility to cell death in lympho-
cytes from carriers bearing at least one E4 allele [23]. In
vitro studies have evidenced that apolipoprotein E4
is less efficient in binding HNE, a cytotoxic lipid
peroxidation product. These findings suggest that the
Apo E4 isoform increases susceptibility to oxidative
damage, thereby possibly predisposing to the develop-
ment of AD.
8.2.2 Oxidative Stress and Toxicity of Mutant APP,
Presenilins, and Tau
Since the proposal of the amyloid hypothesis of AD,
toxic mechanisms caused by mutant APP and presenilins
related to an increased production of Aβ have been
extensively studied. Cells exposed to Aβ undergo apopto-
tic cell death, and the toxicity of Aβ has been shown to be
related to the production of ROS [24, 25]. Furthermore,
toxicity of Aβ depends on its aggregation state, which can
be influenced by oxidation. Thus oxidative stress
can cause formation of toxic Aβ species, which in turn
can further exacerbate accumulation of ROS in a vicious
cycle (Fig. 8.1). This could also explain why the preva-
lence of AD increases with advancing age—due to rising
oxidative stress levels with aging favoring Aβ toxicity.
Toxicity of Aβ is also evident in cell cultures over-
expressing APP/Aβ. PC12 cells transfected with mutant
APP Swedish showed higher sensitivity to ROS-induced
cell death and increased mitochondrial impairment after
challenge with hydrogen peroxide [26]. Similar observa-
tions were obtained in human neuroblastoma cells (SH-
SY5Y) overexpressing human wild-type APP (wtAPP)
[27]. The study demonstrated that chronic exposure to
Aβprotein resulted inactivity changesof complexes III and
IV of the oxidative phosphorylation system (OXPHOS) in
mitochondria coupled with a drop of ATP levels and an
increase of ROS production, which may finally instigate
loss of synapses and neuronal cell death in AD. Further-
more, treatments of untransfected SH-SY5H cells with Aβ
or human amylin aggregates induced an increase of ROS
production and had a negative impact on mitochondrial
respiration by their action on OXPHOS system [25].
Toxicity of Aβ has also been evidenced in animal
models of the disease. Mice transgenic for mutant APP
have high levels of Aβ in their brains and show an age-
dependent formation of Aβ plaques similar to the plaques
found in AD patients. Increased markers of oxidative
stress have been detected in brains of transgenic mice
bearing mutant APP, accompanied by markers for mito-
chondrial damage [28]. Furthermore, mutant APP trans-
genic mice show reduced levels of the antioxidant enzyme
copper/zinc superoxide dismutase [29]. In agreement,
increased markers of oxidative stress and reduced antiox-
idant defense by catalase as well as a trend toward
reduced activity of SOD were found in brains from
FAD patients [30]. The results provide an important
link of studies on toxicity of mutant APP in cell culture
and animal models mimicking the pathogenesis of the
disease in FAD patients, all of them bearing mutations
finally causing an increased generation of Aβ.
Mutations in the presenilins PS1 and PS2 account for
the majority of FAD cases and have similarly been
linked with oxidative stress. Oxidative toxicity of mutant
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presenilins can be either (i) due to increased formation
of toxic Aβ, especially the Aβ 1-42 isoform, or (ii) due to
direct toxic effects of mutant presenilins. Several muta-
tions in the presenilins have been found that consistently
lead to increased production of the long Aβ 1-42 from its
precursor protein APP [31], resulting in increased Aβ
levels and toxicity via the above-mentioned mechanisms.
Expression of mutant presenilins in cell culture and
transgenic mice sensitizes cells to apoptotic stimuli by
increasing ROS production and mitochondrial damage
[32, 33]. Furthermore, brains from PS1 mutant transgenic
mice display reduced activities of antioxidant enzymes
[34], and lymphocytes from these mice display increased
sensitivity to apoptosis accompanied by high intracellular
ROS and calcium levels [35]. Interestingly, increased ROS
accumulation, disturbed calcium homeostasis, and dimin-
ished levels of antioxidants have also been identified in
peripheral cells from FAD patients bearing APP or PS
mutations as well as in cells from sporadic AD patients
[36]. These results suggest that the oxidative toxicity
observed in transgenic animal models of the disease can
indeed play an important role to the pathogenesis of
sporadic as well as familial AD in humans.
The secondmain hallmark lesion ofAD is intracellular
neurofibrillary tangles (NFTs) built up of hyperpho-
sphorylated Tau. This protein may block the transport
of mitochondria, leading to energy deprivation and
oxidative stress at the synapse as well as to neurodegen-
eration [37]. Functional analysis showed mitochondrial
dysfunction in transgenic mice (pR5 mice) expressing
P301Lmutation of Tau, with a reduced complex I activity
and, with age, impaired mitochondrial respiration and
ATP synthesis. Mitochondrial dysfunction was associat-
ed with higher levels of ROS in aged pR5 mice. Increased
Tau pathology as in aged homozygous pR5mice revealed
modified lipid peroxidation levels and upregulation of
antioxidant enzymes in response to oxidative stress.
These findings demonstrated for the first time that not
only the Aβ but also the Tau pathology acts on the
enzyme metabolism of the brain and the oxidative con-
ditions in AD. However, more recently, the successful
development of double, and even triple, transgenicmouse
models has facilitated the investigation of pathogenic
mechanisms in AD and assisted in an understanding of
the interplay of Aβ and Tau on bioenergetics processes in
vivo [37]. These findings support the idea that Aβ andTau
act synergistically in amplifying mitochondrial respirato-
ry deficits, mainly of complex I and IV activities [18].
8.2.3 Is Oxidative Stress an Early Event
in the Pathogenesis of AD?
From the above evidence it can be concluded that oxida-
tive stress is a feature of sporadic as well as familial forms
of AD. However, it remains to be elucidated whether
oxidative stress is a primary factor in the pathogenesis of
the disease or only a secondary contributing mechanism.
The fact that oxidative damage and mitochondrial dys-
function can be detected at early stages in animal models
[28]—even before the presence of Aβ plaques [38]—and
that oxidative stress parameters have been detected at
highest levels in early stages of the disease in AD patients
[39] suggest that oxidative stress is a primary event in the
course of the disease. This is supported by studies that
reported a reduced risk of AD in users of antioxidant
vitamin supplements [40]. Although further clinical trials
are needed, antioxidant therapeutic approaches seem to
be most effective at very early stages of AD and are even
better utilized to modulate disease risk.
8.3 NEUROSTEROIDS
Steroid hormones are now well-defined molecules that
aremainly produced by endocrine glands, such as adrenal
gland, gonads, and placenta. They are involved in the
control of a lot of physiological processes, from repro-
ductive behavior to stress responsiveness. With their
ability to cross cellular membranes, and thus the blood-
brain barrier, steroid hormones have also an important
role in the development, maturation, and differentiation
of the central and peripheral nervous systems.
Three decades ago, Baulieu and co-workers were the
first to show a steroid production within the nervous
system itself. They discovered that some steroids, such as
pregnenolone (PREG) and dehydroepiandrosterone
(DHEA), were more concentrated in the brain than in
the plasma [41]. In addition, they could show that the level
of these steroids remained elevated in the brain even after
adrenalectomy and castration. These molecules are now
called “neurosteroids” and are defined as neuroactive
steroids that are synthesized within the nervous system,
independently of peripheral endocrine glands. Enzymatic
activities of proteins involved in steroidogenesis have been
shown in many regions of the central and peripheral
nervous systems, in neurons as well as in glial cells [42].
Pharmacological and behavioral studies showed that
neurosteroids were implicated in several physiological
mechanisms, for example, cognition, anxiety, depression,
neuroprotection, and even nociception [43]. Thus the
conservation of the ability to produce neurosteroids
during vertebrates’ evolution suggests that this category
of molecules is important for living beings.
8.3.1 Biosynthesis of Neurosteroids
Neurosteroids derive from cholesterol and other blood-
borne steroidal precursors. The first step of neurosteroi-
dogenesis is the transfer of molecules of cholesterol from
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the outer to the inner mitochondrial membrane. Free
cholesterol accumulates outside ofmitochondria andbinds
to the steroidogenic acute regulatory protein (StAR), a
hormone-induced mitochondria-targeted protein that
initiates cholesterol transfer into mitochondria. Then,
molecules are transported insidemitochondria byaprotein
complex including translocator protein (TSPO), a choles-
terol-binding mitochondrial protein also known under the
name of peripheral-type benzodiazepine receptor (PTBR),
which permits cholesterol transfer into mitochondria and
subsequent steroid formation [44]. This translocation from
the outer membrane to the inner membrane of mitochon-
dria is the rate-limiting step in the production of neuro-
steroids. In fact, the ability of cholesterol to enter into
mitochondria to be available to cytochrome P450 choles-
terol side chain cleavage enzyme (P450scc), located in the
inner side of the mitochondrial membrane and responsible
for the conversion of cholesterol to PREG, will determine
the efficiency of steroidogenesis.
PREG, precursor of all steroid hormones, is then
transported to the endoplasmic reticulum, where it is
metabolized to form neuroactive steroids (Fig. 8.2). The
next enzymatic step in neurosteroidogenesis is the conver-
sion of PREG into DHEA by the cytochrome P450c17
enzyme (P450c17), alsocalled17α-hydroxylase/17,20 lyase.
This enzyme catalyzes the 17α-hydroxylation of PREG in
a two-step reaction that gives first 17-hydroxyPREG
(17OH-PREG) and then the final product, DHEA. Each
step requires the molecules NADPH and O2.
PREG can also be catalyzed by another enzyme
called 3β-hydroxysteroid dehydrogenase (3β-HSD) into
progesterone (PROG). In general, 3β-HSD uses NADþ
as a cofactor to oxidize hydroxysteroids, such as PREG,
17OH-PREG, and DHEA, into their respective ketos-
teroids, PROG, 17OH-PROG, and androstenedione.
Then, neurosteroidogenesis follows two main pathways
with PROG as precursor: the androgen/estrogen path-
way and the corticoid pathway.
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Fig. 8.2 Main biochemical pathways for neurosteroid biosynthesis and metabolism in the vertebrate brain. 17OH-PREG,
17-hydroxypregnenolone; 17OH-PROG, 17-hydroxyprogesterone; DHEA, dehydroepiandrosterone; DOC, deoxycorticosterone;
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In the first pathway, PROG is metabolized by the
same enzyme as PREG, the cytochrome P450c17, which
converts PROG into androstenedione with the 17-
hydroxyPROG as an intermediate product of reaction.
Androstenedione is then converted in a reversible man-
ner into testosterone by another hydroxysteroid dehy-
drogenase called 17β-HSD. Of note, this enzyme
possesses several isoforms, and one of them, 17β-HSD-
10, also called ABAD (Aβ binding alcohol dehydroge-
nase) or ERAB (endoplasmic reticulum-associated
amyloid β-peptide binding protein), is in mitochondrial
matrix. This isoform was recently linked to AD because
of its ability to bind Aβ peptide, thus inducing mito-
chondrial dysfunction [45]. 17β-HSD is also responsible
for the reversible conversion of estrone, an estrogen
stemming from aromatization of androstenedione by
the enzyme aromatase into estradiol. The second way
to synthesize estrogens is via testosterone molecules,
which can, in turn, be metabolized into estradiol by
aromatase or continued metabolism via the androgen
pathway. The 5α-reductase enzyme (5α-R), a microsom-
al NADPH-dependent protein, intervenes at this level
and catalyzes the transfer of two atoms of hydrogen from
NADH to form the 5α-reduced metabolite of testoster-
one, dihydrotestosterone (DHT) [42]. Finally, the enzyme
3α-hydroxysteroid oxido-reductase (3α-HSOR), also
called 3α-hydroxysteroid dehydrogenase, catalyzes the
reversible conversion of DHT into the neuroactive steroid
3α-androstanediol.
The latter enzymes also intervene at another level, in
the second main steroidogenic pathway which starts with
PROG. In fact, PROG is successively metabolized by the
5α-R and the 3α-HSOR to form dihydroprogesterone
(DHP) and 3α/5α-tetrahydroprogesterone (3α/5α-THP),
also known under the name allopregnenolone, another
neuroactive steroid.
To finish by the corticoid pathway, molecules of
deoxycorticosterone (DOC), stemming from the trans-
formation of PROG by the enzyme 21-hydroxylase
(21-OHase), are in turn successively converted into
dihydroxydeoxycorticosterone (DHDOC) and tetrahy-
droxydeoxycorticosterone (THDOC) by the 5α-R and
the 3α-HSOR, respectively.
8.3.2 Mechanisms of Action of Neurosteroids
The main role of steroid hormones produced by gonads
or adrenal glands is now well defined and consists of a
feedback loop on the hypothalamus-pituitary axis, to
inhibit or activate their own synthesis. Thus they act at a
distance from their glands of origin in an endocrine way.
In contrast, neurosteroids are synthesized by the nervous
system and act on the nervous system in an autocrine/
paracrine configuration [46]. The ability of neurosteroids
to cross cellular membranes allows them to act on
nuclear receptors and to have a genomic action by
regulating gene transcription. This action seems to be
important during neonatal life, when it has been shown
that neurosteroids, such as PROG or estradiol, are able
to promote dendritic growth, spinogenesis, synaptogen-
esis, and cell survival, particularly in the cerebellum [47].
The most studied steroid nuclear receptors are the
estrogen receptors α and β, which are expressed in
metabolic tissue such as adipose tissue, skeletal muscle,
liver, and pancreas, as well as in the central nervous
system. Some studies have demonstrated that these
receptors play a role in the regulation of glucose homeo-
stasis and lipid metabolism [48], whereas other studies
showed that they were also implicated in neuroprotec-
tion [49].
Neurosteroids can also act via membrane receptors
and play a role in general as allosteric modulators of
neurotransmitter receptors. For example, sulfate esters
of DHEA and PREG are known to be excitatory
neurosteroids and can inhibit the effect of GABA, an
inhibitor neurotransmitter, at physiological concentra-
tion by acting via the GABAA receptor [46]. On the
contrary, allopregnenolone is a positive allosteric mod-
ulator of GABAA receptors, strengthening the effects of
GABA. PREG sulfate can also potentiate the effect of the
main excitatory neurotransmitter glutamate by binding
to N-methyl-D-aspartate (NMDA) receptors. On the
other hand, it is well known that neurosteroids modulate
neurotransmitter binding sites or receptors including
calcium channels and P2X receptors in the brain, spinal
cord, as well as dorsal root ganglia (DRG) [50].
Furthermore, recent clinical and pharmaceutical
studies showed that estrogens can interact with several
neurotransmitter systems, such as the cholinergic and
serotoninergic systems, to influence cognitive perfor-
mance in animals and humans [51]. Thus neurosteroids
seem to play an important role in the nervous system
during development as well as in adult brain, by regu-
lating gene transcription and different neurotransmitter
systems. Their implication was already demonstrated in
several pathologies, such as AD or neuropathic pain [42,
52]. Thus it can be speculated that they might be an
important therapeutic target to develop in the next
years.
8.4 NEUROSTEROIDS AND OXIDATIVE
STRESS
During recent years, a growing body of evidence has
shown that neurosteroids, in particular estrogens, are
implicated in the regulation of oxidative stress by acting
on mitochondria [53]. However, on one hand, depending
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on the level of oxidative stress within cells estrogens can
have a protective effect or, on the contrary, show a
negative action on cell survival. On the other hand,
oxidative stress itself can have an effect on neurosteroid
production within nerve cells.
8.4.1 Regulation of Neurosteroidogenesis by Oxidative
Stress and Aβ Peptide
It is established that steroids can be synthesized by
nonglandular tissue within the nervous system. But the
regulation of their biosynthesis is still poorly understood.
Recent findings showed that several glial cells, in particu-
lar oligodendrocytes, upregulated their production of
DHEA under oxidative stress conditions induced by
treatment with Aβ peptide or Fe2þ [54]. Modulation
of neurosteroid production was also observed in neuro-
blastoma (SH-SY5Y) cells overexpressing the key AD
proteins, APP/Aβ or Tau (Fig. 8.3) [52]. Indeed, over-
expression of human wild-type Tau (hTau 40) protein
induced an increase in production of progesterone,
3α-androstanediol, and 17-hydroxyprogesterone, in con-
trast to overexpression of the abnormally hyperpho-
sphorylated Tau bearing the P301L mutation and
leading to a decrease in the production of these neuro-
steroids. In parallel, a decrease of progesterone and
17-hydroxyprogesterone production was observed in cells
expressing human wild-type APP (wtAPP), whereas
P
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Fig. 8.3 Effect of toxic concentrations of Aβ peptides and abnormally hyperphosphorylated Tau protein on neurosteroid
biosynthesis. Aβ induced a drop of the level of progesterone (PROG), estradiol, and 3α-androstanediol by acting on reactive
oxygen species (ROS) formation and mitochondrial function and/or directly on steroidogenesis. The presence of abnormally
hyperphosphorylated Tau protein had the same effect by inducing a decrease of progesterone, 17-hydroxyprogesterone (17OH-
PROG), and 3α-androstanediol. On the other hand, it has been shown that nontoxic concentrations of Aβ induced an increase in
estradiol and 3α-androstanediol levels (this pathway is marked by *)
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3α-androstanediol and estradiol level were increased. The
latter finding was additionally confirmed with in vitro
treatment experiments [4]. APPwt SH-SY5Y cells secrete
Aβ levels within the nanomolar concentration range.
Consistently, treatment of native SH-SY5Y cells with
“nontoxic,” that is, non-cell death-inducing, Aβ1-42 con-
centrations in vitro revealed an increase in estradiol
production, whereas toxic Aβ1-42 concentrations within
the micromolar range strongly reduced estradiol levels
revealing the exact opposite effect. Of note, oxidative
stress was able to modify neogenesis of neurosteroids in
a similar pattern [55]. In fact, treatment withH2O2 for 24 h
or 48 h induced a decrease of estradiol synthesis that was
correlated to a downregulation of the aromatase, the
enzyme responsible for estradiol formation from testos-
terone. Furthermore, an increase of cell death was
observed in the presence of letrozole, an inhibitor of
aromatase. This suggests that endogenous estradiol for-
mation is very important for human neuroblastoma cells
and plays a critical role in cell survival. Interestingly, when
cells were pretreated with estradiol, it was possible to
rescue neuroblastoma cells from H2O2 as well as from
letrozole-evoked death. In agreement, similar results were
also found in stress condition experiments using heavy
metals, such as cobalt and mercury, and once again
estradiol was able to reverse their deleterious effect by
reducing oxidative stress and β-amyloid secretion [56].
8.4.2 Estrogens and Neuroprotection
Neuroprotective effects of estrogens against a variety of
brain injuries have been described for many years.
Treatment with 17β-estradiol was able to protect the
brain against excitotoxicity, Aβ peptide-induced toxici-
ty, free radical generators, and ischemia in animal
studies [53], but the basis of these effects is still poorly
understood. It was recognized from former studies that
estrogen depletion in postmenopausal women represents
a significant risk factor for the development of AD and
that an estrogen replacement therapy may decrease this
risk and even delay disease progression [57, 58].
However, results from the “Woman’s Health Initia-
tive Memory Study” (WHIMS) including 4532 postmen-
opausal woman aged over 68 years indicated a twofold
increase in dementia after 4.2 years of treatment (p.o.
treatment with premaxin plus medroxyprogesterone). In
addition, it indicated potential risks for breast cancer,
pulmonary embolism, and stroke [59, 60]. Besides war-
rantable criticism with regard to the synthetic hormones
used in the WHIMS trial, the outcome results were
unexpected and disappointing. One can ask the ques-
tion, “How could it be that so many scientific studies
before the WHIMS trial were wrong?” Thus the current-
ly prevailing view points about the “critical window
hypothesis” [16] are asking about the critical period in
which one might expect a neuroprotective effect to
occur. The results of the WHIMS study also initiated a
discussion about a two-edged effect of estradiol. Thus
estradiol can possibly also exhibit a “prooxidant effect”
in the presence of ongoing oxidative stress [53]. Thereby,
estradiol can be hydroxylated to give catecholestrogens
that can enter a redox cycle generating superoxide
radical. In an oxidative environment, this redox cycling
can lead to a continuous formation of ROS that ampli-
fies even more oxidative stress and increases neuronal
loss.
On the contrary, animal studies, especially in rodents
and transgenic mice models for AD, seem to confirm
positive effects of estrogen treatment on the pathophysi-
ology of the disease. It has been shown that treatment
with estrogen in mice expressing mutations in human
APP (Swedish and Indiana) had an impact on APP
processing, decreasing levels of Aβ and so its aggregation
into plaques [61]. In triple transgenic AD mice, depletion
of sex steroid hormones induced by ovariectomy in adult
females significantly increased Aβ accumulation and had
a negative impact on cognitive performance [62]. Treat-
ment of these ovariectomized mice with estrogens was
able to prevent these effects. Of note, when PROG was
administered in combination with estrogens, the benefi-
cial effects on Aβ accumulation were blocked but not
effects on cognitive performance. Furthermore, PROG
reduced Tau hyperphosphorylation when administered
alone. This suggests that estrogen and PROGcan interact
to regulate APP processing but can also act independent-
ly on different AD pathways.
At the cellular level, estrogen was able to activate
antioxidant defense systems by reducing ROS produc-
tion, limiting mitochondrial protein and DNA damage,
and improving the activity of the electron chain trans-
port during oxidative phosphorylation [53]. Thus estro-
gen can have direct antioxidant effects by increasing
reduced glutathione (GSH) levels and decreasing oxida-
tive DNA damage in mitochondria of ovariectomized
female rats [63]. This is correlated with an upregulation
of the expression of two enzymes: manganese superoxide
dismutase (Mn-SOD) and glutathione peroxidase, both
of them implicated in the antioxidant defense system. Of
note, estrogen can modulate the redox state of cells by
intervening in several signaling pathways, such as
MAPK, G protein-regulated signaling, NF-κB, c-fos,
CREB, phosphatidylinositol-3-kinase, PKC, and Ca2þ
influx [3, 64]. On the basis of this complex mode of
action, estrogen seems to be able to decrease oxidative
stress markers, including lipid peroxidation, protein
oxidation, and DNA damage.
Recently, it has been proposed that estrogens exert
their beneficial effects by acting directly on mitochondria
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via estrogen receptor β (ERβ) [65]. In fact, incubation of
isolated mitochondria from rat brain with estradiol leads
to a decrease of H2O2 production by this organelle
coupled with an increase of the mitochondrial mem-
brane potential. Moreover, estradiol seems to prevent
the release of cytochrome c by mitochondria (a mecha-
nism known to induce apoptosis of cells by activating
the caspase cascade in the cytoplasm), which increases
the efficiency of the respiratory chain. In addition,
estrogens are able to bind to nuclear receptors, such as
estrogen receptor α and β (ER α/β), and to act
as transcription factors. Thus estrogens enhanced the
expression of the antiapoptotic proteins, Bcl-2 and Bcl-
xL, preventing the initialization of the cell death pro-
gram by mitochondria [3]. They were also able to
increase the expression of F1 subunits of ATP synthase
and glucose transporter subunits and regulate enzymes
involved in the tricarboxylic acid (TCA) cycle, which has
the effect of improving glucose utilization by cells.
As described recently, estrogens can have an effect on
the transcription of mitochondrial genes, especially
on the electron transport chain components [66]. Treat-
ment of ovariectomized female rats with estradiol
induced an increase of mitochondrial respiratory function
translated into an enhancement of O2 consumption and
coupled to an increased expression and activity of cyto-
chrome c oxidase (electron transport chain complex IV).
Finally, another means for estrogens to avoid nega-
tive effects of oxidative stress is to regulate calcium
homeostasis by inducing mitochondrial sequestration
of cytosolic calcium [53]. In fact, an imbalance of
calcium handling can lead to an increase of ROS
production by activating the enzyme nitric oxide
synthase, which can sensitize neural cells to oxidative
damage. It has been shown that estradiol treatment of
primary hippocampal neurons was able to potentiate
glutamatergic response via NMDA receptor, which
resulted in an increased influx of calcium in cells. This
effect was coupled with an induction of mitochondrial
sequestration of cytosolic calcium and an increase of the
mitochondrial calcium load tolerability, to avoid calci-
um-induced excitotoxicity and to promote cell survival.
8.5 CONCLUSION
In summary, it is now clear that oxidative stress is an
important actor involved in AD pathophysiology and
intervenes already at an early disease stage. Further-
more, good evidence is provided that neurosteroids, such
as estrogens, are able to limit oxidative damage by
reducing lipid peroxidation, protein oxidation, Ca2þ
overload in cytosol, and DNA damage in mitochondria
as well as in the nucleus. These effects are mediated by
several mechanisms, from transcription of genes coding
for antioxidant enzymes to the regulation of antiapop-
totic pathways, by way of improvement of mitochondri-
al respiratory chain efficiency and glucose metabolism.
Thus, with their abilities to counter excess oxidative
stress, estrogens seem to be able to prevent AD-related
toxic mechanisms, such as Aβ peptide aggregation, Tau
hyperphosphorylation, and neuronal loss. Better human
studies taking into account the critical window hypothe-
sis are essential before drawing a final conclusion on
efficacy of neurosteroids in prevention of AD.
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Abstract
Alzheimer’s disease (AD) is a conformational disease that is characterized by amyloid-b (Ab) deposition in the brain. Ab
exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as
well as mitochondrial dysfunction. Recent reports indicate that Ab may also interact directly with intracellular proteins such
as the mitochondrial enzyme ABAD (Ab binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial
dysfunction occurs early in AD, and Ab’s toxicity is in part mediated by inhibition of ABAD as shown previously with an
ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role
of ABAD in Ab toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Ab-ABAD
interaction in a pull-down assay while it also prevented the Ab42-induced down-regulation of ABAD activity, as measured
by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Ab42
toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Ab42-induced impairment of
mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our
previous finding of shared aspects of the toxicity of Ab and human amylin (HA), with the latter forming aggregates in Type 2
diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We
found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two
amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a
promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-
out.
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Introduction
In the Alzheimer’s disease (AD) brain, amyloid-b (Ab) has a
central yet only partly understood role in the neurodegenerative
process [1]. Apart from constituting the amyloid plaque as a
classical hallmark lesion of AD, Ab acts via a plethora of pathways
to induce synaptic and neuronal degeneration [2–4]. Many studies
reveal that in exerting its toxicity, Ab binds to specific receptors
and/or lipids at the neuronal cell membrane, and some studies
even suggest a disruption of ion homeostasis by forming channels
or pores [5,6]. To better understand what the prerequisites are for
Ab toxicity, we and others used transgenic mouse models and
found that Ab mediates its toxicity in part through the NMDA
receptor, with an essential role for the microtubule-associated
protein tau [7–9], that similar to Ab, also forms insoluble
aggregates in the AD brain. Over-activation of the NMDA
receptor complex results in excessive nitric oxide (NO) levels,
causing down-stream protein misfolding and aggregation, as well
as mitochondrial dysfunction. The toxic signaling pathway further
involves the release of mitochondrial cytochrome c and the
activation of down-stream caspases as well as the formation of
ROS (reactive oxygen species) [10–12], highlighting mitochondria
as a prime down-stream target of Ab [13–15].
Interestingly, mitochondria represent not only an indirect
target; instead, in several studies Ab has been localized to [16]
and shown to act directly on mitochondria [17,18] whose function
it impairs [19–22]. Among the mitochondrial proteins to which Ab
has been shown to bind is the enzyme amyloid-binding alcohol
dehydrogenase (ABAD) [23,24]. ABAD interacts with Ab and is a
major determinant of Ab toxicity [17,25,26]. Specifically, in mice
doubly transgenic for ABAD and the Ab-precursor APP, the toxic
effects of Ab are aggravated compared to what is found in APP
single transgenic mice [17].
ABAD is the Type 10 member of a protein family, known as
17b-hydroxysteroid dehydrogenases (HSD17B) [27]. The enzyme
is found in mitochondria, while the other known fourteen family
members are confined to the endoplasmic reticulum (ER) sug-
gesting that ABAD has a specialized function within mitochondria
[28]. ABAD converts estradiol to estrone [29], and its levels are
critical as optimal estradiol levels are an important determinant of
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neuronal survival [29]. In post-menopausal women, the estrogen
replacement therapy has been shown to delay the onset of AD
[30]. In the placenta and in ovaries, ABAD inactivates estradiol by
oxidizing it to estrone [31,32], and this may also occurs in testis
[33]. Interestingly, ABAD levels themselves are sensitive to
estradiol levels suggesting a feedback loop in the regulation of its
activity [34].
The many reports of ABAD’s enzymatic action on various
substrates in vivo have been challenged, however, by strong evidence
that a catalytically inactive mutant of ABAD as identified in a young
boy had no ill effects on his health [35]. In addition, ABAD was
found to be one of only three proteins that comprise the fully
functional mammalianmitochondrial RNAse P [36], a function that
may not require enzymatic activity and that links ABAD directly to
the production of mitochondrial electron transport chain proteins
and reactive oxygen species (ROS) generation [37].
Binding of Ab to ABAD induces a conformational change that
is inhibited by NAD+ (nicotinamide adenine dinucleotide), with
binding of Ab and NAD+ being mutually exclusive [38]. Ab
binding results in the loss of ABAD function and ultimately,
neuronal apoptosis [39,40]. To directly determine whether Ab-
induced toxicity is mediated by ABAD inhibition and to establish
estradiol levels as a suitable readout, we here employed the use of
AG18051, a novel ABAD inhibitor [41].
Materials and Methods
Cell culture and incubation with amyloid peptides
SH-SY5Y neuroblastoma cells (DSMZ, Braunschweig, Ger-
many; DSMZ No. ACC 209) were grown in Dulbecco’s Modified
Eagle Medium: F-12 (DMEM: F-12) supplemented with 2 mM
L-glutamine, 1% penicillin/streptomycin and 10% fetal bovine
serum (FBS) (GIBCO, Basel, Switzerland) [42,43]. Ab42, human
amylin (HA), biotinylated Ab42 and biotinylated HA were
purchased from Bachem (Germany) (H-1368, H-7905, H-5642
and 3004028, respectively). The negative control, biotin, was
purchased from Sigma (B4639). Biotinylated and unmodified
Ab42 were dissolved in DMSO to make stocks of 5 mM and
stored at 280uC until use. Biotinylated and unmodified HA were
dissolved in 0.01 M acetic acid (AA) to make stocks of 5 mM and
also stored at 280uC until use. Biotin was dissolved in DMSO to
make stocks of 5 mM and kept at 280uC until use. Aging of the
peptides was induced by shaking at 1000 rpm for 4 days at 37uC.
0.5 mM Ab42 or human amylin (HA) was used for all experiments
in this study, while the treatment duration was always 5 days.
Pre-treatment experiments were performed by incubating
SH-SY5Y cells with 0.05 mM AG18051 for 24 hours, washing 3
times with warm PBS, and then treating the cells with 0.5 mM
Ab42 or HA for 5 days. Co-treatment experiments were done by
incubating SH-SY5Y cells for 5 days with 0.05 mM AG18051 and
0.5 mM Ab42 or HA, respectively.
LDH and MTT assays
LDH and MTT assays were chosen to provide indications for
cell viability after treatments. Assays were obtained from Roche
and were performed according to the manufacturer’s protocols.
Briefly, cells were exposed to the various treatments, after which
the medium was retrieved for LDH analysis, while the remaining
cells were washed 3 times with sterile PBS and the MTT assay
performed with the cells.
Pull-down assay
SH-SY5Y cells were grown to 70% confluency and treated
with vehicle, biotinylated Ab42, biotinylated HA, or biotin,
respectively, at a final concentration of 0.5 mM for 5 days. In
addition, 0.5 mM biotin and 0.5 mM biotinylated Ab42, respec-
tively, was co-incubated with 0.05 mM AG18051 for 5 days. After
5 days, cells were once washed with pre-warmed PBS and
immediately scraped with 500 mL ice-cold IP buffer (10 mM Tris,
0.1 M NaCl, 1 mM EDTA), supplemented with the Complete
EDTA-free protease inhibitor cocktail (1:25) (Roche, Basel,
Switzerland), and spun at 14 0006 g for 10 minutes at 4uC.
20 ml of magnetic Dynabeads MyOneTM Streptavidin T1
(Invitrogen) were added to each tube and tubes were rotated for
30 minutes at room temperature. Beads were subsequently washed
3 times with 16 PBS, followed by boiling in loading buffer
containing b-mercaptoethanol at 95uC for 5 minutes at 1000 rpm
to release bound peptides. Samples were then briefly spun down at
room temperature and supernatants loaded onto 12% glycine gels
for electrophoresis and Western blotting.
Quantification of estradiol as a functional read-out of
ABAD activity
After treatment with amyloid peptides and controls, the cell
culture medium was collected and cells were resuspended in cell
lysis buffer consisting of 150 mM Tris HCl, 150 mM NaCl, 1%
NP-40, 0.1% SDS, 2 mM EDTA and Complete protease inhibitor
(1:50) (Roche Diagnostics). The estradiol assay was performed
according to the manufacturer’s guidelines (Estradiol EIA Kit,
Cayman). In brief, the plate was loaded with samples, along with
the estradiol tracer and the specific antiserum to estradiol and
incubated for one hour at room temperature. After five washing
steps, Ellman’s Reagent was added and the plate developed for
60 minutes with gentle shaking at room temperature. The
calculated estradiol concentration was normalized to the total
protein content of the samples.
Figure 1. Ab42 binds to and impairs ABAD activity, while HA
(human amylin) does not. (A) Treatment of SH-SY5Y human
neuroblastoma cells with Ab42 causes decreased levels of estradiol,
indicative of an impairment of ABAD activity, while HA does not. Results
are means 6 SE, (n = 5 to 6 per group), **, P,0.01 (B) Pull-down of
ABAD from SH-SY5Y cells shows that different from HA, Ab42 can bind
to ABAD in vitro. (C) Structure of the ABAD inhibitor, AG18051 (adapted
from Kissinger et al., JMB 2004).
doi:10.1371/journal.pone.0028887.g001
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Mitochondrial respiration in vital cells
After treatment with amyloid peptides and controls, mito-
chondrial oxygen consumption was measured at 37uC using an
Oroboros Oxygraph-2k system. Five million cells were added to
2 ml of a mitochondrial respiration medium containing
0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate,
20 mM taurine, 10 mM KH2P04, 20 mM HEPES, 110 mM
sucrose and 1 g/l BSA (pH 7.1). To measure the state 4
respiration of complex I, 5 mM pyruvate and 2 mM malate
were added and cells permeabilised with 15 mg/ml digitonin.
Afterwards, 2 mM ADP was added to measure state 3
respiration. The integrity of the mitochondrial membrane was
checked by the addition of 10 mM cytochrome c. After
determining coupled respiration, 0.4 mM FCCP (Carbonyl
cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added
and respiration was measured in the absence of a proton
gradient. To inhibit complex I activity, 0.5 mM rotenone was
added.
Determining ROS levels
Levels of ROS were measured using different fluorescent probes
that allow detection at different cellular sites. The non-fluorescent
probe 29,79-dichlorodihydrofluorescein diacetate (H2DCF-DA)
was used to measure cytosolic ROS, most notably hydrogen
peroxide [44]. To determine levels of superoxide anion radicals,
DHE was used, which is oxidized to the fluorescent ethidium
cation by O2.2 [22]. For detection of mitochondria-associated
ROS we used the probe dihydrorhodamine (DHR), which
localizes to mitochondria and when oxidized by ROS, particularly
peroxinitrite, fluoresces to the positively charged rhodamine 123
derivate. Treated cells (Ab42, HA, and vehicle) were loaded with
10 mM H2DCF-DA, 10 mM DHR or 10 mM DHE, respectively,
for 15 min. After washing twice with Hank’s balanced salt (HBS)
solution, the formation of fluorescent products was measured by
detecting the emitted fluorescent units per 56105 cells using the
Fluoraskan Ascent FL multiplate reader (Labsystems, Helsinki,
Finland) (i) at 485 nm (excitation)/538 nm (emission) for both
Figure 2. Effects of the ABAD inhibitor AG18051 on cell viability and estradiol levels. (A) LDH assay of SH-SY5Y human neuroblastoma
cells incubated with increasing concentrations of AG18051 (normalized to 1 for control) shows that the ABAD inhibitor is not toxic at concentrations
of 0.1 mM and below. (B) Treatment of SH-SY5Y cells with increasing concentrations of AG18051 causes reduced levels of estradiol. *, P,0.05.
doi:10.1371/journal.pone.0028887.g002
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dichlorofluorescein (DCF) generated from H2DCF-DA via
oxidation, and DHR, and (ii) at 530 nm (excitation)/590 nm
(emission) for DHE, as previously described [45].
Results
Ab42 binds to and down-regulates ABAD activity,
different from human amylin
Ab exerts its toxicity in part by impairing ABAD [17], an
enzyme known to convert estrone to estradiol. To determine the
toxicity of the major fibrillogenic form of Ab and the role ABAD
has in this process, we incubated human SH-SY5Y neuroblastoma
cells for 5 days with Ab42, followed by measuring estradiol levels
in the cell lysate. We found that its levels were significantly
decreased after Ab42 exposure (p,0.0001) (Fig. 1A). To
determine if the deregulation of ABAD activity is a common
phenomenon shared by Ab with other amyloidogenic proteins, we
treated the cells also with human amylin (HA), a protein twice the
size of Ab and known to form aggregates in another disease with
protein aggregation, Type 2 diabetes mellitus (T2DM). However,
Figure 3. The Ab-mediated decrease in estradiol levels is prevented by AG18051. (A) Scheme of pre- and co-incubation treatment. (B) Pre-
treatment of cells with AG18051 for 24 hours prior to adding Ab42 maintains estradiol levels compared to the vehicle control, (C) as does co-
treatment. **, P,0.01.
doi:10.1371/journal.pone.0028887.g003
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different from Ab42, HA did not cause reductions in estradiol
levels (p,0.0001) (Fig. 1A).
Data obtained by x-ray crystallography of Ab42-ABAD
complexes indicate that it may be the direct association of Ab42
and ABAD that inhibits ABAD activity, as an association of Ab
with ABAD prevents it from binding to its physiological sub-
strate, NAD+ [17]. Since HA, different from Ab42, did not
down-regulate ABAD activity as measured by estradiol levels, and
as it is known that Ab42 is capable of inhibiting ABAD activity by
direct interaction [38], we sought to determine whether HA,
similar to Ab, would interact with ABAD. Therefore, SH-SY5Y
cells were incubated with 0.5 mM biotinylated Ab42 (BAb),
biotinylated HA (BHA), biotin or vehicle for 5 days. We found
by pull-down that while biotinylated Ab42 was bound to ABAD,
biotinylated HA, along with the negative control, was not (Fig. 1B).
Together with the estradiol activity assay, this suggests that the
reductions in estradiol levels caused by Ab42 may be mediated by
a direct interaction of Ab with ABAD.
The ABAD inhibitor AG18051 causes reduced estradiol
levels
To better understand the effect of Ab on estradiol levels we used
AG18051, a small molecule inhibitor of ABAD with high affinity
[41,46] (Fig. 1C). AG18051 exerts its inhibitory effect by
occupying the substrate-binding site of ABAD, which results in
the formation of a covalent adduct with the NAD+ cofactor. As the
interaction of ABAD with NAD+ is necessary for its activity,
disrupting ABAD/NAD+ complex formation obliterates ABAD
activity, resulting in decreased estradiol levels. We first determined
the toxicity profile of AG18051 in our SH-SY5Y cell culture
system. Concentrations of AG18051 up to 0.1 mM were not
overtly toxic and therefore, concentrations within the 0.05–
0.1 mM range were chosen for subsequent studies (Fig. 2A). The
toxicity at higher concentrations argues for a proper dosing. The
concentration range applied by us is consistent with the IC50
determined for AG18051 in a previous study [47,48]. With
increasing concentrations of the inhibitor, as expected, estradiol
levels were reduced (Fig. 2B). At 0.05 mM however, there was a
slight, but non-significant increase in estradiol levels suggesting
compensatory mechanisms.
AG18051 prevents Ab42-induced reductions in estradiol
levels
To determine whether AG18051 has an effect on the Ab42-
induced reduction of estradiol levels (Fig. 1A) and whether the
putative neuroprotective effect is via a ‘priming effect’ of the cells,
we both pre- and co-incubated SH-SY5Y cells with Ab42 and
0.05–0.1 mM AG18051 as outlined in the scheme (Fig. 3A). For
both treatment conditions, we found that this maintained estradiol
levels in the lysate, compared to a significant reduction in the
Ab42-only treatment (Fig. 3B,C). This suggests that AG18051 is
neuroprotective, and that it may exert its neuroprotective effect
either by priming cells to become resistant to the effects of Ab42,
or via a direct inhibition of the Ab42-ABAD interaction as
previously suggested [41].
AG18051 partially prevents ABAD-Ab42 interaction
To determine whether AG18051 treatment reverses the Ab42-
induced toxicity because AG18051 directly blocks the physical
interaction between Ab42 and ABAD, SH-SY5Y cells were
treated with 0.5 mM of biotinylated Ab42 (BAb) in the presence of
0.05 mM AG18051. We found that co-incubation of AG18051
significantly decreased the amount of ABAD pulled down by
biotinylated Ab42 (BAb) (Fig. 4). This suggests that AG18051
may prevent Ab42 toxicity by directly inhibiting the associ-
ation of Ab42 with ABAD. In addition, this also suggests that
AG18051 may exert its neuroprotective effects via additional
pathways other than a direct inhibition of the Ab42-ABAD
interaction.
Ab42-mediated reduction in cell viability prevented by
ABAD inhibitor AG18051
Having determined 0.05–0.1 mM as a suitable concentration
range for AG18051, we tested its putative neuroprotective effect in
Ab42 toxicity. SH-SY5Y cells were incubated with 0.5 mM Ab42
with or without AG18051, and toxicity was determined as
increased levels of LDH compared to vehicle control. Co-
incubation of Ab42 with either 0.05 or 0.1 mM AG18051,
respectively, resulted in a significant decrease in LDH levels back
to control levels (Fig. 5A). This indicates that inhibiting ABAD
activity protects from Ab toxicity.
We next investigated the effect of Ab on metabolic functions
and found that besides significantly increasing LDH levels, 0.5 mM
Ab42 also caused a significant decrease in MTT absorbance,
suggesting impaired metabolic functions caused by this amyloido-
genic peptide (Fig. 5B). Co-incubation of Ab42 with either 0.05 or
0.1 mM AG18051, respectively, resulted in a smaller decrease of
MTT absorbance (Fig. 5B,C). Since MTT measurements are an
indicator of mitochondrial health, the results suggest that Ab42
induces cell toxicity, as reflected by LDH levels, at least in parts via
impaired mitochondrial functions, with inhibition of the mito-
chondrial enzyme ABAD providing partial protection.
Figure 4. Pull-down of ABAD from SH-SY5Y cells shows that
different from HA, Ab42 can bind to ABAD in vitro. The presence
of AG18051 significantly decreases the amount of ABAD pulled down
by biotinylated Ab42 (BAb). *, p,0.05.
doi:10.1371/journal.pone.0028887.g004
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AG18051 restored Ab42-induced deficits on oxidative
phosphorylation (OXPHOS) capacity
To investigate the protective effect of AG18051 against Ab42
toxicity at the mitochondrial level, we used a high-resolution
respiratory protocol that we have established previously [49].
Specifically, physiological substrate combinations were used to
investigate mitochondrial function in SH-SY5Y cells (Fig. 6). We
compared OXPHOS, i.e. the entire electron transport system
(ETS) that is composed of the four mitochondrial enzymes
(complex I–IV) and the F1F0ATP synthase, in cells treated with
either vehicle, Ab42, AG18051, as well as in cells that were pre-
treated with AG18051 followed by exposure to Ab42 (see scheme,
Fig. 3A). We used the NADH generating substrates pyruvate and
malate to determine state 4 respiration (Fig. 6). State 3 respiration
measures the capacity of mitochondria to metabolize oxygen and
the selected substrate in the presence of a defined amount of ADP,
which is a substrate for the ATP synthase (complex V). State 4
respiration represents a ‘‘basal-coupled’’ rate of respiratory chain
activity and reflects activities of respiratory chain complexes and
proton leakage across the inner mitochondrial membrane. We
observed significantly reduced state 3 and state 4 respirations in
Ab42-treated cells (Fig. 6). After uncoupling with FCCP, the
respiratory rate increased in the absence of a proton gradient,
which indicates the maximum capacity of electron transport chain.
This maximum OXPHOS capacity was again significantly
impaired in Ab42-treated (Fig. 6).
Of note, AG18051 was able to significantly ameliorate the
Ab42-induced global failure of mitochondrial respiration, but by
Figure 5. The ABAD inhibitor AG18051 prevents the toxicity and metabolic impairment caused by Ab. (A) Co-incubation of AG18051
and Ab42 maintains the Ab42-induced change in LDH levels at baseline levels. (B) The metabolic impairment as determined with the MTT assay is also
prevented by co-incubation of Ab42 with AG18051. (C) Pre-incubation of the cells with AG18051 for 24 hours prior to adding Ab42 is similarly
protective to Ab’s toxicity as measured with the MTT assay. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g005
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itself had no effect per se on oxygen consumption attaining levels
comparable to vehicle treatment (Fig. 6).
AG18051 prevents the increase in ROS levels caused by
Ab42
Increased ROS levels have been implicated in AD [50,51]. We
had previously found that treatment of SH-SY5Y cells with Ab42
caused significantly increased ROS (reactive oxygen species) levels,
reflecting mitochondrial dysfunction and cell toxicity [52]. As pre-
incubation with AG18051 was capable of preventing the toxicity
induced by Ab42, we pre-treated SH-SY5Y cells with AG18051
and exposed them then to Ab42. Interestingly, cells pre-treated
with 0.05–0.1 mM AG18051 were effectively protected from any
Ab42-induced ROS production, attaining levels comparable to
vehicle treatment (Fig. 7). This suggests that AG18051 may
prevent cell toxicity induced by Ab42 in part by preventing the
generation of ROS. In addition, the results also suggest that
ABAD dysfunction may be upstream of ROS production since
AG18051 can prevent ROS generation. Alternatively, AG18051
may trigger high estradiol levels, thereby counteracting ROS.
AG18051 only partially protects against reductions in cell
viability and estradiol levels in SH-SY5Y cells when
deregulated by human amylin (HA)
Previously, we had found that Ab42 and HA share toxicity
pathways via deregulation of mitochondrial proteins [52].
However, as shown above, Ab42 binds to and down-regulates
ABAD activity, while HA fails to do so (Fig. 1). We nonetheless
sought to determine whether AG18051 would have an effect in the
toxicity assays used above to measure Ab toxicity. We found that
HA induced an increase in LDH levels revealing its toxicity
(Fig. 8A), and a corresponding decrease in MTT absorbance
revealing its effect on metabolic functions (Fig. 8B). Co-incubation
of AG18051 with HA significantly prevented the increase in LDH
levels when compared with HA alone, but did not fully maintain
LDH to the levels of vehicle treatment indicating only a partial
protection from HA-induced toxicity (Fig. 8A). Co-incubation of
AG18051 with HA did not have any significant impact on MTT
levels (Fig. 8B).
AG18051 prevents the increase in ROS levels caused by
Ab42 and HA
Increased ROS levels have not only been implicated in AD but
also T2DM [50,51]. We had previously found that ROS levels in
SH-SY5Y cells are significantly increased upon exposure to either
Ab42 or HA [52]. To determine if the limited protective effect
seen by AG18051 on HA-induced toxicity may be due to an
inhibition of ROS generation, we pre-incubated SH-SY5Y cells
with AG18051 and then exposed them to HA. Similar to Ab42
(Fig. 7), pre-treatment with 0.05 mM AG18051 completely
prevented ROS generation by 0.5 mM HA (Fig. 9). Taken
together with the ROS data obtained for Ab42 (Fig. 7), this
suggests that AG18051 may be neuroprotective by preventing
ROS generation induced by either Ab42 or HA.
Discussion
Mitochondrial dysfunction has been recognized as a prominent,
early event in AD, but the underlying mechanisms are only partly
understood [53]. As a mediator of Ab toxicity in AD, a role has
been proposed for the mitochondrial protein ABAD, with
evidence for a direct interaction of Ab and ABAD [17]. Whether
in the AD brain, intracellular Ab - either in mitochondria or in the
cytoplasm - is present at sufficiently high quantities to have a
decisive role in disease is a matter to debate that has been revived
by the recent analysis of Ab plaque-forming 3xTg-AD using a
panel of Ab- and APP-specific antibodies [54]. Our current study
however adds to the body of data revealing a role for ABAD in
mediating Ab, irrespective of its mode of interaction.
By using the novel compound inhibitor of ABAD, AG18051 [41],
we revealed that Ab-mediated toxicity, metabolic impairment and
Figure 6. High-resolution respirometry revealed a reduction of oxygen consumption in Ab42-treated cells that was restored after
pre-treatment with AG18051. O2 flux and consumption by vital cells was measured after addition of different agents: pyruvate/glutamate, ADP,
FCCP, rotenone. Two-way ANOVA revealed a significant difference between the cellular respiration of the cells treated either with vehicle, Ab42 or
AG18051 alone, or AG18051 plus Ab42 (p,0.0001) (see scheme Fig. 3A). The respiratory rates of mitochondria were significantly reduced in Ab42-
treated cells compared to control (vehicle treated) cells and cells pre-treated with AG18051 (24 h) before exposure to Ab42. Values represent the
means 6 S.E. from n= 3–5 independent measurements. Post-hoc Bonferroni’s Multiple Comparison Test analysis for single experimental respiratory
conditions: *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0028887.g006
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reductions in estradiol levels could be abrogated. However different
from Ab, the inhibitor only partially restored the toxicity of HA, that
shares with Ab its amyloidogenic properties, and it had no effect at
all on the impaired metabolic activities or the reduced estradiol
levels caused by HA. The compound though abolished both the
Ab42- and HA-induced increases in ROS levels. These effects may
or may not require a direct interaction of Ab and ABAD. Provided
that Ab enters mitochondria and binds ABAD, it is believed to gain
access to the mitochondrial matrix via intracellular trafficking. Our
pull-down experiments using a biotinylated preparation of Ab
reveal that this peptide binds to ABAD in a lysate, while in contrast,
HA does not.
One of the established functions of ABAD is to convert in an
equilibrium reaction estrone to estradiol, a known anti-oxidant in
neuronal survival [31–33,55]. Additional substrates are known for
ABAD, such as the mitochondrial 2-methyl-3-hydroxybutyryl-
CoA [40,56].
ABAD is up-regulated in AD brain areas affected by Ab
pathology such as the cortex and hippocampus, as well as in Ab-
producing mouse models [17,23,26,57]. In neuroblastoma cells,
the cytotoxic effects of Ab are enhanced by ABAD over-
expression, and blocked with anti-ABAD antibodies [58].
Moreover, synthetic Ab fragments have been shown to bind and
inhibit ABAD in vitro [39]. As cells expressing catalytically inactive
mutants of ABAD failed to show an enhanced sensitivity to Ab, it
has been suggested that it is the enzymatic activity that is required
for mediating Ab toxicity [38]. In vivo, ABAD over-expression
potentiates the toxic effects of Ab, and obliteration of Ab-ABAD
complexes restores cell viability and memory deficits in transgenic
mice [17,26]. This inhibition was achieved using a truncated
version of ABAD as a decoy peptide (ABADDP) [17,26]. The
authors of the study concluded that segregating ABAD from Ab
protects both mitochondria and neurons from Ab toxicity by
restoring ABAD’s physiological functions.
Rather than employing a decoy peptide, we decided to use the
small compound, AG18051, a novel ABAD inhibitor to investigate
its putative protective effects. We performed co- and pre-
incubation experiments to determine whether the restoration of
estradiol levels by AG18051 is due to a direct inhibition of the
Ab42-ABAD interaction, or an indirect mechanism. By determin-
ing estradiol levels as a functional read-out of ABAD activity, we
found that exposure to Ab42 significantly decreased estradiol
levels (Fig. 3B, C). We have been using SH-SY5Y cells, a well-
established neuroblastoma cell line [43], to determine the effects of
AG18051 on ABAD. We found that pre-treatment of SH-SY5Y
cells with AG18051 before Ab42 exposure (Fig. 5C) was sufficient
to prevent the decrease in cell viability. This suggests that
AG18051 is capable of blocking Ab42 toxicity, possibly in part
by directly binding to ABAD and preventing the Ab42 toxicity
mediated by ABAD.
To determine whether these changes are due to ABAD
specifically, we performed co-incubation treatments of a novel
ABAD inhibitor, AG18051, with Ab42. We found that AG18051
effectively obliterated the toxic effects of Ab42 as demonstrated by
the restoration of LDH release and MTT absorbance to levels
indistinguishable from the vehicle control. Furthermore, AG18051
restored estradiol levels upon down-regulation by Ab42. This
effect is seen both in the cell lysate and the medium (data not
shown), suggesting that Ab42 exerts its toxicity by interfering with
intracellular levels of estradiol while also decreasing its secretion
Figure 7. AG18051 pre-treatment prevents ROS generation
induced by Ab. Ab causes reduced cellular (DCF) as well as
mitochondrial ROS (DHR), e.g. reduced mitochondrial superoxide anion
radicals (DHE). Levels are restored to vehicle upon pre-treatment with
AG18051, irrespective of whether the SH-SY5Y cells have been
incubated with Ab or HA. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g007
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into the extracellular environment. Our data indicate that Ab42-
induced toxicity is mediated by ABAD in part via the deregulation
of estradiol, which may contribute to cell toxicity.
To determine whether the change in estradiol levels is due to a
direct blockage of Ab42 by ABAD, we performed a pull-down
using biotinylated Ab42 in the presence of AG18051 (Fig. 4). We
found that AG18051 significantly decreased ABAD binding to
biotinylated Ab42, suggesting that AG18051 may be neuropro-
tective, in part by disrupting the physical interaction of ABAD
with Ab42. However, as binding was not completely abolished,
our results suggest that AG18051 may also act indirectly to
prevent cell toxicity. This is supported by the fact that AG18051 is
capable of preventing ROS production by HA (Fig. 9) even though
HA does not seem to bind to ABAD (Fig. 1B).
To unravel the effects of Ab42 and the involvement of ABAD
on the mitochondrial respiratory capacity, we performed whole
cell recording of total cellular respiration in SH-SY5Y cells
(Fig. 6). Consistent with previous findings investigating the effect
of a stable APP over-expression in SH-SY5Y cells gaining a
chronic overproduction of Ab within the low nanomolar range
[49], we observed a comparable impairment of oxygen con-
sumption rates in cells treated with Ab42 species for 5 days. Of
note, we present for the first time clear evidence that pre-
treatment with AG18051 prevented SH-SY5Y cells from a
decline in metabolic energy pathways induced by Ab42. The
capacity of mitochondria to re-phosphorylate ADP in state 3 is
dependent on the degree of coupling. Thus, pre-treatment with
AG18051 prevented the ETC (electronic transport chain) from
Ab42 toxicity and rescued the coupling state of mitochondria.
Importantly, the comparison of the mitochondrial energetic
capacity in cells treated with vehicle or AG18051 revealed a
similar bioenergetic homeostasis indicating that the inhibitor,
by itself, had no significant effect on respiration. These results
corroborate our findings demonstrating an AG18051-induced
Figure 8. The ABAD inhibitor AG18051 partially prevents the toxicity of HA, but not its metabolic impairment. (A) Co-incubation of HA
with AG18051 partially maintains levels of LDH release in SH-SY5Y cells suggesting that the toxicity of HA is partially mediated by ABAD. (B)
Treatment with 0.5 mM HA significantly decreases metabolic activity as shown with the MTT assay, which is not prevented with co-incubation with
AG18051. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0028887.g008
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prevention of ROS formation caused by Ab42, which in turn
impairs mitochondrial function.
That a defective or insufficient mitochondrial function might
play a potentially pathogenic role in another epidemic disease,
Type 2 diabetes mellitus (T2DM), has emerged in recent years
[59,60]. The association of diabetes with obesity and inactivity
indicates an important, and potentially pathogenic, link between
fuel and energy homeostasis and the emergence of metabolic
disease. Given the central role for mitochondria in fuel utilization
and energy production, mitochondrial dysfunction at the cellular
level can impact whole-body metabolic homeostasis [61]. T2DM
is characterized by HA deposition in the pancreas, and AD by Ab
deposition in the brain [59]. Ab and HA share a common b-sheet
secondary structure, a strong determinant in toxicity [62,63].
Supporting this notion we have shown previously that Ab and HA
share a mitochondrial toxicity profile [52]. In the present study we
found that HA caused toxicity and impaired metabolic functions.
When we co-incubated HA with AG18051 using the same
conditions as for Ab42, AG18051 significantly decreased levels of
LDH compared to just HA alone, suggesting that HA toxicity is in
part mediated by ABAD (Fig. 8A). Interestingly, co-incubation of
AG18051 with HA did not significantly change levels of MTT
absorbance, an established assay of mitochondrial function
(Fig. 8B) [64]. We have previously shown that to mitochondria,
at equimolar concentration, HA is more toxic than Ab42 [52].
This suggests that a higher concentration of AG18051 may be
required to restore the HA-induced mitochondrial toxicity.
Interestingly, while the MTT assay is a reliable test for metabolic
impairment, it does not always precisely reflect neuroprotective
effects, suggesting that the LDH assay is more accurate in
determining neurotoxicity [65]. It is therefore possible that the
neuroprotective effects of AG18051 against HA treatment differs
from that of Ab42. By extrapolation, this also means that HA and
Ab42 may exert a differential toxicity on ABAD. This is a
possibility, as exposure to HA did not alter estradiol levels, differ-
ent from Ab42 (Fig. 1A).
Pre-treatment of SH-SY5Y cells with AG18051 prevented both
the cellular and mitochondrial ROS formation induced by Ab42
and HA suggesting that ABAD is involved in their mechanism of
toxicity. We have shown previously that increased ROS
generation and reduced mitochondrial complex IV activity was
the common mechanism of toxicity of HA and Ab42 [52]. This is
in agreement, in the case of Ab, with other reports showing that
Ab results in ROS generation and reduction of complex IV in AD
mouse models and that there is a direct involvement of ABAD in
these processes [17,66,67]. Now it appears that HA ROS gener-
ation is also mediated by ABAD. However, while AG18051 may
be protecting against most of the toxic effects of Ab42, it does so
only partially for HA. This indicates that HA may have additional
toxicity pathways unrelated to ROS generation or ABAD.
The mechanism of protection by AG18051 is probably through
its inactivation of ABAD’s catalytic activity. Inactive mutants of
ABAD do not enhance the toxicity of Ab that is observed when
wildtype ABAD is over-expressed, despite the fact that Ab still
binds to the mutant ABAD with the same affinity as wild-type
[68]. It has also been reported that siRNA-ABAD and the
subsequent reduction of ABAD expression prevents the toxic
effects of Ab in SH-SY5Y cells induced to over-express ABAD by
corticosterone and Ab [67]. But why would the catalytic activity of
ABAD be harmful when Ab is bound to it? In view of the
participation of ABAD in mitochondrial RNAse P, which is
responsible for the centrally important processing of the
mitochondrial ETC mRNA [37], one possibility is that ABAD’s
primary function is as an RNAse P and that Ab and HA induce a
toxic gain of function related to its catalytic activity compromising
its RNAse P function. This would result in aberrant processing of
the ETC mRNA, a dysfunctional ETC and ROS generation. Ab
may do this directly by binding to ABAD and, while there is no
Figure 9. AG18051 pre-treatment prevents ROS generation
also induced by HA. As for Ab, HA causes reduced cellular (A) as well
as mitochondrial ROS (B), e.g. reduced mitochondrial superoxide anion
radicals (C). Levels are restored to vehicle upon pre-treatment with
AG18051. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g009
ABAD Inhibition Restores Amyloid-b’s Toxic Effects
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28887
evidence that HA directly interacts with ABAD, our study shows
that ABAD is nevertheless key to the toxicity of HA.
In conclusion, we extend previous findings on the role of
mitochondria, and in particular the mitochondrial enzyme ABAD,
in mediating Ab42 toxicity. We established a neuroprotective
effect of AG18051, a novel ABAD-specific inhibitor, and showed
that it promotes cell survival in part by preventing the generation
of ROS and stabilizing estradiol levels. Our findings extend
previous studies suggesting ABAD activity as a suitable biomarker
for impaired brain functions. We further present AG18051 and
related compounds for consideration in therapeutic strategies
targeting AD.
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